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Ph.D. Dissertation by Vijay A. Ramchandani 
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On April 22, 1997, a memorandum was received from the lnvestigational Pharmacy of 
MCV Hospitals stating that there was an error in the preparation of the intravenous 
ethanol solutions for the IV study (see Attachment 1). It appears that the Pharmacy 
prepared and dispensed 10%v/v ethanol solutions instead of the 10%w/v solutions that 
we had requested. ln other words, the intravenous ethanol solutions that were used in 
the study contained 8%w/v ethanol, and not 10%w/v ethanol. 
As a result of this, the ethanol doses administered during Leg O and the active legs of 
the randomized phase of the study were 20% lower that what had been calculated for 
administration. 
After careful review and repeating the pharmacokinetic and phannacodynamic analysis 
of the data, as well as the statistical analysis, it was detennined that this error did not 
affe.ct the main conclusions of the study. The primary differences were in the estimates 
of the volumes of distribution, Vdc and Vdss, which were about 20% higher than the 
estimates obtained using the actually administered doses . The estimates of the other PK 
and PD parameters did not change significantly. 
As a result of the error and the subsequent re-analysis of the data, there are some 
corrections to some of the tables and text in the dissertation. These are limited to 
chapter 4. The corrections include: 
1. Changes to Figure 4.1 and Tables 4.7, 4.8, 4.11, 4.13 and 4.14. The corrected 
figures and tables are attached to this addendum (Attachment 2). 
2. Section 4.3.28 on page 136 should read: 
4.3.28 Drug preparation and administration 
On the morning of dosing, subjects received a one-hour IV infusion of 
ethanol. A total dose of 0.48 g ethanol/kg body weight for male subjects and 
0.40 g ethanol/kg body weight for female subjects was administered as a 
10%v/v (8%w/v) solution in normal saline over 1 hour. The infusion was 
administered ... 
3. Section 4.3 .4B on page 147 should read: 
4.3.48 Drug preparation and administration 
During each study period, subjects received one of the following treatments 
according to the sequence he/she was randomized to. Dosing consisted of 
two infusions: Infusion I was administered for 1 hour, followed by Infusion II 
which will be administered over the next 5 hours. The total dose of ethanol, 
which was individualized for each subject based on his/her pharmacokinetic 
parameters, was administered as a 10%v/v (8%w/v) solution in normal 
saline. Placebo doses consisted of normal saline. The infusions were 
administered ... 
4. The last paragraph on page 192 (continuing on to page 194) should read: 
The mean intrinsic PK parameters, estimated by compartmental methods 
across subjects and treatments, along with the inter-individual and intra-
individual variability measures (%GOV) are presented in table 4.14, by 
gender. The mean(± S.D.) Vmax was 347 (± 77) mg/Uhr across subjects and 
treatments. The mean(± S.D.) Km was 254 (± 83) mg/Lacross subjects and 
treatments. The mean± SD Vdss was 41 (± 7) Lacross treatments for male 
subjects, and 30 (± 6) L across treatments for female subjects. The mean (± 
S.D.) k12 was 0.95 (± 0.45) hr"1 across subjects and treatments. The mean(± 
S.D.) k21 was 2.41 (± 1.55) hr"1 across subjects and treatments. This 
corresponds to a distribution half-life of around 0.23 hours (or around 14 
minutes), indicating that the distribution phase for ethanol is quite rapid. 
5. The sentence (starting on the fourth line) on page 257 should read: 
The mean(± S.D.) Vmax was 347 (± 77) mg/L/hr across subjects and 
treatments; the mean(± S.D.) Km was 254 (± 83)mg/L across subjects and 
treatments; the mean± SD Vdss was 41 (± 7) Lacross treatments for male 
subjects, and 30 (± 6) L across treatments for female subjects. The mean (± 
S.D.) k12 was 0.95 (± 0.45) h(1 across subjects and treatments and the 
mean(± S.D.) k21 was 2.41 (± 1.55) hr"1 across subjects and treatments. 
This corresponds to a distribution half-life of around 0.23 hrs (or around 14 
minutes). 
ATTACHMENT I 
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22 April 1997 
Patricia Slatt.um. PharmO 
Am; Phllllps. Phanno"1 
DlluUon for Ethanol Study 
This memo is to docu nent the telephone conversation that we had 
previously regarding the ~centraUon of ethanol for the study conducted In 
1994 and 1995 with Vl}ay ,\o.'"1Chandanl as well as your study that Is currently 
ongoing. 
It has been brought to m- 1 attention thal the 10% ethanol solution that was 
expected to be made ror i>oth of these studies has actually been 8.01%. 
8lclosed you will find a copy of the MCV Instruction card that was used In 
preparlng the doses for e21c:h paUent In both studies. 
You wm see that the USf'/NF was Incorrectly !nterpretad to be % by weight 
as wfv, when It should havl' been %w/w. You will also see that the density of 
pure alcohol was not UMd In calculating the final concentraUon. We picked 
the density at 15.56 degntes because that Is what the Bureau of Standards 
recommends. So, you w'~I .,ee that the density of pure alcohol that we used 
Is 0. 7936glml. 
The calculations for the pr, ti>araUons that were given to the subjects enrolled 
In this study ere as follow:; 
We used-- 98% vN t ,thanol: 98ml of pure alcohol 
100ml or total solution 
The density of purv olcohol (see enclosed alcoholometrlc table) Is = 
0.7936 g/ml 
So, a 98% v/v Is~ x 0.793_6g I ml = 77.8% w/V 
10Cml 
Now the· solution tt;,1t was made used 103ml or 98% v/v ethano:, so 
the actual concenlrr.ttlon Is determined to be: 
Z1&l.. =· . x a of ethanol 
100ml 1 :i3ml ot 98o/ov/v 
• 80.13g 
80.13g • ~ • 8.01% w/v 
1000ml t 00ml 
As we discussed, we wi:t oonUnue making the solution as we have In the 
past. The solution wlll bt.• 1.-.beled as an 6% solution and not a 10% solution 
from this point on. I 'J.1derstand that you wlll be In touch with Vijay 
Ramchandanl regarding .t;ls Issue, please ·rorward him this information. 
Coples of this wlll be kept , .. , our flies aa well. Please call me tf you need any 
further lnfonnaUon for our rucords at 8-7901. 
ATTACHMENT 2 
I Medical Screening I 
Phannacokinetic Screen and Familiarization Period 
Lego 
Males : 0.48 g/kg IV Ethanol infused over 1 hour 
Females: 0 .4 g/kg IV Ethanol infused over I hour 
Assessment of 
PK parameters 
Yrrw, Km, Yd 
Dose Individualization 
RANDOMIZATION 
Four-way Crossover (Legs l - 4) 
Treatment Infusion I Infusion II 
(1 hour) (5 hours) 
A ethanol placebo 
B placebo ethanol 
C ethanol ethanol 
D placebo placebo 
Figure 4.1 Study Design Flow Chart 
Table 4.7 Mean (%COY) Phannacok.inetic parameters by gender for Leg O for intravenous ethanol study 
Dose Cmu Vrrw Km Vd 
[g/kg] [mg/LJ [mg/U(g/kg)) 1 (mg/Uhr) (mg/LJ (LI [Ukg)2 
Males 0.48 924 1924 241 163 47 0.48 
(n=8) (19%) (19%) (27%) (41 %) (16%) (16%) 
Females 0.40 821 2052 250 164 35 0.43 
(n=8) (20%) (20%) (13%) (37%) (18%) (16%) 
All - 1988 245 164 41 0.45 
(o= 16) (19%) (20%) (38%) (22%) (18%) 
I : Dose--corrected c,,.. 2: body-weight corrected Vd 
Table 4.8 Doses calculated from Leg O PK parameters for crossover phase of 
intravenous ethanol study. 
Trt A Trt B Trt C 
[g/kg] [g/kg] [g/kg] 
Males 0.60 (12%) 0.96 (8%) 1.11 (8%) 
(n=8) 
Females 0.53 (13%) 0.85 (12%) 1.00(11 %) 
(n=8) 
All 0.57 (14%) 0.91 (11 %) 1.05 (11 %) 
(n=l6) 
Population• 0.56 1.00 1.11 
I: Doses predicted for treatments A, B and C based on previously 
published parameter estimates (Vm.u=232 mg/Uhr, K,,,=82 . 1 mg/L, 
Vd=0.53 Ukg) 
Table 4.11 Mean (%COY) Non-compartmenta1 Pharmacokinetic parameters by gender for crossover phase of inttavenous 
ethanol study 
Treannent Cmu T"""' I AUCoo Vmu Km 
I Vd 
fmg/L) f mg/U(g/kg}l1 [hr) :lmg/L •brll [mglL •br/(g/kg))3 llmglUb.r] [mg/L]I ' ILi 
A 
Males 1182 2000 1.0 4854 8631 147 307 37 
(n=8) (1 6%) (21 %) (0.8-1.0) (64%) (75%) ' (27%) (40%) (15 %) 
Females 1'056 2021 1.0 373). 7018 157 275 27 
(n=8) (1 4%) (21 %) (1.0-1.3) (24%) (21 %) 
' 
(18%) (34 %) (15%) 
AU lUIJ 20iJ.O 1.0 4292 7fi90 152 291 32 
(n=l6) (16%) (20%) (0 .8-1 .3) (53%) (58%) (22%) (37 %) (21 %) 
B 
Males 1048 1094 6.0 5960 6243, 195 503 62 
(n=8) (16%) (15 %) (5 .0-6.3) (22 %) (23 %) (1 5 %) (38%) (9 %) 
Females lOU 1189 6.0 5396 6.397 176 408 50 
(m=8) ( 18%) (13 %) (6 .0~.3) (24%) (25%) (1 5 %) (53%) (1 4%) 
All ' 1029 U42 6.0 5678 6320 185 456 56 
{n=l6) (16%) (17 %) (5.0~.3) (23%) (23%) (15 %) (44%) 0 6 %) 
C 
Males 1286 U72 l.O 9835 8'984 203 400 22 
(n = 8) (16%) (20%) (L0-6 .0) (25 %) (29%) (29 %) (51 %) (24%) 
Females 1253 1269 1.0 10253 10283 197 512 2n 
(n=8) (12%) (1 6 %) (0 .8-6.0) (26%) (25 %) (34%) (57 %) (37 %) 
All 1269 1220 1.0 li0044 %33 200 456 21 
(n=8) (14%) (18 %) (0 .8-6.,0) (25 %) (27%) (30%) (55 %) (30%) 
I : T ..... e~pressed as Medlian (Range) 2: Dose-correc1ed C.... 3: Dose-oorrected AUC... 
Table 4. 13 Mean (%COV) Comparnnental Pha.rm.acokinetic parameters by gender for cross.over phase of intravenous 




v.,... Km Vdc k 12 b1 Vdss 




Males 318 267 25 1.00 1.45 44 0.59 
(n = 8) (28%) (39%) (26%) (27%) (51 %) 0 8%) (15%) 
Females 314 215 21 0.96 2.53 32 0.50 
(n=8) (16%) (37%) (22 %) (43 %) (65%) (23%) (9 %) 
AU 316 24.1 23 0.98 l.99 38 0.54 
(n= 16) (22%) (39%) (25 %) (34%) (68%) (25 %) I (15%) 
B I 
Males 35' 284 29 0.68 2.45 40 0.54 
(n=8) (24%) (37%) (8%) (55 %) (59%) (1 7 %) (13%) 
Females 35' 232 23 1.06 3.9'2 30 0.47 
(n= 8) (22%) (31 %) (27 %) (69%) (52%) (15 %) (9%) 
AU 35' 257 u 0.87 3.18 3S O.Sl 
(n= 16) (22%) (35%) (21 %) {68 %) (59%) (22%), (14%) 
C 
Ma.Jes 361 284 25 0.82 1.85 38 0.51 
(n=8) (24%) (26%) ( 14%) (26%) (58%) (16%) (13 %) 
Females 378 240 18 1.19 2.28 28 0.45 
(n=8} (17 %) (22%) (25 %) (41 %) (53%) (15 %) (1 1%) 
All 3701 262 22 1.00 2.06 .33 0.48 
(n= 16) (20%) (25%) (24%) (41 %) (55 %) (21 %) (14'%) 
I: body weight-corrected Vdss 
Table 4. l4 Mean Compartmental PK parameter estimates across treannears for males (M) and Females (F) for intravenous 
ethanol study 
Vmv. Km k12 la1 Vdss 
[mg!Uhr] [mg/LI [hr·•1 [hr"'] [L] 
M F All M F All M F All M F All M F ALI 
' 
Overall Mean 345 350 347 279 229 254 0.83 1.07 0.95 1.92 2.91 2.41 41 30 35 
I 
lnter- I 
Individual 25% 19% 22% I 33% 29% 33% 31% 51% 48% 60% 60% 64% l7% 18% 23% 
variability I 
II (%COY) I 
' 
lncra-
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ABSTRACT 
PHARMACOKINETICS AND PHARMACODYNAMICS OF ETHANOL IN 
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Department of Pharmacy and Pharmaceutics 
The goal of this project was to investigate the effect of input-rate (oral and intravenous) 
and degree of exposure on the pharrnacok:inetics of ethanol and on subjective and 
objective measures of impairment, as well as on the development of acute tolerance to 
the effects of ethanol in young, healthy volunteers. 
The primary objective of this research was to test the following hypotheses: 
1) the rate and degree of ethanol exposure (oral and intravenous) in normal healthy males 
and females affect the pharrnacok:inetics (PK) and pharrnacodynarnics (PD) of ethanol in 
a non-linear fashion; 2) the EEG changes after ethanol administration correlate with 
changes in psychometric performance and subject-rated impairment, as well as serum 
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ethanol concentrations; and 3) acute tolerance develops to the subjective effects of ethanol 
which is IW1 reflected in changes in electroencephalographic (EEG) activity or 
psychometric performance. 
This study was conducted in two parts. Part I was a five-way crossover pilot study in six 
healthy male volunteers to evaluate the effect of dose and dose-rate on the PK and PD 
of ethanol. This study evaluated changes in EEG activity, psychometric performance and 
subjective impairment to evaluate the relationship between these subjective and objective 
measures, and the relationship between these measures and serum ethanol concentrations. 
Part II was a 4-way crossover study in 16 healthy male and female subjects to study the 
PK-PD relationship for intravenous (IV) ethanol and acute tolerance development to the 
effects of ethanol. In this study, subjects were administered individualized intravenous 
ethanol infusions, to achieve a target concentration of 1000 mg/L after different durations 
of exposure. This study was designed to i:nvestigate the PK of ethanol, as well as to 
assess changes in EEG activity, psychometric performance and subjective impairment. 
This study evaluated the relationship between these measures, and the relationship 
between these measures and serum ethanol concentrations, as well as the delevopment 
of acute tolerance to the effects of ethanol. 
Results from both studies showed that: 1) Ethanol, after oral and intravenous 
administration, follows capacity-limited pharmacokinetics. Intrinsic PK parameters, V max• 
K,,, and Vd were independent of dose and input-rate, but were associated with fairly high 
inter-individual variability. 2) Ethanol, after oral and intravenous administration, induced 
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a transient slowing of the EEG and impairment in psychometric performance. The 
magnitude of the changes in these measures appeared to be dose-related as well as input-
rate-related (observed in the IV study), however there was a fairly large degree of 
variability in response between individuals. 3) Ethanol, after oral and intravenous 
administration, induced transient subjective impairment, which was dose-related and 
input-rate-related, and correlated with serum ethanol concentrations across treatments. 
4) A subset of subjects (2/6 males in the oral ethanol study, and 2/8 males and 4/8 
female subjects in the IV study) were classified as "non-responders" based on their lack 
of subjective response to ethanol, despite serum ethanol concentrations, psychometric 
impairment and EEG changes that were consistent with the other subjects. S) There was 
significant exposure-related acute tolerance development to the subjective effects of 
ethanol observed in both studies. This acute tolerance development could be characterized 
by a PK-PD model incorporating tolerance as a compensatory feedback mechanism to 
counter-regulate the direct subjective impairment effect of the drug. Acute tolerance was 
not observed for the psychometric impairment or changes in EEG activity, indicating 
that there was a temporal disparity be~een objective and subjective impairment 
following ethanol administration . 6) The EEG changes were not correlated with the 
psychometric or subjective impairment. 7) There was a significant gender difference 
observed in the Cm.ax and Vd~ for ethanol, probably due to gender differences in body 
weight and body water content. There was also a significant gender difference observed 
in the magnitude of ethanol-induced subjective impairment, with females showing a lower 
degree of subjective impairment, despite achieving similar concentrations and 
demonstrating similar psychometric impairment and EEG changes. This gender difference 
may be partly confounded by the larger proportion of female "non-responders" compared 
to the male "non-responders" in the study. 
CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1 INTRODUCTION 
Ethanol is probably the most widely used drug in the world. It is commonly self-
prescribed rather than prescribed by a clinician and the dose detennined either by 
tradition , social context or the achievement of a pharmacological end-point (self-titration) 
(Holford, 1987). Almost no other substance has been as comprehensively investigated as 
ethanol, not only because it is one of the oldest and most ubiquitous abused "drugs" in 
human history, but also because of its unique dynamic and kinetic behavior (Martin et 
al. , 1984). Although considered at one time (in the Middle Ages) as the "elixir of life", 
it is now recognized that the therapeutic value of ethanol is extremely limited and that 
chronic ingestion of excessive amounts presents a major social and medical problem 
(Rall, 1990). 
1.2 BACKGROUND 
1.2.1 Pharmacokinetics of Ethanol 
Ethanol is unusual among drugs in several aspects of its pharmacokinetics. Particularly 
·l 
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striking is the great biological inter-subject variability in alcohol consumption patterns 
as well as in alcohol elimination, in the pattern of short-term fluctuations of serum 
ethanol concentrations, and in the partitioning of alcohol between the blood and other 
body fluids and tissues even at equilibrium (Dubowski, 1985). 
Absorption 
After oral ingestion, it is almost completely absorbed, primarily from the small intestine, 
by passive diffusion (Holford, 1987; Wilkinson et al., 1977). Ethanol ingested on an 
empty stomach is very rapidly absorbed with peak serum concentrations occurring 
between 30 to 90 minutes. The rate of alcohol absorption after oral administration is 
greatly influenced by the nature and concentration of the alcoholic beverage (O'Neill et 
al., 1983; Dubowski, 1987; Wilkinson, 1977), the rate of ingestion (O'Neill et al., 
1983), the fed or fasted state (Sedman et al. , 1978), the nature and composition of food 
(Sedman et al., 1978), as well as a multitude of other physical, biological, psychological, 
and temporal factors. Several studies have investigated the effect of these factors , either 
individually or in combination, on the peak. concentration of ethanol achieved as well as 
the time of peak concentration. These studies have revealed the following: 
1) Highly concentrated solutions of ethanol, when ingested, are relatively slowly 
absorbed, because of the inhibitory effect of these high concentrations on gastric 
emptying, thus delaying the arrival of the ethanol in the small intestine where most of 
the absorption occurs (Dubowski, 1983; Wilkinson et al. , 1977). 
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2) Large volumes of very dilute solutions are also absorbed relatively slowly, possibly 
due to the slowing effect of the volume on gastric emptying rate (Hunt and Macdonald, 
1954; Wilkinson et al. , 1977). 
3) Food has a large effect on ethanol absorption. Both the nature of the food (solid or 
liquid), as well as the composition of the food (carbohydrate or fat or protein) are 
important determinants of the peak ethanol concentration. The concomitant ingestion of 
various foods with ethanol results in lower peak concentrations and increased time to 
peak concentration. It is postulated that this effect is also mediated by the delaying of 
gastric emptying time resulting from the in~e of carbohydrate or fatty foods (Sedman 
et al., 1978). 
Wilkinson et al. (1977) have successfully developed a PK model, incorporating gastric 
emptying as a first-order process from the stomach to the small intestine along with first-
order absorption from the intestine into the body compartment and capacity-limited 
elimination from the body compartment, to describe the ethanol-concentration profiles 
obtained following oral administration of ethanol to healthy male volunteers. 
Distribution 
The distribution of ethanol throughout the body is largely governed by the water content 
of various organs and tissues, especially · at equilibrium, since it is a small, polar, 
completely water soluble molecule. The volume of distribution of ethanol is comparable 
to total body water, which is about 60% of body weight (Marshall et al., 1984; Holford, 
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1987). No plasma protein binding has been reported for ethanol. 
Elimination 
Elimination of ethanol occurs primarily through metabolism with minute fractions of the 
administered dose being excreted in the breath (0.7%), sweat (0.1 %), and urine (0.3%) 
(Holford, 1987). Metabolism primarily occurs in the liver via enzymatic oxidation by 
alcohol dehydrogenase to acetaldehyde (Lunquist and Wolthers, 1958; Wagner et al., 
1976; Rall, 1990). 
For the first half of this century, the classical view of ethanol kinetics in humans was that 
the elimination of ethanol occurred at a constant rate and was independent of the 
concentration of ethanol in the body. In 1933, Widmark developed an equation, based 
on zero-order kinetics, to describe the ~ncentration-time relationship for ethanol 
(Wilkinson , 1980). The use of this zero-order model was widespread until 1958, when 
Lunquist and Wolthers (1958) first proposed that the Michaelis-Menten model for enzyme 
kinetics could be used to describe the elimination of ethanol in humans. In this model, 
elimination by a particular enzyme system is characterized by the elimination capacity, 
i.e., the maximum elimination rate (V.,.J, and the concentration at which the enzyme 
system metabolizes its substrate at 50% of the elimination capacity (1(...). For many drugs 
that are metabolized, typical (therapeutic) concentrations are low relative to the K.n, and 
the elimination can be parameterized by a single PK parameter, i.e. , clearance (apparent 
first-order elimination). Ethanol is unusual because "typical" concentrations are in excess 
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of the K,,,, and both V aw and K,,, must be known to determine the elimination rate. The 
elimination rate is non-linearly related to the concentration, and the elimination is 
considered to be capacity-limited. When concentrations are much higher than the K,,,, the 
elimination approaches V aw and the elimination rate is approximately zero-order, i.e. , 
the elimination rate is independent of the ethanol concentration. When concentrations are 
below the K,,,, the elimination rate approximates a first-order process. 
Several investigators (Wagner et al., 1976, Wilkinson et al., 1976, Wilkinson et al., 
1977, Rangno et al., 1981) have used PK models incorporating capacity-limited 
elimination models, using PK parameters, V aw and K,,,, to describe the overall 
elimination process for ethanol. Some investigators have attempted to fit models 
incorporating parallel first-order pathways of elimination to ethanol-concentration-time 
data to include the contribution of the fractions excreted in urine, breath, and sweat to 
the overall elimination process (O'Neill et al., 1984; Wilkinson, 1980; Holford, 1987). 
One-compartment models with capacity-limited elimination are most commonly used to 
describe the ethanol concentration vs. time profile, although investigators have used two-
compartment models to incorporate the rapid distribution phase that is observed, 
especially after intravenous infusions of ethanol (Hartman et al., 1988). 
Mean population estimates for the PK parameters for ethanol elimination, from studies 
done in young healthy males, are 8.5 g/hr/70 kg for V aw, 80 mg/L for K,,,, and 37 
U70kg for Vd (Holford, 1987). There is considerable variability in the estimates of K,,, 
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from different studies (Holford, 1987). This may be a consequence of the differences in 
sampling schedules of terminal sampling time points, when concentrations are less than 
or equal to the K,.,. This may also be due to differences in the limit of quantitation of the 
different analytical methods used for the analysis of ethanol in various biological fluids, 
such as gas chromatography (Wilkinson et al., 1975), enzymatic methods (Poklis and 
Mackell, 1979), immunoassay methods (Cary et al., 1984; Abbott TDx Manual, 1995), 
as well as the estimation of ethanol concentrations in breath (Harger et al., 1950; Mason 
and Dubowski, 1976). 
Factors affectio& ethanol pharmacokinetics 
In addition to the factors affecting the absorption of ethanol listed above, the oral 
absorption of ethanol depends on other factors including the dose (Wagner et al., 1976; 
Pikaar et al., 1988; Wagner and Patel, 1972) and the rate of ingestion (Dubowski, 1985; 
O'Neill et al., 1983) as well as individual factors such as gender, body-weight and body 
composition (Sutker et al., 1987; Marshall et al., 1983). Since ethanol follows capacity-
limited elimination kinetics, an increase in dose results in a disproportionate increase in 
serum concentration and area under the curve (a measure of systemic exposure). 
However, the intrinsic pharmacokinetic parameters V 111&1 and K,., are thought to be 
independent of dose. The rate of input can also affect the peak concentration and time 
of peak concentration as described earlier. However, the rate of ingestion would not be 
expected to influence the intrinsic pharmacokinetic parameters for ethanol. 
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Factors that influence ethanol elimination include ethanol intake, food, other drugs, 
gender, body weight, body composition, as well as genetic influences (Wilson et al. , 
1984; Thurman et al ., 1989; Frezza et al. , 1990; Sedman et al. , 1978; Pikaar et al. , 
1988; Lane et al. , 1985; Holford, 1987; Marshall et al. , 1983). 
Acute ethanol intake can affect the elimination rate of ethanol as shown by the study by 
Wilson et al. (1984) who demonstrated an increase in the elimination rate for ethanol 
following the administration of a second dose during the elimination phase of the first 
dose administered a few hours earlier. This may be explained in part by an increase in 
hepatic blood flow since ethanol has been shown to increase hepatic blood flow and 
therefore could increase its own elimination (Mendeloff, 1954). The effect of chronic 
ethanol use on the pharmacokinetics of ethanol has been the subject of some debate 
because studies in humans are difficult to interpret due to inadequately controlled factors 
such as duration and quantity of chronic exposure. One study that observed the effect of 
several weeks of ethanol consumption in non-alcoholic subjects on the pharmacokinetics 
of ethanol found that the elimination rate ·was not significantly altered after 45 g/day 
ethanol consumption for 3 weeks (Holtzman et al., 1985). However, since the authors 
used rero-order pharmacokinetic models to estimate the ethanol elimination rates, these 
results should be interpreted with some caution. 
Food, especially that rich in fat or carbohydrates, also appears to reduce the elimination 
parameters for ethanol, as demonstrated by Sedman et al. (1978). However, since these 
foods may also affect hepatic blood flow which could have affected the estimates of K,,. 
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and V ,...., this may be a confounding factor in the interpretation of the studies done by 
Sedman et al. (1978). 
Although there are several studies investigating the effect of ethanol on other drugs 
administered concurrently (Lane et al., 1985), there are few studies evaluating the effect 
of other drugs on ethanol pharmacokinetics or pharmacodynamics. Studies have 
demonstrated the lack of effect of drugs such as cimetidine and ranitidine on ethanol 
elimination (Holtzman, 1985), while studies evaluating the influence of nicotine and 
smoking on ethanol elimination have demonstrated that ethanol elimination rates were 
increased by 20% in subjects who drank but did not smoke, and by 45% in subjects who 
drank and smoked compared with subjects who did neither (Kopun and Poping, 1977). 
One study evaluating the effect of oral contraceptives on ethanol pharmacokinetics 
reported that ethanol elimination rates in women who used oral contraceptives were about 
20% lower than in women who did not use oral contraceptives (Jones and Jones, 1984). 
Although the subjects in both groups were matched for weight, the subjects in the 
contraceptive group had 11 % lower peak concentrations. This may reflect differences in 
volumes of distribution between the two groups and may account, in part, for the 
differences in elimination rates observed between the two groups in this study. In 
general, the influence of interacting drugs· and diseases on ethanol disposition has not 
been studied systematically, and the only studies performed to date have several 
limitations that makes the interpretation of the results somewhat problematic. 
Gender and body-weight differences have been implicated as significant determinants of 
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ethanol disposition in several studies (Sutker et al., 1987; Marshall et al. , 1983; Radlow 
and Hurst, 1985). A study by Marshall and his colleagues in 1983 investigating the 
elimination of ethanol in male and female subjects reported that females achieved 
significantly higher peak serum ethanol concentrations and areas under the curve than 
males following oral administration of 0.5 g/kg ethanol. The authors also reported that 
women had a significantly lower volume of distribution than male subjects, although their 
elimination rates were similar. However, this study used zero-order kinetic analysis. In 
this study, the investigators demonstrated that the apparent volume of distribution was 
significantly correlated with total body water (measured using a tritiated-water dilution 
method) suggesting that the gender differences in ethanol pharmacokinetics are secondary 
to gender differences in body water content. Since ethanol distributes into total body 
water, women have smaller volumes of distribution for ethanol than men and therefore 
achieve higher peak concentrations for a given dose of ethanol than men. 
Another study reported that differences in peak concentrations following equivalent doses 
of ethanol administered to men and women were due to differences in first-pass 
metabolism of ethanol in the gastrointestinal tract, which was significantly correlated with 
gastric alcohol dehydrogenase activity (Frezza et al., 1990). The investigators concluded 
that females have lower gastric alcohol dehydrogenase activity resulting in a lower degree 
of first-pass metabolism and therefore in higher concentrations compared to males. 
However, some studies have demonstrated no differences in the first-pass metabolism of 
ethanol between males and females (Ammon et al., 1996). 
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1.2.2 Pharmacodynamics of Ethanol 
Pharmacodynamics, or the relationship between drug concentration in the systemic 
circulation and pharmacological effect(s), has been the subject of numerous studies. 
Understanding this relationship is important because it contributes to the inter-individual 
variability observed in drug response. In general, determining the relationship between 
drug concentration and response is also necessary for optimization of drug therapy. 
Studies of the pharmacodynamics of centrally acting drugs have been limited by the 
difficulty in obtaining quantitative measures of CNS response (Dingemanse et al., 1988). 
In general, measures of drug effect used in pharmacodynamic studies should be 
quantitative, objective, non-invasive, reproducible (both within and between individuals), 
and sensitive to changes in drug concentration. The measure should also have some 
relationship to the therapeutic or toxic clinical effects of the drug (Slattum, 1992). The 
following sections discuss some of the pharmacodynamic measures that have been used 
to characterize the pharmacodynamics of e~anol. 
1.2.2a Neuropharmacology of Ethanol 
Ethanol is considered to be a central nervous system (CNS) depressant and its responses 
characteristically include euphoria, impaired thought processes, and decreased mechanical 
efficiency (Evan et al., 1974). Although alcoholic drinks are viewed as stimulating, this 
apparent stimulation is a result of depression of the inhibitory control mechanisms of the 
brain (Rall, 1990). However, as intoxication becomes more advanced, there is 
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progressive depression of CNS function that can ultimately lead to respiratory depression, 
coma and even death. 
For many years it has been thought that ethanol, like volatile anesthetics exerts its 
depressant effects on the CNS by perturbation of the neuronal membrane lipids (Rall, 
1990; Tabakoff and Hoffman, 1987; Dietrich et al., 1989). This membrane hypothesis 
of the mechanism of action of ethanol has been widely accepted, and other studies have 
since refined this hypothesis resulting in the view that the interactions of ethanol are 
specific to certain regions of the membrane, reflecting the nonunifonn distribution of 
integral membrane proteins (Tabakoff and Hoffman , 1987). Ethanol also has selective 
effects on specific membrane bound enzyme systems, such as selective inhibition of the 
monoamine oxidase enzyme system (Tabakoff et al., 1985), and enhanced sensitivity of 
neuronally localized Na+, K+ -A TPase (Marks et al. , 1984). Ethanol has also been shown 
to interact with specific neuroreceptors and receptor-effector coupling systems, including 
activation of catecholamine receptor-associated adenylate cyclase in the brain (Luthin and 
Tabakoff, 1984; Saito et al. , 1985), inhibition of binding of ligands associated with the 
chloride channel complex of the GABA receptor (but not the binding of GABA or 
benzodiazepines to their receptors) (fhyagarajan and Ticku, 1985), and suppression of 
the excitatory effects of endogenous glutamate at the NMDA receptor (Deitrich et al., 
1989). However, all these effects were observed in animal models or in-vitro systems, 
and the relationship between the effect of ethanol on these systems and the observed 
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behavioral effects of ethanol in humans are somewhat unclear and remain to be 
unravelled. 
l.2.2b Effects on psychometric performance 
Psychometric performance tests have been used to assess the pharmacodynarnics of 
several centrally-acting drugs, including ethanol (Hindmarch, 1980). These psychomotor 
tests provide a non-invasive and quantitative measure of motor and cognitive function and 
allow comparison between different drugs or between different doses of the same drug 
(Hindmarch, 1980). Studies evaluating the:se effects of centrally-acting drugs measure 
drug-induced changes in various aspects of human performance, including cognition, 
attention, memory and motor aspects. These studies also attempt to determine the 
physiological mechanisms that have been altered by these drugs, including neurochemical 
effects, changes in cerebral blood flow and ~terations in patterns of neuroelectric activity 
(Wesnes et al., 1987). A large number of tasks have been used to evaluate the cognitive 
effects of drugs ranging from the ability to rapidly tap a stylus to simulated car driving. 
The introduction of computerized psychometric testing procedures has resulted in a wider 
range of tests that are able to measure different aspects of performance with a high 
degree of sensitivity (Wesnes et al. , 1987). In order for these tests to be optimally used 
in pharmacodynarnic studies of psychoactive drugs, they should be sensitive to both 
impairment as well as improvement in performance produced by the drug, provide 
quantitative measures of effect, be sensitive to small changes in drug concentration, and 
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should be reproducible, both within and between subjects. The tests should measure both 
cognitive and motor aspects of psychometric perfonnance and should include some 
aspects of functioning that have relevance and importance for daily behavior (Slattum, 
1992). 
However, psychometric tests can sometimes be limited in that they may be prone to 
subjective influences such as learning, motivation, and fatigue, which can affect their 
reproducibility and sensitivity. Also, the relationship between changes in perfonnance on 
the psychometric tasks and the behavioral and psychological effects of the drug are 
sometimes difficult to define (Hindmarch, 1980, Slattum, 1992). 
There is considerable interest in evaluating the effects of ethanol on human perfonnance, 
especially as it relates to the problems associated with drunk driving (Irving and Jones, 
1992). Some studies have been done to ~rrelate the dose or concentration of ethanol 
with impairment in reaction time and cognitive ability to determine what amounts or 
concentrations would be considered unsafe and illegal from a medicolegal perspective 
(Dubowski , 1977;. Irving and Jones, 1992). 
Alcohol has been shown in several studi~s to produce impainnent of psychometric 
function assessed by various tests including tracking, digit symbol substitution, reaction 
time, body sway, hand steadiness and finger tapping (Evan et al., 1974; Sidell and Pless, 
1971; Fagan et al. , 1987; Idestrom and Cadenius, 1968; Wittenborn, 1987). In these 
studies alcohol has been shown to decrease speed and accuracy of performance and 
increase errors in performance consistent with psychomotor impai.rment. 
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In a review of psychometric tests in psychopharmacology (Wittenborn, 1987), the author 
has summariz.ed the different tests used to study the psychometric performance effects 
of ethanol. The results show that alcohol showed impairment effects in 20 out of 22 tests 
that were compared, indicating that alcohol produces significant impairment of 
psychomotor performance and that psychometric tests are sensitive measures of the 
effects of ethanol. 
There are very few studies, however, that have attempted to determine the temporal 
relationship between alcohol concentration and psychometric impairment. Also, there are 
very few studies evaluating the effect of factors such as dose, rate of input (or ingestion), 
or degree of exposure, as well as factors such as age, gender, or interacting drugs, on 
this relationship (Moskowitz et al., 1976, Tabemer, 1980). 
l .2.2c Effects on mood and subjective state 
Most psychoactive drugs, including ethanol, produce changes in mood and perception of 
subjective states. These changes in mood and perception can be measured using various 
scales. These scales are primarily of two types: self-rated or observer-rated, depending 
on the user. These scales can be constructed as questionnaires with multiple choice 
responses, or as visual analog scales. Visual analog scales usually consist of a line with 
its ends defined by the extremes of the variable to be measured, for e.g., "not at all" to 
"extremely" for the variable "DRUNK" on an alcohol impairment scale, and individuals 
makes a mark on the line corresponding to his/her present state with respect to that 
15 
variable. Visual analog scales have been used in several studies to measure drug-induced 
changes in mood and subjective states (Bond and Lader, 1974). They have the advantage 
in that they are easy and quick to complete, easy for the investigator to score, can be 
used repeatedly and reproducibly (Bond and Lader, 1974; Slattum, 1992). They are less 
subject to motivational and learning effects, although they can be subject to fatigue or 
boredom effects if measured too frequently. They do require subject co-operation and 
thus could be difficult to complete in very sedated to hyperactive subjects (Slattum, 
1992). 
Ethanol has been studied by investigators interested in its behavioral effects. The 
detrimental effects of alcohol on human performance as well as on subjective measures 
of impairment are well documented (Begleiter and Platz, 1972; Jones and Vega, 1973; 
Moskowitz and Burns, 1976; Schuckit, 1984). Ethanol produces numerous mood effects 
ranging from increased alertness to relaxation and a state of well-being or euphoria 
(Ekman Get al., 1963; Lukas et al. , 1986). These behavioral effects have been measured 
by various subjective visual analog scales including the Subjective High Assessment Scale 
(SHAS) (Shuckit and Gold, 1983; Lex et al., 1988), Drug Effects Questionnaire (DEQ) 
(de Wit et al., 1990), various versions of the Profile of Mood states (POMS) (McNair 
et al., 1971; deWit et al. , 1990; Nagoshi et.al., 1992), the State-Trait Anxiety Inventory 
(STAI) (Sutker et al., 1987), various versions and sub-scales of the Addiction Research 
Center Inventory (Hill et al., 1963; Turkkan et al., 1988), and a multitude of empiric 
scales derived from the above-listed scales (Kaplan et al., 1985; Radlow and Hurst, 
16 
1985; Gengo et al., 1990). 
These studies also show that ethanol produces dose-related changes in subjective 
measures of intoxication, perceived impairment and sedation. These scales have been 
shown to be fairly sensitive to the effects of ethanol on subjective state and mood. 
l .2.2d Effects on electroencephalography · 
Quantitative EEG is being increasingly used to study the pharmacodynamics of 
psychoactive drugs (Dingemanse et al., 1988; Fink, 1982; Kroboth et al., 1988; Slattum, 
1992; Jagannathan, 1995). The EEG provides an ongoing record of the neuroelectric 
activity of the brain, either in the resting state or under different activation procedures 
(e.g., repetitive photic stimulation, drug administration etc.). Although the scalp-recorded 
EEG is an overall measure of brain activity, it provides one of the best and most direct 
measures available for assessing the functional state of the CNS (Begleiter and Platz, 
1972). Quantitative EEG is objective and non-invasive, and derived parameters change 
gradually with changes in plasma drug concentrations. Repeated or continuous measures 
of the EEG can be made, although a familiarization session before the study is advisable 
to avoid a first-session effect due to anxiety (Fink and Irwin, 1983; Slattum, 1992; 
Jagannathan, 1995). There are several environmental factors that can influence the results 
of studies evaluating the EEG as a quantitative measure of drug effect (Sannita, 1990). 
The ability to monitor ongoing neuroelectric activity allows for the investigation of the 
relationship between subjective states, behavioral changes, and electrophysiological 
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activity of the CNS at baseline as well after administration of a psychoactive drug such 
as ethanol. Of particular interest is the question whether alcohol-induced EEG changes 
parallel the gradual ethanol-induced changes in subjective and behavioral responses 
(Begleiter and Platz, 1972). 
Studies investigating the effects of acute ·ethanol administration on the adult human 
electroencephalogram (EEG) have been generally consistent (Ehlers et al., 1989; Ehlers 
and Shuckit, 1990). Most studies report an increase in EEG amplitude, particularly in 
the alpha band (8 to 12 Hz) and a slowing of the dominant alpha frequency following low 
to moderate doses of ethanol (Begleiter and Platz, 1972; Lukas et al., 1986; Ehlers and 
Shuckit, 1989, Ehlers and Shuckit, 1991 , Kaplan et al., 1988). After the ingestion of 
larger doses, an increase in lower frequencies (delta: 0 to 4 Hz, and theta: 4 to 8 Hz) is 
observed and is associated with profound sedation (Ehlers and Shuckit, 1991; Lukas et 
al., 1986, Lukas and Mendelson, 1986). Studies have also emphasized a large degree of 
individual variability in responses to alcohol (Lehtinen, 1978, 1985). The studies 
evaluating the effects of ethanol on the EEG are limited in that they were primarily 
aimed at evaluating EEG responses as objective measures to identify populations at risk 
for alcoholism rather than evaluating the EEG as a pharmacodynamic measure. Thus, 
these studies did not evaluate the complete time course of the ethanol-induced EEG 
changes. Most studies evaluated initial effects during the first two hours after ethanol 
administration. 
Several factors have been shown to modify the acute response in individuals following 
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ethanol administration including quantity and frequency of drinking (Cloninger et al., 
1984), family history of alcoholism (Shu~kit, 1984; Pollock et al., 1986), individual 
differences in ethanol metabolism (Zeiner et al. , 1979), as well as the baseline (pre-drug) 
EEG activity (Ehlers et al., 1989). There are several reports of studies evaluating 
differences in EEG activity (both at baseline and following ethanol administration) in 
subjects at risk for alcoholism, but these studies have generally been inconclusive and 
inconsistent (Cohen et al., 1990; Ehlers et al., 1990; Pollock et al., 1983). 
1.2.3 Acute tolerance development to effects of ethanol 
The phenomenon, of decreased effect with prolonged exposure to a drug is called 
tolerance (Porchet et al., 1988). When the tolerance develops within the time course of 
a single dose, it is called acute tolerance or tachyphylaxis. Development of acute 
tolerance has been recognized for a number of drugs, including centrally-acting drugs 
such as cocaine (Chow et al., 1985; Ambre et al., 1988), caffeine (Shi et al. , 1993), 
morphine (Ekblom et al. , 1993, Ouellet and Pollack, 1995)) and nicotine (Porchet et al. , 
1988). Tolerance development may be related to changes in the number of receptors in 
the target tissue (down-regulation), decreased receptor-effector coupling, depletion of 
secondary endogenous messengers, and/or a physiological adaptation by counter-
regulatory feedback systems (Danhof and Mandema, 1994). 
Acute tolerance to alcohol was first described by Mellanby, who reported a lower 
impairment at a given ethanol concentration in the descending limb of the ethanol 
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concentration-time curve than at the same. concentration in the ascending limb of the 
curve (Genga et al . , 1990). Since then, several studies have characterized the 
development of acute tolerance to single doses of ethanol (Goldberg, 1943; Moskowitz 
et al. , 1976; Vogel-Sprott, 1979; Radlow and Hurst, 1985; Jones and Vega, 1972). 
However, there are also reports describin.g the lack of tolerance to alcohol's effects 
(Genga et al., 1990; Wilson et al., 1984; Kaplan et al., 1985; Sidell et al., 1971; 
Linnoila et al., 1978; Pishkin et al., 1983; Rohrbaugh et al., 1987). 
One explanation for this inconsistency may be the endpoint used to measure the 
pharmacological effects of ethanol. Endpoints that measure subjective perception of 
intoxication, such as those used by Radlow and Hurst (1985) and Jones and Vega (1972), 
indicate the development of acute tolerance. In general, data from studies measuring 
subjective assessments are consistent with the development of acute tolerance. The 
opposite conclusion is reached when objective psychological functions are assessed, such 
as the psychometric tests used by Kaplan et al. (1985) and Rohrbaugh et al. (1987), 
among others. Gengo et al. (1990) observed that subjective impairment effects following 
ethanol administration were lower during the declining phase of the concentration-time 
profile relative to the effects during the ascending phase of the concentration-time profile, 
whereas scores on the Digit Symbol Substitution Test (DSST), a psychometric test, were 
similar at comparable concentrations on the ascending and descending limbs of the 
concentration-time profile. Generali y, stud~es measuring psychomotor perfonnance fail 
to show significant acute tolerance to ethanol. 
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Other factors that may influence the development of acute tolerance include the rate and 
direction of change of concentration and the degree and rate of prior exposure to ethanol. 
Gender, age and previous ethanol use may also be contribution factors, however, they 
have not been studied in a rigerous manne~. 
Several paradigms can be used to study the development of acute tolerance to the effects 
of drugs, especially alcohol. One method is to compare effects at the same concentrations 
during the ascending and descending limbs of the alcohol concentration-time curve (Jones 
et al. , 1972; Gengo et al., 1990). Another IJlethod is to compare the responses following 
the administration of paired IV infusions of the drug separated by different intervals of 
time, such as the method used by Porchet et al. (1988) for nicotine and by Shi et al. 
(1993) for caffeine. In such a paradigm, a decrease in the response following the second 
infusion relative to the first infusion can be interpreted as the development of acute 
tolerance. 
Yet another method is to study the time course of the effects of ethanol at "steady-state", 
i.e. , when concentrations in the body are constant. In such a paradigm, a diminution of 
the effects of ethanol, despite maintenance of constant plasma (or serum) concentrations, 
can be interpreted as the development of acute tolerance. A dosing regimen can be 
designed to control the rate of input such that levels can be maintained fairly constant 
over prolonged durations. Intravenous administration of ethanol can provide good control 
of the input rate, which is critical to the achievement of these constant levels. The study 
by Kaplan et al. (1985) is the only study found that used this approach. In this study, 
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ethanol was administered orally to achieve a breath ethanol concentration equivalent to 
a serum ethanol concentration between 800 and 1000 mg/L, then a maintenance dose was 
given every 30 minutes to maintain the alcohol concentration at that level for 6 hours. 
Several measures, including postural sway, manual tracking, word recall test (a measure 
of cognitive ability), as well as subjective measures of intoxication using visual analog 
scales, were evaluated. The results from this study indicated that ethanol resulted in 
psychometric impairment and subjective impairment, but no acute tolerance development 
was observe.cl to the motor or physiological effects; however, acute tolerance was 
observe.cl for the word recall test. 
Although there are several studies demonstrating the development of acute tolerance to 
the effects of ethanol, there are no studies assessing the quantitative aspects of acute 
tolerance to ethanol. In order to model the rate and extent of tolerance development, 
modifications of the classical effect model may be use.cl (Holford, 1992). Ideally, such 
a model would allow the characterization of both full and partial tolerance as well as any 
rebound effects, as well as the characterization of the time course of effect upon 
continuous as well as repeated intermittent administration. Quantitative information on 
the rate and extent of acute tolerance development can provide a description of the 
pharmacodynamic properties of particular drugs to which tolerance develops. This 
description can be use.cl to choose drug regimens minimizing the development of 
tolerance. Since many drugs of abuse, including ethanol are subject to tolerance 
development, quantitation of this tolerance development may improve the understanding 
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of the specific temporal patterns of drug abuse and related complications. 
Various phannacokinetic-phannacodynamic (PK-PD) models have been developed to 
quantitate the tolerance development for several drugs, including furosemide 
(Hammarlund et al., 1985), nitroglycerin (Bauer and Fung, 1994), cocaine (Chow et al., 
1985; Ambre et al., 1988), caffeine (Shi et al. , 1993), morphine (Ekblom et al., 1993, 
Ouellet and Pollack, 1995)) and nicotine (Porchet et al., 1988). There are however no 





The hypotheses guiding this research project are: 
1. the rate and degree of ethanol exposure (oral and intravenous) in young healthy 
males and females affect the pharmacokinetics and pharmacodynamics of ethanol 
in a non-linear fashion. 
2. the EEG changes after ethanol administration (oral and intravenous) correlate with 
changes in psychometric performance and subject-rated impairment, as well as 
serum ethanol concentrations. 
3. acute tolerance develops to the subjective effects of ethanol which is IlQl reflected 
in changes in EEG activity or psychometric performance. 
This study was conducted in two parts. Part I was a pilot study in healthy male 
volunteers to study the effect of dose and input-rate on the pharmacokinetics and 
pharmacodynamics after oral administration of ethanol. This study was a double-blind, 
placebo-controlled, five-way crossover study in six healthy male subjects. Subjects were 
administered two doses of oral ethanol (0.3 g/kg and 0.6 g/kg), each at two input- rates 
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(20 minutes and 50 minutes), and placebo. This study was designed to investigate the 
pharmacokinetics of ethanol, as well as to assess changes in pharmacodynamic measures, 
such as EEG, psychometric performance and changes in subjective measures of 
impairment, following oral ethanol administration. This study evaluated the relationship 
between these subjective and objective measures of impairment, and the relationship 
between these measures and serum ethanol.concentrations. 
Part II was a study in healthy male and female subjects evaluating the pharmacokinetic-
pharmacodynamic relationship after intravenous administration of ethanol and acute 
tolerance development to the effects of ethanol. This study was a double-blind, placebo-
controlled, four-way crossover study in sixteen healthy subjects (8 males and 8 females). 
Subjects were administered individualized intravenous ethanol infusions, at different rates 
to achieve a target concentration of 1000 mg/Lat the end of 1 hour (treatment A), at the 
end of 6 hours (treatment B), as well as to achieve the target concentration at the end of 
the first hour and to maintain that concentration at "steady-state" for the next five hours 
(treatment C). 
This study was designed to investigate the pharmacokinetics of ethanol, as well as to 
assess changes in pharmacodynamic measures, such as EEG, psychometric performance 
and changes in subjective measures of impairment, following individualized intravenous 
ethanol infusions . in a concentration-con_trolled fashion. This study evaluated the 
relationship between these subjective and objective measures of impairment, and the 
relationship between these measures and serum ethanol concentrations. This study also 
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evaluated the development of acute tolerance to the effects of ethanol, and attempt to 
demonstrate the temporal disparity between objective impairment and subjective 
impainnent. This study also examined gender differences in ethanol pharmacokinetics and 
phannacodynamics. 
2.2 RA TI ON ALE AND SIGNIFICANCE 
This research aims to assess the relationship between serum ethanol concentrations, EEG 
changes, changes in psychometric perfonnance and changes in subjective measures of 
impainnent after administration of ethanol,.both oral and intravenous, at different rates. 
This research is also aimed at examining the development of acute tolerance to the 
pharmacological effects of ethanol, as measured by these pharmacodynamic end-points. 
Of special interest is to characterize the temporal disparity between the perfonnance 
impainnent and perceived impainnent following ethanol administration to healthy 
subjects, as well as to evaluate whether ethanol-induced EEG changes correlate with 
perfonnance impairment or with subjective impairment. 
The relevance of acute tolerance, particularly in subjective effects is considerable. The 
temporal disparity between objective impairment and subjective impairment can result in 
an inability to accurately self-assess sobriety at a time when blood ethanol levels begin 
to decline. This may result in the person judging his/her impainnent at the time of 
perfonnance of tasks such as driving as not significant enough to influence their skills 
and could have a significant impact on serious problems such as drunk driving. This 
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research would allow the evaluation of a clinical paradigm to assess the time-course of 
acute tolerance development to the pharmacological effects of ethanol, including effects 
on the EEG, on psychometric performance and on perceived impairment. This paradigm 
would also allow the evaluation of the effect of input-rate and degree of acute exposure 
on the pharmacok:inetics, pharmacodynamics and tolerance development. This approach 
can be used to study the development of acute tolerance, not only to these effects, but 
also to other pharmacological effects of ethanol, such as neuro-endocrine or 
cardiovascular effects in various populations such as healthy elderly volunteers, 
alcoholics, as well as subjects at high risk for alcoholism such as children of alcoholics. 
Comparison of the differences in pharmacokinetics and pharmacodynamics of ethanol as 
well as to acute tolerance development in these populations may help to further increase 
our understanding of the inter-individual differences in sensitivity to ethanol's effects 
Recognition of the complexity of the relationships between ethanol dose, time and 
pharmacological effects is essential for the development of a paradigm for measuring the 
influence of factors such as gender, age and concomitant drugs on the effects of ethanol. 
Ethanol can also be viewed as a model CNS depressant for the evaluation of objective 
PD end-points, such as EEG, psychometric tests and subjective measures of mood and 
behavior, as well as other end-points such as neuro-endocrine concentrations and 
cardiovascular responses for ethanol and other psychoactive drugs in order to correlate 
these surrogate measures with concentration or dose. 
CHAPTER 3 
ORAL ETHANOL STUDY 
3.1 SPECIFJC AIMS 
The specific aims of this study were: 
(1) To investigate the phannacokinetics and pharmacodynarnics following administration 
of two single, escalating doses, each at two different dose rates, of oral ethanol in 
healthy male subjects. 
(2) To assess changes in objective measures of impairment viz., EEG and psychometric 
performance, as well as subjective measures of impairment after oral ethanol 
administration. 
(3) To examine the relationship between changes in the objective measures and subjective 
measures of impairment, and the relationship between these measures and serum ethanol 
concentrations. 
3.2 STUDY DESIGN 
This study was a randomized, double-blind, placebo-controlled, five-period crossover 
study in six (6) healthy male volunteers. The start of each study period was separated by 
a washout period of at least 1 week. Subjects received one of the following five 
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treatments during each study period: 
Treatment A: ethanol 0.3 g/kg body weight administered over 20 minutes (low-fast); 
Treatment B: ethanol 0.6 g/kg body weight administered over 20 minutes (high-fast); 
Treatment C: ethanol 0.3 g/kg body weight administered over 50 minutes (low-slow); 
Treatment D: ethanol 0.6 g/kg body weight administered over 50 minutes (high-slow); 
and 
Treatment E: placebo. 
Each subject was assigned to one of the three randomization sequences listed in table 3.1 
by an unblinded pharmacist, and received each treatment exactly once. Six subjects were 
scheduled to be enrolled into the study with two subjects assigned to each sequence. 
3.3 EXPERIMENT AL METIIODS 
3.3.1 s~s 
Six healthy male volunteers participated in the study. Subjects were considered for 
inclusion if they were healthy male non-smokers between the ages of 21 and 35 years. 
All subjects were determined to be healthy based on the results of medical screening 
consisting of: (a) medical history, (b) physical examination, (c) vital signs (supine and 
standing systolic and diastolic blood pressure, heart rate and body temperature) as well 
as an orthostatic test, (d) 12-lead EKG including a 30 second rhythm strip, (e) laboratory 
screen consisting of SMAC-20, CBC and urinalysis, as well as a urine drug test and 
Table 3.1 Randomiz.ation sequences for oral ethanol study 
Sequence Period 1 Period 2 Period 3 
I E A B 
II C D E 
m A B C 
A: t:manol U.J rfli:: ooo wet !bl over J,V llllllUtes g i y g 
B: Ethanol 0 .6 g/ke body weight over 20 minutes 
C: Ethanol 0.3 g/kg body weight over SO minutes 












breath alcohol test. 
Subjects were excluded from the study if (a) they were smokers, (b) they had a clinically 
significant history of renal, hepatic, cardiovascular, gastro-intestinal, neurological, 
pulmonary, or hematologic disease, (c) they had a history of alcohol abuse, drug 
addiction, psychological dependence on drugs, or psychiatric illness, (d) they had first 
degree relatives (mother, father, or siblings) with a history of mental illness or 
alcohoVdrug abuse, (e) they took any medications chronically or had taken any 
prescription medication or investigational drugs for at least 4 weeks before entering the 
study, (t) had an average daily caffeine intake greater than the equivalent of two cups of 
coffee, or (g) had an average weekly alcohol intake greater than 6 oz. (180 ml) of 
ethanol (approximately twelve 12 oz. beers). 
Before enrolling in the study, each subject signed an informed consent form attesting that 
the study procedures were explained to him and that his participation in the study was 
voluntary. 
After successfully completing the medical screening, all subjects underwent an EEG and 
psychometric test familiarization period. D!:!ring this period, EEG recordings were made 
for about 4 hours to familiarize subjects to the EEG procedures to minimize any first-
session anxiety effects. Subjects also learned and practiced the psychometric tests to 
optimize their performance and to minimi.z.e any learning effects during the study. 
Within one week after each subject completed the study, the physical examination and 
vital signs, laboratory tests, and EKG were repeated. 
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3.3.2 PROCEDURF.S 
The clinical study was conducted at the General Clinical Research Center (GCRC) unit 
at the Medical College of Virginia Hospitals, Medical College of Virginia-Virginia 
Commonwealth University. The Committee on the Conduct of Human Research at MCV-
VCU reviewed and approved the study protocol, and the informed consent form (August 
1991) prior to the start of the study. The protocol, including revisions, as well as the 
consent form are in Appendix A. The study was conducted from February through July 
of 1992. 
During each of the five study periods, the following procedures were followed: 
3.3.2A Admission to Clinical Research Unit 
Subjects were admitted to the GCRC unit on the evening of the day prior to each day of 
ethanol or placebo dosing and were discharged on the morning after the day of ethanol 
or placebo dosing. Subjects were instructed not to consume any medications (including 
OTC medications and vitamins) or caffeine for 72 hours before each study period and 
during each study period. Subjects also had to abstain from alcohol starting 72 hours 
before the first treatment period through the end of the study. All subjects had a negative 
urine drug screen and breath alcohol test on admission for each study period. All subjects 
completed a verbal probe concerning r~nt medical history as well as alcohol and 
medication use on admission for each study period. 
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3.3.2B Drug Preparation and Administration 
During each treatment period, the subjects received one of the following five treatments: 
Treatment A: ethanol 0.3 g/kg body weight.given in four equal "drinks" every 5 minutes 
at 0, 5, 10 and 15 minutes, followed by 2 placebo "drinks" at 30 and 45 minutes after 
the start of dosing; 
Treatment B: ethanol 0.6 g/kg body weight given in four equal "drinks" every 5 minutes 
at 0, 5, 10 and 15 minutes, followed by 2 placebo "drinks" at 30 and 45 minutes after 
the start of dosing; 
Treatment C: ethanol 0.3 g/kg body weight given in four equal "drinks" every 15 
minutes at 0, 15, 30 and 45 minutes, with 2 placebo "drinks" at 5 and 10 minutes after 
the start of dosing; 
Treatment D: ethanol 0.6 g/kg body weight given in four equal "drinks" every 15 
minutes at 0, 15, 30 and 45 minutes with 2 placebo "drinks" at 5 and 10 minutes after 
the start of dosing; 
Treatment E: Placebo given in 6 equal "drinks" at 0, 5, 10, 15, 30 and 45 minutes. 
Each treatment was given exactly once and in random order according to the 
randomization sequence (table 3.1). Both the subjects and the investigators were blinded 
with respect to treatment. During each treatment period, subjects consumed six "drinks" 
according to the dosing schedule in table 3.2, in an attempt to blind subjects to the 
different rates of input. 
Ethanol was administered as a 25% solution of 90.4 proof Vodka (Smirnoff Vodka, Ste 
Table 3.2 Dosing schedule for oral ethanol study 
Time Treatment1 
(min] 
A B C D 
0 X2 X X X 
5 X X p p 
10 X X p p 
15 X X X X 
30 pl p X X 
45 p p X X 
J: A= cUlallol 0.3 t/k: g g over zo III.LDUtes, H = 1:.UW1ol U.b gtkg over OJ 1I1.1.Dutes, 
C = Ethanol 0.3 g/kg over 50 mi.outes, D = Ethanol 0.6 g/kg over 50 mi.out.es, 
E = Placebo. 
2: X .., Ethanol "drink". 










Pierre Smirnoff Fis, Hartford, CT) in fruit juice (equal parts orange and grapefruit). The 
"drink" was given ice-cold in an opaque container with a lid and was sipped with a 
straw. A vodka-soaked gauze pad was placed under the lid in an attempt to blind the 
subject to the contents. The placebo "drink" consisted of fruit juice and contained a small 
amount of ethanol (5 % of the dose) in a further attempt to blind the subject. 
Doses were prepared by an unblinded pharmacist, who assigned subjects randomly to one 
of the randomization sequences. A sealed copy of the randomization schedule was 
available at the research unit in case of an emergency. 
3.3.2C Blood Sampling 
Prior to dosing, a heparin containing catheter was inserted into a forearm vein for access 
to blood sampling. 
Six ml blood samples for determination of serum ethanol concentration were collected 
in red-top tubes with no additives at the following times: pre-dose and 10 min, 20 min, 
35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 
8 hr and 12 hr after ethanol or placebo dosing. The blood was allowed to clot, 
centrifuged (within 1 hour of sampling) for 10 minutes, serum harvested and stored at 
-200 C until analysis by the TDx Analyzer (Abbott Laboratories, N. Chicago, IL). 
The total volume of blood drawn for ethairol determination during the study was about 
540 ml over the five-week period of the study. 
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3.3.2D Electroencephalography (EEG) 
Five minute segments of 28-channel EEG, using a Neuroscience Brain Imager 
(NeuroScience Services, Mesa, AZ), were recorded for each subject with eyes closed at 
the following times: pre-dose and 20 min, 35 min, 1 hr, 1.25 hr, 1.5 hr, 1. 75 hr, 2 hr, 
2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo 
dosing. Subjects were asked to count back from 500 by threes in an attempt to maintain 
vigilance during the recordings. Omni-prep (D.0.Weaver and Co., Aurora, CO) was 
used to prepare the scalp prior to electrode placement and Electro-gel (Electro-Cap 
International Inc., Dallas, TX) was used as the conducting gel. The electrodes were 
placed using an Electro-cap (Electro-Cap International Inc., Dallas, TX) according to the 
10/20 International System (Spehlman R, 1981) with 8 additional electrodes located 50% 
between the standard I 0/20 placement. L~ked ears were used as the reference. Four 
additional channels were used to monitor for vertical and lateral eye movements and 
electromyographic activity. All electrodes were made of tin. The electrode impedances 
were checked before each recording, and maintained at less than 5.6 kO and similar 
between electrodes. The raw EEG was stored on an optical disk until later analysis. Any 
disturbances in the room or subject movement during the EEG recording were 
documented. The Brain Imager filers were set as follows: Low filter - 0.3 Hz, High filter 
- 40 Hz, Notch filter - off. System integrity checks were performed biweekly throughout 
the study to ensure stability of channel calibration and proper filter settings. 
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3.3.2E Psychometric Performance Tests (PPT) 
A battery of three psychometric tests was completed by each subject at the following 
times: pre-dose and 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 
6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing. The battery consisted of a 
computem.ed card-sorting task (CST), co~putem.ed motor performance task, finger 
tapping (Fl) and a 90 second pencil-and-paper digit symbol substitution test (DSST) 
(Lezak, 1976). The computem.ed psychometric tests were part of the STIM software 
package (Neuroscan Inc., Herndon, VA). In the morning before dosing for each period, 
subjects practiced the psychometric test battery twice. 
3.3.2F Subject-Rated Impairment (SRI) Scales 
A 100 mm visual analog scale, based on the Subjective High Assessment Scale (SHAS) 
(Shuckit, 1984), was completed by each subject at the following times: pre-dose and 20 
min, 35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 
7 hr, 8 hr and 12 hr after ethanol or pla~o dosing. The scale had 11 items: IIlGH, 
DRUNK, CONFUSED, DIZZY, CLUMSY, FLOATING, SLURRED SPEECH, 
UNCOMFORTABLE, FEEL GREAT, FEEL TERRIBLE and ALCOHOL EFFECTS. 
Subjects indicated their perceived level of intoxication response for each item by placing 
a mark on an unnumbered 100 mm scale that ranged from "not at all" to "extremely". 
3.3.2G Observer-Rated Impairment (ORI) Scales 
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A 100 mm visual analog scale was completed by a blinded investigator (VAR) for each 
subject at the following times: pre-dose and 20 min, 35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 
hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or 
placebo dosing. The scale had 3 items: HIGH, DRUNK and CONFUSED. The blinded 
investigator indicated his perception of the subject's level of intoxication by placing a 
mark on an unnumbered 100 mm scale that ranged from "not at all" to "extremely". 
3.3.2H Safety Measurements 
Vital signs, i.e. , blood pressure (sitting) and heart rate, were measured, using a 
Dynamap (Critikon Inc., Tampa, FL), at the following times: pre-dose and 1 hr, 2 hr, 
3 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing. 
All subjects were observed for symptoms and signs of clinical intolerance to the drug or 
procedures and asked to report any adverse effects. These were evaluated by the Medical 
Monitor (MJ) for their clinical significance and potential need for treatment. 
3.3.21 Diet 
On the evening prior to dosing, subjects received a light snack. Subjects fasted from 
midnight on the evening before ethanol ~r placebo dosing until six hours after drug 
administration. Water was permitted ad libitum throughout each study period. Dinner 
and a snack were served 10 and 14 hours after dosing respectively. Caffeine-free 
beverages were served with meals. The same menu was served on corresponding days 
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of each study period. 
3.3.21 Discharge from Clinical Research Unit 
Subjects were discharged on the morning of the day after ethanol or placebo dosing. A 
breath alcohol test was done prior to discharge at the end of each treatment period to 
ensure that the subjects did not have detectable ethanol levels. 
A study flow sheet is presented in table 3.3. When the study measurements were 
scheduled at the same time, they were conducted in the following sequence: 1) blood 
samples 2) EEG 3) PPT 4) SRI and ORI scales and 5) safety measurements, with the 
blood sample being collected at exactly the scheduled time. 
When each subject completed the study, ~e was asked to assess which treatment he 
believed he had received during each period of the study. 
3.3.3 SAMPLE ANALYSIS 
Analysis of serum samples for ethanol concentrations was performed in the 
Biopharmaceutical Analysis Laboratory at the Department of Pharmacy and 
Pharmaceutics at MCV-VCU. Performance validation and sample analysis were 
conducted with the guidance of Clark March in the Biopharmaceutical Analysis 
Laboratory at the Department of Pharmacy and Pharmaceutics at MCV-VCU. 
3.3.3A Analytical Method for Ethanol in Serum 
Table 3.3 Study period flow sheet for oral ethanol study 
· 12 -10 ·I 0 0.17 0 .33 0.58 0.83 I 1.25 I.S 1.75 2 2.S 3 3.S 4 s 6 7 8 10 12 14 l4 
Admisaioo X 
Dosing < > 
SAC X X X X X X X X X X X X X X X X X X X 
EEG X X X X X X X X X X X X X X X X X X X 
PPT X X X X X X X X X X X X X X X X X 
SIU/OR.l X X X X X X X X X X X X X X X X X X 
VS X X X X X X X X X X X 
Meal, X X X X X 
Diochlrg~ X 
SAC: Serum Samples for Alcohol Determination, EEG: Electroencephalography, PPT: Psychometric Performance Battery, SRI/ORI: Subject Rated 
Impairment & Observer Rated Impairment Scale, VS: Vital Signs (blood pressure, heart rate, temperature) 
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The analytical method used to measure ethanol concentrations in serum was fluorescence 
polarization immunoassay using the TDx Analyzer (Abbott Laboratories Inc., N. 
Chicago, IL). The TDx ethanol assay is a reagent system for the quantitative 
measurement of ethanol in human whole blood, serum, plasma or urine. 
The assay utilizes radiative energy attenuation (REA) technology. The ethanol 
concentration is determined by the combined catalytic reactions of alcohol dehydrogenase 
(ADH) and diaphorase (Dase) to generate a dye. The reaction scheme is as follows: 
ADH 
EtOH + NAD ------+ Acetaldehyde + NADH + H+ 
Dase 
NADH +MIT--- - --+ NAD + MT-Formaz.an 
where NAD: Nicotinamide Adenine Dinucleotide 
NADH: Nicotinamide Adenine Dinucleotide reduced 
MIT: Monotetrazolium dye 
The relationship between the concentration of ethanol and measured fluorescence intensity 
is established by generating a standard curv~. Six calibrators of known concentrations (0, 
250, 500, 1000, 2000 and 3000 mg/L) are run and the resulting attenuated fluorescence 
signal is measured. The calibration is then stored in the instrument. When an unknown 
is read, the concentration is calculated directly from the stored calibration curve (TDx 
Manual, 1995). 
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3.3.3B Assay Procedure 
Materials and Reagents: The ethanol calibrators (standards), serum controls and reagent 
packs were obtained from Abbott Labs. The calibrator pack consists of six vials of 
accurately measured amounts of ethanol in an aqueous solution at the following 
concentrations: 0, 250, 500, 1000, 2000 and 3000 mg/L. The serum controls pack 
consisted of three vials of ethanol in human serum at the following concentrations: 
Control L: 500 mg/L (range: 425 - 575 mg/L), Control M: 1000 mg/L (range: 900 -
1100 mg/L), and Control H: 2500 mg/L (range: 2250 - 2750 mg/L). The reagent pack 
consisted of three vials, labelled S, T and P. Vial S was the substrate solution containing 
< 5 % Nicotinamide adenine dinucleotide in sodium citrate buffer. Vial Twas the enzyme 
solution containing < 5 % yeast alcohol dehydrogenase and < 1 % diaphorase in a protein 
stabilizer solution containing components of whole blood in buffer. Vial P was the 
indicating solution containing < 1 % monotetrazolium dye and <0.01 % fluorescein in 
solvent. The TDx dilution buffer, sample cartridges and sample cuvettes were purchased 
from Abbott Labs. 
Calibration: A six-point calibration curve was generated by running six calibrators of 
known concentrations (0, 250, 500, 1000, 2000 and 3000 mg/L) and measuring the 
resulting attenuated fluorescence signal. The calibration was then stored in the 
instrument. When a sample was run, the concentration was calculated directly from the 
stored calibration curve (fDx Manual, 1995). 
Summary of Method: The sample cartridges and cuvettes were placed in the carousel. 
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The carousel has a capacity to run up to 20 samples in a single run. Individual samples 
or controls were pipetted into the sample wells of the sample cartridges. The carousel 
was then placed in the analyzer and the run was initiated. The samples were pipetted into 
the dilution well and diluted with the TDx buffer. The diluted sample was pipetted into 
the cuvette and the reagents were sequentially added, allowed to incubate and the 
resulting attenuated fluorescence measured by the fluorometer within the instrument. The 
concentration was calculated directly from the stored calibration curve and printed. 
3.3.3C Performance Characteristics for Ethanol in Serum 
The performance characteristics, including specificity, sensitivity, precision, and accuracy 
by recovery were determined by Abbott Labs, as detailed in the TDx Manual (1995). 
The following is a brief description of these characteristics. 
Specificity: Specificity was determined by assaying several compounds of interest 
(ethanol, n-butanol, n-propanol, isopropanol, ethylene glycol, propylene glycol, 
methanol, acetone) in concentrations upto 10000 mg/L. The only compounds that showed 
reactivity greater than 0.1 % were Ethanol (100%), n-butanol (10.7%) and n-propanol 
(36%) (TDx Manual , 1995). 
Sensitivity: Sensitivity was defined in the TDx manual (1995) as the lowest measurable 
concentration distinguishable from zero with 95 % confidence. The reported limit of 
quantitation (LOQ) was 100 mg/L. 
Precision: Reproducibility was reported in the TDx manual (1995) to be acceptable when 
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5 replicates of ethanol solutions at 400, 1000 and 2500 mg/L were run on 10 different 
occasions over a period of 2 weeks. Between run and within run variability was reported 
to be less than 6 % . 
Accuracy by Recovery: Recovery was determined by adding known quantities of ethanol 
to serum and saline to levels of 200, 500, 1000, 2000 and 3000 mg/L. The TDx was 
calibrated with the serum-based controls and the saline-based controls were assayed 
relative to that calibration. % Recovery was calculated as: 
% recovery = (Cone in saline)/(target conc)*lOO 
Results indicated an average recovery of 100.3 ± 2.7% (fDx Manual, 1995). 
3.3.30 Performance Validation for Ethanol in Serum 
Sensitivity: To experimentally test the reported sensitivity limit, as well as to determine 
if concentrations below the limit set by Abbott Labs could be accurately and reliably 
quantitated, the experimental limit of quantitation (ELOQ) was estimated. For this, 
standards were prepared at concentrations of 50 mg/L and 100 mg/L by diluting 1 ml of 
the appropriate calibrators (500 mg/L and 1000 mg/L respectively) to 10 ml with blank 
serum. These were run in replicates of 5 each along with controls. Precision was 
estimated by calculating the %Relative Standard Deviation (%RSD) and accuracy was 
estimated by calculating the %Difference From Nominal (%DFN, calculated as 
[observed-nominal]/nominal x 100) for each run. The lowest concentration that gave 
%RSD and %DFN less than 20% was determined to be the ELOQ. 
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Results: The 100 mg/L standard gave an RSD of 4% and DFN of 6%. The 50 mg/L 
standard solution was prepared five times and each time the RSD and DFN were greater 
than 20%. Therefore 100 mg/L was determined to be the ELOQ. 
Precision and Accuracy: In this study, the precision and accuracy were determined by 
pooling the data from the controls run during the sample analysis and calculating the 
%RSD and %DFN respectively. In addition to the three controls supplied by Abbott Labs 
(L, M and H), a control at 100 mg/L (C~ntrol X) was prepared by diluting the 1000 
mg/L standard and run along with the other controls during sample runs. 
Results: Table 3.4 lists the %RSD and %DFN calculated from values pooled from 
controls run along with samples during the.analysis of subject samples. The %DFN for 
all controls is S 15% which is within acceptable limits. The %RSD for controls L, M 
and H were s9% which is within acceptable limits. The %RSD for Control X was 27% 
which is larger than the pre-set criteria of 20%. This may be consequence of using two 
different batches of controls during sample analysis. In an attempt to overcome this 
problem, the instrument was re-calibrated for a smaller concentration range (100 to 2000 
mg/L) and the sample volume was increased from 2 µl to 4 µI, but the results from these 
attempts were inconsistent and resulted in %RSD and %DFN larger then 20%. Finally, 
it was decided to re-calibrate the instrument for the original concentration range (100 to 
3000 mg/L), then re-run all samples in the concentration range of 100 to 250 mg/L. 
Controls X and L were run with the samples, and these values were pooled with the 
values obtained from earlier runs. Estimates of the sample concentration from both runs 
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Table 3.4 Measures of precision and accuracy of analytical method for ethanol 
Experimental Limit of Quantitation 100 mg/L 
(ELOQ) 
Valid Concentration Range 100 to 3000 mg/L 
Precision (%RSD) Control X (100 mg/L): 19% 
Control L (500 mg/L): 9% 
Control M (1000 mg/L): 7% 
Control H (2500 mg/L): 4% 
Accuracy (%DFN) Control X (100 mg/dL): 15% 
Control L (500 mg/dL): 11 % 
Control M (1000 mg/dL): I% 
Control H (2500 mg/dL): 3% 
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were used in the pharmacokinetic analysis · to account for the high assay variability at 
lower concentrations. The overall %RSD and %DFN for Control X were 19% and 15%, 
respectively. Using the results of duplicate sample runs effectively decreased the %RSD 
by a factor of ./2 (Chamberlain, 1985). 
3.3.3E Analysis of subject samples 
The TDx assay was used to determine ethanol concentrations in serum from the six 
subjects that completed the clinical study. There were a total of 18 samples per subject 
per period and four active treatment periods per subject (fotal samples ,., 432) . 
Calibration was performed prior to perfom:iance validation. All four controls (X, L, M 
and H) were run at the start of subject sample analysis to ensure that the calibration 
curve was stable and valid . The samples for a single study period for each subject were 
split, and nine samples were run on each carousel along with 2 of the controls (X, L, M 
and H). 
This analytical method for the determination of ethanol concentrations in serum was 
simple, specific, adequately sensitive, precise and accurate within acceptable limits for 
the purposes of this study. 
3.3.4 PHARMACOKINETIC ANALYSIS 
Pharmacokinetic analysis of the serum ethanol concentration-time data was performed by 
noncompartmental and compartmental methods. 
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3.3.4A Noncompartmental Methods 
Serum ethanol concentration vs. time profiles were constructed for each subject and 
treatment on both linear and semi-logarithmic scales. The following PK parameters were 
estimated from the concentration-time data for each subject and treatment: maximum 
concentration (C....J, time to achieve maximum concentration (f....J, area under the 
concentration-time curve extrapolated to infinity (AUC.,J, apparent total body clearance 
(Cl._./F), apparent volume of distribution (Vd/F), maximum elimination rate (V .....J and 
Michaelis-Menten constant (K.,,). emu was estimated as the maximum observed serum 
concentration and T mu as the time (relative to the start of dosing) that emu occurred. 
AUC00 was calculated as: 
C: AUC = AUC -1- -
CD tnp A 
where AUC,,..., is the AUC from Oto the time (t.J of the last measured concentration (CJ 
calculated by the trapezoidal rule (Gibaldi and Perrier, 1982) and C,l>.. is the AUC 
extrapolated from t.i to infinity (AUCexltl4>). >.., which is the terminal slope of the log 
concentration vs. time profile, was estimated as V mu/K,,,. 
Cl..,.,/P was calculated as: 
D 
ata/F = AUC 
CD 
where D is the total administered dose. 
Vd/P was calculated as: 
48 
Vcf F = cr"" /F • MRI 
where MRT is the mean residence time calculated as: 
MRT = AUMC... T 
AUC... 2 
where Tis the duration of input (20 minutes or 50 minutes), and AUMC
00 
is the area 
under the moment curve extrapolated to infinity, calculated by determining the area 
under the moment curve (AUMC) from· 0 to the time (t..) of the last measured 
concentration (CJ by the trapezoidal rule by summing individual areas calculated by 
and then extrapolating to infinity as follows (Gibaldi and Perrier, 1982): 
C•t C AUMC = AUMC + _!!_!! + ---!? 
"' tnp >.. >.,2 
Although the MRT calculated in this manner is adjusted for the input time into the 
absorption compartment, it is not the systemic MRT since it includes the mean absorption 
time, which cannot be subtracted out from the estimate of MRT. Also, the estimation of 
the terminal exponential slope of the concentration-time profile implicitly assumes a first-
order process (Gibaldi and Perrier, 1982). Although, the elimination of ethanol does 
approximate a first-order process at low concentrations (relative to the K,..), the 
elimination is best characterized by a capacity-limited process and presents a limitation 
in the interpretation of the MRT and subsequent estimation of the Vd/F. 
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V..,, was estimated from the slope (slopel) of the linear regression performed on the 
initial apparent linear declining phase of the concentration-time profiles as: 
V,.,.. = - slope] 
K., was estimated from the slope (slope2) of the linear regression performed on the 
tenninal apparent linear declining phase of the log concentration-time profiles as: 
K =-m 2.303 * slope2 
Descriptive statistics, including mean, standard deviation, coefficient of variation 
(%COY), median and range were calculated for each parameter by treatment and subject 
as well as across treatments. 
3.3.48 Compartmental Methods 
Compartmental analysis was performed for individual serum concentration-time data in 
order to estimate the intrinsic pharmacokinetic parameters, maximum elimination rate 
(V ....J, Michaelis-Menten constant (K,..), apparent volume of distribution (Vd/F) and first-
order absorption rate constant (kJ. Model fitting was performed using Scientist (version 
2.0 for Windows, MicroMath Inc., Salt Lake City, UT). Several PK models were 
evaluated, such as models with first-order or zero-order input functions, models with one 
or two compartments, incorporating capacity-limited elimination with and without a 
parallel first-order elimination pathway. Weighing schemes of 1 and 1/y were evaluated. 
Noncompartmental PK parameter estimates were used as initial estimates for V ....,., K,,. 
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and Vd/F, and a population mean estimate of 2.0 hr-1 was used as the initial estimate for 
k. (Rangno et al., 1981). The model which best fit the data was selected based on several 
goodness of fit criteria: maximization of the coefficient of determination and Model 
Selection Criteria (Scientist Manual, 1994), minimization of the standard deviation of the 
parameter estimates, random scatter in the plots of residuals vs. independent variables, 
normal distribution of the residuals and visual inspection of observed values and fitted 
curves. 
The final PK model selected was a one compartment body model with zero-order input 
into the absorption compartment and first-order absorption into the central compartment, 
with capacity-limited elimination (figure 3.1). The best fits were obtained with a weight 
of I, i.e., unweighted. Descriptive statistics, including mean, standard deviation, %COY, 
median and range were calculated for each PK parameter by treatment and subject as 
well as across treatments. 
In addition to compartmental analysis of individual subjects and treatments, the final PK 
model, based on individual treatments and subjects, was fit simultaneously to 
concentration-time data across all four active treatments for each subject. This approach 
allowed better estimation of the intrinsic PK parameters for each subject, by 
incorporating the intra-subject variability in PK; however, it did not allow separate 
estimation of the inter-individual and intra-individual variability for the PK parameters. 
In this approach, the dose and duration of input (T) were incorporated as independent 
variables along with time, and concentration was the dependent variable. Weighing 
D, Tin lea 
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schemes of 1 and 1/y were compared, with unweighted fitting resulting in better fits. The 
mean PK parameter estimates obtained for each subject from the individual model fits 
were used as initial estimates. Goodness of fit was assessed using the same criteria as 
described above for the individual model fits. Descriptive statistics, including mean, 
standard deviation, %COV, median and range were calculated for each PK parameter 
across subjects. 
3.3.5 PHARMACODYNAMIC ANALYSIS 
Pharmacodynamic analysis included the analysis of data from the EEG recordings, 
psychometric perfonnance tests, as weU as the SRI and ORI scales. 
3.3.5A EEG Analysis 
EEG recordings were stored on optical disks and analyred off-line. Each of the 5-minute 
recordings was reviewed and edited to remove each 2.5 second epoch that was 
contaminated with artifacts (eye movement, muscle movement, electrode artifacts, or 
other disturbances noted during the recording). The remaining artifact-free epochs were 
averaged to form an average topographical map for each recording using the statistical 
operations program on the Brain Imager. The file containing the average amplitude in 
each of the five classical frequency bands (delta: 0.39 - 3.0 Hz; theta: 4.3 - 7.8 Hz; 
alpha: 8.2 - 11. 7 Hz; beta I: 12.1 -16.0 Hz; and beta II: 16.4 - 30 Hz) at each of the 28 
electrodes was transferred from the Brain Imager to an IBM compatible 80486 computer 
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and imported into a spreadsheet program (Quattro Pro, Borland International, Scotts 
Valley, CA) developed by Dr. Slattum (1992) for further processing. 
From each average recording , the following PD measures were obtained: total power (in 
µ V1) across all electrodes and across all frequency bands, total power across all 
electrodes within each frequency band, relative power across all electrodes within each 
frequency band, and spectral edge (in Hz). 
Power was determined for each average recording by squaring the amplitude (in µ V) of 
the EEG signal at each electrode in each frequency band. Total power in each frequency 
band was calculated by summing the power across all electrodes for the given frequency 
band. Total power across all frequency bands was calculated by summing the total power 
across all five frequency bands. Relative power in each frequency band was calculated 
by dividing the total power of the frequency band by the total power across all 5 
frequency bands. The spectral edge, which is the frequency below which 87% of the 
EEG activity is located, was also determined. 
3.3.5B Psychometric Performance Test Analysis 
For each of the psychometric tests, the following measures were obtained: 
1. Card Sorting Task (CST): total categories completed and number of erroneous 
responses determined at each time-point; 
2. Finger Tapping Task (FT): the average rate (taps per second) of finger tapping for 
both the dominant and non-dominant hands determined based on three trials at each time 
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point; 
3. Digit Symbol Substitution Task (DSS'I): the total number of substitutions completed 
in the 90 second testing interval as well as the number of erroneous responses detennined 
at each time point. 
3.3.5C Impairment Scales Analysis 
For the SRI and ORI scales, a score between O and 100 was obtained for each item, by 
measuring the number of millimeters between the left end of the scale and the mark 
placed by the subject at each time point. Since two of the six subjects in the study were 
classified as ·non-responders· and did not show consistent responses on the SRI scales 
(maximal observed response less than 20 mm for treatments Band D) , even though they 
showed consistent psychometric impairment and EEG changes, subjects were given a 
"non-responder" score (NR) of O if they were non-responders or 1 if they were 
responders. 
3.3.50 Pharmacodynamic Analysis 
Response-time profiles, i.e., plots of change in response measure from pre-dose baseline 
vs. time plots, for each subject during each treatment period were plotted for each 
response measure. The PD response measures evaluated were: 
EEG measures: total power across all bands, total power in each of the 5 frequency 
bands (delta, theta, alpha, beta I, beta II)! relative power in each of the 5 frequency 
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bands (delta, theta, alpha, beta I, beta II), spectral edge; 
PP measures: total categories and number of errors for CST, average tap-rate for 
dominant and non-dominant hands for Fr, total attempts and number of errors for DSST; 
Impairment Scales: score for each of the 11 items on the SRI scales and 3 items of the 
ORI scales. 
Phannacodynamic parameters including baseline response (EJ, maximal or minimal 
observed response CE.nu• or E....,•) and time of maximal or minimal observed response 
(t...u or t....) were derived for each PD measure. The baseline response (EJ was defined 
as the response prior to drug administration at O hour. E_• was determined as the 
highest response observed during the first 6 hours after drug administration, and E.....""' 
was determined as the lowest response o~served during the first 6 hours after drug 
administration. The E_• and E....,• were determined from data obtained only during 
the first 6 hours after drug administration because the responses were expected to be the 
greatest during this period. The t...u (or t,,.;J was determined as the time after the start of 
dosing that E...u""' (or E.....""') occurred . 
Descriptive statistics, including mean , standard deviation, %COY, median and range 
were calculated for each PD parameter by treatment and subject as well as across 
treatments. 
In addition, response vs. serum concentration profiles were plotted for each response 
measure for each subject at each treatment, to evaluate the effect-concentration 
relationship as well as the development of acute tolerance to the effects. The presence 
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of a clockwise hysteresis loop in the response-time profiles would be consistent with 
,. 
development of acute tolerance for that response. 
3.3.6 STATISTICAL ANALYSIS 
Statistical analysis was performed to 1) evaluate the dose-related and rate-related changes 
in the pharmacok:inetic and pharmacodynamic end-points, EEG, psychometric 
performance and subjective impairment following administration of two escalating single 
oral doses of ethanol at two different rates in healthy male subjects; and 2) to determine 
the relationship between the EEG changes after oral ethanol administration and changes 
in psychometric performance and subjective impairment. 
Because there are many variables of interest in this statistical analysis, the multiplicity 
of desired inferential statements about the data become problematic. Adjusting the level 
of significance (a) for the multiple statistical comparisons, as made in traditional 
confirmatory analysis, would result in e~tremely small a values and virtually no 
likelihood of detecting any statistically significant differences considering the small 
sample siz.e. Therefore, using the concept of descriptive data analysis, expected 
differences between treatments based on previously reported studies and patterns apparent 
from examining the data were evaluated statistically without adjusting the level of 
significance (Abt, 1987, Abt, 1990). The results of these analyses were used to make 
descriptive inferential statements about the data, but not to reject the null hypothesis. 
Hypotheses generated by this study would have to be confirmed by prospective studies 
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involving a larger number of subjects. 
Primary pharmacokinetic parameters that were evaluated using descriptive data analysis 
included apparent volume of distribution (Vd/F), absorption rate constant (kJ , maximum 
elimination rate (V .....J, and Michaelis-Menten constant (K,..). These PK parameters were 
selected to evaluate the effect of dose and dose-rate on these intrinsic PK parameters for 
ethanol. Primary pharmacodynamic measures that were evaluated included peak changes 
CE...uobL.E,, or E,...,obL.E,,) in total EEG power, changes in relative EEG power in the theta, 
and alpha bands, peak changes in tap-rate for the non-dominant hand for FT, peak 
changes in the items, "DRUNK", and "ALCOHOL EFFECTS" on the SRI scales, and 
peak changes in the item "DRUNK" on the ORI scales. These PD parameters were 
selected based on changes seen in these measures in previously reported studies (Ehlers 
and Shuckit, 1991; Lukas et al., 1986; Wittenborn, 1987; Shuckit, 1984) as well as 
patterns apparent from preliminary examination of the data. Statistical comparisons for 
the other PD end-points (including changes in relative EEG power in the delta, beta I and 
beta II bands, changes in EEG spectral edge, changes in tap-rate for the dominant hand 
for FT, changes in the item "IIlGH" on the SRI as well as ORI scales) were treated as 
exploratory data analysis. These were u~ to generate hypothesis rather than to make 
formal conclusions based on the data. 
The significance of the baseline (EJ as a covariate was examined to evaluate the 
relationship between the baseline of the response and the change in PD response. Also, 
the NR score was used as a covariate in the statistical comparison of PD measures to 
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evaluate its effect on the PD response. 
To evaluate the treatment effects on the PK and PD measures, the PK parameters and 
summary PD parameters {E,,_*-E., or l;,...o1>&..E.,, lm,u or U for the primary PD measures 
for each treatment were compared across treatments using statistical techniques 
appropriate for a 5-way crossover design. The model used to fit the data was of the 
form: 
y ijtJ = µ + O; + 'I) + rt(i) + a, + E~J 
i = I,II,m (sequences); 
j = 1,2,3,4,5 (periods); 
k = 1,2,3,4,5,6 (subjects); 
1 = A,B,C,D,E (treatments) (only active treatments A,B,C,D for PK 
parameters); 
where Y ijkJ is the response for the kth subject in the ith sequence in the jth period after 
the Ith treatment, µ is the overall mean, o; is the effect of the ith sequence, 'l'j is the 
effect of the jth period, rtG> is the effect of the kth subject nested within the ith sequence, 
a1 is the effect of the Ith treatment, and Eijt! is the random error associated with Y ijtl· The 
Eijtl are assumed to be normally distributed random variables with a mean of O and 
variance u,2. It is also assumed that the nested effects for subject are randomly and 
independently distributed with a mean of O and common variance of u?, and independent 
Of Eijtl. 
Model fitting was performed using PROC MIXED in SAS (version 6.07, SAS Institute, 

Table 3.5 Sample SAS code for PROC MIXED 
proc mixed data=save.DATAl; 
class trt period seq sub; 
model y=seq period trt covarl covar.2 
random sub(seq); 
* 
estimate 'A vs. B' trt 1 -1 0 o; 
* 
estimate 'A vs. C' trt 1 0 -1 0. ,
* 
estimate 'A vs. D' trt 1 0 0 -1; 
* 
estimate 'B vs. C' trt 0 1 -1 O; 
* 
estimate 'B vs. D' trt 0 1 0 -l; 
* 
estimate 'C vs. D' trt 0 0 l -l; 
make 'predicted' out=pred; 
make 'fitting' out=fit; 
DAT Al : data set 
trt: treatment, seq: sequen.ce. sub: subject 
covarl, covat2: covariates 
I predicted; 
• : estimatestatemeots used for multiple comparisons only for overall significance 
s 
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parameters <E-,.• for SRI-ALCOHOL EFFECTS score) were performed individually 
to assess the significance of the relationship between the EEG changes and changes in 
PP and SRI. The coefficient of determination was determined for each of the regressions 
as an index of the association between the two variables. Since this was a crossover study 
and results obtained for different treatments in the same subject are not independent, the 
regression was only performed for observations for treatment B {high-fast), since the 
greatest change in the PD measures would be expected for this treatment. Regression was 
performed using Microsoft Excel (version 5, Microsoft Inc., WA). This test allowed us 
to determine if the EEG changes were more closely related to changes in PP or to 
changes in subject-rated impairment measures. 
3.4 RESULTS AND DISCUSSION 
3.4.1 CLINICAL RESULTS 
3.4. lA Subject Demographics 
Six male subjects were entered into the study after successfully passing the medical 
screening, and all six subjects completed all five periods of the study. Demographic and 
physical characteristics of the subjects are shown in table 3.6. The subjects were 
between 21 and 32 years of age. Their weight ranged from 68 to 98 kg with an mean of 















Demographic and physical characteristics of subjects in oral ethanol study 
Age Weight Height Race Handed- Alcohol 
ness consumption 
'[yrs) [ig] [cm] [#driJW/week] 
26 73.6 170.0 Caucasian Right 1 
29 68.4 171.3 African-American Right < l1 
I 
22 73.6 172.5 Caucasian Right 11 
32 98.2 177.5 Caucasian Right 7 
28 81.0 ' ns.8 
I 
Caucasian Right 4 
21 71.8 175.0 Caucasian Right 6 
I I 26 77.8 174.2 5 
4 10.8 3.5 4 
16% 14% 2% 
' 
84% 












than 1 to 11 alcoholic beverages per week. 
3.4.lB Adverse Events 
In general, all subjects tolerated the study procedures and study drug well. There were 
no adverse events reported for the placebo (treatment E) and low-dose treatments 
(treatments A and C). One subject (subject~) reported mild nausea about 1.5 hours after 
receiving each of the high-dose treatments (Band D), which lasted for about 1 hour and 
resolved without any treatment. One subject (subject 1) had mild nausea accompanied by 
vomiting at about 1.5 hours after receiving each of the high-dose treatments (B and D), 
which lasted for about 1 hour and resolved without any treatment. 
3.4.2 PHARMACOKINETICS 
3.4.2A Noncompartmental Analysis 
Serum ethanol concentration vs. time profiles for each treatment and subject are shown 
in Appendix Bl. Figure 3.2 shows the serum ethanol concentration vs. time for all 
subjects by treatment. As figure 3.2 illustrates, the high-dose treatments Band D resulted 
in higher concentrations, about twice the concentrations observed after the low-dose 
treatments A and C. Also, the time of peak concentrations appear to be later for the 
slow-input treatments C and D compared to the fast-input treatments A and B. 
Elimination profiles are consistent with capacity-limited elimination, showing an initial 
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Figure 3 .2 Serum ethanol concentration vs. time for all subjects by treatment for oral ethanol study 
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linear (apparent zero-order) decline, and a later exponential (apparent first-order) decline. 
Mean pharmacokinetic parameters determined by noncompartmental analysis are 
presented in table 3. 7. c_ increased approximately two-fold with a two-fold increase 
in the dose (from 0.3 g/kg to 0.6 g/kg); the population variability appeared to decrease 
with the increase in dose. This was seen for both fast and slow input treatments. c_ 
(mean ± S.D.) values were 401 ± 133 mg/Land 347 ± 82 mg/L for treatments A and 
C, respectively, and 754 ± 114 mg/Land 724 ± 108 mg/L for treatments B and D, 
respectively. Dose-corrected c_ values were not significantly different across treatments 
(see figure 3.3). 
Figure 3.4 shows a plot of the mean (S.E.) T_ by treatment. T_ was not significantly 
different between treatments, although there was a trend toward larger Tawt values for 
slow-input treatments compared to the fast-.input treatments, especially at the high dose 
(median Tlllll of 1.0 hrs for treatment B versus 1.6 hrs for treatment D). Since Tlllll was 
determined as the time at which the Caw< was observed, its determination was limited by 
the sampling schedule, and since concentrations were not measured continuously but at 
discrete time-points, this resulted in some ~nsoring of the data. 
AUC00 increased approximately three-fold with a two-fold increase of the dose (from 0.3 
g/kg to 0.6 g/kg); the population variability appeared to decrease with an increase in dose 
(see figure 3.5). This was seen for both fast and slow input treatments. AUC00 (mean ± 
S.D.) values were 991 ± 258 mg/L*hr and 835 ± 209 mg/L*hr for treatments A and 








(n = 6) 
D 
(n=6), 
Mean (%COY)· Non-companmental phannacokinetic parameters by treatment across .subjects for ethanol oral 
study 
c_ 111 T I I, AUCOO v_ Ka, Vd/F i mu 
(mg/LJ ( mg/U(g/kg)JZ (hr) [mg/L41lr) [mg/L •br/(glkg) )3 l[mg/Uhrl ! (mgfLJ [LI 
401 1338 LO 991 3303 136 240 71 
(33%) (33%) (0.6-1.8) (26%) (26%) (31 %) (30%) (49%) 
754 1256 1.0 31.85 530S4 138 173 42 
(15%) (15%) (0.6- l.8) (11 %) (11 %) (22%) (57%) (2l %) 
347 U57 J.3 
I 
922 3072 160 189 87 
(24%) (24%) I co.6-1.5) (32%) (32%) (36%) (52%) (37%) 
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and D, respectively. Dose-corrected AUC00 estimates were statistically different between 
low-dose treatments and high-dose treatments (p=0.0004). This finding is consistent with 
non-linear, capacity-Limited pharrnacokinetics for ethanol. The precision of the AUC00 
estimates was estimated by calculating the percent AUC extrapolated (%AUCc.nnp) by 
dividing the AUCo.nn,, by the AUC00• The %AUCc.ctnp ranged from < 1 % to 22% across 
individual AUC00 calculations. CL,.,/F (mean ± S.D.) estimates were 414 ± 107 ml/min 
and 463 ± 162 ml/min for treatments A and C respe.ctively, and 249 ± 53 ml/min and 
265 ± 67 ml/min for treatments B and D respe.ctively. CL,.,/F showed a statistically 
significant decrease with the increase in dose (p =0.0118), although the estimates did not 
appear to change with an increase in input-rate. This is consistent with non-linear 
elimination of ethanol. As table 3. 7 indicates, the intrinsic PK parameters, Y .,...., K,., and 
Yd/F estimated by noncompartmental analysis did not appear to be different across 
treatments. Table 3.8 lists the intrinsic PK parameter estimates by subject across 
treatments, along with the %COY for each subject which is a measure of intra-subject 
variability. The mean intrinsic PK parameters, estimated by non-compartmental methods 
across subjects and treatments, along with the inter-individual and intra-individual 
variability measures (%COY) are presented in table 3.9. The mean(± S.D.) Y.,.... was 
145 (± 41) mg/Uhr across subjects and treatments. The mean(± S.D.) K,,, was 208 (± 
92) mg/Lacross subjects and treatments. !}le mean (± S.D.) Yd/F was 63 (± 29) L 
across subjects and treatments. As table 3.9 indicates, the inter-individual variability, 
as measured by the %COY, was considerable for the PK parameters, espe.cially for the 
Table 3.8 
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Mean (%COY) Non-compartmental intrinsic pharmacokinetic parameters 
by subject across treatments for oral ethanol study 
Subject No. vmu K,., 
[mg/Uhr] [mg/L] 
1 117 144 
(n=4) (25%) (70%) 
2 92 171 
(n=4) (16%) (48%) 
3 140 208 
(n=4) (18%) (46%) 
4 182 219 
(n=4) (27%) (39%) 
5 184 292 
(n=4) (5%) (19%) 
6 156 211 
(n=4) (4%) (52%) 
Table 3.9 Non-compartmental intrinsic pharmacokinetic parameters across 
subjects and treatments for oral ethanol study 
V_,_ K.n ViF 
[mg/Uhr] [mg/L] [L] 
Overall Mean 145 208 63 
(n=24) 
Inter-Individual 









K,,.. Among other things, this may be a ~nsequence of the sparse terminal sampling 
schedule and the relatively poor precision in the analytical methods, particularly at low 
concentrations. For all parameters, intra-individual variability was lower than the inter-
individual variability. 
In summary, noncompartmental analysis of the serum ethanol concentration-time data 
indicated that ethanol follows dose-dependent, capacity-limited elimination. The intrinsic 
PK parameters, V mu., K,,., and Vd/F were independent of dose and dose-rate, and the 
mean parameter estimates are consistent with values observed in other studies evaluating 
ethanol PK following oral administration of doses ranging from 0.14 to 1.25 g/kg 
(Wilkinson et al., 1977; Holford, 1987). The noncompartmental parameter estimates 
provided good initial estimates for the compartmental analysis of the serum ethanol 
concentration-time data. 
3.4.2B Compartmental Analysis 
A one-compartment body model with zero-order input into the absorption compartment 
and first-order absorption into the central compartment, with capacity-limited elimination 
was fit to the individual serum ethanol concentration vs. time profiles. The fits were 
considered to be adequate based on the coefficient of determinations (r), which ranged 
from 0. 792 to 0.978 and Model Selection Criteria (MSC), which ranged from 1.036 to 
3.313, random scatter in the plots of residuals vs. independent variable, normal 
distribution of the residuals as well as visual inspection of observed and fitted curves. 
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The standard deviations and calculated %COVs of the parameter estimates were high, 
especially for Vmv. with %COVs ranging from 34% to 1365%, and for K,,, with %COVs 
ranging from 135 % to 2380 % , indicating significant imprecision in the parameter 
estimates. 
Individual concentration vs. time profiles illustrating the observed values and fitted 
curves are shown in Appendix B2. Figure 3.6 shows the serum ethanol concentration vs. 
time profile (observed values and fitted curves) by treatment for a representative subject 
(subject 2). Table 3.10 lists the compartmental PK parameter estimates by treatment. 
Statistical comparison of the intrinsic PK parameters indicated no significant differences 
across treatments or subjects. Table 3.11 lists the intrinsic PK parameter estimates by 
subject across treatments, along with the %COY for each subject which is a measure of 
intra-subject variability. The mean intrinsic PK parameters, estimated by compartmental 
methods across subjects and treatments, along with the inter-individual and intra-
individual variability measures (%COY) are presented in table 3.12. The mean (± SD) 
Ymv. was 226 (± 92) mg/Uhr across subjects and treatments. The mean(± SD) K,,, was 
176 (± 59) mg/Lacross subjects and treatments. The mean (± SD) Yd/F was 52 (± 15) 
L across subjects and treatments. The mean (± SD) k. was 3.8 (± 2.4) hr·• across 
subjects and treatments corresponding to an absorption half-life of 0.18 hrs (or about 11 
minutes). As table 3.12 indicates, the inter-individual variability, as measured by the 
%COY, was considerable for the PK parameters, especially for the k. and K,,,. This may 
be a consequence of the sampling schedule and the relatively poor precision in the 
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Figure 3.6 Semm Ethanol Cooomtration vs. time profile by lreatmeot for a representative subject (subject 1) for oral ethanol study 






Table 3.10 Mean (%COV) Compartmental pharmacokinetic parameter estimates by 
treatment across subjects for oral ethanol study 
Trt vmax K,,, VJF K. 
[mg/Uhr] [mg/L] [L] [hr1] 
A 270 176 49 4.2 
(n=6) (41) (23) (27) (57) 
B 188 153 54 3.4 
(n=6) (40) (34) (33) (54) 
C 255 174 50 4.5 
(n=6) (40) (37) (22) (72) 
D 192 200 57 3.1 
(n=6) (33) (40) (36) (76) 
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Table 3.11 Me.an (%COY) Compartmental pharmacok.inetic parameters by subject 
across treatments for oral ethanol study 
Subject vmu. K,,, ViF ~ 
No. [mg/Uhr] [mg/L] [L] [hr1] 
1 148 136 57 2.6 
(n=4) (25) (31) (19) (31) 
2 141 142 50 2.4 
(n=4) (12) (36) (19) (27) 
3 257 177 54 2.7 
(n=4) (15) (31) (14) (29) 
4 236 208 71 3.8 
(n=4) (56) (31) (36) (15) 
5 312 205 42 8.4 
(n=4) (36) (28) (10) (23) 
6 263 186 41 2.9 
(n=4) (9) (41) (12) (59) 
Table 3.12 Compartmental phannacokinetic parameters across subjects and 
treatments for oral ethanol study 
vmu K,,, ViF K. 
[mg/Uhr] [mg/L] [L] [h.r'°I] 
Overall Mean 226 176 52 3.8 
(n =24) 
Inter-Individual 









analytical methods, particularly at low concentrations. For all parameters, intra-individual 
variability was lower than the inter-individual variability. 
In summary, a one-compartment model with zero-order input into the absorption 
compartment and first-order absorption into the central compartment, with capacity-
limited elimination was adequately fit to the individual concentration-time data. The mean 
and inter-individual variability estimates of the intrinsic PK parameters V 11,..,0 K,,, and 
Vd/F are consistent with values estimated in other studies of the PK of oral ethanol using 
capacity-limited elimination models (Wagner and Patel, 1972; Wilkinson, 1980; Sedman 
et al., 1978; Holford, 1987). The estimate of k,. obtained in this study was within the 
range of absorption rate constants estimated in other studies (Rangno et al., 1981; 
Holford, 1987). The k,. estimated in this study is probably not a reflection of a true first-
order process, since its value is expected to be influenced by the zero-order rate of input 
into the absorption compartment. The variability in k,. is consistent with the inter-
individual variability in absorption of ethanol observed in other studies (Wagner and 
Patel, 1972; Rangno et al., 1981; Wilkinson et al., 1977) and may be a consequence of 
the inherent variability in physiological processes such as gastric emptying observed 
between individuals. 
In addition to fitting the individual concentration vs. time profiles, the final PK model, 
as described above, was also fit simultaneously to concentration-time data across all four 
active treatments for each subject. 
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Results of the simultaneous fit of individual subject concentration-time data across 
treatments indicated that the fits were adequate based on the coefficients of 
determinations (r), which ranged from 0.'716 to 0.968 and Model Selection Criteria 
(MSC), which ranged from 1.047 to 3.243, random scatter in the plots of residuals vs. 
independent variable, normal distribution of the residuals as well as visual inspection of 
observed and fitted curves. The standard deviations and calculated %C0Vs of the 
parameter estimates were somewhat high, especially for V ...... with %C0Vs ranging from 
17% to 235%, and for K,,, with %COVs ranging from 53% to 305%. 
Individual concentration vs. time profiles illustrating the observed values and fitted 
curves are shown in Appendix B3. Table 3.13 lists the PK parameter estimates obtained 
by subject, for the simultaneous fit. The PK parameter estimates were not significantly 
different across subjects. The mean (± S.1?.) V mu was 193 (± 46) mg/Uhr, the mean 
(± S.D.) K,,, was 174 (± 79) mg/L, the mean (± S.D.) Vd/F was 53 (± 12) mg/Land 
the mean (± S.D.) k,. was 3.3 (± 2.5) hr·1• The inter-individual variability was 
comparable to that observed from compartmental analysis of individual data. 
Table 3. 14 compares the mean (%COY) PK parameter estimates obtained from all three 
methods of PK analysis: non-compartmental, individual compartmental and simultaneous 
compartmental analysis. As table 3.14 indicates, the parameter estimates and their 
variability measures were comparable across the different methods. Figure 3. 7 (a-d) 
illustrates the correlation between the parameter estimates obtained by the individual 
compartmental and simultaneous compartmental methods. The plots show a high degree 
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Table 3.13 Compartmental intrinsic pharmacokinetic parameters from simultaneous 
fitting of treatments by subject for oral ethanol study 
Subject No. V f1>U. K,.. Vd/F k. 
[mg/Uhr] [mg/L] [L] [hf"I] 
I 132 143 57 2.1 
2 139 125 48 2.1 
3 234 8_3 47 2.6 
4 209 281 76 3.0 
5 230 153 44 8.4 
6 214 260 49 1.9 
Mean 193 174 53 3.3 
S.D. 46 79 12 2.5 
%COY 24% 45% 23% 76% 
Table 3.14 Comparison of pharmacokinetic parameter estimates from non-
compartmental, compartmental and simultaneous compartmental 
analysis 
vmu. K,,, Vd/F k. 
[mg/Uhr] [mg/L] [L] [hr-'] 
Non- 145 208 63 NE' 
compartmental (29%) (45%) (47%) 
Analysis 
(n=24) 
Compartmental 226 176 52 3.8 
Analysis (41 %) (34%) (29%) (63%) 
(n=24) 
Sumultaneous 193 174 53 3.3 
Compartmental (24%) (45%) (23%) (76%) 
Analysis 
(n=6) 
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Figure 3. 7a Plot of V max obtained from simultaneous fits vs. mean (S.E.) V max 
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Figure 3. 7b Plot of Km obtained from simultaneous fits vs. mean (S.E.) Km 
obtained from individual fits by subject for oral ethanol study 
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Figure 3.7c Plot of Vd/F obtained from simultaneous fits vs. mean (S.E.) Vd/F 
obtained from individual fits by subject for oral ethanol study 
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Figure 3.7d Plot of k,, obtained from simultaneous fits vs. mean (S.E.) k,, 
obtained from individual fits by subject for oral ethanol study 
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of correlation and random scatter of points about the line of identity, indicating that the 
two methods result in comparable parameter estimates. The individual compartmental 
analysis allows the estimation of inter-individual variability as well as intra-individual 
variability if the same subject receives active treatment on more than one occasion. 
Although the simultaneous compartmental method provides only an estimate of inter-
individual variability, it has the advantage in that it incorporates the intra-individual 
variability, which results in more accurate parameter estimates for each subject. 
3.4.3 PHARMACODYNAMICS 
3.4.3A EEG 
Baseline-corrected response vs. time profiles for the EEG measures evaluated, including 
total power across all frequency bands, total and relative power within each of the five 
frequency bands (delta, theta, alpha, beta I and beta II) and spectral edge are shown in 
Appendix C. A review of these plots reveal· the following: 1) a transient increase in total 
power across all treatments, including placebo, 2) no consistent changes in relative delta 
power across subjects and treatments, 3) increases in relative alpha power seen only for 
treatment D (high-slow), 4) increases in relative power in theta, beta I and beta II bands 
seen only for the high-dose treatments (Band D), and 5) increases in spectral edge seen 
only for the high-dose treatments (Band D). 
The means and %COV of the baseline EEG measures are presented in table 3.15. The 
Table 3.15 Pharmacodynamic parameters (Means and %COY) for EEG measures 
across treatments and subjects 
Total Power 
Trt E,, [µV2] E_. [µV2] E_.-Eo [µ V2] Tmu [hr]1 
A 15508 (48%) 30138 (62%) 14630 (111 % ) 2.8 (0.3-5.0) 
B 14210 (51 %) 25663 (54%) 11453 (79%) 1.0 (0.6-2.5) 
C 14565 (45%) 26279 (51 %) 11714 (80%) 2.9 (0.8-6.0) 
D 14746 (47%) 27273 (61 %) 12982 (90%) 2.3 (0.8-6.0) 
E 17520 (83%) 28544 (62%) 11023 (67%) 3.0 (0.8-4.0) 
Relative Delta Power 
Trt E,, [-] E...... [-] l;.....-E,, [-] T mu [hr]' 
A 0.488 (38%) 0.695 (20%) 0.207 (109%) 3.3 (1.8-5.0) 
B 0.510 (37%) 0.699 (6%) 0.188 (101%) 3.5 (2.5-6.0) 
C 0.463 (42%) 0.654 (31 %) 0.191 (110%) 4.5 (2.5-6.0) 
D 0.538 (43%) 0.677 (10%) 0.139 (135%) 2.5 (l.5-5.0) 
E 0.470 (44%) 0.619. (40%) 0.149 (94%) 4.5 (1.3-6.0) 
Relative Theta Power 
Trt Eo [-] E...... [-] E......-Eo [-] Tmu [hr]' 
A 0.187 (18%) 0.232 (23%) 0.049 (71 %) 1.8 (0.3-5.0) 
B 0.181 (21 %) 0.250 (18%) 0.069 (27%) 1.9 (0.6-6.0) 
C 0.176 (19%) 0.253 (20%) 0.077 (74%) 1.3 (0.6-5.0) 
D 0.184 (7%) 0.252 (14%) 0.068 (44%) 2.0 (0.8-4.0) 
E 0.178 (22%) 0.226 (24%) 0.048 (56%) 1.6 (0.3-6.0) 
I: T _ expresseo as Me<111m (range) 
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Table 3.15 contd. 
Relative Alpha Power 
Trt I;,[-] I;,,.. (-] l;,,..-Eo [-] Tmu [hr] 1 
A 0.260 (71 %) 0.501 (37%) 0.241 (79%) 0.6 (0.3-5.0) 
B 0.247 (89%) 0.452 (40%) 0.205 (72%) 0.6 (0.3-0.8) 
C 0.286 (70%) 0.443 (42%) 0. 157 (113%) 1.6 (0.6-6.0) 
D 0.215 (92%) 0.460 (39%) 0.245 (77%) 3.6 (0.6-6.0) 
E 0.276 (74%) 0.422 (50%) 0.147 (116%) 0.9 (0.3-6.0) 
Relative Beta I Power 
Trt I;,[-] I;,,.. [-] I;,,..-Eo [-] T mu [hr]1 
A 0.031 (45%) 0.042 (37%) 0.012 (76%) 1.6 (0.3-5.0) 
B 0.030 (42%) 0.065 (35%) 0.034 (67%) 2.3 (0.3-4.0) 
C 0.031 (54%) 0.043 (35%) 0.012 (77%) 2.0 (0.8-4.0) 
D 0.029 (67%) 0.062 (42%) 0.033 (54%) 2.5 (0.8-4.0) 
E 0.035 (66%) 0.043 (60%) 0.008 (252%) 4.0 (0.3-6.0) 
Relative Beta 11 Power 
Trt Eo [-] Emix [-] I;....-Eo [-] T mu [hr]I 
A 0.034 (30%) 0.058_ (34%) 0.023 (93%) 0.6 (0.3-1.8) 
B 0.032 (37%) 0.067 (40%) 0.035 (73%) 1.0 (0.3-6.0) 
C 0.043 (44%) 0.055 (33%) 0.012 (91 %) 2.4 (0.3-5.0) 
D 0.035 (72%) 0.060 (23%) 0.025 (83%) 1.0 (0.3-6.0) 
E 0.041 (60%) 0.053 (54%) 0.012 (70%) 0.3 (0.3-5.0) 
1: T ex resseo as Meo1an (range) 
... p 
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Table 3.15 contd. 
Spectral Edge 
Trt Eo [Hz] ~[Hz] ~-E0 [Hz] T ..... [hr]1 
A 9.7 (10%) 11.3 (11 %) 1.7 (89%) 0.3 (0.3-1.8) 
B 9.6 (12%) 12.0 (11 %) 2.4 (77%) 0.3 (0.3-0.8) 
C 10.3 (14%) 11.3(11%) 1.0 (98%) 2.9 (0.3-5.0) 
D 9.5 (25%) 11.6 (13%) 2.1 (47%) 1.0 (0.8-6.0) 
E 10.2 (23%) 11.4 (17%) 1.1 (66%) 0. 7 (0.3-6.0) 
1: T ... expressea as Mea1an (range) 
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baseline measures were not different across subjects and treatments, but showed 
considerable variability, except for relative theta power and spectral edge. 
Figures 3.8 - 3.14 show the mean (± S.E.) peak changes in the EEG measures, 
including total power, relative power in each of the five frequency bands, delta, theta, 
alpha, beta I and beta II) , and spectral edge, by treatment. 
Statistical comparison of the E.nax ob, or E...m ob, and t.n..x or t...a, for the EEG measures 
revealed significant treatment differences only for relative theta power (p=0.04). 
Multiple comparisons indicated that the hig~-dose treatments were significantly different 
from the low-dose treatments and placebo, however the low-dose treatments were 
indistinguishable from placebo. Also, there were no differences between fast and slow 
input treatments both at low and high doses. Residuals were found to be nonnally 
distributed for these variables. There were _no significant sequence or period effects on 
any of the EEG variables evaluated. The p values for the significance of the baseline 
response as a covariate was less than 0.05 for all the EEG variables evaluated except for 
relative theta power. This indicates that the baseline differences account for a significant 
proportion of the variability in EEG response between treatments. 
The increases in theta power, along with the increases in beta power and decrease in the 
spectral edge are consistent with the increase in EEG power and a generalized slowing 
of the EEG that have been previously reported in the literature following administration 
of oral doses of ethanol comparable to doses administered in this study (Begleiter and 
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EEG resJX>nses following ethanol administration observed in this study are also in 
agreement with the published literature ~htinen et al., 1978; Lehtinen et al., 1985). 
The EEG did not prove to be a very sensitive measure of the CNS effects of ethanol, 
showing changes only at the high dose relative to placebo. There did not appear to be 
an effect of input-rate on the EEG measures evaluated. 
3.4.3B Psychometric Performance Tests 
Baseline-corrected resJX>nse vs. time profiles for the PPT measures evaluated, including 
categories completed and number of errors for the CST, average tap-rate for the 
dominant and non-dominant hands for FT and total attempts and number of errors for 
DSST are shown in Appendix D. Table _ 3.16 lists the baseline (EJ, maximum or 
minimum observed resJX>nse <Emu""" or Eu.obi) and time of Em.xo1>• or Em..o1>• (t.o.u or U 
for each of the PPT measures evaluated . Figures 3.15 - 3.17 show the peak changes in 
the PPT measures evaluated by treatment, including total attempts and number of errors 
for DSST and peak change in dominant and non-dominant hand tap-rate for FT. 
Results for the CST indicate that there were no consistent changes in either of the 
measures. There was a high degree of variability in baseline resJX>nses as well as in the 
peak resJX>nses measured. Also, a learning effect was observed across periods with 
improvement in performance over time independent of treatment. 
There appeared to be a transient decrease in the total attempts followed by a later 
increase in total attempts for the DSST, as ·well as a transient increase in the number of 
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Table 3.16 Pharmacodynamic parameters (Means and %COY) for PPT measures 
across treatments and subjects 
DSST-Total Attempts 
Trt I;,[-] I;..;.."[-] E0-I;..;.. [-] Tm.u [hr] 1 
A 62 (16%) 53 (19%) 8 (58%) 1.6 (0.8-6.0) 
B 55 (25%) 51 (24%) 6 (92%) 1.6 (0.8-4.0) 
C 59 (21 %) 52 (21 %) 7 (73%) 1.5 (0.8-2.5) 
D 58 (25%) 46 (25%) 12(71%) 1.6 (l .5-3.0) 
E 55 (24%) 52 (22 %) 4 (87%) 1.8 (1.5-5.0) 
DSST-Number of Errors 
Trt I;,[-] E...... [-] I;.....-Eo [-] Tmax [hr]1 
A 3 (169%) 7 (55%) 5 (86%) 2.8 (1.8-5.0) 
B 2 (159%) 7 (78%) 6 (60%) 2.1 (0.8-3.0) 
C 3 (121 %) 7 (112%) 4 (119%) 1.9 (1.8-2.0) 
D 2 (185%) 8 (85%) 6 (57%) 2.8 (l.5-4.0) 
E 3 (122%) 6 (103%) 3 (99%) 2.3 (0.8-6.0) 
FT-Dominant Hand Tap-rate 
Trt E0 [taps/sec] E.nu, [taps/sec] E0 -E.nu, [taps/sec] Tm.u [hr]1 
A 6.1 (14%) 5.6 (16%) 0.5 (99%) 3.5 (0.3-6.0) 
B 6.2 (15%) 5.1 (21 %) 1.0 (56%) 0. 7 (0.3-6.0) 
C 6.0 (14%) 5.5 (17%) 0.5 (98%) 1.4 (0.8-4.0) 
D 6.2 (15%) 5.5 (18%) 0.7 (47%) 1.6 (0.8-4.0) 
E 5.7 (17%) 5.6 (1-2 %) 0.2 (117%) 4.0 (1.5-5.0) 
I: 1 ex resse<J as Mea1an -{range) 
.... p 
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Table 3.16 contd. 
Ff-Non-dominant Hand Tap-rate 
Trt E,, [taps/sec] ~ [taps/sec] E0 -E,,.;., [taps/sec] Tmax [hr]1 
A 6.0 (12%) 5.5 (1-3%) 0.6 (66%) 0.7 (0.3-1.5) 
B 6.0 (14%) 5.1 (18%) 0.9 (46%) 0.6 (0.3-1.8) 
C 5.7 (18%) 5.4 (16%) 0.3 (62%) 0.8 (0.3-3.0) 
D 5.7 (18%) 5.0 (21 %) 0.8 (56%) 1.9 (0.6-2.5) 
E 5.5 (10%) 5.4 (14%) 0.2 (95%) 2.5 (0.6-3.0) 
l: 1 _ expressea as Median (range) 
16 
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errors for the DSST. The greatest effect was seen for treatment D, however, the 
variability in the responses was considerable. The response for the DSST measures was 
also confounded by learning effects, however, baseline variability in DSST measures was 
low. Statistical comparison of PD parameters for DSST did not reveal any significant 
differences between treatments. There was, however, a significant period effect observed 
for the I;,...• for the total attempts (p=0.001). 
Although the effects of ethanol on the card-sorting test and on the DSST have been 
demonstrated in other studies (Wittenborn, 1987, Gengo et al. , 1990), the lack of effect 
seen in this study may be attributed to task difficulty and inadequate training of the 
subjects prior to drug administration. 
There appeared to be a dose-related decrease in the tap-rate for both hands for the Fr, 
with a greater effect seen for the non-dominant hand . Baseline variability was relatively 
low across subjects and treatments. Statistical comparison of E..,;., ob• for the non-dominant 
hand as well as for the dominant hand indicated significant differences across treatments 
(p=0.014 for dominant hand tap-rate and p=0.023 for non-dominant hand tap-rate). 
Multiple comparisons revealed that the two high-dose treatments (B and D) were 
significantly different from the two low-dose treatments (treatments A and C) and 
placebo (treatment E), but were not different from each other. The low-dose treatments 
were indistinguishable from each other and from placebo. The p values for the 
significance of the baseline response as a covariate was less than 0.05 for the E..,;.,• for 
both hands. This indicates that the baseline response is a significant determinant of the 
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Ff response to ethanol. The NR score (see section 3.3.5E) was also a significant 
covariate in the statistical analysis of the E,,,., o1>1 values across treatments. This indicates 
that there may be a correlation between the lack of subjective response of the non-
responders and the degree of psychomotor. impainnent as measured by Ff. Statistical 
comparison of T ..... values revealed no significant differences across treatments. There did 
not appear to be any effect of input-rate on the Ff measures. 
The decrease in total attempts and increase in number of errors for the DSST as well as 
the decrease in tap-rate for Ff are consistent with psychometric impairment. The 
psychomotor impainnent appeared to be dose-related, but showed consistent, and in some 
cases statistically significant changes only for the high-dose treatments. The impainnent 
in psychometric performance is consistent with the published literature on performance 
impainnent following oral administration of ethanol doses to achieve concentrations in 
the range of 800 to 1000 mg/L (Evan et al., 1984, Moskowitz et al., 1976, Wittenborn, 
1987). 
Also, there did not appear to be any effect of input-rate on the PPT measures evaluated. 
The effect of input-rate on psychometric performance was evaluated by Moskowitz et al. 
(1976), who found that subjects who cons.urned the dose of ethanol rapidly (ingestion 
time: 15 minutes) performed more poorly than subjects who consumed the dose of 
ethanol slowly (ingestion time: 1 hour). The lack of effect of input-rate on psychometric 
performance observed in our study may be due to the relatively small difference in the 
slow and fast input-rates (20 minutes vs. 50 minutes) used in our study, as well as the 
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fairly high variability due to individual differences in performance impairment. 
3.4.3C Impairment Scales 
Baseline-corrected response vs. time profiles for the SRI and ORI measures evaluated, 
including scores for the items "HIGH", "DRUNK" AND "ALCOHOL EFFECTS" on 
the SRI scale, as well as scores for the items "HIGH" and "DRUNK" on the ORI scale 
are shown in Appendix E. Response vs. time profiles for the other items on the SRI and 
ORI scales are not included since they did not show a consistent response across subjects 
and treatments. 
Table 3.17 lists the baseline (E.,), maximum observed response <Em.uot>a) and time of 
E...u• (U for each of the SRI and ORI items listed above. Figures 3.18 - 3.22 show 
the peak changes in the SRI and ORI measures evaluated by treatment, including 
"IDGH", "DRUNK" and "ALCOHOL EFFECTS" for the SRI scales, and "HIGH" and 
"DRUNK" for the ORI scales. 
The SRI and ORI scales were very sensitive to the effects of ethanol, with the most 
sensitive items being "IDGH", "DRUNK" and "ALCOHOL EFFECTS" on the SRI scale 
and "HIGH" and "DRUNK" on the ORI scale. There were dose-related increases in the 
E...uot>a for these items, with both low and high doses showing statistically significant 
increases in E...uo1>• from placebo. Some subjects also showed a delayed t_., especially 
at the high dose, indicating that there was an input-rate-related effect on the SRI and ORI 
scales. 
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Table 3.17 Phannacodynamic parameters (Means and %COV) for SRI/ORI 
measures across treatments and subjects 
SRI - HIGH Score 
Trt E,, [mm] E...... [mm] E......-E0 [mm] T ....... [hr]' 
A I (140%) 13 (86%) 12 (90%) 0.5 (0.3-0.6) 
B 1 (126%) 32 (64%) 31 (65%) 0.6 (0.3-1.3) 
C 1 (175%) 10 (67%) 9 (75%) 0.8 (0.3-1.5) 
D 1 (126%) 33 (73%) 32 (77%) 1.2 (0.3-3.0) 
E 1 (113%) 1 (77%) 0 (155%) 0.3 (0.3-0.8) 
SRI - DRUNK Score 
Trt E,, [mm] E...... [mm] E......-E,, [mm] Tmu [hr]1 
A 1 (122%) 8 (59%) 7 (60%) 0.9 (0.3-2.5) 
B 1 (126%) 25 (60%) 24 (61%) 0.6 (0.3-1.3) 
C 1 (167%) 5 (103%) 4 (111 %) 1.3 (0.3-2.0) 
D 1 (100%) 29 (81 %) 27 (86%) 1.5 (0.3-3.0) 
E 1 (126%) 2 (73%) 1 (122%) 0.6 (0.3-6.0) 
SRI - ALCOHOL EFFECTS Score 
Trt E0 [mm] E...... [mm] E......-E0 [mm] Tmu [hr]' 
A 1 (89%) 17 (50%) 16 (54%) 0.6 (0.3-2.0) 
B 1 (126%) 40 (47%) 39 (47%) 0.6 (0.3-1.5) 
C 1 (159%) 14 (54%) 14 (57%) 0.8 (0.6-1.5) 
D 1 (245%) 34 (73%) 34 (75%) 1.4 (0.6-2.5) 
E 1 (126%) 3 (88%) 2 (144%) 0.5 (0.3-0.8) 
1: T ... expressea as Mea1an (range) 
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Table 3.17 contd. 
ORI - IIlGH Score 
Trt E., [mm] E....i [mm] E....i-E0 [mm] T ..... [hr]I 
A 1 (245%) 16 (54%) 16 (53%) 0.9 (0.3-1.5) 
B 0 (0%) 23 (38%) 23 (38%) 1.0 (0.6-1.5) 
C 0 (0%) 11 (65%) 11 (65%) 1.4 (0.3-1.5) 
D 0 (0%) 26 (30%) 26 (30%) 1.8 (0.8-2.0) 
E 0 (0%) 2 (157%) 2 (156%) 0.3 (0.3-1.8) 
ORI - DRUNK Score 
Trt E., [mm] E....i [mm] E....i-E., [mm] T ..... [hr]' 
A 0 (0%) 6 (59%) 6 (59%) 1.1 (0.3-1.5) 
B 0 (0%) 21 (44%) 21 (44%) 1.5 (1.3-2.0) 
C 0 (0%) 5 (111%) 5 (111%) 1.0 (0.3-1.5) 
D 0 (0%) 20 (58%) 20 (58%) 1.9 (0. 8-3.0) 
E 0 (245%) 1 (155%) 1 (167%) 0.3 (0.3-1.3) 
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Figure 3.21 Baseline-corrected E .... for ORI-IIlGH score by treatment for oral ethanol study 
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Figure 3.22 Baseline~rrect.ed E-.. for ORI-DRUNK score by treatment for oral ethanol study 
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Two of the six subjects (subjects l and 3) did not show a consistent response on the SRI 
and ORI scales, even though they showed EEG changes and psychometric impairment 
consistent with the other subjects. These two subjects were classified as "non-
responders". Figure 3.23 shows the SRI-It ALCOHOL EFFECTS" score vs. time, by 
treatment, for two representative subjects (subject 1 - non-responder and subject 4 -
responder). In order to incorporate this in th·e statistical analysis, these two subjects were 
given a "non-responder" score (NR) of 0, while the other four subjects ("responders") 
were given a score of l. This score was used as a covariate in the statistical analysis. 
Statistical comparison of the E...... obi and t.nu revealed significant treatment differences for 
all the SRI and ORI variables. Significant differences were observed for all of the five 
measures evaluated (SRI-"HlGH": p=0.0006, SRI-"DRUNK": p=0.0020, SRI-
" ALCOHOL EFFECTS": p=0.0013, ORI-"HIGH": p=0.0010, ORI-"DRUNK": 
p=0.0001). Multiple comparisons indicated that, for all the five measures, the low doses 
(A and C) were indistinguishable from placebo (E) and from each other, while the high 
doses (Band D) were significantly different_ from low-doses and placebo. There were no 
significant differences between the two high dose treatments. The t.nu parameter showed 
significant differences only for one measure, ORI-"DRUNK" (p=0.0135). Multiple 
comparisons revealed significant differences for treatment B (high-fast) vs. placebo and 
treatment D (high-slow) vs. the other treatments. There were no differences between 
treatments A, C and E. There were no significant sequence or period effects. The 
baseline response was not a significant covariate in the analysis, however the NR score 
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Figure 3.23 SRI-ALCOHOL EFFECTS vs. time profiles by treatment for representative 
oon-respooder subject (subject I) and representative responder subject (subject 4) 
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was a significant covariate for all the variables tested (p<0.05), indicating that the NR 
score was an important detenninant of the differences in response on the SRI and ORI 
scales across treatments. 
In summary, the SRI and ORI scales provided sensitive measures of the subjective effects 
of ethanol. The most sensitive items on the scales were "HIGH", "DRUNK" and 
"ALCOHOL EFFECTS", showing dose-related as well as input-rate related (at the high 
dose) changes in scores consistent with· perceived impairment. These results are 
consistent with results obtained by other investigators who have used scales similar to the 
SRI scales (Shuckit, 1984; Lex et al., 1988; Gengo et al., 1990), indicating that these 
scales are indeed sensitive measures of the subjective effects of ethanol. 
3.4.3D PK-PD Correlation and Tolerance Development 
In order to evaluate the PK-PD relationship for ethanol, response vs. serum ethanol 
concentration profiles were plotted for several of the PD measures evaluated. The PD 
measures that were plotted vs. serum concentrations included the relative theta power 
from the EEG measures, tap-rate for the non-dominant hand for FT from the PPT, and 
the score on the item "ALCOHOL EFFECTS" on the SRI scales. Response vs. 
concentration plots for each of these measures are presented by subject and treatment in 
Appendix F. 
A review of the plots for baseline-corrected relative theta power vs. serum ethanol 
concentrations resulted in the following ob~rvations: 
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1) Effect-concentration profiles revealed no consistent patterns across subjects or 
treatments. 
2) For the low-dose treatments A and C, several of the subjects showed an initial 
decrease in relative theta power followed by a later increase that went above baseline 
values for some subjects. The changes in- relative theta power did not appear to be 
correlated to concentrations for these treatments. 
3) For the high-dose treatments B and D, there was a general increase in relative theta 
power with concentration. For treatment B, 3 of the 6 subjects showed an initial transient 
decrease in relative theta power prior to the increases in relative theta power. For 
treatment D, the initial transient decrease ·was seen in 3 of the 6 subjects. Only one 
subject (subject 6) showed the presence of a clockwise hysteresis loop in the response vs. 
concentration profile. 
In summary, there was no consistent effect-concentration correlation for the EEG 
measures evaluated. There was some correlation between peak concentration and peak 
effect, but the time-course of changes in concentration and effect were inconsistent. 
A review of the plots for baseline-corrected non-dominant hand tap-rate vs. serum 
ethanol concentrations resulted in the following observations: 
1) Increasing concentrations generally were associated with decreases in tap-rate. 2) for 
treatment A, 2 of the 6 subjects (subjects 1 and 5) actually showed an increase in tap-
rate, indicating an improvement rather than impairment in psychomotor performance. 
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Also, two of the subjects (subject 2 and 4) showed some degree of clockwise hysteresis 
with a smaller change in tap-rate at later time-points during the descending limb of the 
profile relative to the change at earlier ti~e-points during the ascending limb of the 
profile, at similar concentrations. 
3) For treatment C, one subject (subject 5) showed an increase in tap-rate, while one 
subject (subject 6) showed an initial increase in tap-rate followed by a later sustained 
decrease in tap-rate. 
4) For treatment B, one subject (subject 1) showed an initial increase in tap-rate followed 
by a decrease in tap-rate at later-time points. Three of the subjects (subjects 2, 3, 4) 
showed a clockwise hysteresis pattern with greater degrees of impairment at earlier time-
points during increasing concentrations followed by lower degrees of impairment, and 
in some cases improvement in performance at later-time points during declining 
concentrations. 
5) For treatment D, one subject (subject 5) showed a consistent increase in performance 
with no indication of impairment. Three subjects (subjects 2, 4, 6) showed an 
improvement in performance at later time points, but tap-rates went above baseline values 
only for one subject at later time-points. 
In summary, low-dose treatments showed inconsistent changes in tap-rate, while high 
doses showed concentration-related impairment. At the high dose, the fast-input treatment 
(treatment B) showed impairment in performance followed by improvement in 
performance at later time points in some of the subjects. The slow-input treatment 
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(treatment D) showed initial impairment, with some improvement in performance at later 
time-points, however the degree of improvement was smaller than that observed for 
treatment B. This later improvement in performance may be due to acute tolerance 
development to the psychometric impairment effects of ethanol. Another explanation for 
this phenomenon may be the development of acute learning effects. The relatively large 
variability in the time course of the tap-ra~ following the different doses and dose-rates 
of ethanol as well as the learning effects may have precluded the development of a clear 
relationship between changes in finger-tapping rate and concentration. 
A review of the plots for baseline-corrected SRI-Alcohol Effect Scores vs. serum ethanol 
concentrations resulted in the following observations: 
1) There was a consistent increase in SRI scores with concentrations at earlier time points 
that appeared to be correlated, i.e., higher concentrations were associated with a higher 
degree of subjective impairment as assessed by the SRI scores. 
2) At later time-points, the effect appeared to decline faster than concentrations resulting 
in the presence of clockwise hysteresis loops in the effect vs. concentration proflles. 
Clockwise hysteresis loops were observed in 3 of the 6 subjects for treatment A, and in 
5 of the 6 subjects for treatments B, C and D. Figure 3.24 shows the SRI-Alcohol effect 
vs. concentration profiles by treatment for a representative subject (subject 2). The 
degree of hysteresis was dose-related with higher doses showing larger degrees of 
hysteresis indicated by a rightward shift in the descending limb by about 300 mg/L with 
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an increase in dose. 
3) Only one subject (subject 4) showed consistent concentration-related impairment 
without the presence of hysteresis. 
4) Even the subjects who were classified as non-responders had effect-concentration 
profiles that showed clockwise hysteresis. 
Follow-up analysis for other items of the SRI scale, including the items "IDGH" and 
"DRUNK", as well as for the ORI scale items "IDGH" and "DRUNK" revealed the 
same pattern of initial concentration-related impairment and the presence of clockwise 
hysteresis, although the most profound effect was observed for the SRI-Alcohol Effects 
scores. 
These findings are consistent with the development of acute, exposure-related tolerance 
development to the subjective impairment effects of ethanol. This means that the degree 
of subjective impairment perceived by the subject was higher during the ascending limb 
of the ethanol concentration-time curve than at similar concentrations during the 
descending limb of the ethanol concentration-time curve. During the drug elimination 
phase, the effect declined faster than drug concentrations such that subjects did not 
perceive themselves to be impaired even though they had significant measurable 
concentrations of ethanol and exhibited psychometric impairment as measured by finger-
tapping. This means that there was a temporal disparity between perceived impairment 
and performance impairment during the descending limb of the ethanol concentration -
time curve. 
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These findings are consistent with the results of other studies evaluating subjective and 
objective impairment following oral ethanol administration to achieve concentrations 
comparable to the serum concentrations achieved in this study (Radlow and Hurst, 1985, 
Jones et al., 1987, Kaplan et al., 1985, Gengo et al., 1990, Rohrbaugh et al. , 1987). A 
review of the results of these studies indicate that, in general, objective measures of 
impairment, such as psychometric performance measures, show no acute tolerance 
development, while subjective measures that rely on the subjective perception of 
impairment appear to show the development of acute tolerance to ethanol. Results of this 
study also indicate that the tolerance appears to be exposure-related, however, the 2.5 
fold increase in input-rate (from 20 minutes to 50 minutes) did not appear to have an 
effect on the development of acute tolerance to the subjective effects. Considering the 
large variability in absorption of ethanol as.well as in the pharmacodynamics of ethanol, 
the 2.5 fold difference in the input-rate may not have been large enough to evaluate an 
input-rate effect on the PK and PD of oral ethanol in this study. 
3.4.3E PK-PD Modelling of the Acute Tolerance Development to Subjective 
Effects of Ethanol 
A PK-PD model was developed to describe the tolerance development to the subjective 
impairment following oral ethanol administration. The SRI-ALCOHOL EFFECTS (SRI-
AE) measure was selected since it was shown to be the most sensitive subjective measure 
of ethanol's effect. The SRI-AB and concentration data were fit individually for each 
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subject and treatment. The data sets were imported from a spreadsheet (Microsoft Excel 
version 5, Microsoft Inc., WA) and directly imported into the program used for the 
fitting, Scientist (version 2.0 for Windows, MicroMath Inc., Salt Lake City, UT). 
Model Development: The first model evaluated was the hypothetical antagonistic 
metabolite model first used to describe tolerance development to the cardiovascular 
effects of nicotine (Porchet et al., 1988). This model incorporates tolerance as a result 
of (non-competitive) antagonism produced by a hypothetical metabolite induced by a first 
order process. The model consists of three parts. The first is a pharmacokinetic model 
(one compartment model with capacity-limited elimination for ethanol). The second is 
a pharmacodynamic model linked to the PK model that relates the serum concentration 
of ethanol (C) to the observed effect E using the linear relationship, 
E = S * C 
where S is the slope or sensitivity factor for the effect-concentration relationship. The 
third part of the model is the tolerance model consisting of a hypothetical metabolite 
(C..J which is related to the central PK compartment by a first-order rate constant k11&\1. 
The metabolite is eliminated by a first o~der process Ck..mo) . The overall PD model 
equation is: 
S•C E = ----
l + < c_) 
Ca.10 
where CllldO is the potency of the antagonist, or the concentration required to produce 
115 
50% antagonism. 
This model was coded in Scientist. Initial estimates were obtained from simulations using 
different values of the parameters. The model was fit to the individual concentration-
effect (SRI-AE) data. The PK parameters were fixed to the final estimates obtained 
during the PK modelling of the data (done previously, see section 3.4.2B). 
After attempting to fit several data sets, it was realized that this model works best with 
data with repeated inputs of drug. The onset and offset of effect are governed by a single 
rate constant, therefore the fastest the effect can decline is at the same rate as the 
concentration of the metabolite. Since the metabolite concentration is a function of the 
parent drug, the effect cannot decline faster than the elimination rate of the parent drug 
(in the case of formation-rate limited metabolite kinetics). Therefore this model is 
incapable of describing the existing data. It cannot be used to model acute tolerance 
within the same dose without repeated inputs (as done in the original study by Porchet 
et al., 1988). Therefore it was determined that other models of tolerance would have to 
be evaluated. One of the models that was evaluated and finally used for our data was the 
model originally developed by Bauer and Fung (1994) to describe nitroglycerin-induced 
hemodynarnic tolerance in experimental heart failure. The final model used incorporates 
the PK model (one compartment with capacity-limited elimination) linked to the PD 
model which relates concentration (C) tQ effect (E) (see figure 3.25). The model 
postulates that the primary (direct) effect, rather than the drug concentration, is the 
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tolerance to the effect is a result of compensatory feedback mechanisms that are produced 
to counter-regulate the direct effect. 
The direct drug effect (Eo) was modelled as: 
Eo=S*C 
where S is the slope factor or Sensitivity. 
The feedback effect ~ was modelled using two rate constants (k... and k.,,y). The 
differential equation was 
&,s. = k... *Eo - k.,,r *Er,s 
The net observed effect E was calculated as 
E=Eo - Er,s 
This model was coded in Scientist. Initial estimates were obtained from simulations using 
different values of the parameters. The model was fit to the individual concentration-
effect (SRI-AE) data. The PK parameters were fixed to the final estimates obtained 
during the PK modelling of the data (done previously, see section 3.4.2) . Weights of 1 
and 1/y were evaluated. Goodness of fit was assessed by evaluating the coefficient of 
determination (r2), Model Selection Criteria (MSC) , parameter estimates and their 
standard deviations, residual analysis, and visual observation of the observed points and 
fitted effect-time profiles as well as observed and fitted hysteresis loops (in effect-
concentration plots). · 
Results: Individual fits were determined to be acceptable based on goodness of fit 
criteria described· above. Weights of 1/y did not appear to improve the fit. The 
118 
correlations for the final model ranged from 0.860 to 0.997, and MSC ranged from 1.21 
to 5.21. Table 3.18 lists the final parameter estimates for the model parameters, S, k,,o 
and k.,,y. Figure 3.26 shows the observed values and fitted curves for the SRI-AE score 
vs. concenttation plots by treatment for a representative subject (subject 2). 
As Table 3.18 indicates, the overall S does· not appear to be different across treatments. 
However, the S for responders appears to be higher than for non-responders. The slope, 
S, can be considered as a measure of individual sensitivity to the effect of ethanol for a 
unit change in concenttation, in the absence of tolerance. The finding that the estimate 
of S is lower for the non-responders compared to the responders is a result of the 
classification of the subjects based on their subjective response to ethanol. S can serve 
as a valuable measure to evaluate differences in sensitivity to the effects of ethanol (in 
the absence of tolerance) for other surrogate measures of ethanol's effect (that can be 
linearly related to concenttation), as well as in different populations of subjects, such as 
women, elderly subjects and alcoholic subjects. 
The rate constants, k,,o and ko,r, did not appear to be different across treatments, and did 
not differ between responders and non-responders. The relatively large COY% may be 
a result of the small sample sizes (n=2 for non-responders and n =4 for responders). The 
mean k,,o of 0. 75 hr"1 translates to an onset half-life of tolerance of 0. 9 hours, and the 
mean ko,r of 1.42 hr-1 translates to an onset half-life of tolerance of 0.5 hours. 
One observation from the PK-PD modelling is that the model predicts a rebound effect, 
i.e., the net effect falls below the baseline. This cannot be observed in the data since the 
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Table 3.18. Parameter estimates for PK-PD model of SRI-AE effects by treatment. 
Trt A Trt B Trt C Trt D 
s 
All (n=6) 0.060 (83%) 0.070 (68%) 0.070 (81 %) 0.066 (78%) 
NR1 (n=2) 0.075 (40%) 0.023 (19%) 0.039 (27%) 0.020 (7%) 
R2 {n=4) 0.053 {114%) 0.094 (42%) 0.086 (77%) 0.089 {54%) 
k... 
All (n=6) 0.79 (56%) 0.84 (42%) 1.11 (57%) 0.61 (55%) 
k.,,r 
All (n=6) 2.69 (105%) 1.30 (31 %) 1.72 (45%) 0.95 (41 %) 
I: NR - Non-Responder 2: R - Responder 
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mood scales do not pennit measurement of effects below the baseline (zero). 
In summary, the feedback model of tolerance that characterizes acute tolerance as a result 
of compensatory feedback mechanisms that are produced to counter-regulate the direct 
effect of the drug resulted in an adequate fit to the subjective effect-concentration-time 
data from this study. This model has been previously used to describe the hemodynamic 
effects of nitroglycerin (Bauer and Fung, 1994), and to our knowledge, this is the first 
attempt to use this model to describe tolerance to the CNS effects of a centrally-acting 
drug. The general fonn of this model can accommodate changes in drug input, allowing 
the flexibility of examining the effect of different input regimens (doses and dose-rates) 
on the development of acute tolerance to the subjective effects of ethanol. 
3.4.3F Correlation of Phannacodynamic Measures 
Since one of the aims of this study was to evaluate the EEG as a surrogate measure of 
the CNS effect of ethanol, and to assess the relationship between the EEG changes and 
changes in PP as well as the relationship between the EEG changes and SRI, linear 
regression of the E.n.x • for relative theta power on the E,..;., o1>, for non-dominant hand tap-
rate, and on the E.n.x• for SRI-ALCOHOL EFFECTS score were performed individually 
to assess the significance of the relationship between the EEG changes and changes in 
PP and SRI. Since this was a crossover study, the regression was only performed for 
observations for treatment B (high dose-fast input). 
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dominant hand tap-rate for treatment B. J'he coefficient of determination was 0.159 
(n =6), which is not significant, but does indicate a trend toward a weak association 
between these two objective m·easures. 
Figure 3.28 shows the plot of E...u• for relative theta power vs. the E...u°"' for SRI-
Alcohol Effects score for treatment B. As figure 3.28 illustrates, there does not appear 
to be a consistent relationship between the two variables. Also, the coefficient of 
determination was 0.002 (n=6). This indicates that there does not appear to be an 
association between changes in EEG measures and changes in subjective impairment 
measures. 
Thus, it appears from comparison of the regressions of EEG measures individually on 
psychometric performance measures and on subjective impairment measures, that, if 
anything, the EEG changes are more closely associated with PPT changes rather than 
with the subject-rated impairment measures, It should be noted, however, that neither of 
the associations were statistically significant, and that these comparisons were only 
performed for peak changes in these measures, and that the comparisons were only done 
for one treatment. 
3.5 CONCLUSIONS 
The following conclusions can be made from the oral ethanol study which was a pilot 
study designed to evaluate the effect of do~ and dose-rate on the pharmacokinetics and 
pharmacodynamics of ethanol in six healthy male subjects. Table 3.19 lists the results 
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Table 3.19. Summary of Inferential Statistical Analysis 
Measure Treatment Multiple comparisons Baseline as NR score as 
Effect covariate covariate 
Pharmacoltinetic Measures 
v ... NS 1 - - -
K... NS - - -
Vd/F NS - - -
k. NS - - -
Pharmacodynamic Measures 
TQta! PQW~[ 
E ... -F.o NS - p=0.018 NS 
t,,,.. NS - NS NS 
R~I. Th~il PQw~r 
E ... -f.o p=0.041 A;&!J;), E;&!B,C,D NS NS 
t,,,.. NS - p=0.038 NS 
R~I. Ali;!hil PQw~r 
E_,.-f.o NS - p=0.000 NS 
t,,,.. NS - NS NS 
L~fi hind Iilu-rilt~ 
f.o-Eu p=0.022 A;&! B,D; C ;&! B,D; p=0.014 p=0.010 
E;tB,D 
t,,... NS - NS p=0.005 
SRI-Drunk 
E ... -F.o p=0.002 A;tB,D; C¢B,D; NS p=0.017 
E;&!B,D 
t,,,.. NS - NS NS 
SRI-Als;QhQI Effects 
E ... -f.o p=0.001 A¢B,D; C;&!B,D; NS p=0.039 
E;&!B,D 
t,,,.. NS - NS NS 
ORI-Drunk 
E ... -F.o p=0.000 A¢B,D; C¢B,D; NS p=0.004 
E¢B,D 
t,,,.. NS - NS NS 
1: N~ = not s1 nificant g 
125 
of the inferential statistical analysis performed for the primary PK and PD measures 
evaluated in this study. 
1) Ethanol, after oral administration, foJlows capacity-limited pharmacokinetics. The 
serum ethanol concentration vs. time profile was best described by a one-compartment 
model with zero-order input into the absorption compartment and first-order absorption 
in to the central compartment, and capacity-limited elimination. The intrinsic PK 
parameters estimated for ethanol were V mu, K,,,, Vd/F and k.. The mean (± SD) V mu 
was 226 (± 92) mg/Uhr across subjects and treatments. The mean(± SD) K,,, was 176 
(± 59) mg/Lacross subjects and treatments. The mean(± SD) Vd/F was 52 (± 15) L 
across subjects and treatments. The mean(± SD) k. was 3.8 (± 2.4) hr1 across subjects 
and treatments. The intrinsic PK parameters were independent of dose and input-rate, but 
were associated with considerable inter-individual variability, especially K,,, and k.- Inter-
individual variability was higher than inter~individual variability for all the intrinsic PK 
parameters. The PK parameters estimated in this study are consistent with previously 
reported PK parameters for oral ethanol (Holford, 1987). 
2) Ethanol induced changes in measures of psychometric impairment, mainly finger-
tapping, although the high variability and small sample sizes resulted in statistically 
significant changes only at the high doses (treatments Band D) relative to the low doses 
(treatments A and C) and placebo (treatment E). The card-sorting test and the DSST did 
not show significant changes probably due to large variability and confounding with 
learning effects. 
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3) EEG measures also showed statistically significant differences only for the peak 
change in relative theta power at the high doses (treatments Band D) compared to the 
low doses (treatments A and C) and placebo (treatment E). The EEG measures also 
showed considerable variability, both at baseline as well as following ethanol 
administration. 
4) Ethanol induced significant dose-i:elated changes in measures of subjective 
impainnent. The SRI and ORI scales proved to be the most sensitive measures of 
ethanol's effect. Some of the measures also showed input-rate-related changes following 
oral ethanol administration. 
5) There was significant acute, exposure-related tolerance to the subjective 
impainnent induced by ethanol. The tolerance development could be characterized by a 
PK-PD model incorporating tolerance as a compensatory feedback mechanism to the 
direct impainnent effect of the drug. The model allowed the estimation of ethanol 
sensitivity with the model parameter S. Acute tolerance development was not observed 
for the psychometric performance measures or the EEG measures, indicating a temporal 
disparity between the perceived and performance impairment induced by ethanol. 
6) Two of the 6 subjects in the study were classified as "non-responders" based on 
their lack of subjective response to ethanol administration, even though they demonstrated 
consistent psychometric impairment and EEG changes. 
7) The EEG changes were not correlated to the psychometric impairment or to the 
subjective impairment induced by ethanol. 
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This study had some limitations, including that it was a pilot study in a small sample of 
six healthy male subjects. The considerable individual variability in response to ethanol 
administration would require larger sample sizes in future studies to result in statistically 
significant conclusions. Also, the poor perfonnance of the psychometric tests in the study 
indicated that a battery of simpler psychometric tests, that had been validated to be 
sensitive to ethanol's effects should be used in future studies in order to obtain measures 
that were associated with less variability and greater sensitivity to ethanol. Lastly, the 2.5 
fold difference in input-rate (20 minutes vs. 50 minutes) was not large enough, relative 
to the large variability in the physiological processes that govern oral absorption, such 
as gastric emptying, to observe any clear input-rate-related differences in ethanol 
pharmacokinetics or pharmacodynamics. Using a larger difference in input-rate may be 
one method of overcoming this limitation, however, a better method would be to 
administer the ethanol intravenously. Intravenous administration would allow more 
precise control over the input-rate and the achievement of accurate and precise target 
concentrations. 
CHAPTER 4 
INTRAVENOUS ETHANOL STUDY 
4.1 SPECIFIC AIMS 
The specific aims of this study were: 
(1) To investigate the pharmacok:inetics and pharmacodynamics of different individualized 
doses and dose rates of IV ethanol and the development of acute tolerance to ethanol in 
healthy male and female subjects. 
(2) To assess changes in objective measures of impairment viz., EEG and psychometric 
performance, as well as subjective measures of impairment after IV ethanol 
administration. 
(3) To examine the relationship between changes in the objective measures and subjective 
measures of impairment, and the relationship between these measures and serum ethanol 
concentrations. 
(4) To examine gender differences with respect to ethanol pharmacokinetics and 
pharmacodynamics. 
4.2 STUDY DESIGN 
This study was a randomized, double-blind, placebo-controlled, five-period, four-way 
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crossover, concentration-controlled study in sixteen (16) healthy volunteers (8 males and 
8 females). The start of each study period was separated by a washout period of at least 
1 week. 
The study was conducted in two phases: After passing the medical screening, subjects 
underwent an open-labelled Pharmacokinetic Screen and Familiarization Period (Leg 0). 
This period was aimed at familiarizing subjects to the study procedures, including the 
EEG and the psychometric test battery, as well as to estimate their individual PK 
parameters. During this period, subjects r~ived a I-hour IV infusion of ethanol. Male 
subjects received 0.6 g/kg and female subjects received 0.5 g/kg ethanol as a 1-hour 
infusion. Female subjects received a lower dose since it was anticipated that they would 
achieve higher levels, and possibly greater adverse effects, if given the same dose as the 
male subjects. Blood samples were drawn during this period to determine serum ethanol 
concentrations. These concentrations were used to estimate their individual PK 
parameters, V mu, K,,, and V dss. These parameter estimates were then used to design an 
appropriate dosing regimen to achieve a target concentration of 1000 mg/L for the 
crossover phase of the study. A target concentration of 1000 mg/L would be expected 
to achieve an adequate degree of intoxication and impairment, without many adverse 
effects. Also, this concentration was considered to be the legal limit for intoxication in 
the state at the start of the study (the current legal limit for intoxication is 800 mg/L or 
0.8%). After the PK screen and familiarization period, subjects were randomized to the 
crossover, concentration-controlled phase (Legs I through 4) of the study (figure 4.1). 
I Medical Screening I 
Pharmacokinetic Screen and Familiarization Period 
Males: 0.6 g/kg IV Ethanol infused over 1 hour 
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During the crossover phase of the study, each treatment consisted of two infusions, 
Infusion I which had a duration of 1 hour, followed by Infusion II, which lasted for 5 
hours. Subjects received one of the following four treatments during each study period: 
Treatment A: Infusion I - ethanol infused at a rate designed to achieve the target 
concentration of 1000 mg/Lat the end of infusion I (1 hour); Infusion II - placebo. 
Treatment B: Infusion I - placebo; Infusion II - ethanol infused at a rate designed to 
achieve the target concentration of 1000 mg/Lat the end of infusion II (6 hours) . 
Treatment C: Infusion I - ethanol infused at a rate designed to achieve the target 
concentration of 1000 mg/Lat the end of infusion I (1 hour); Infusion II - ethanol infused 
at a rate designed to maintain the target concentration at "steady-state" for the duration 
of Infusion II (5 hours). 
Treatment D: Infusion I - placebo; Infusion II - placebo. 
Figure 4.2 shows the desired concentration-time profiles for each of the active 
treatments. 
F.ach subject was assigned to one of the four randomization sequences, based on a latin-
square design, listed in table 4.1, by an unblinded pharmacist, and received each 
treatment exactly once. Sixteen subjects were scheduled to be enrolled into the study such 
that two male subjects and two female subjects were assigned to each randomization 
sequence. 
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Figure 4.2 Expected concentation-time profiles for treatment A (Panel 1), treatment B (Panel 2), 
and treatment C (Panel 3) for crossover phase of intravenous ethanol study. 
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Table 4.1 Randomii.ation sequences for intravenous ethanol study 
Sequence Leg 1 Leg 2 Leg 3 Leg 4 
I A B C D 
11 B D A C 
m C A D B 
IV D C B A 
Trt A: lntusaon l: J ~lDB.llOI lntus1on U: ,>11.une 
Trt B: Infusion I: Saline Infusion II: Ethanol 
Trt C: Infusion I: Etha.ool Infusion II: Etha.ool 
Trt D: Infusion I: Saline Infusion Il: Saline 
Infusion I: 0 - 1 hr, Infusion II: 1 - 6 hrs. 
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4.3. 1 SUBJECTS 
Sixteen healthy volunteers, 8 male and 8 female, participated in the study. Subjects were 
considered for inclusion if they were healthy non-smokers between the ages of 21 and 
35 years. In addition, all female subjects in the study were using oral contraceptives as 
their method of birth control. 
All subjects were determined to be healthy based on the results of medical screening 
consisting of: (a) medical history, (b) physical examination, (c) vital signs (supine and 
standing systolic and diastolic blood pressure, heart rate and body temperature) as well 
as an orthostatic test, (d) 12-lead EKG including a 30 second rhythm strip, (e) laboratory 
screen consisting of SMAC-20, CBC and urinalysis, as well as a urine drug test and 
breath alcohol test. In addition, female subjects had to have a negative serum ~-hCG test, 
indicating that they were not pregnant. 
Subjects were excluded from the study if {a) they were smokers, (b) they had a clinically 
significant history of renal, hepatic, cardiovascular, gastro-intestinal, neurological, 
pulmonary, or hematologic disease, (c) they had a history of alcohol abuse, drug 
addiction, psychological dependence on drugs, or psychiatric illness, (d) they had first 
degree relatives (mother, father, or siblings) with a history of mental illness or 
alcohol/drug abuse, (e) they took any medications chronically or had taken any 
prescription medication or investigational drugs for at least 4 weeks before entering the 
study, except for the use of oral contraceptives by female subjects, (t) had an average 
daily caffeine intake greater than two cups of coffee, or (g) had an average alcohol intake 
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greater than 6 oz. (180 ml) of ethanol (approximately twelve 12 oz. beers) per week. 
During screening, subjects completed an alcohol use questionnaire based on the Khavari 
Alcohol Test (Khavari and Farber, 1978). This questionnaire provided infonnation about 
the frequency and quantity of consumption of the three major types of alcoholic 
beverages (beer, wine and spirits). Based on the responses provided, the Annual Absolute 
Alcohol Intake (AAAI) in gms/year was calculated as a quantitative measure of previous 
alcohol use for each subject. 
Before enrolling in the study, each subject signed an infonned consent fonn attesting that 
the study procedures were explained to him/her and that his/her participation in the study 
was voluntary. 
Within one week after each subject completed the study, the physical examination and 
vital signs, laboratory tests, and EKG was repeated. 
4.3.2 PROCEDURES FOR PK SCREEN AND FAMILIARlZATION PERIOD 
The clinical study was conducted at the General Clinical Research Center (GCRC) unit 
at the Medical College of Virginia Hospitals, Medical College of Virginia-Virginia 
Commonwealth University. The Committee.on the Conduct of Human Research at MCV-
VCU reviewed and approved the study protocol, and the informed consent fonn 
(December 1993) prior to the start of the study. The protocol, including revisions, as 
well as the consent fonn are in Appendix H. The study was conducted from June 1994 
through June 1995. 
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4.3.2A Admission to Clinical Research Unit 
Subjects were admitted to the GCRC unit on the evening of the day prior to the day of 
ethanol administration and were discharged on the morning after the day of ethanol 
administration. Subjects were instructed that no medications except oral contraceptives 
(including OTC medications and vitamins), or caffeine were to be consumed for 72 hours 
before the study period and during the study period. Subjects also abstained from alcohol 
starting 72 hours before the first treatment period through the end of the study. All 
subjects had a negative urine drug screen and breath alcohol test on admission for the 
study period. In addition, all female subjects had a negative ~-hCG test for pregnancy. 
All subjects completed a verbal probe concerning recent medical history as well as 
alcohol and medication use. 
4.3.2B Drug preparation and administration 
On the morning of dosing, subjects received a one-hour IV infusion of ethanol. A total 
dose of 0.6 g ethanoVkg body weight for male subjects and 0.5 g ethanoVkg body weight 
for female subjects was administered as a 10% solution in normal saline over 1 hour. 
The infusion was administered via an indwelling catheter that was inserted into a forearm 
vein in the dominant arm prior to dosing. Doses were prepared by the Investigational 
Pharmacy at MCV, and the treatment was open-labelled. 
4.3.2C Blood Sampling 
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Prior to dosing, a heparin containing catheter was inserted into a forearm vein of the 
non-dominant arm for access to blood sampling. 
6 ml blood samples for determination of ethanol concentration were collected in red-top 
tubes with no additives at the following times: pre-dose and 15 min, 30 min, 45 min, 1 
hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the 
infusion. The blood was allowed to clot, centrifuged (within 1 hour of sampling) for 10 
minutes, serum harvested and stored at -200 C until analysis by the TDx Analyrer 
(Abbott Laboratories, N. Chicago, IL). 
4.3.2D Electroencephalography (EEG) 
Five minute segments of 28-channel EEG, using the NeuroScan EEG equipment 
(NeuroScan Inc. , Herndon, VA), were recorded for each subject with eyes closed at the 
following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 
hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the infusion. Subjects were asked to 
count back from 500 by threes in an attempt to maintain vigilance during the recordings. 
Omni-prep (D.O.Weaver and Co., Aurora, CO) was used to prepare the scalp prior to 
electrode placement and Electro-gel (Electro-Cap International Inc., Dallas, TX) was 
used as the conducting gel. The electrodes were placed using an Electro-cap (Electro-Cap 
International Inc., Dallas, TX) according to the 10/20 International System with 8 
additional electrodes located 50% between the standard 10/20 placement. Linked ears 
were used as the reference. Four additional channels were used to monitor for vertical 
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and lateral eye movements and electromyographic activity. All electrodes were made of 
tin. The electrode impedances were checked before each recording, and maintained at 
less than 5 kohms and similar between electrodes. The raw EEG was stored on an optical 
disk until later analysis. Any disturbances in the room or subject movement during the 
EEG recording were documented. The NeuroScan filers were set as follows: Low filter -
0.1 Hz, High filter - 60 Hz. System calibration checks were performed biweekly 
throughout the study to ensure stability of channel calibration and proper filter settings. 
4.3.2E Psychometric Performance Tests (PP'I) 
A battery of four psychometric tests from the CDR Microcomputeriz.ed Assessment 
System (Cognitive Drug Research Ltd, Reading, U.K.) was completed by each subject 
at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 
hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the infusion. The psychometric 
test battery consisted of an immediate word recall test, a number vigilance test, a 
tracking test and a word recognition test. The test battery was computeriz.ed and 
responses were recorded using a response module fitted with two buttons, one marked 
"YES" and the other "NO" (Wesnes et al., 1987). For the tracking test, subjects used 
a joy-stick to track the target. In the evening before dosing for Leg 0, subjects practiced 
the psychometric test battery twice. 
4.3.2F Subject-Rated Impairment (SRI) Scales 
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A 100 mm visual analog scale, based on the Subjective High Assessment Scale (SHAS) 
(Shuck.it, 1984), was completed by each subject at the following times: pre-dose and 15 
min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr 
after the start of the infusion. The scale was similar to the one used for the oral ethanol 
study and had 12 items: HIGH, DRUNK, CONFUSED, DROWSY, DIZZY, CLUMSY, 
FLOATING, SLURRED SPEECH, UNCOMFORTABLE, FEEL GREAT, FEEL 
TERRIBLE and ALCOHOL EFFECTS. Subjects indicated their perceived level of 
intoxication response for each item by placing a mark on an unnumbered 100 mm scale 
that ranged from "not at all" to "extremely". 
4.3.2G Observer-Rated Impairment (ORI) Scales 
A 100 mm visual analog scale was completed by a blinded investigator (VAR) for each 
subject at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, l.66 
hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the infusion. The scale 
was similar to the one used in the oral ethanol study and had 4 items: HIGH, DRUNK, 
CONFUSED and DROWSY. The blinded investigator indicated his perception of the 
subject's level of intoxication by placing a mark on an unnumbered 100 mm scale that 
ranged from "not at all" to "extremely". 
4.3.2H Safety Measurements 
Blood pressure (sitting) and heart rate were measured, using a Dynamap (Critikon Inc., 
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Tampa, FL), at the following times: pre-dose and 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 
hr and 8 hr after the start of the infusion. 
All subjects were observed for symptoms a.pd signs of clinical intolerance to the drug or 
procedures and asked to report any adverse effects. These were evaluated by the Medical 
Monitor (IG) for their clinical significance and potential need for treatment. 
4.3.21 Diet 
On the evening prior to dosing, subjects received a light snack. Subjects fasted from 
midnight on the evening before ethanol administration until 4 hours after the start of the 
infusion. Water was permitted ad libirum throughout the study period. Dinner and a 
snack were served 9 and 14 hours after th<: start of the infusion respectively. Caffeine-
free beverages were served with meals. 
4.3.2J Discharge from Clinical Research Unit 
Subjects were discharged on the morning of the day after ethanol administration. A 
breath alcohol (Alcosenser) test was done prior to discharge at the end of each treatment 
period to ensure that the subjects did not have detectable ethanol levels. 
A study flow sheet is included (Table 4.2). When the study measurements were 
scheduled at the same time, they were conducted in the following sequence: 1) blood 
samples 2) EEG 3) PPT 4) SRI and ORI scales and 5) safety measurements, with the 
Table 4.2 Study Period Flow Sheet for Leg O of intravenous ethanol study 
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blood sample being collected at exactly the scheduled time. 
4.3.3 DETER.MINA TION OF DOSING REGIMENS FOR ACHIEVING 
CONCENTRATION-CONTROL 
I. Estimation of PK Parameters from PK Screen and Familiarization period. 
The following subject-specific parameters. were estimated from the individual serum 
concentration-time data from the PK screen and familiarization period (Leg 0): 
V mu: Maximum elimination rate 
K,.,: Michaelis-Menten constant 
Vdss: Volume of distribution. 
Initial estimates for the pharmacokinetic parameters were obtained from the slopes of the 
linear and semi-log concentration-time plots as follows: 
V mu was estimated from the slope (slopel) of the linear regression performed on the 
initial apparent linear declining phase of the concentration-time profiles as: 
v ..... = - slope] 
K,., was estimated from the slope of the linear regression (slope2) performed on the 
terminal apparent linear declining phase of the log concentration-time profiles as: 
vmlll K = - ---=:..:..._-
m 2.303 * slope2 
Vd88 was calculated as: 
Vdss = a'" * MRT 
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where CL is the total clearance and MRT is the mean residence time calculated by non-
compartmental methods (see section 4.3.5B for equations for calculation of CL,.. and 
MRT). 
A one-compartment model with zero-order input and capacity-limited elimination (figure 
4.3) was used to fit the concentration-time data for each subject using Scientist (version 









{Vmax * C) 
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~+CJ 
where dC/dt is the rate of change of concentration (C) and ko is the infusion rate in 
mg/hr. 
Goodness of fit criteria included maximization of the coefficient of determination and 
Model Selection Criteria, minimization of the standard deviation of the parameter 
estimates, random scatter in the plots of residuals vs. independent variable, normal 
distribution of the residuals as well as visual inspection of observed and fitted curves 
(Scientist Manual, 1994). 
The final estimates of the parameters, V DWl' K,,., and V dss, were used in the determination 
Central Compn 
D, Tinr vm.u. 
7 Cc,i ~ 
[-Yd. Km 
Figure 4.3 One compartment body model for leg O for intravenous ethanol study 
-t 
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of an appropriate dosing regimen for that subject for the remaining four legs of the study. 
n. Calculation of Doses for Lees 1 - 4. 
During the crossover phase of the study (Legs I - 4), subjects received the following 
treatments according to the randomiz.ation sequences. F.ach treatment consisted of two 
infusions. Infusion I had a duration of I hour. Infusion II, which immediately followed 
Infusion I, had a duration of 5 hours: 
Treatment Infusion I Infusion II 
A Dose IA placebo 
B placebo Dose Il8 
C Dose le Dose lie 
D placebo placebo 
For treatment A, the dose for Infusion I (Dose IJ was calculated from the subject's 
individual parameters to achieve a target concentration (Cwa.J of 1000 mg/L (± 10%) 
at the end of the infusion (T ""1 = 1 hour) as follows: 
For treatment B, the dose for Infusion Il (Dose Ils) was calculated from the subject's 
individual parameters to achieve a target concentration (Cwa.J of 1000 mg/L (± 10%) 
146 
at the end of the infusion <Twn=5 hours) as follows: 
For treatment C , the dose for Infusion I (Dose le, identical to Dose I.J was calculated 
from the subject's individual parameters to achieve a target concentration (Ci.vi.J of 1000 
mg/L (± 10%) at the end of the infusion <T1n11= 1 hour) as follows: 
V * C Dose/ = C * Vd + mu ra,get * Vdss * T ,_ 
C target ss Tc + C -Y· A.,,, talge( 
The dose for Infusion II (Dose Ile) was calculated to maintain concentrations at the target 
level (1000 mg/L ± 10%) over the next 5 hours <T1n11=5 hrs) as follows: 
V • C Dose/I = max ,a,,;., • Vd * T 
C Tc + C ss Inf11 
.. ..,,, ,a,,;., 
The doses calculated using the above equations were adjusted based on simulated 
concentration vs. time profiles using calculated doses and estimated PK parameters. All 
parameter estimations and dose calculations were performed by the author and the final 
doses to be administered were provided to the Investigational Pharmacy, MCV-VCU. 
The pharmacist prepared and dispensed the appropriate solutions according to the 
randomization sequences. 
4.3.4 PROCEDURES FOR RANDOMIZED, CROSSOVER STUDY 
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4.3.4A Admission to Clinical Research Unit 
Subjects were admitted to the GCRC unit on the evening of the day prior to the day of 
ethanol or placebo administration and were discharged on the morning after the day of 
ethanol or placebo administration. Subjects were instructed that no medications except 
oral contraceptives (including OTC medi~tions and vitamins), or caffeine were to be 
consumed for 72 hours before each study period and during each study period. Subjects 
also abstained from alcohol starting 72 hours before the first study period through the end 
of the study. All subjects had a negative urine drug screen and breath alcohol test on 
admission for each study period. In addition, all female subjects had a negative 13-hCG 
test for pregnancy. All subjects completed a verbal probe concerning recent medical 
history as well as alcohol and medication use. 
4.3.4B Drug preparation and administration 
During each study period, subjects received one of the following treatments according 
to the sequence he/she was randomized to:Dosing consisted of two infusions: Infusion 
I was administered for l hour, followed by Infusion II which will be administered over 
the next 5 hours. The total dose of ethanol, which was individualized for each subject 
based on his/her pharmacokinetic parameters, was administered as a 10% solution in 
normal saline. Placebo doses consisted of normal saline. The infusions were administered 
via an indwelling catheter that was inserted into a forearm vein in the dominant arm prior 
to dosing. 
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Doses were prepared by an unblinded pharmacist at the Investigational Pharmacy, MCV-
VCU, who assigned subjects to one of the four randomization sequences such that 2 male 
and 2 female subjects were randomized to each sequence. Each treatment was given 
exactly once and in random order according to the randomization sequence. Both the 
subjects and the investigators were blinded to treatment. A sealed copy of the 
randomization schedule was available at the research unit in case of an emergency. 
4.3.4C Blood Sampling 
Prior to dosing, a heparin containing catheter was inserted into a forearm vein in the 
non-dominant arm for access to blood sampling. 
6 ml samples for <;tetennination of ethanol concentration were collected in red-top tubes 
with no additives at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 
1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 
12 hr and 14 hr after the start of Infusion I. The blood was allowed to clot, centrifuged 
(within 1 hour of sampling) for 10 minutes, serum harvested and stored at -20" C until 
analysis by the TDx Analyzer (Abbott Diagnostics, N. Chicago, IL). 
4.3.40 Electroencephalography (EEG) 
Five minute segments of 28-channel EEG, using the NeuroScan EEG equipment 
' 
(NeuroScan Inc., Herndon, VA), were recorded for each subject with eyes closed at the 
following times: pre-dose and 15 min, 30 tnin, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 
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hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr after the 
start of Infusion I. The materials, equipment and methods used were the same as for Leg 
0 (section 4.3.20). The raw EEG was stored on an optical disk until later analysis. 
4.3.4E Psychometric Perfonnance Tests (PPT) 
A battery of four psychometric tests from the CDR Microcomputerized Assessment 
System (Cognitive Drug Research Ltd, Reading, U.K.) was completed by each subject 
at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 
hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr after 
the start of Infusion I. The psychometric test battery battery consisted of an immediate 
word recall test, a number vigilance test, a tracking test and a word recognition test, and 
was identical to the battery used in Leg 0. The equipment and methods used were the 
same as for Leg O (see section 4.33.2E). 
4.3.4F Subject-Rated Impairment (SRI) Scales 
A 100 mm visual analog scale, based on the Subjective High Assessment Scale (SHAS), 
was completed by each subject at the following times: pre-dose and 15 min, 30 min, 45 
min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 
9 hr, 11 hr, 12 hr and 14 hr after the start of Infusion I. The SRI scale was identical to 
the scale used for Leg O (see section 4.3.2F), and subjects indicated their perceived level 
of intoxication response for each item by placing a mark on an unnumbered 100 mm 
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scale that ranged from "not at all" to "extremely". 
4.3.4G Observer-Rated Impairment (ORI) Scales 
A 100 mm visual analog scale was completed by a blinded investigator (VAR) for each 
subject at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 
hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 
hr after the start of Infusion I. The ORI scale was identical to the scale used for Leg 0 
(see section 4.3.2G), and the blinded investigator indicated his perception of the subject's 
level of intoxication by placing a mark on an unnumbered 100 mm scale that ranged from 
"not at all" to "extremely". 
4.3.4H Safety Measurements 
Blood pressure (sitting) and heart rate were measured , using a Dynamap (Critikon Inc., 
Tampa, FL) , at the following times: pre-dose and 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 
hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr after the start of Infusion I. 
All subjects were observed for symptoms and signs of clinical intolerance to the drug or 
procedures and asked to report any adverse _effects. These were evaluated by the Medical 
Monitor (IG) for their clinical significance and potential need for treatment. 
4.3.41 Diet 
On the evening prior to dosing, subjects received a light snack. Subjects fasted from 
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midnight on the evening before ethanol administration until 4 hours after the start of 
Infusion I. Water was permitted ad libirum throughout the study period. Dinner and a 
snack were served 9 and 14 hours after the start oflnfusion I respectively. Caffeine-free 
beverages were served with meals. 
4.3.4] Discharge from Clinical Research Unit 
Subjects were discharged on the morning of the day after ethanol or placebo 
administration. A breath alcohol (Alcosenser) test was done prior to discharge at the end 
of each treatment period to ensure that the subjects did not have detectable ethanol levels. 
A study flow sheet is included (table 4.3). When the study measurements were scheduled 
at the same time, they were conducted in the following sequence: 1) blood samples 2) 
EEG 3) PPT 4) SRI and ORI scales and 5) safety measurements, with the blood sample 
being collected at exactly the scheduled time. 
After each subject had completed the study, they were asked to assess which treatment 
they believed they had received during each period of the study. 
4.3.5 SAMPLE ANALYSIS 
4.3 .5A Analytical Method for Ethanol in Serum 
Analysis of serum samples for ethan9l concentrations was performed in the 
Biopharrnaceutical Analysis Laboratory at the Department of Pharmacy and 
TabJe 4.3 Study Period Flow Sheet for Legs l -4 of intravenous ethanol study 
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Pharmaceutics at MCV-VCU. Performance validation and sample analysis were 
conducted with the guidance of Clark March in the Biopharmaceutical Analysis 
Laboratory at the Department of Pharmacy and Pharmaceutics at MCV-VCU. 
4.3.5B Assay Procedure 
The analytical method used to measure ethanol concentrations in serum was fluorescence 
polarization immunoassay using the TDx Analyzer (Abbott Laboratories, Inc. North 
Chicago, IL). The assay method used was identical to the method used for the 
measurement of ethanol concentrations for the oral ethanol study. The assay principles 
and procedures, including materials and methods are described in section 3.3.3B. 
4.3.5C Performance Characteristics and Validation for Ethanol assay 
Performance characteristics and performance validation methods and results are described 
in section 3.3.3C and section 3.3.30. Table 4.4 lists the figures of merit for the 
analytical method. 
4.3.50 Analysis of subject samples 
The TDx assay was used to determine ethanol concentrations in serum from sixteen 
subjects that completed the clinical study. There were a total of 20 samples per subject 
per period and four active treatment periods per subject (Leg O and treatments A, B and 
C). The total number of samples was about 1000. Calibration was performed prior to 
Table 4.4 Figures of merit for TDx assay method for determination of serum 
ethanol concentrations 
Experimental Limit of Quantitation 100 mg/L 
(ELOQ) 
Valid Concentration Range 100 to 3000 mg/L 
Precision (%RSD) Control X (100 mg/L): 19% 
Control L (500 mg/L): 9% 
Control M (1000 mg/L): 7% 
Control H (2500 mg/L): 4% 
Accuracy (%DFN) Control X (10 mg/dL): 15% 
Control L (50 mg/dL): 11 % 
Control M (100 mg/dL): 1 % 
Control H (250 mg/dL): 3% 
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performance validation. All four controls (X, L, Mand H, where X = 100 mg/L, L=500 
mg/L, M = 1000 mg/L, and H =2500 mg/L) were run at the start of subject sample 
analysis to ensure that the calibration curve was stable and valid. The samples for a 
single study period for each subject were split and ten samples were run on each carousel 
along with 2 of the controls (X, L, M and H). This analytical method for the 
determination of ethanol concentrations in serum was simple, specific, adequately 
sensitive, precise and accurate within acceptable limits for the purposes of this study. 
4.3.6 PHARMACOKINETIC ANALYSIS 
4.3.6A Evaluation of concentration-control 
In order to evaluate the ability of the dose calculation algorithm used for achieving the 
desired concentrations for the crossover phase of the study and to assess whether 
adequate concentration-control had been achieved, the maximum concentrations (C.....J 
achieved were determined for each treatment and compared to the target maximum 
concentration, Cuiset· 
For treatment C, the average "steady-state" concentration (C.v,ss) was calculated as the 
average of all concentrations measured during Infusion II (1 hr through 6 hr time-points) 
for each subject (CSS<1-6,). 
The percent coefficient of variation (%COY) of these steady-state" concentrations 
(COY c.v,) was calculated to assess the degree of fluctuation of the "steady-state" 
156 
concentrations about the Covass as: 
S.D. of Cs.l{i-6) COVa~ = * 100 
c,~ss 
Also, the percent difference from target (%DFr) was calculated to assess the magnitude 
of the error in achieving the average target concentration as: 
The COV Cova is a measure of the precision of the achieved concentrations, while the 
%DFf is a measure of the accuracy of the achieved concentrations relative to the target 
concentration. 
4.3.6B Noncompartmental Methods 
Serum ethanol concentration vs. time profiles were constructed for each subject and 
treatment on both linear and semi-logarithmic scales. The following PK parameters were 
estimated from the concentration-time data for each subject and treatment by non-
compartmental methods: maximum concentration (C_J, time to achieve maximum 
concentration (T_J, area under the concentration-time curve extrapolated to infinity 
(AUC.,J, total body clearance (CL,,J, volume of distribution (Vdss), maximum 
elimination rate (V _J and Michaelis-Menten constant (K,J. C"""' was estimated as the 
maximum observed serum concentration and T m.u as the time (relative to dosing) that Cm.u 
occurred. 
AUC00 was calculated as: 
C AUC = AUC + ---E 
.. lnl' A 
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where AUCin., is the AUC from Oto the time (tJ of the last measured concentration (CJ 
calculated by the trapezoidal rule and C0 0, is the A UC extrapolated from t. to infinity 
(AUC~ (Gibaldi and Perrier, 1982). >. was estimated as V m.u/K,,,. 
ex._ was calculated as: 
CL = let 
where D is the total administered dose. 
Ydss was calculated as: 
D 
AUC.., 
where MRT is the mean residence time calculated as: 
MRT = AUMCm T 
AUC.., 2 
where T is the duration of the infusion ( 1 hr for treatment A, 5 hours for treatment B 
and 6 hours for treatment C) and AUMC00 is the area under the moment curve 
extrapolated to infinity, calculated by determining the area under the moment curve 
(AUMC) from 0 .. to the time (t,.) of the last measured concentration (CJ by the 
trapezoidal rule by summing individual areas calculated by 
AUMC = (~*4 + <;•tz)•('i - 4) 
2 
and then extrapolating to infinity as follows: 
AUMC = AUMC + Ca*la 





(Gibaldi and Perrier, 1982). The infusion duration for treatment C was taken to be 6 
hours, although treatment C consisted of two infusions administered at different rates for 
different durations (1 hour and 6 hours). 
V mu was estimated from the slope (slope}.) of the linear regression performed on the 
initial apparent linear declining phase of the concentration-time profiles as: 
v,.a.r = - slope] 
I<,,, was estimated from the slope of the linear regression performed on the terminal 
apparent linear declining phase of the log concentration-time profiles as: 
vmax K = - - - -=;.;__-
m 2.303 * slope2 
Descriptive statistics, including mean, standard deviation , coefficient of variation 
(%COY), median and range were calculated for each parameter by treatment and subject 
as well as across treatments. 
4.3.6C Compartmental Methods 
Compartmental analysis was performed for individual serum concentration-time data to 
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estimate the intrinsic pharmacokinetic parameters, maximum elimination rate (V .....J, 
Michaelis-Menten constant (K.J and volume of distribution (Vdss). Model fitting was 
performed using Scientist (version 2.0 for Windows, MicroMath Inc., Salt Lake City, 
lIT). Several models were evaluated, such as one and two-compartment body models 
with multiple zero-order inputs, and incorporating capacity-limited elimination with and 
without a parallel first-order elimination pathway. Weighing schemes of 1 and 1/y were 
evaluated. Non-compartmental PK parameter estimates were used as initial estimates for 
V _,., K.. and Vdss. The best model was selected based on several goodness of fit criteria: 
maximization of the coefficient of de~rmination and Model Selection Criteria, 
minimization of the standard deviation of the parameter estimates, random scatter in the 
plots of residuals vs. independent variable, normal distribution of the residuals as well 
as visual inspection of observed and fitted curves (Scientist Manual, 1994). 
Initial attempts at model fitting were aimed at fitting a one-compartment model to the 
individual concentration-time data using the same model as that used for the Leg O data. 
However, most of the profiles showed a significant distribution phase at the end of the 
infusion that was better fit using a two-compartment model. Thus, the final model 
selected was a two-compartmental body model with zero-order input into the central 
compartment, first-order distribution to and re-distribution from the peripheral 
compartment, with capacity-limited elimination (figure 4.4). The best fits were obtained 
with a weight of 1. Descriptive statistics, including mean, standard deviation, %COY, 
median and range were calculated for each parameter by treatment and subject as well 
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as across treatments. 
4.3. 7 PHARMACODYNAMIC ANALYSIS 
4.3.7A EEG Analysis 
EEG recordings were stored on optical disks and analyred off-line. F.ach of the 5-minute 
recordings was reviewed and edited to remove each 2.5 second epoch that was 
contaminated with artifacts (eye movement, muscle movement, electrode artifacts, or 
other disturbances noted during the recording). The remaining artifact-free epochs were 
averaged to form an average file for each recording using the statistics program of the 
NeuroScan software (version 3.0, Neuroscan Inc., Herndon, VA). The file containing 
the average power and relative power in each of the five classical frequency bands (delta: 
0.39 - 3.0 Hz; theta: 4.3 - 7.8 Hz; alpha: 8.2 - 11.7 Hz; beta I: 12.1 -16.0 Hz; and beta 
II: 16.4 - 30 Hz) at each of the 28 electrodes was imported into a spreadsheet program 
(Microsoft Excel version 5.0, Microsoft Inc., Seattle WA) for further processing. 
From each average recording, the following PD measures were obtained: total power 
across all electrodes and across all frequency bands, total power across all electrodes 
within each frequency band and relative power across all electrodes within each 
frequency band. 
Power was determined for each average recording by squaring the amplitude of the EEG 
signal at each electrode in each frequency band. Total power in each frequency band was 
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calculated by summing the power across all electrodes for the given frequency band. 
Total power across all frequency bands was calculated by summing the total power across 
all five frequency bands. Relative power in each frequency band was calculated by 
dividing the total power of the frequency band by the total power across all 5 frequency 
bands. 
4.3.7B Psychometric Performance Tests Analysis 
For each of the psychometric tests, the following measures were obtained: 
1. Immediate word recall: Accuracy (% words correctly recalled) 
2. Number vigilance: Accuracy (% correct) and Reaction time (msec) 
3. Tracking: Mean tracking error or mean distance between cursor and target during the 
test (cm) 
4. Word recognition: Sensitivity (a measure of accuracy of word recognition) and 
reaction time (msec). 
4.3.7C Impairment Scales Analysis 
For the SRl and ORl scales, a score between O and 100 was obtained for each item, by 
measuring the number of millimeters between the left end of the scale and the mark 
placed by the subject at each time point. Since two of the eight male subjects and four 
of the female subjects in the study were "non-responders" and did not show consistent 
responses on the SRl scales (maximal observed response less than 20 mm) even though 
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they showed consistent psychometric impairment and EEG changes, subjects were given 
a "non-responder" score (NR) of O if they were non-responders or 1 if they were 
responders. 
4.3.70 Pharmacodynamic Analysis 
Response-time profiles, i.e. , plots of change in response measure from pre-dose baseline 
vs. time plots, for each subject during each treatment period were plotted for each 
response measure. The PD response measures evaluated were: 
EEG measures: total power across all bands, total power in each of the 5 frequency 
bands (delta, theta, alpha, beta I, beta II), relative power in each of the 5 frequency 
bands (delta, theta, alpha, beta I, beta II); 
PP measures: accuracy for immediate word recall, accuracy and reaction time for number 
vigilance, mean tracking error for tracking and sensitivity and reaction time for word 
recognition; 
Impairment Scales: scores for each of the 12 items on the SRI scales and 4 items of the 
ORI scales. 
Pharmacodynamic parameters including baseline response (E..), maximal or minimal 
observed response (E....,.• or E,,,;,,ob•) and time of maximal or minimal observed response 
(t...u or W were determined for each PD measure. The baseline response (EJ was 
defined as the response prior to drug administration at O hour. E...... o1>, was determined as 
the highest response observed during the first 12 hours after the start of Infusion I (first 
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6 hours for treatment A) and Em.,obe was determined as the lowest response observed 
during the first 12 hours after the start of Infusion I (first 6 hours for treatment A). The 
E......o1>e and E,,...o1>e were determined from data obtained only during the first 12 hours after 
the start of Infusion I (first 6 hours for treatment A) because the responses were expected 
to be the greatest during this period. 
Descriptive statistics, including mean, standard deviation, %COY, median and range 
were calculated for each parameter by treatment and subject as well as across treatments. 
In addition, response vs. concentration profiles were plotted for each response measure 
for each subject at each treatment, to evaluate the effect-concentration relationship as well 
as the development of acute tolerance to the effects. The presence of a clockwise 
hysteresis loop in the response-time profiles would be consistent with development of 
acute tolerance for that response. 
4.3.8 STATISTICAL ANALYSIS 
Statistical analysis was performed 1) to evaluate the input-rate related changes in the 
pharmacok:inetic and pharmacodynamic end-points, EEG, psychometric performance and 
subjective impairment following administration of fast , slow and "steady-state" infusions 
of ethanol in healthy male and female subjects, as well as to evaluate the development 
of tolerance to these objective and subjective measures; 2) to evaluate gender differences 
in ethanol pharmacokinetics and pharmacodynamics and 3) to determine the relationship 
between the EEG changes after IV ethanol. administration and changes in psychometric 
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performance and subjective measures of impairment 
Because there are many variables of interest in this statistical analysis, the multiplicity 
of desired inferential statements about the data become problematic. Adjusting the level 
of significance (a) for the multiple statistical comparisons, as made in traditional 
confirmatory analysis, would result in extremely small a values and virtually no 
likelihood of detecting any statistically significant differences. Therefore, using the 
concept of descriptive data analysis, as described in section 3.3.6 for the oral ethanol 
study, expected differences between treatments based on previously reported studies and 
patterns apparent from examining the data were evaluated statistically without adjusting 
the level of significance (Abt, 1987; Abt, 1990). The results of these analyses were used 
to make descriptive inferential statements about the data, but not to reject the null 
hypothesis. Hypotheses generated by this study would have to be confirmed by 
prospective studies involving a larger number of subjects. 
Primary pharmacokinetic parameters that were evaluated using descriptive data analysis 
included volume of distribution {Vdss), maximum elimination rate (V m,u) and Michaelis-
Menten constant (K,.J. Primary pharmacodynamic measures that were evaluated included 
peak changes in relative EEG power in t!ie theta and alpha bands, peak changes in 
reaction time for the number vigilance test, peak changes in the sensitivity measure of 
the word recognitjon test, peak changes in the items, "DRUNK", and "ALCOHOL 
EFFECTS" on the SRJ scales, and peak changes in the item "DRUNK" on the ORJ 
scales. Statistical comparisons for the other PD end-points (including changes in total 
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power, changes in relative EEG power in the delta, and beta bands, changes in accuracy 
measures of the immediate word recall and number vigilance tests, changes in mean 
tracking error of the tracking test, changes in reaction time for the word recognition test, 
changes in the item "HIGH" on the SRI as well as ORI scales) were treated as 
exploratory data analysis. These were used to generate hypothesis rather than to make 
formal conclusions based on the data. 
The significance of the baseline (EJ as a covariate was examined to evaluate the 
relationship between the baseline of the response and the PD response. The NR score 
was used as a covariate in the statistical comparison of PD measures to evaluate its effect 
on the PD response. The AAAl measure of previous alcohol use was also used as a 
covariate to evaluate the effect of previous alcohol history on the PD responses measured 
in this study. 
To evaluate the treatment effects on the PK and PD measures, the PK parameters and 
summary PD parameters (E.,,.,.• or E,,,;,,•, Tmu or T......) for the primary PD measures for 
each treatment were compared across treatments and across gender using statistical 
techniques appropriate for a 4-way crossover design. The model used to fit the data was 
of the form: 
yijklm = µ + O; + ~j + rt(i) +a,+ Pm+ fijklm 
i = I,II,m,IV (sequences); 
j = 1,2,3,4 (periods); 
k = 1,2, ... ,16 (subjects); 
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1 = A,B,C,D (treatments) (only active treatments A,B,C for PK 
parameters); 
m = male,female (gender); 
where Y ~ is the response for the kth subject of the mth gender in the ith sequence in 
the jth period after the Ith treatment, µ is the overall mean, o; is the effect of the ith 
sequence, -ri is the effect of the jth period, rt<D is the effect of the kth subject within the 
ith sequence, a 1 is the effect of the Ith treatment, 13m is the effect of the mth gender and 
Eijtl is the random error associated with Y ijtl· The "iik1m are assumed to be normally 
distributed random variables with mean of O and variance q,2. It is also assumed that the 
nested effects for subject are randomly and independently distributed with a mean of 0 
and common variance of ur2, and independent of "ijtlm· 
Model fitting was performed using PROC MIXED in SAS (SAS Institute, Cary, NC). 
This procedure allows the modelling of the mean of the dependent variable, y, as well 
as the variance of y. The estimation method used for the covariance parameters was 
restricted maximum likelihood (REML). The variance of y was modelled by evaluating 
two variance structure matrices, simple (random effect) and autoregressive. For most 
variables, the simple structure resulted in better model fits based on maximization of the 
Akaike's Information Criterion (SAS/STAT User's Guide, 1990, SAS Technical Report, 
1992). The level of significance (a) was set at 0.05. In case of significant differences 
(p<0.05), multiple comparisons were performed using the ESTIMATE procedure in 
SAS (SAS/STAT User's Guide, 1990). 
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Residuals were tested for normality using PROC UNIV ARIA TE in SAS (SAS/ST AT 
User's Guide, 1990). This procedure generates box plots and normal probability plots, 
which were examined to test for normality of the residuals. This procedure also computes 
the Shapiro-Wilk statistic, W, for the nulJ hypothesis that the residuals are normally 
distributed. The null hypothesis of normality was rejected if the probability of a smaller 
value of W was less than 0.05. 
One of the aims of this study was to assess the relationship between the EEG changes 
and changes in PP as well as the relationship between the EEG changes and SRI. In 
order to achieve this, linear regression of the EEG parameters <Em.uo1>a for relative theta 
power) on the PP parameters <Em....""" for number vigilance reaction time), and on the 
SRI parameters <Em....""" for SRI-ALCOHOL EFFECTS score) were performed 
individually to assess the significance of the relationship between the EEG changes and 
changes in PP and SRI. Since this was a crossover study, the regression was only 
performed for observations for treatment A.' The level of significance {a) was set at 0.05. 
This test allowed us to determine if the EEG changes were more closely associated with 
PP changes or with the changes in subject-rated impairment. 
4.4 RESULTS AND DISCUSSION 
4.4.1 CLINICAL RESULTS 
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4.4.lA Subject Demographics 
Sixteen subjects, eight males and eight females, were entered into the study after 
successfully passing the medical screening, and all sixteen subjects completed all five 
periods of the study. Demographic and physical characteristics of the subjects are shown 
in table 4.5. The subjects were between 22 and 33 years of age. The weights of male 
subjects ranged from 60 to 84 kg with an mean of 74 kg. The weight of female subjects 
ranged from 50 to 85 kg with an mean of ~ kg. 
Table 4.5 also lists the Annual Absolute Alcohol Intake (AAAJ) in gms/year for each 
subject. The median AAAI for male subjects was 236 gms/year and for female subjects 
was 232 gms/year. There was, however, ·considerable variability with AAAI values 
ranging from 32 gms/year to 1288 gms/year across subjects. 
4.4.lB Adverse Events 
In general, all subjects tolerated the study drug and procedures reasonably well. Table 
4.6 lists the adverse events experienced by the subjects by treatment. The most common 
adverse event that was associated with ethanol was the intermittent local stinging and pain 
at the site of the infusion, which was generally transient and usually resolved by the end 
of the first hour of the infusion. Other adverse events associated with ethanol 
administration were nausea, vomiting, dizziness and headache. The dizziness and nausea 
generally occurred at about the same time as the occurrence of the peak concentrations, 



























Demographic and physical characteristics of subjects in intravenous 
ethanol study 
Gender Age Weight Height Race Alcohol 
consumption 
[yrs) fkg) · [cm] AAAI 
(gms/year] 
Male 27 77 .8 181 Caucasian 496 
Male 25 74.4 188 Caucasian 206 
Male 24 68.4 185 Caucasian 95 
Male 32 70.5 178 Caucasian 343 
Male 27 60.2 177 Caucasian 36 
Male 30 74.5 169 Asian 125 
Male 33 81.2 174 Caucasian 266 
Male 22 83.7 183 Caucasian 1288 
28 73.8 179 357 
14% 10% 3% 113% 
22-32 60.2-83.7 169-188 3lt-1288 
Female 26 60.9 158 Caucasian 339 
Female 22 61.5 170 Indian-American 330 
Female 31 49.4 165 Caucasian 239 
Female 32 84.6 172 Caucasian 179 
Female 23 69 .3 170 Caucasian 516 
Female 23 58.2 160 Caucasian 53 
Female 23 54.3 159 Hispanic 224 
Female 30 70.9 175 African-American 32 
26 63.8 166 239 .. · .. ·\ 
16% 17% 4% .:, ' . 0 66% . ., ,~ 
54.3-84.6 159-175 
... 
.. ·-= i:oJ~516 j):i~· U-31 
' , .. .. 
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Table 4.5a. Responder/Non-Responder Score for subjects in IV ethanol study 
Subject No. Responder (R)/ NR Score 
Non-Responder (NR) 
Status 
l NR 0 
2 R l 
3 R 1 
4 R 1 
5 R 1 
6 R 1 
7 R 1 
8 NR 0 
9 NR 0 
10 R 1 
11 NR 0 
12 R 1 
13 NR 0 
14 R 1 
15 NR 0 
16 R 1 
Table 4.6 Adverse events by treatment for intravenous ethanol study 
Adverse Event Number of subjects (out of 16) reporting 
Leg 0 Trt A Trt B Trt C Trt D 
intermittent stinging 10 10 7 11 1 
at mfusion site 
Ethanol.-likce taste 8 4 2 4 0 
on tongue 
nausea 2 4 3 9 0 
(with vomiting) (1) (3) (1) (5) (0) 
dizziness/ l 3 3 7 0 
. 
lightheadedness 
headache 3 5 5 9 I 
I 




end of that treatment period. 
4.4.2 PHARMACOKINETICS 
4.4.2A Evaluation of concentration-control 
Serum ethanol concentration vs. time profiles for Leg O for each treatment and subject 
are shown in Appendix 11. Figure 4.5 shows the serum ethanol concentration vs. time 
for all subjects by gender for Leg 0. Table 4. 7 lists the PK parameters obtained from the 
data from Leg 0. The mean ± S. D. c ....... for male subjects was 924 ± 175 mg/L and for 
female subjects was 821 ± 166 mg/L. Dose.:corrected c ....... values were higher for female 
subjects than for male subjects (1641 ± 331 mg/U(mg/kg) for female subjects and 1539 
± 291 mg/U(mg/kg) for male subjects). 
Intrinsic PK parameters V ....... , K,,, and Vdss were estimated by fitting a one-compartment 
model with zero-order input and capacity-limited elimination to the individual 
concentration-time profiles. The fits were considered to be adequate based on the 
coefficient of determinations and Model Selection Criteria; random scatter in the plots 
of residuals vs. independent variable; normal distribution of the residuals as well as 
visual inspection of observed and fitted curves. 
As table 4. 7 indicates, the intrinsic PK elimination parameters, V ....... and K,,, , did not 
appear to be different between male and female subjects. The mean ± S.D. V ....... across 
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Table 4.7 Mean (%COV) Pharmacokinetic parameters by gender for Leg O for intra.venous ethanol study 
Dose c....,. V ..... K,,. Vd 
i [glk.g] [mg/L] [mg/U(g~g)]I (mgllJhr) {mg/L] [L] (Llk.g)2 
Males 0.6 924 1539 241 163 47 ! 0.6 
(n=S) (19%) (19%) (27%) (41 %) (16%) (15%) 
Females o.s 821 1641 250 164 35 
I 
0.5 
(n=S) (20%) (20%} (13%) (37%) (18%) (15%) 
AU - ]590 245 164 41 0.6 
I (n = l6) 
I 
(19%) (20%) (38%) (22%) (16%) 






subjects was 164 ± 62 mg/L. The mean ± S.D. Vdss for male subjects was 47 ± 8 L 
and for female subjects was 35 ± 6 L. However, when the Vdss was corrected for 
weight, the mean estimates for male and female subjects did not appear to be different. 
This indicates that the apparent gender difference in volumes of distribution is due to the 
differences in weight between males and females. The differences in V dss also explains 
the significant difference in dose-corrected emu between male and female subjects. 
Table 4.8 lists the mean ± SD of the doses calculated from the estimated PK parameters 
for the crossover phase of the study by treatment. There were no differences between the 
calculated doses (in g/kg) between male .and female subjects. The mean (± S.D.) 
calculated doses were 0. 71 (± 0.10) g/kg for treatment A, 1.13 (± 0.13) g/kg for 
treatment B and 1.31 (± 0. 14) g/kg for treatment C. The variability in the calculated 
doses was also fairly low, with %COY ranging from 11 % to 14% across treatments. 
This indicates that the subjects in this study were fairly similar with respect to their 
ethanol phannacokinetics, and that differences in body weight accounted for most of the 
differences in PK parameters observed in these subjects. 
Table 4.8 also lists the doses that would have been predicted for treatments A, Band C 
using previously published PK parameter estimates for ethanol (Holford, 1987). 
Comparison of the calculated doses for the subjects in this study with these population-
predicted doses indicated that on average, the doses in g/kg were similar, within 10% of 
each other. This was observed across treatments and indicates that the subjects in this 
study had phannacokinetic characteristics for ethanol that were fairly representative of 
Table 4.8 
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Doses calculated from Leg O PK parameters for crossover phase of 
intravenous ethanol study. 
Trt A Trt B Trt C 
[g/kg] [g/kg] [g/kg] 
Males 0.75 (12%) 1.20 (8%) 1.38 (8%) 
(n=8) 
Females 0.66 (13%) 1.06 (12%) 1.25 (11 %) 
(n=8) 
All 0.71 (I4%) 1.13 (II%) 1.31 (11%) 
(n= 16) 
Population 1 0.65 1.10 1.22 
I: Doses preructe tor treatments A, H ano c oaseo on previously 
published parameter estimates (V_,= 232 mg/Uhr, K,.=82.1 mg/L, 
Vd = 0.53 L/kg) 
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the population (Holford, 1987). However, the PK screen and familiariz.ation period was 
necessary to incorporate the considerable inter-individual variability in the PK parameters 
in the calculation of doses. If all the subjects had been given fixed doses, and even if 
they had been dosed on the basis of their body weight, the resulting variability in 
achieved concentrations could have been as high as 20%, as seen for the Cm.ax values for 
Leg 0. Thus, the PK screen and familiariz.ation period was essential to the study design, 
which was to achieve concentration-control, i.e., to achieve and maintain concentrations 
within about 10% of the target concentrations. 
Serum ethanol concentration vs. time profiles for each subject, by treatment, for the 
crossover phase of the study are shown in Appendix 12. Figure 4.6 shows the serum 
ethanol concentration vs. time for all subjects by treatment. 
Table 4.9 lists the actual Cmax values achieved for treatments A and B, by gender . As 
Table 4. 9 indicates, the mean ± S. D. Cmax for treatment A was 1119 ± 175 mg/L and 
for treatment B was 1029 ± 168 mg/L. The achieved peak concentrations were, on 
average about 12% higher than the target concentration of 1000 mg/L for treatment A 
and about 3 % higher than the target concentration for treatment B. 
There were no significant differences in Cmax values between male and female subjects, 
even though the mean Cmax values for male subjects for treatment A was higher than for 
female subjects (1182 mg/L for male subjects vs. 1056 mg/L for female subjects). This 
apparent difference may be due to subject 8, who was identified as a pharmacokinetic 
outlier, showing the highest achieved concentrations across treatments. He also appeared 
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Mean (COV % ) emu achieved for crossover phase of intravenous ethanol 
study. 
Trt A Trt B Trt C 
[mg/L] [mg/L] [mg/L] 
Males 1182 (16%) 1048 (16%) 1286 (16%) 
(n=8) 
Females 1056 (14%) 1011 (18%) 1253 (12%) 
(n=8) 
All 1119 (16%) 1029 (16%) 1269 (14%) 
(n=l6) 
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to have a much slower elimination rate for ethanol than the other subjects. PK analysis 
indicated that his V mu estimated from Leg O data was quite different from the estimate 
obtained from compartmental analysis of ~ncentration-time data from the crossover 
phase of the study. It appears that his PK parameters may not have been accurately 
estimated during Leg 0, resulting in peak concentrations that were as much as 40% 
higher than the target concentration. 
Table 4.10 lists the measures of precision and accuracy for achieved concentrations for 
treatment C. The mean ± S.O. Cavass achieved was 1070 ± 144 mg/L, which was almost 
identical for male and female subjects. The mean %OFT was 7% indicating that, on 
average, the steady-state concentrations were 7 % higher than the target stead-state 
concentration of 1000 mg/L. However, the range for the %OFT was quite high , with 
values ranging from -14% to 38%, indicating that there were some subjects whose c .. ,ss 
was not within the desired range of target steady-state concentrations (1000 mg/L ± 
10 % ) . The mean COV c.,, was 9 % across subjects, indicating that, on average, the 
concentrations at steady-state fluctuated by 9% about the mean. The COV c.,1 values 
ranged from 5% to 14%. 
In summary, it appears that the PK screen followed by dose individualization allowed the 
incorporation of the inter-individual variability in PK parameters in the calculation of the 
doses administered in the study. Also, the- peak concentrations as well as the "steady-
state" concentrations achieved in this study were within acceptable limits of accuracy and 
precision. 
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Table 4.10 Measures of precision and accuracy for concentrations achieved for 







c • ..,ss' cov~y.2 
[mg/L] [%] 
1070 (15%) 9% (5%-14%) 
·. 
1071 (13%) 8% (5%-10%) 
1070 (13%) 9% (5%-14%) 
I: C . ex ,res.sea as 1'1ean (~<.:Ov) 
..i,a p 
2: COV c... expressed as Mean (Range) 
3: ~OFT expressed as Mean (Range) 
%DF1'1 
[%] 
7%( -14% - 38%) 
7% (-20% - 21 %) 
7% (-14% - 38%) 
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4.4.2B Non-Compartmental Analysis 
Non-compartmental analysis was performed on the individual concentration-time profiles 
by subject and treatment. Figure 4.6 shows the concentration vs. time profiles for all 
subjects by treatment. As figure 4.6 illustrates, peak concentrations were achieved at the 
end of the infusion for treatments A and B. For treatment C, peak concentrations were 
generally achieved at the end of Infusion 1 (1 hour), followed by a rapid distribution loss 
with concentrations subsequently levelling off to steady-state concentrations. This rapid 
distribution phase was also apparent for most subjects after treatment A. Terminal 
elimination profiles are consistent with capacity-limited elimination, showing an initial 
linear (apparent zero-order) decline, and a later exponential (apparent first-order) decline. 
Mean pharmacokinetic parameters determined by non-compartmental analysis are 
presented in table ~.11. Dose-corrected Cmax values were not significantly different across 
treatments, but showed differences between male and female subjects across treatments. 
Tmax was observed at the end of the infusion for treatments A and B. The Tmax values for 
treatment C ranged from 1 to 6 hours, with a median of 1.0 hours. Mean ± S.D. AUC00 
values were 4292 ± 2289 mg/L*hr for treatment A, 5678 ± 1296 mg/L*hr for treatment 
Band 10044 ± 2487 mg/L*hr for treatment C. The precision of the AUC00 estimates 
was assessed by calculating the percent AUC extrapolated (%AUCoxtnp) by dividing the 
AUC.Xltlp by the AUC00• The %AUC.11r1p was ranged from 2% to 29% across individual 
AUC00 calculation~. 
CL,.. (mean ± SD) estimates were 211 ± 62 ml/min, 235 ± 47 ml/min and 156 ± 37 
Table 4.11 Mean (%COV) Non-<:ompannental Pharmacolcinetic parameters by gender for crossover phase of 
intravenous ethanol study 
Treatment emu Tmax 1 I AUCOO vmax K,,, Vd ': 
[mg/L] [mg/U(g/kg)]2 [bt) [mglL•br] [mg/L*hrf(g/kg)l3 [mg/Uhri [mglL) [LJ 
A I 
Males 1182 22 1.8 1 4854 88 147 307 37 
(n=S) (16%) (16%) (0.8-1.0) (64%) (64%) (27%) (40%) (15%) 
Females 1056 26 1.0 3731 89 157 275 27 
(n=8) (14%) {17%) (1.0-1.3) (24%) (20%) (18%) (34%) (15%) 
All 1119 24 1.0 4292 89 152 291 32 
(n = l6) (16%) (18%) (0.8-1.3) (53%) (45%) (22%) (37%) (21 %) 
B 
1 • Males 1048 12 6.0 · 5960 '67 195 503 · 62 , 
(n =8) I (16%) (8%) (5,0-6.3) (22%) (17%) (15%) (38%) (9%) 
Females lOll IS I 6.0 5396 81 176 408 50 
(n=8) (18%) (15%) (6.0-6.3) (24%) (19%) (15%) (53%) (14%) 
All I 1029 13 6.0 5678 74 185 456 56 
(n= 16) I (16%) (18%) (5.0-6.3) (23%) (20%) (15%) (44%) (16%) 
c 
Mal.es 1286 13 1.0 9835 96 203 400 22 
(n=8) (16%) (ll %) (1.0 .. 6.0} (25%) (20%) (29%) (51 %) (24%) 
Females 1253 16 1.0 , 10253 130 197 1: 512 20 
{n=8) (12%) (11 %) I (0.8-6.0) (26%) (22%) (34%) I! (57%) (37%) 
All 1269 14 . 1.0 II 10044 113 200 i' 4S6 21 
(n=S) (14%) (16%) I {0.8-6.0) (25%) (26%) (30%) 
1
i (55%) (30%) 




ml/min for treatments A, Band C respectively . 
As table 4.11 indicates, the intrinsic PK parameters, V mu., K,,, and Vdss did not appear 
to be different across treatments. However, the Vdss was different between male and 
female subjects. Table 4.12 lists the mean intrinsic PK parameters, estimated by non-
compartmental methods across treatments, by gender, along with the inter-individual and 
intra-individual variability measures (%COV). The mean(± SD) Vmu. was 179 (± 47) 
mg/Uhr across subjects and treatments. The mean (± SD) K,,, was 401 (± 207) mg/L 
across subjects and treatments. The mean (± SD) Vdss was 36 (± 16) L across 
treatments. As table 4.12 indicates, the inter-individual variability, as measured by the 
%COV, was considerable for the PK parameters, especially for the K,,,. This may be a 
consequence of the sampling schedule and the relatively poor precision in the analytical 
methods, particularly at low concentrations. For all parameters, the intra-individual 
variability was lower than the inter-individual variability. 
4.4.2C Compartmental Analysis 
A two-compartmental body model with multiple zero-order inputs into the central 
compartment, first-order distribution to and re-distribution from the peripheral 
compartment, with capacity-limited elimination was fit to the individual ethanol 
concentration vs. time profiles. Initial attempts to fit a one-compartment model, similar 
to the model used for Leg O data did not result in adequate fits due to the presence of a 
distributional component in the declining phase of the ethanol concentration-time profiles 
Table 4.12 .Mean Non-compartmental PK parameter estimates across treatments, by gender, for intravenous. ethanol 
study 
i 
vrmi K. Vdss 
[mg/Uhr] '[mg/L) [L] 
Males Females AU Males Females All Males Females All 
(n =24) (n=24) (n=48) (n=24) (n=24) (n=48) (n=24) (n=24) (n =48) 
i 
Overall Mean 181 [77 179 403 3'98 401 40 32 36 
Inter-Individual 
variability 27% 26% 26% 47% 57% 52% 44% 45% 45% 
(%COY) . I 
Intra-Individual 






for treatments A, Band C, which was not very evident for data from Leg O. 
The final fits were considered to be adequate based on the coefficients of determination, 
which ranged from 0.873 to 0.996 and Model Selection Criteria, which ranged from 
0.931 to 4.380; random scatter in the plots of residuals vs. independent variable; normal 
distribution of the residuals as well as visual inspection of observed and fitted curves. 
The standard deviations and calculated %C0Vs of the parameter estimates were 
considerably high, especially for Vmu. with %C0Vs ranging from 41 % to 689%, and for 
K,., with %COVs ranging from 77% to 1519%. 
Individual concentration vs. time profiles· illustrating the observed values and fitted 
curves are shown in Appendix 13. Figure 4.7 shows the observed values and fitted curves 
by treatment for a representative subject (subject 7) . 
Table 4.13 lists the compartmental PK parameter estimates by treatment and gender. The 
estimates for V mu. showed a statistically significant difference between treatments 
(p=0.0023). Multiple comparisons revealed that treatment A was different from 
treatments B and C, which were not different from each other. This statistically 
significant difference may be due to differences in sample schedule, i.e. , treatment A 
consisted of a 1-hour infusion, and samples were collected for upto 13 hours after the 
end of the infusion whereas samples were C?llected only upto 8 hours after the end of the 
infusion for treatments B and C, thus allowing for a better estimate of V mu. for treatment 
A. The estimates for K,., were not significantly different across treatments or subjects 
when compared statistically. The Vdss estimates were not different between treatments, 
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Figure 4. 7 Serum ethanol concentration v.s time profiles (observed values and fitted curves) by treatment for 
a representative subject (subject 7) for crossover phase of IV ethanol srudy 
r-[ot,,l 
-'D 0 
Table 4.13 Mean (%COV) Comparmental Pharmacokinetic parameters by gender for crossover phase of intravenous 
ethanol study 
' Treatment vmll K,,, Vdc k12 k 21 Vdss 
[mg/Uhr] (n,_g/L) [LI [bJ':11 I (hrlJ [LJ [L/kg]' 
A 
I Ma1es 320 279 32 0.93 1.41 ss 0.7 
(n=8) (26%) (39%) (25%) (28%) (54%) (18%) (15%) 
Females 318 216 26 0.91 2.11 41 0.6 
(n=8) (17%) 
I 
(30%) (21 %) (45%) (60%) 
I 
(26%) (W%) 
All 319 247 29 0.92 1.76 48 0.7 
(n=16) (21 %) (37%) (25%) (36%) (61 %} (26%), (15%) 
B 
Males 357 278 . 36 0.67 ' 2.10 ·.so 0.7 
(n=8) (24%) (39%) (8%) (54%) (57%), (15%) (13%) 
Females 360 231 28 1.08 3.58 38 0.6 
(n=8) (22%) (31 %) (28%) (67%) (57%) 05%) (8%) 
All 359 25.S 32 0.88 2.84 44 0.6, 
I (n=l6) (22%) (37%) (22%) (68%) (63%) (21%) {13%) 
I 
C 
Males 359 277 31 0.79 1.63 48 0.6 
(n=8) (23%) (25%) (13%) (27%) ,(53%) (17%), (l4%) 
Females 379 23,3 .23 l..15 2.0, 36 0.6 
(n=8) (17%) (25%) ,(24%) (42%) (49%) (15%) I ( l2%) 
' 
I All 369 255 .27 0.97 1.86 42 0.6 
(n = 16) (20%) {26%) {24%) (42%) (5 1 %) (22%) (15%) 




but showed a significant gender difference ( mean ( ± S. D.) V dss of 51 ( ± 9) L for male 
subjects and 38 (± 8) L for female subjects across treatments). The estimates for k12 did 
not show any significant differences between treatments, however a significant difference 
was observed for the estimates of k21 (p=0.0209). Multiple comparisons revealed that 
treatment B was different from treatments A and C, which were not different from each 
other. This may be due to the difficulty in estimating distribution and re-distribution rate 
constants for drugs following multi-compartment characteristics when given as long 
duration infusions, since the drug undergoes distribution during the infusion and the 
distribution phase may not be as readily observed as for a drug with two-compartment 
characteristics given as a short infusion (as in treatment A). This phenomenon has been 
observed for other drugs as well, which show a rapid distribution phase when given as 
a short infusion, but the distribution phase is not as apparent when given as a slow 
prolonged infusion, and is called the "vanishing exponential" for drugs following first-
order pharmacokinetics (Gibaldi and Perrier, 1982). 
The mean intrinsic PK parameters, estimated by compartmental methods across subjects 
and treatments, along with the inter-individual and intra-individual variability measures 
(%COY) are presented in table 4.14, by gender. The mean (± S.D.) V mu was 349 (± 
75) mg/Uhr across subjects and treatments. The mean (± S.D.) K,,, was 252 (± 83) 
mg/L across subjects and treatments. The mean ± SD V dss was 51 ( ± 9) L across 
treatments for male subjects, and 38 (± 8) Lacross treatments for female subjects. The 
mean (± S.D.) k12 was 0.92 (± 0.40) hr·• !)-Cross subjects and treatments. The mean(± 
Table 4.14 Mean Compartmentll PK parameter estimates across tfeatments for males (M) and Females (F) for 
intravenous ethanol study 
v-.x K.. k12 ~1 Vd55 
[mg!L/br) [mg/L] [hr-t) [hf"·] [L] 
M F All M F All M ' F AJI M F All M F All 
I 
I 
Overall Mean 346 352 349 278 227 252 0.80 1.05 0.92 l.72 2.59 2.15 51 38 I 45 
I 
I 
' Inter- I 










S.D.) k21 was 2.15 (± 1.4) hr'"1 across subjects and treatments. This corresponds to a 
distribution half-life of around 0.23 hours (or around 14 minutes), indicating that the 
distribution phase for ethanol is quite rapid. 
As table 4.14 indicates, the inter-individual variability, as measured by the %COY, was 
considerable for the PK parameters, especially for k12, k21 and K,,.. This may be a 
consequence of the sampling schedule and the relatively poor precision in the analytical 
methods, particularly at low concentrations. For all parameters, intra-individual 
variability was lower than the inter-individual variability. The mean and inter-individual 
variability estimates of the intrinsic PK parameters are consistent with values reported 
in other studies evaluating the PK of IV ethanol (Wagner et al., 1976; Wilkinson et al., 
1976; Holford, 1987; Rangno et al., 1981). The mean estimate of K,,. of 252 mg/L 
obtained in this study is higher than the population estimate of 80 mg/L reported in other 
studies (Wilkinson, 1980; Holford, 1987). However, these studies have emphasized the 
large variability in K,,. (upto 10-fold) due to differences in sampling schedules, assay 
precision and sensitivity at concentrations around the K,,., as well as inter-individual 
differences in PK of ethanol. The estimates of Vdss are consistent with values obtained 
in other studies and demonstrate gender differences consistent with differences in body 




Baseline-corrected response vs. time profiles for the EEG measures evaluated, including 
total power across all frequency bands, total and relative power within each of the five 
frequency bands (delta, theta, alpha, beta I and beta II) are shown in Appendix J. A 
review of these plots reveal the following: 
1) total power showed a transient increase across all treatments, including placebo. 
2) relative delta power showed a transient increase for active treatments A, B and C 
relative to placebo, that was observed only. for male subjects. 
3) relative theta power showed an initial increase across all treatments followed by a 
transient decrease that was observed for the active treatments only in male subjects. 
Female subjects did not show a consistent decrease in relative theta power following 
ethanol administration. 
4) relative alpha power showed a transient decrease that was treatment-related, however, 
this was seen only for male subjects. 
5) relative beta (I and II) power showed consistent decreases following ethanol 
administration relative to placebo. This was observed for all subjects. 
These observations are consistent with an increase in EEG power in the slow bands and 
a corresponding decrease in EEG power in the fast bands. This results in a generalired 
slowing of the EEG power following ethanol administration. 
The means and %COY of the baseline EEG measures are presented in table 4.15. The 
baseline measures were not different across subjects and treatments, and showed fairly 
Table 4.15 Pharmacodynamic parameters (Means and %COV) for EEG measures 
across treatments and subjects 
Table 4.15a Total Power 
Total Power 
Treatment E.. [µ\12] ~ [µV2] E,,,ax-Eo [µ V2J T ..... [hr]I 
A 
Males 390 (22%) 469 (22%) 79 (67%) 2.5 (0.8-6.0) 
Females 417 (22%) 492 (16%) 76 (58%) 1.8 (0.3-5.0) 
All 403 (22%) 481 (18%) 77 (61 %) 2.0 (0.3-6.0) 
B 
Males 406 (25%) 487 (20%) 82 (71 %) 6.8 (0.5-12.0) 
Females 409 (26%) 505 (24%) 96 (73%) 6.2 (1.3- 9.0) 
All 407 (25%) 496 (22%) 89 (71 %) 6.5 (0.5-12.0) 
C 
Males 407 (21 %) 512 (26%) 105 (84%) 6.8 (0.5-11.0) 
Females 407 (25%) 523 (17%) 115 (50%) 1.7 (0.3- 5.0) 
All 407 (22%) 517 (22%) 110 (66%) 3.0 (0.3-11.0) 
ll 
Males 368 (24%) 463 (23%) 95 (88%) 6.5 (1.3-12.0) 
Females 405 (27%) 481 (23%) 77 (36%) 4.0 (0.5- 6. 7) 
All 386 (25%) 472 (22 %) 86 (71 %) 6.0 (0.5-12.0) 
I: T _ expressed as Mea1a.o (range) 
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Table 4.15b Relative Delta Power 
Relative Delta Power 
Treatment E,, ["] E..... [-] l;....-E0 [-] Tmu [hr]1 
A 
Males 0.396 (18%) 0.514 (12%) 0. 117 ( 60%) 3.5 (0.8-6.0) 
Females 0.448 {19%) 0.499 {16%) 0.059 {118%) 4.0 (0.3-6.0) 
All 0.422 {19%) 0.506 {"14%) 0.088 {84%) 4.0 (0.3-6.0) 
B 
Males 0.416 (24%) 0.517 ( 9%) 0.104 (87%) 5.0 (0.3-9.0) 
Females 0.442 (15%) 0.497 (18%) 0.065 (93%) 4.8 (1.0-9.0) 
All 0.429 (19%) 0.507 (14%) 0.085 (91 %) 5.0 (0.3-9.0) 
C 
Males 0.390 (23%) 0.548 f 9%) 0.158 (52%) 4.5 (1.0-11.0) 
Females 0.450 (16%) 0.528 (10%) 0.078 (58%) 2.5 (0.8- 6.0) 
All 0.420 (20%) 0.538 ( 9%) 0.118 (64%) 4.0 (0.8-11.0) 
D 
Males 0.451 (17%) 0.509 (15%) 0.058 (75%) 4.0 (0.3- 6.3) 
Females 0.447 (17%) 0.511 (14%) 0.064 (96%) 5.3 (0.3-12.0) 
All 0.449 (16%) 0.510 (14%) 0.061 (85%) 4.0 (0.3-12.0) 
l: -i_, expressea as Mcotan (range) 
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Table 4.15c Relative Theta Power 
Relative Theta Power 
Treatment E.,c-J I;..;,. [-] Eo-I;..;,. [-] Tinin [hrjl 
A 
Males 0.294 (21 %) 0.225 (14%) 0.069 (67%) 3.5 (0.8-6.0) 
Females 0.255 (25%) 0.222 (21 %) 0.035 (144%) 2.0 (0.3-6.0) 
All 0.275 (23%) 0.224 (17%) 0.052 (96%) 2.5 (0.3-6.0) 
B 
Males 0.293 (27%) 0.223 (12%) 0.070 (91 %) 4.0 (0.3-11.0) 
Females 0.249 (28%) 0.223 (29%) 0.030 (109%) 6.8 (1.3-11.0) 
All 0.271 (28%) 0.223 (21 %) 0.050 (106%) 6.3 (0.3-11.0) 
C 
Males 0.301 (25%) 0.216 (15%) 0.085 ( 75%) 7.3 (2.0-11.0) 
Females 0.245 (28%) 0.216 (33%) 0.031 (109%) 4.0 (1. 7-12.0) 
All 0.273 (28%) 0.216 (25%) 0.058 ( 98%) 6.2 (1. 7-12.0) 
D 
Males 0.264 (23%) 0.227 (19%) 0.037 (87%) 3.5 (0.5-11.0) 
Females 0.247 (28%) 0.227 (29%) 0.021 (109%) 1.0 (0.3-12.0) 
All 0.256 (25%) 0.227 (27%) 0.029 (97%) 2.5 (0.3-12.0) 
1: l _. ex pres.sea as M001an (raoge) 
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Table 4.15d Relative Alpha Power 
Relative Alpha Power 
Treatment E., ["] E..... [-] E..-E..... [-] TIIUl:I [hrjl 
A 
Males 0.181 (18%) 0.132 (18%) 0.050 (53%) 3.5 (0.8-6.0) 
Females 0.172 (35%) 0.142 (31 %) 0.030 (144%) 3.0 (0.8-5.0) 
All 0.176 (26%) 0.137 (25%) 0.040 (90%) 3.5 (0.8-6.0) 
B 
Males 0.167 (19%) 0.127 (15%) 0.042 (71 %) 5.0 (1.3-9.0) 
Females 0.173 (33%) 0.137 (36%) 0.037 (87%) 6.3 (2.0-7 .0) 
All 0.170 (27%) 0. 132 (21 %) 0.039 (76%) 6.2 (1.3-9.0) 
C 
Males 0.179 (20%) 0.122 (15%) 0.057 (49%) 4.0 (1. 7-11.0) 
Females 0.169 (33%) 0.124 (25%) 0.045 (67%) 5.0 (0.5- 6.3) 
All 0.174 (26%) 0.123 (20%) 0.051 (57%) 4.5 (0.5-11.0) 
D 
Males 0.160 (16%) 0.141 (18%) 0.019 (87%) 3.5 (0.3-6.3) 
Females 0.174 (32%) 0.131 (17%) 0.045 (92%) 4.5 (0.5-9.0) 
All 0.167 (25%) 0.136 (17%) 0.032 (105%) 4.0 (0.3-9.0) 
I: T_ expresseo as Mea1an (range) 
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Table 4.15e Relative Beta I Power 
Relative Beta I Power 
Treatment E.,["] E..... [-] E.....-E.. [-] Tmu [hr] 1 
A 
Males 0.095 (8%) 0.083 (16%) 0.012 (93%) 3.5 (0.8-5.0) 
Females 0.089 (21 %) 0.086 (15%) 0.006 (108%) 2.8 (1.0-6.0) 
All 0.092 (15%) 0.084 (15%) 0.009(106%) 3.5 (0.8-6.0) 
B 
Males 0.091 (12%) 0.080 (14%) 0.012 (60%) 7.5 (1.3-9.0) 
Females 0.097 (29%) 0.087 (18%) 0.012 (145%) 1.8 (0.3-8.0) 
All 0.094 (22%) 0.083 (16%) 0.012 (108%) 6.3 (0.3-9.0) 
C 
Males 0.097 ( 6%) 0.074 (11 %) 0.023 (37%) 4.5 (1. 7-11.0) 
Females 0.097 (28%) 0.083 (17%) 0.014 (107%) 3.5 (0.3-6.0) 
All 0.097 (20%) 0.079 (16%) 0.018 (68%) 4.5 (0.3-11.0) 
D 
Males 0.090 ( 8%) 0.081 (11%) 0.009 (65%) 4.0 (0.3-6.3) 
Females 0.095 (22%) 0.085 (18%) 0.010 (68%) 2.0 (0.3-8.0) 
All 0.093 (17%) 0.083 (15%) 0.010 (65%) 3.5 (0.3-8.0) 
1: 1_ expre&SCD a.s Moo1an (range) 
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Table 4.15f Relative Beta II Power 
Relative Beta II Power 
Treatment e.,n ~[-] E,,-~ [-] Tmia [hr]I 
A 
Males 0.033 (10%) 0.028 (21 %) 0.006 (99%) 3.0 (0.5-5.0) 
Females 0.035 (18%) 0.030 (19%) 0.005 (68%) 1.7 (0.3-6.0) 
All 0.034 (15%) 0.029 (20%) 0.005 (84%) 1.8 (0.3-6.0) 
B 
Males 0.033 (17%) 0.028(20%) 0.005 (116%) 6. 7 (2.0-12.0) 
Females 0.038 (27%) 0.031 (12%) 0.008 (132%) 5.5 (0.3-8.0) 
All 0.035 (24%) 0.029 (17%) 0.007 (125%) 6.3 (0.3-12.0) 
C 
Males 0.034 (17%) 0.024 (16%) 0.010 (44%) 5.7 (2.0-11.0) 
Females 0.039 (29%) 0.029 (18%) 0.010 (94%) 4.5 (0.8-8.0) 
All 0.037 (25%) 0.026 (19%) 0.010 (72%) 5.0 (0.8-11.0) 
ll 
Males 0.034 (18%) 0.028 (5%) 0.006 (85%) 2.8 (0.3-12.0) 
Females 0.037 (20%) 0.032 (19%) 0.005 (49%) 6.7 (0.8-9.0) 
All 0.036 (19%) 0.030 (15%) 0.006 (73%) 5.0 (0.3-12.0) 
I: T _ expressed as Mea1an (range) 
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low variability ranging from 15 % to 28 % between subjects across measures. 
Figures 4.8 - 4 .13 show the peak changes in the EEG measures, including total power, 
relative power in each of the five frequency bands, delta, theta, alpha, beta I and beta 
11) , by treatment for male and female subjects. 
Statistical comparison of the ~ o1>a or E.nu, • for the EEG measures revealed significant 
treatment differences for relative alpha power (p=0.0337), relative beta I power 
(p=0.0093) and for relative beta II power (p=0.0226). Multiple comparisons indicated 
that treatment C was significantly different from treatments A, Band D, while A and B 
could not be distinguished from placebo. Residuals were found to be normally distributed 
for these variables. There was a significant treatment-by-gender interaction for the E..u., o1>a 
for relative alpha power. Further comparison of treatment means by gender revealed that 
the significant differences between active treatments A, B and C and placebo (treatment 
D) was observed only for male subjects (p=0.0055), while female subjects did not show 
significant differences in relative alpha power across treatments. There were no 
significant sequence or period effect on any of the EEG variables evaluated. The p values 
for the significance of the baseline response as a covariate was less than 0.05 for all the 
EEG variables evaluated except for relative beta I power. This indicates that the baseline 
response contributed significantly to the overall variability in the EEG response to 
ethanol. The NR score and AAAI were not significant as covariates in the analysis, 
indicating that these variables did not contribute significantly to the overall variability in 
the magnitude of the EEG response to ethanol. 
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Figure 4.8 Baseline-corrected pea.le change in total power by treatment 
for rv ethanol study 
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Figure 4.9 Baseline-corrected pea.le change in relative delta power by treatment 
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Figure 4. 10 Baseline-corrected peak change in relative theta power by treatment 
for IV ethanol study 
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Figure 4 . 11 Baseline-corrected peak change in relative alpha power by treatment 
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Figure 4 .12 Baseline-corrected peak change in relative beta I power by treatment 
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Figure 4.13 Baseline-corrected peak change in relative beta II power by treatment 
for IV ethanol study 
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The E...u• for relative delta power and E,,,;..ob• for relative theta power showed a trend 
toward treatment-related differences, but the p values did not reach statistical significance 
(p value for E,,....• for relative delta power=0.0537, and for E,,,;..ob• for relative theta 
power=0.0972). 
There was also a trend toward lower EEG responses for relative delta and relative theta 
power for female subjects compared to male subjects, but the differences did not reach 
statistical significance. Statistically significant differences between males and females 
were observed only for relative alpha pow~r. 
Statistical comparison of the f-.x or f.nio for the EEG measures revealed significant 
treatment differences for total power (p=0.0023), relative theta power (p=0.042), 
relative alpha power (p=0.0246) and relative beta II power (p=0.0135). Multiple 
comparisons indicated that, in general, treatment A was significantly different from 
treatments B, C and D for total power, relative theta power and relative beta II power. 
Residuals were found to be nonnally distributed for these variables. There was a 
significant period effect observed for relative theta power and relative alpha power. The 
baseline response was not a significant covariate for any of the f-.x or f.nio estimates for 
any of the EEG measures evaluated except for relative theta power. The NR score was 
a significant covariate only for the t.u for relative alpha power. Alcohol history (AAAI) 
was a significant covariate for the f.nio for relative theta, relative alpha and relative beta 
II power, indicating that the AAAI may contribute significantly to the overall variability 
in the timing of the EEG response to ethanol. There were no significant gender 
207 
differences observed for any of the t_. or t...... comparisons. 
The increases in relative delta power, along with the decreases in relative theta power 
as well as the decrease in relative power of the fast bands (alpha and beta) are consistent 
with the increase in EEG power and a generalized slowing of the EEG following ethanol 
administration that have been previously reported in the literature (Ehlers and Shuckit, 
1990; Begleiter and Platz, 1972; Lukas et al., 1986; Kaplan et al., 1988), although these 
studies have investigated EEG changes following oral ethanol administration, and there 
have been no studies prior to this evaluating EEG changes following intravenous ethanol 
administration. The EEG effects of ethanol show treatment-related changes, and some 
of the time to peak measures show a significant effect of input-rate on the EEG measures 
evaluated. Gender differences were observ~ in the EEG response to ethanol indicating 
that, in general, females tended to respond less to the effect of ethanol on the increase 
in slow activity and decrease in alpha activity at the same achieved serum ethanol 
concentrations compared to the male subjects. Statistically significant gender differences 
were observed only for relative alpha power. 
4.4.3B Psychometric Performance Tests 
Baseline-corrected response vs. time profiles for the primary PPT measures evaluated, 
including reaction time for number vigilance and sensitivity for word recognition are 
shown in Appendix K. Response-time profiles for the other measures are not included 
since they did not show any consistent time:related changes. Table 4.16 lists the baseline 
Table 4.16 Pharmacodynamic parameters (Means and %COY) for PPT measures 
across treatments and subjects 
Table 4.16a Immediate Recall Accuracy 
Immediate recall accuracy 
Treatment ~ (-] E,,,;.. [-] ~-E,,,.., [-] Tmin [hr] 1 
A 
Males 7.1 (38%) 3.3 (40%) 3.8 (66%) 1.2 (0.3-4.0) 
Females 8.2 (17%) 3.2 (31 %) 5.0 (19%) 1.2 (0.3-3.0) 
All 7.7 (28%) 3.3 (35%) 4.4 (44%) 1.2 (0.3-4.0) 
B 
Males 7.0 (37%) 2.8 (72%) 4.3 (54%) 4.5 (0.3-7.0) 
Females 8.1(15%) 3.1 (41%) 5.1 (34%) 4.5 (1.0-6.7) 
All 7.6 (27%) 2.9 (56%) 4.7 (43%) 4.5 (0.3-7.0) 
C 
Males 8.0 (28%) 2.6 (33%) 5.4 (42%) 1.8 (0.5-7.0) 
Females 8.0 (16%) 2.9 (56%) 5.1 (14%) 2.5 (0.8-6.0) 
All 8.0 (22%) 2.8 (46%) 5.3 (31 %) 2.0 (0.5-7.0) 
D 
Males 7.2 (34%) 3.7 (34%) 3.5 (43%) 6.3 (1.3-12.0) 
Females 7.3 (18%) 3.7 (32%) 3.6 (40%) 1.8 (0.3- 7.0) 
All 7.2 (26%) 3.7 (32%) 3.5 (40%) 4.5 (0.3-12.0) 
I : ~I- expressea as Median (range) 
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Table 4.16b Number Vigilance Accuracy 
Number vigilance accuracy 
Treatment Eo [msec] E,..;,. [ msec] Eo-E,..;,. [ msec] Tmin [hr]1 
A 
Males 96.3 (9%) 70.8 (39%) 25.4 (103%) 1.7 (0.3-3.0) 
Females 98.8 (2%} 91.7 (9%) 7.1 (134%) 0.5 (0.3-6.0) 
All 97.5 (6%) 81.3 (28%) 16.3 (131 %) 1.3 (0.3-6.0) 
B 
Males 99.2 (2%) 65.4 (45%) 33.8 (85%) 6.3 (1.7-7.0) 
Females 98.8 (2%) 88.8 (15%) 10.0 (126%) 4.0 (0.8-7.0) 
All 99.0 (2%) 77.1 (33%) 21.9 (113%) 5.5 (0.8-7.0) 
C 
Males 96.3 (4%) 67.5 (41 %) 28.8 (85%) 4.0 (0.3-6.0) 
Females 98.3 (3%) 87.9 (14%) 10.4 (99%) 2.5 (1.3-9.0) 
All 97.3 (3%) 77.7 (30%) 19.6 (104%) 3.0 (0.3-9.0) 
D 
Males 93.8 (6%) 84.2 (18%) 9.6 (145%) 0.8 (0.3-6.0) 
Females 97.1 (6%) 89.6 (14%) 7.5 (94%) 1.0 (0.3-6.0) 
All 95.4 (6%) 86.9 (16%) 8.5 (125%) 1.0 (0.3-6.0) 
l: ·, ,. exp~ as Median (range) 
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Table 4. 16c Number Vigilance Reaction l'ime 
Number vigilance reaction time 
Treatment F,o [msec] I;...,. ( msec] 1;..,.,.-1?-o Ta,u [hr]I 
[msec] 
A 
Males 422.6 (10%) 549.0 (16%) 126.4 (52%) 1.8 (0.8-6.0) 
Females 391.4 (8%) 476.9 (11 %) 85.5 (55%) 1.8 (0.8-4.0) 
All 407.0 (10%) 513.0 (15%) 105.9 (56%) 1.8 (0.8-6.0) 
B 
Males 413.5 (13%) 537.4 (18%) 123.9 (44%) 5.0 (0.3-9.0) 
Females 393.7 (9%) 473.9 (13%) 80.2 (60%) 6.0 (1. 7-7 .0) 
All 403.6 (11 %) 505.6 (17%) 102.0 (53%) 5.5 (0.3-9.0) 
C 
Males 415.1 (12%) 566.8 (13%) 151.8 (28%) 3.5 (0.5-7.0) 
Females 400.9 (11 %) 506.5 (12%) 105.6 (40%) 5.0 (1.3-7 .0) 
All 408.0 (11 %) 536.7 (14%) 128.7 (37%) 4 .0 (0.5-7.0) 
Q 
Males 436.4 (14%) 477.5 (15%) 41.l (86%) 4.0 (2.0-7 .0) 
Females 406.6 (15%) 450.0 (15%) 43.5 (66%) 1.2 (0.3-6.3) 
All 421.5 (14%) 463.8 (15%) 42.3 (74%) 3.0 (0.3-7.0) 
I : 1 ... eJP.pressea as Moo1an (range) 
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Table 4.16d Tracking Mean Error 
Tracking mean error 
Treatment Eo [cm] E.na. [cm] E.na.-Eo [cm] Tmu. [hr)1 
A 
Males 25.27 (16%) 45.03 (58%) 19.75 (122%) 1.2 (0.3-4.0) 
Females 27.94 (12%) 33.54 (16%) 5.61 (44%) 1.0 (0.3-6.0) 
All 26.61 (15%) 39.29 (48%) 12.68 (143%) 1.2 (0.3-6.0) 
B 
Males 27.57 (17%) 43.04 (51 %) 15.47 (126%) 6.3 {l.0-12.0) 
Females 26.64 (18%) 33.82 (16%) 7. 17 (46%) 6.3 {0.8- 7.0) 
All 27.10 (17%) 38.43 (42%) 11.32 (125%) 6.3 (0.8-12.0) 
C 
Males 24.66 (21 %) 38.58 (21 %) 13.93 (60%) 3.0 (0.3-7.0) 
Females 28.59 (10%) 41.68 (34%) 13.09 (107%) 3.0 (0.3-6.3) 
All 26.62 (17%) 40.13 (28%) 13.51 (82%) 3.0 (0.3-7.0) 
D 
Males 25.05 (20%) 30.08 (11 %) 5.03 (70%) 1.3 (0.3-6.7) 
Females 26.48 (14%) 38.25 (40%) 11.77 (114%) 2.5 (0.3-6. 7) 
All 25.76 (17%) 34.16 (34%) 8.40 (120%) 1.8 (0.3-6.7) 
1: T _ expressea as Me,hao (range) 
212 
Table 4.16e Word Recognition Sensitivity 
Word recognition sensitivity 
Treatment F.o [-] E...m [-] F.o-E...m [-] Tmin [hr] 1 
A 
Males 0.728 (18%) 0.206 (143%) 0.522 (51 %) 2.2 (0.5-4.0) 
Females 0.860 (12%) 0.430 (46%) 0.431 (35%) 1. 7 (0.3-6.0) 
All 0.794 (17%) 0.318 (85%) 0.476 (45%) 1. 7 (0.3-6.0) 
B 
Males 0.734 (14%) 0.217 (106%) 0.517 (49%) 5.0 (1.7- 6.3) 
Females 0.839 (13%) 0.332 (76%) 0.507 (36%) 5.7 (0.3-12.0) 
All 0.787 (15%) 0.274 (88%) 0.512 (42%) 5.0 (0.3-12.0) 
C 
Males 0.702 (17%) -0.007(532%) 0.710 (39%) 4.0 (1.3-7 .0) 
Females 0.855 (22%) 0.310 (75%) 0.545 (21%) 5.0 (0.8-6.7) 
All 0.779 (22%) 0.151 (214%) 0.627 (35%) 4.0 (0.8-7.0) 
D 
Males 0.771 (18%) 0.411 (31 %) 0.360 (19%) 6.2 (2.0-12.0) 
Females 0.724 (16%) 0.384 (52%) 0.341 (37%) 4.5 (0.5-12.0) 
All 0.748 (17%) 0.397 ~1 %) 0.350 (28%) 5.5 (0.5-12.0) 
1: 1..., expresse.o as Median (range) 
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Table 4.16f Word Recognition Reaction time 
Word recognition reaction time 
Treatment Eo [msec] E,,,... [ msec] E,,,...-Eo T llll1 [hr] I 
[msec] 
A 
Males 659.5 (13%) 1286.3 (58%) 626.8 (116%) 1.8 (0.3-4.0) 
Females fi'J2 .7 (6%) 745.8 . (9%) 143.1 (40%) 0.9 (0.3-2.0) 
All 631.1 (11 %) 1016.1 (57%) 385.0 (145%) 1.3 (0.3-4.0) 
B 
Males 722.4 (19%) 963.8 (24%) 241.4 (74%) 3.5 (0.3-6.7) 
Females 613.0 (9%) 766.9 (13%) 153.9 (45%) 3.5 (0.5-7.0) 
All 667.7 (18%) 865.4 (23%) 197.6 (70%) 3.5 (0.3-7.0) 
C 
Males 685.7 (13%) 1101.3 (32%) 415.7 (81 %) 4.0 (0.5-7.0) 
Females 628.4 (11 %) 777.7 (14%) 149.3 (36%) 6.0 (3.0-9.0) 
All 657.1 (13%) 939.5 (32%) 282.5 (96%) 5.0 (0.5-9.0) 
D 
Males 661.2 (16%) 898.8 (35%) 237.6 (112%) 3.8 (1.3-11.0) 
Females 637.6 (9%) 758.5 (18%) 120.9 (79%) 4.2 (0.8-12.0) 
All 649.4 (13%) 828.6 (29%) 179.2 (113%) 3.8 (0.8-12.0) 
I: T_ expressea as Mea1an (range) 
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(EJ, maximum or minimum observed response <Emu• or E...m"•") and time of E...axob• or 
E.....,o1>1 (t,,_ or t,,,;J for each of the PPT measures evaluated. Figures 4.14 - 4.18 show the 
peak changes in the PPT measures, including accuracy for immediate word recall , 
accuracy and reaction time for number vigilance, mean tracking error for tracking and 
sensitivity and reaction time for word recognition 
Response-time profiles for PPT measures indicated that the psychometric test battery was 
sensitive to ethanol and showed increase in reaction-time for the number vigilance and 
word recognition tests, decrease in the sensitivity measure of the word recognition test, 
increase in tracking error and decrease in accuracy of the immediate recall test. 
Treatment A showed a greater impairment ?f psychometric performance as measured by 
these tests compared to treatment B. Peak increases in speed measures and peak 
decreases in accuracy measures were comparable for treatments A and C. The 
psychometric performance impairment during the steady-state phase of treatment C was 
sustained and no acute tolerance development was observed. Baseline variability for all 
tests was fairly low across treatments. However, there appeared to be a fatigue effect 
on some of the tests, indicated by slight changes in performance scores for treatment D 
(placebo). This may be due to the frequency of the testing, as well as the duration for 
which these tests were performed during each study period. 
Statistical comparison of E...axo1>• for number vigilance reaction time showed significant 
treatment differences, but no significant· gender differences. Multiple comparisons 
revealed that the active treatments (A, Band C) were significantly different from placebo 
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Figure 4.14 Immediate Recall Accuracy (Mean ± S.E.) by treatment for 
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Figure 4.15 Number vigilance reaction time (Mean ± S.E.) by treatment for 
IV ethanol study 
215 
0 










Cl i .g 
~ ·a 0 
uY 1 0 
i:! 







Figure 4.17 Word Recognition Sensitivity (Mean± S.E.) by treatment 
for IV ethanol study 
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Figure 4.18 Word Recognition reaction time (Mean ± S.E.) by treatment 
for IV ethanol study 
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(treatment D) , but not from each other. Statistical comparison for l;,,;..oba for word 
recognition sensitivity also showed significant treatment differences, but no significant 
gender differences. Multiple comparisons revealed that the active treatments (A , Band 
C) were significantly different from placebo (treatment D), and that treatments A and B 
were different from treatment C, but not from each other. Statistical comparison of the 
other measures, viz. changes in accuracy ·measures of the immediate word recall and 
number vigilance tests, changes in mean tracking error of the tracking test and changes 
in reaction time for the word recognition test revealed significant treatment differences 
only for the immediate word recall accuracy, with multiple comparisons indicating that 
the active treatments were significantly different from placebo. 
Statistical comparison of T m&l or T min values revealed significant differences for all the 
primary and secondary measures. Multiple comparisons indicated, in general, that time 
of peak impairment for treatment A was significantly different from those of treatments 
Band C. 
For all the statistical tests, treatment-by-gender interactions were not significant. Also, 
the baseline response was not a significant covariate except for the immediate word recall 
test. The alcohol history (AAAI) and non-responder score were also not significant 
covariates, indicating that they did not contribute significantly to the overall variability 
in the response measures. Also, residual analysis for all the comparisons indicated that 
the distribution of the residuals were not significantly different from a normal 
distribution, except for the word recognition reaction-time. Therefore, the statistical 
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analysis was repeated on the log-transformed data, after which the residuals were found 
to be normally distributed. 
The increase in reaction-time for the number vigilance and word recognition tests, 
decrease in the sensitivity measure of the word recognition test, increase in tracking error 
and decrease in accuracy of the immediate recall test are consistent with psychometric 
impairment. Word recognition sensitivity and number vigilance reaction time were the 
most sensitive measures of the psychometric performance battery completed by the 
subjects in this study. The measures showed significant treatment-related differences, as 
well as significant rate-related differences: between treatments A and B for the word 
recognition sensitivity. The impairment in psychometric performance is consistent with 
other studies evaluating performance impairment following ethanol administration (Evan 
et al., 1984; Moskowitz et al., 1976; Wittenborn, 1987; van Harten et al. , 1992; 
Fluckiger et al., 1988). Input-rate had a significant effect on the degree of impairment, 
with the fast-input treatment resulting in greater psychometric impairment than the slow-
input treatment. There were no significant gender difference in the psychometric 
impairment induced by ethanol across treatments in this study. 
4.4.3C Impairment Scales 
Baseline-corrected response vs. time profiles for the SRI and ORI measures evaluated, 
including scores for the items HIGH, DRUNK and ALCOHOL EFFECTS on the SRI 
scale as well as scores for the items HIGH and DRUNK on the ORI scale are shown in 
' 
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Appendix L. Response vs. time profiles for the other items on the SRI and ORI scales 
are not included since they did not show a consistent response across subjects and 
treatments. 
Table 4.17 lists the baseline (EJ, maximum observed response CE.n..x"1") and time of 
E,,.,..• (U for each of the SRI and ORI items listed above. Figures 4.19 - 4.23 show 
the peak changes in the SRI/ORI measures, including scores for the items HIGH, 
DRUNK and ALCOHOL EFFECTS on the SRI scale, as well as scores for the items 
HIGH and DRUNK on the ORI scale. 
The SRI and ORI scales were very sensitive to the effects of ethanol, with the most 
sensitive items being HIGH, DRUNK and ALCOHOL EFFECTS on the SRI scale and 
HIGH and DRUNK on the ORI scale. There were input-related increases in the E......®• 
for these items, with both fast and slow input treatments showing increases in E......®' 
from placebo, however the changes in the scores for treatment B (slow input) increased 
more gradually relative to the scores for treatment A (fast-input). E......®' values for 
treatment C were consistent with treatment A, indicating rapid achievement of peak 
impairment scores. 
Two of the eight male subjects (subjects 1 and 8) and four of the eight female subjects 
(subjects 9, 11, 13 and 15) did not show a consistent response on the SRI and ORI 
scales, even though they showed EEG changes and psychometric impairment consistent 
with the other subjects. These subjects were classified as "non-responders". In order to 
incorporate this in the statistical analysis, 1:11ese subjects were given a "non-responder" 
Table 4.17 Pharmacodynamic parameters (Means and %COY) for SRI/ORI 
measures across treatments and subjects 
Table 4.17a SRI - lilGH 
SR1-lilGH 
Treatment ~ [-] E....x [-] E....x-~ [-] Tmu [hr]' 
A 
Males 1 (214%) 30 (93%) 30 (96%) 1.0 (0.3-1.7) 
Females 1 (215%) 13 (119%) 12 (113%) 0.6 (0.3-1.7) 
All 1 {226%) 22 (109%) 21 {112%) 1.0 {0.3-1.7) 
~ 
Males 0 (185%) 15 {102%) 14 {105%) 6.0 (3 .0-6.0) 
Females 4 (240%) 13 (190%) 9 (172%) 3.5 (1.3-8.0) 
All 2 (319%) 14 (142%) 12 (129%) 5.0 (l.3-8.0) 
C 
Males 0 (283%) 41 (61 %) 41 (62%) 2.0 (0.3-6.0) 
Females 2 (283%) 21 (112%) 19(111%) 0.8 (0.3-3.0) 
All 1 (374%) 31 (83%) 30 (84%) 1.0 (0.3-6.0) 
ll 
Males 1 (138%) 2 (94%) 1 (107%) 0.4 (0.3-11.0) 
Females 0 (198%) 1 (113%) 1 (107%) 0.3 (0.3- 7.0) 
All 1 (159%) I (103%) 1 (114%) 0.3 (0.3-11.0) 
I: 1-... ex resseo as Me;(llan (range) p 
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Table 4.17b SRI - DRUNK 
SRI-DRUNK 
Treatment ~ [-] Ema.[-] Ema.-~[-] Tmax [hr]1 
A 
Males I (185%) 56 (63%) 55 (64%) 1.0 (0.5-3.0) 
Females 0 (185%) 15 (114%) 15 (116%) 0.6 (0.3-1.7) 
All 0 (192%) 35 (96%) 35 (97%) 0.8 (0.3-1.7) 
I! 
Males 0 (283%) 25 (98%) 25 (99%) 4.0 (1.3-7.0) 
Females 1 (283%) 7 (103%) 6 (113%) 4.5 (1.3-6.3) 
All 0 (336%) 16 (124%) 16 (128%) 4.0 (1.3-7.0) 
C 
Males 0 (185%) 58 (57%) 51 (58%) 2.5 (0.8-6.3) 
Females 0 (283%) 20 (84%) 20 (85%) 1.3 (0.3-3.0) 
All 0 (215%) 39 (83%) 38 (83%) 1.7 (0.3-6.3) 
n 
Males 1 (119%) 3 (118%) 2 (155%) 0.5 (0.3- 4.0) 
Females 0 (198%) I (95%) 1 (107%) 0.6 (0.3-11.0) 
All 1 (146%) 2 (145%) 1 (177%) 0.5 (0.3-11.0) 
1: T_ expresseo as Mcaulll (range) 
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Table 4.17c SRI - ALCOHOL EFFECTS 
SRI-ALCOHOL EFFECTS 
Treatment F.o [-] ~ [-] ~-F.o [-] Tmu [hr]' 
A 
Males 0 {185%) 61 (57%) 60 {57%) 0.9 (0.5-1.7) 
Females 0 {198%) 30 (103%) 29 (105%) 1.0 (0.5-6.0) 
All 0 (193%) 45 (78%) 45 (79%) 1.0 (0.5-6.0) 
B 
Males 0 (283%) 40 (72%) 39 (74%) 5.0 (l. 7-11.0) 
Females 1 (225%) 18 (76%) 18 (80%) 6.0 (1.7- 6.3) 
All 0 (250%) 29 (84%) 28 (87%) 5.5 (1. 7-11.0) 
t 
Males 0 (283%) 69 (44%) 69 (45%) 2.0 (1.0-12.0) 
Females 0 (0%) 32 (69%) 32 (69%) 1.0 (0.5- 6.0) 
All 0 (400%) 51 (63%) 50 (64%) 1.0 (0.5-12.0) 
ll 
Males 1 (151 %) 2(111%) 2 (133%) 0.5 (0.3-9.0) 
Females O (185%) 1 (103%) 1 (107%) 1.4 (0.3-9.0) 
All 0 (165%) 2 (112%) 1 (126%) 0.8 (0.3-9.0) 
l: ·1 _ e:i.pressea as Median (range) 
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Table 4. 17d ORJ - lDGH 
ORI-HIGH 
Treatment ~ [-] E....x [-] E....x-~ [-] Tmu: [hr]• 
A 
Males 0 (0%) 29 (68%) 29 (68%) 1.0 (0.3-1.3) 
Females 0 (0%) 18 (67%) 18 (67%) 1.0 (0.5-2 .0) 
All 0 (0%) 23 (72%) 23 (72%) 1.0 (0.3-2.0) 
B 
Males 0 (0%) 14 (127%) 14 (127%) 5.0 (1.3-6.0) 
Females 0 (0%) 11(111%) 11 (111 %) 4.5 (1.3-6.3) 
All 0 (0%) 13 (119%) 13 (119%) 5.0 (1.3-6.3) 
C 
Males 0 (0%) 27 (58%) 27 (58%) 1.0 (1.0-5.0) 
Females 0 (0%) 21 (52%) 21 (52%) 1.0 (0.8-2.0) 
All 0 (0%) 24 (56%) 24 (56%) 1.0 (0.8-5.0) 
D 
Males 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
Females 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
All 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
I : T- expressea as Moo1an {range) 
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Table 4.17e ORI - DRUNK 
ORI-DRUNK 
Treatment ~ [-] E..... [-] E.....-F-o [-] Tmu: [hr]I 
A 
Males 0 (0%) 48 (42%) 48 (42%) 1.0 (l.0-2.0) 
Females 0 (0%) 20 (73%) 20 (73%) 1.0 (0.3-3.0) 
All 0 (0%) 34 (65%) 34 (65%) 1.0 (0.3-3.0) 
B 
Males 0 (0%) 30 (53%) 30 (53%) 6.0 (5.0-6.3) 
Females 0 (0%) 20 (73%) 20 (73%) 6.0 (4.0-6. 7) 
All 0 (0%) 25 (63%) 25 (63%) 6.0 (4.0-6. 7) 
C 
Males 0 (0%) 44 (55%) 44 (55%) 3.0 (1.0-6.0) 
Females 0 (0%) 22 (41 %) 22 (41 %) 1.8 (0.8-6.0) 
All 0 (0%) 33 (63%) 33 (63%) 2.5 (0.8-6.0) 
D 
Males 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
Females 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
All 0 (0%) 0 (0%) 0 (0%) 0.3 (0.3-0.3) 
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Figure 4.22 ORI-HIGH Score (Mean ± S.E.) by treatment for IV Ethanol Study 
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Figure 4 .23 ORI-DRUNK Score (Mean ± S.E.) by treatment for IV Ethanol Study 
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score (NR) of 0, while the other subjects ("resPonders") were given a score of I. This 
score was used as a covariate in the statistical analysis. 
Statistical comparison of the I;.....o1>• and t_.·revealed significant treatment differences for 
all the SRI and ORI variables. Multiple comparisons for the I;.....ob• values across 
treatments indicated that all three active treatments (A, B and C) were significantly 
different from placebo (treatment D), and that treatment B was significantly different 
from treatments A and C, but treatments A and C were not significantly different from 
each other. Multiple comparisons for the t_. values indicated that, in general, treatment 
B was significantly different from treatments A and C. 
Statistical analysis also revealed a significant effect of gender for the E,,..,,• for the items 
DRUNK and ALCOHOL EFFECTS on the SRI scale and the item DRUNK on the ORI 
scale. This indicates that there was a significant gender difference in the magnitude of 
the change from baseline on these subjective measures of impairment. Females showed 
a lower degree of subjective impairment than male subjects, as measured by the SRI and 
ORI scales. 
Residuals were found to be significantly different from normal for some of the variables 
tested. For these variables, the statistical analysis was performed on the rank-transformed 
data. There were no significant sequence or period effects. The baseline resPonse was 
not a significant covariate in the analysis except for the E,,..,,• for SRI-HIGH. The NR 
score was a significant covariate for the E,,..,,ob• for SRI-ALCOHOL EFFECTS and ORI-
HIGH. There was no significant effect of Alcohol history (AAA!) as a covariate in the 
230 
statistical analysis, indicating that differences in Alcohol history did not contribute 
significantly to the differences between treatments and/or gender. 
In summary, the SRI and ORI scales provided sensitive measures of the subjective effects 
of ethanol in this study. The most sensitive items on the scales were HIGH, DRUNK and 
ALCOHOL EFFECTS, which showed input-rate-related differences. This provided 
conclusive proof that the rate of input of- ethanol is an important determinant of the 
degree of subjective impairment perceived by the individual, so that fast-input results in 
a greater degree of impairment perceived by the individual relative to slow input of 
ethanol. There were also gender differences observed in this study, indicating that 
females experienced lower degrees of ethanol-induced subjective impairment compared 
to the males. Since there were some subjects of each gender that were classified as non-
responders (2 out of 8 males and 4 out of 8 females), this may be a confounding factor 
in the interpretation of this observation . Further research would be necessary to 
prospectively and systematically evaluate the subjective effects of ethanol in responders 
and non-responders of both genders to conclusively prove a true difference in perceived 
impairment induced by ethanol between males and females . 
4.4.30 PK-PD Correlation and Tolerance Development 
In order to evaluate the PK-PD relationship for ethanol, response vs. serum ethanol 
concentration profiles were plotted for several of the PD measures evaluated. The PD 
measures that were correlated to serum concentrations included the relative theta power 
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from the EEG measures, number vigilance reaction time for the PPT battery, and the 
score on the item" ALCOHOL EFFECTS" on the SRI scales. Response vs. concentration 
plots for each of these measures are presented by subject and treatment in Appendix M. 
A review of the plots for baseline-corrected relative theta power vs. serum ethanol 
concentrations resulted in the following observations: 
1) effect-concentration profiles revealed no consistent patterns across subjects or 
treatments. 
2) For treatments A and B, several of the subjects showed an initial transient increase in 
relative theta power followed by a later sustained decrease. In general, the changes in 
relative theta power did not appear to be correlated to concentrations for these 
treatments. 
3) For treatment C, some of the subjects showed a transient increase in relative theta 
power during the initial phase when concentrations were increasing, followed by a 
decrease in relative theta power. However, these changes did not appear to be correlated 
with serum ethanol concentrations. 
In order to evaluate the time-course of the change in relative theta power during the 
"steady-state" infusion phase for treatment C, the relative theta power vs. time profile 
was superimposed on the serum ethanol concentration vs. time profile for each subject. 
These plots are presented in Appendix N 1 and the plot for one representative subject 
(subject 9) is shown in figure 4.24. 
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Figure 4.24 Serum ethanol concentration vs. time and relative theta power vs. time for a 
representative subject (subject 9) for treatment C of IV ethanol study 
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theta power during the first infusion followed by a later more sustained decrease in 
relative theta power that appears to return to baseline values at the end of the second 
infusion. Eight of the subjects (subjects 2, 3, 9, 11, 12, 13, 14, 15) showed only 
increases in relative theta power during the ethanol infusions that was sustained, in some 
cases, during the"steady-state" phase of the treatment, and returned to baseline after the 
end of the second infusion. The other subjects did not show any consistent time-related 
changes in relative theta power. 
In summary, there was no consistent effect-concentration correlation for the EEG 
measures evaluated. 
A review of the plots for baseline-correcte:Cf number vigilance reaction-time vs. serum 
ethanol concentrations resulted in the following observations: 
1) increasing concentrations generally were associated with increases in number vigilance 
reaction time. 
2) for treatment A, most of the subjects showed concentration-related increases in 
reaction-time consistent with psychometric impairment. Only 2 subjects (subjects 5 and 
10) showed a sm.µI clockwise hysteresis loop with smaller changes in reaction time at 
later time points (during the declining phase) compared to the relatively larger changes 
in reaction time at earlier time-points (during increasing concentrations). 
3) for treatment B, most of the subjects showed concentration-related increases in 
reaction-time consistent with psychometric ·impairment. Only 3 subjects (subjects 1, 12 
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and 14) showed a small clockwise hysteresis loop with smaller changes in reaction time 
at later time points (during the declining phase) compared to the relatively larger changes 
in reaction time at earlier time-points (during increasing concentrations). 
4) for treatment C, most of the subjects showed increases in reaction-time with 
concentration. Only 2 subjects (subjects 2 ~d 16) showed a small clockwise hysteresis 
loop with smaller changes occurring at later time-points (during the declining phase) 
relative to the changes in reaction-time at earlier time-points during increasing 
concentrations. 
In order to evaluate the time-course of the change in number vigilance reaction-time 
during the "steady-state" infusion phase for treatment C, the reaction-time vs. time 
profile was superimposed on the serum ethanol concentration vs. time profile for each 
subject. These plots are presented in Appendix N2 and the plot for one representative 
subject (subject 9) is shown in figure 4.25. As the plots indicate, reaction-time increased 
with an increase in serum concentration d1,1ring the first hour (Infusion I). During the 
next five hours (Infusion II), the increase in.reaction-time was sustained and followed the 
serum concentration-time profile, with no acute tolerance development. The response-
time profile also followed the serum concentration-time profile during the declining phase 
after the end of Infusion n. This was observed for all subjects except subject number 7, 
for whom the response returned to baseline faster than the serum concentration. 
In summary, both fast and slow input treatments (A and B) showed psychometric 
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Figure 4.25 Serum ethanol concentration vs. time and number vigilance reaction time vs. 
time for a representative subject (subject 9) for treatment C of IV ethanol study 
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concentration. Treatment C showed impainnent that was correlated with concentration 
and which was sustained during the "steady-state" phase of the treatment, indicating that 
there was concentration-related impairment with no acute tolerance development to the 
psychometric impairment effects of ethanol. 
A review of the plots for baseline-corrected SRl-Alcohol Effect Scores vs. serum ethanol 
concentrations resulted in the following observations: 
I) there was a consistent increase in SRl SC9res with serum concentrations at earlier time 
points, i .e., higher concentrations were associated with a higher degree of subjective 
impairment as assessed by the SRl scores. This was observed during the ascending 
concentration phase for all treatments. 
2) For treatments A and B, at later time-points, the effect appeared to decline faster than 
serum concentrations resulting in the presence of clockwise hysteresis loops in the effect 
vs. concentration profiles. Clockwise hysteresis loops were observed in 10 of the 16 
subjects for treatment A, in 9 of the 16 subjects for treatment B, and in IO out of 16 
subjects for treatment C. Figure 4.26 shows the SRl-ALCOHOL EFFECT vs. 
concentration profiles by treatment for a representative subject (subject 3). 
3) Two subjects in treatment A (subjects 8 and 15), three subjects in treatment B 
(subjects 1, 2 and 8), and two subjects in treatment C (subjects 2 and 8) showed 
inconsistent changes in SRI-ALCOHOL EFFECTS scores with serum ethanol 
concentration. 
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Figure 4.26 SRI-ALCOHOL EFFECTS score vs. serum ethanol concentration 
by treatment for a representative subject (subject 9) for IV ethanol study 
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4) For treatment C, the serum ethanol concentration vs. time and the SRI-ALCOHOL 
EFFECTS score vs. time profiles were plotted on the same time scale to compare the 
time course of the changes in concentration and effect. These plots are presented, by 
subject, in Appendix N3. The plot for a representative subject (subject 9) is shown in 
figure 4.27. Evaluation of these profiles revealed that during the first hour (Infusion I), 
the SRI scores increased with concentration. However, during the "steady state" phase 
(Infusion II), SRI-ALCOHOL EFFECT scores were not sustained, even though serum 
concentrations remained fairly constant. This was observed for 14 of the 16 subjects and 
is consistent with acute pharmacodynamic tolerance development to the subjective effects 
of ethanol. 
Follow-up analysis for other items of the $RI scale, including the items "HIGH" and 
"DRUNK", as well as for the ORI scale items "HIGH" and "DRUNK" revealed the 
same pattern of initial concentration-related impairment and the presence of clockwise 
hysteresis, although the most profound effect was observed for the SRI-Alcohol Effects 
scores. 
In order to evaluate the effect of the rate and extent of ethanol exposure on the 
pharmacodynamics and the development of acute tolerance, the observed effect at the 
time corresponding to the peak concentration CErmaJ was plotted as a function of the 
C and as a function of the partial area under the concentration-time curve until the max, 
end of the infusion for that treatment (AUCTm,u). The AUCTmax provides a measure of the 





1200 i~ ---SRI-AE 15 Ji 1000 800 10 Lt.I E ..J E o-E ~ 600 5 ::r:: I:! 2 ff § ~ ~~ 400 0 < 200 ii! 
0 -5 V) 
0 2 4 6 8 10 12 14 
Time [hr) 
Figure 4.27 Serum ethanol concentration vs. time and SRI-ALCOHOL EFFECTS score vs 
time for a representative subject (subject 9) for treatment C of IV ethanol study 
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vigilance reaction time, and the SRl-ALCOHOL EFFECTS (SRJ-AE) score and are 
presented in figures 4.28 and 4.29. 
An evaluation of the plots of Erm.ax vs. Cm.ax ~eveal that the mean SRI-AE score was lower 
for the slow-input treatment (treatment B), as well as for treatment C at the end of the 
infusion (C6), when compared with the fast-input treatment (treatment A), even though 
the mean Cmu estimates were similar across treatments. This plot also demonstrated the 
decrease in effect from the end of the first infusion (C 1) to the end of the second infusion 
(C6) for treatment C , indicating that the acute tolerance was input-rate-related. The plots 
for number vigilance reaction time and relative theta power did not show this pattern, 
indicating the lack of acute tolerance development to these effects of ethanol. 
The plots of Ermu vs. AUC,.max revealed that the SRl-AE scores decreased as the AUCTmax 
increased from treatment A to B to C. This was not observed for the number vigilance 
reaction time or relative theta power, and indicates that the acute tolerance development 
to the subjective effects of ethanol was exposure-related. 
These findings are consistent with the development of acute, exposure-related tolerance 
development to the subjective impairment effects of ethanol. This means that the degree 
of subjective impairment perceived by the subject was higher during the ascending limb 
of the ethanol concentration-time curve than at similar concentrations during the 
descending limb of the ethanol concentration-time curve. During the drug elimination 
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Figure 4.28 Mean (S.E.) Effect at Tmax [E(fmax)J vs. Mean (S.E.) Cmax by treatment 
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perceive themselves to be impaired even thought they had significant measurable 
concentrations of ethanol and exhibited psychometric impairment as measured by the test 
battery. This means that there was a temporal disparity between perceived impairment 
and perfonnance impainnent during the descending limb of the ethanol concentration -
time curve. Also, treatment C allowed the evaluation of the time course of this tolerance 
development when concentrations of ethanol are sustained at steady-state. The data from 
treatment C are also consistent with acute exposure-related tolerance development to the 
subjective effects of ethanol during the period when concentrations are at "steady-state". 
These findings are consistent with the results of other studies evaluating the subjective 
and objective impainnent induced by ethanol, which conclude that objective measures of 
impainnent do not show acute tolerance development, while subjective measures of 
impainnent do show consistent development of acute tolerance (Radlow and Hurst, 1985; 
Jones et al., 1972; Kaplan et al., 1985; Gengo et al., 1990). Results of this study also 
indicate that the tolerance is input rate-related. Although there was a gender difference 
in the degree of subjective impairment induced by ethanol, there did not appear to be a 
gender difference in the development of acute tolerance to ethanol. 
4.4.3E PK-PD Modelling of the Acute Tolerance Development to Subjective 
Eff~ts of Ethanol 
A PK-PD model was developed to describe the tolerance development to the subjective 
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impainnent following intravenous ethanol administration. The SRI-ALCOHOL EFFECTS 
(SRI-AE) measure was selected since it was shown to be the most sensitive subjective 
measure of ethanol's effect. The SRI-AE and concentration data were fit individually for 
each subject and treatment. The data sets were constructed in a spreadsheet (Microsoft 
Excel version 5, Microsoft Inc. , WA) and directly imported into the program used for 
the fitting, Scientist (version 2.0 for Windows, MicroMath Inc., Salt Lake City, UI). 
Model Development: The model used to fit the individual effect-concentration data was 
similar to the final model used in the oral°ethanol study. The final model used in this 
' 
study was a two-compartment PK model with capacity-limited elimination; the central 
compartment was linked to the PD model which related concentration to the primary 
(direct) effect using the classical E....x model (Holford, 1992) (see figure 4.30). The direct 
effect of the drug is the driving force that activates the tolerance mechanism, implying 
that the tolerance development is a result of compensatory feedback mechanisms that are 
produced to counter-regulate the direct effect. 
The direct effect (Eo) was modelled as: 
where E.n..x is the maximum effect, ECso is the serum concentration required to produce 
an effect that is 50% of the maximum effect, n is the Hill coefficient, reflecting the 
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The feedback effect {EFiJ was modelled using two rate constants (k.... and k,,,r). The rate 
(and extent) of negative feedback is proportional to the magnitude of the direct effect of 
the drug, i.e., the greater the primary (direct) effect, the greater is the rate of negative 
feedback. The differential equation for the feedback effect was: 
Ei,a' = Jc.., *Bo - k,,,r *Ei>s 
The net observed effect E was calculated as 
E=Er,-Ei,s 
The final PD model had five parameters: E......, ECso, n, Jc.., and k,,,r. 
This model was coded in Scientist. Initial parameter estimates for the PD parameters 
were obtained from simulations using different values of the parameters. The model was 
fit to the individual concentration-effect (SRI-AE) data. The PK parameters, v _"' K.,,, 
k12, k21 and Vdss were fixed to the final estimates obtained during the PK modelling of 
the data (done previously, see section 3.4.2). Weights of l and 1/y were evaluated. 
Goodness of fit was assessed by evaluating the coefficient of determination (r), Model 
Selection Criteria (MSC), parameter estimates and their standard deviations, residual 
analysis, and visual observation of the observed points and fitted effect-time profiles as 
well as observed and fitted hysteresis loops (in effect-concentration plots). 
Results: Individual fits were determined to be acceptable based on goodness of fit 
criteria described above. Weights of 1/y did not appear to improve the fit. The 
coefficients of determination for the final model ranged from 0.851 to 0.996, and MSC 
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ranged from 1.62 to 5.11. Parameter estimates for seven of the 48 data-sets (treatment 
B for subject l , treatments Band C for subject 2, treatments A, Band C for subject 8, 
and treatment A for subject 15) could not be obtained due to inconsistent effect-time 
profiles and inability of the model to adequately fit the profiles. 
Table 4 .18 lists the final parameter estimates for the model parameters, E.....,., EC50, n, 
~ and k.,,r. Figure 4.31 shows the observed values and fitted curves for the SRI-AE 
score vs. concentration plots by treatment for a representative subject (subject 3). 
As table 4.18 indicates, the estimates for all the parameters did not appear to be different 
across treatment, however there was a trend toward lower E.....,. values for female subjects 
compared to the male subjects across treatments (Mean ± S.D. E...... for male subjects: 
122 ± 79, and for female subjects: 55 ± 56). Also, the inter-individual variability in the 
parameter estimates was quite high, as indicated by the %COVs in table 4.18. 
Table 4.18 also lists the mean parameter estimates for responders and non-responders by 
treatment and across treatments for male and female subjects. Table 4.18 demonstrates 
that there were no differences in parameter values between responders and non-
responders across treatments, except for the E...... which, on average was about 4-fold 
higher for responders compared to the non-responders. This was seen across treatments 
for both male and female subjects. Figure 4.32 illustrates the differences between male 
and female responders and non-responders with respect to their mean (± S.E.) E...... 
estimates by treatment. 
The mean (± S.D.) estimate for EC50 was 748 (± 333) mg/L across treatments and 
Figure 4 .18 Model parameters (means and %COY) by treatment for PK-PD model of subjective effe.cts of intravenous 
ethanol (Males: n = S, Females: n = S) 
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Trt E....... EC so n k.., k..n- I 
[-] [mg/L] [-] [hf'I] [hi''] 
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Males 124 (49%) 22 ( 0%) 550 (22%) 2.5 (19%) 0.5 ( 45%) 1.6 (70%) 
Females 114 (72%) 16 (85%) 685 (33%) 2.5 (38%) 1.0 (126%) I 2.0 (62%) 
All 120 (54%) 18 (66%) 617 (31 %) 2.5 (29%) 0.7 (118%) l.8 (65%) 
B I 
Males 169 (70%) 3 747 (26%) 2:7 (21 %) 0.9 (65%) I • 1.4 ,(34%) -
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Figure 4.31 SRI-ALCOHOL EFFECTS score vs. serum ethanol concentration 
(observed values and fitted curves) by treatment for a representative 
subject (subject 9) for IV ethanol study 
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Figure 4.32 PK-PD model estimates for Emax for male (M) and female (F) responders (R) 





subjects. The mean (± S.D.) estimate for n was 2. 7 (± 0.6) across treatments and 
subjects. The mean(± S.D.) estimate for koo was 0.7 (± 0.6) hr"1 across treatments and 
subjects. This translates to an onset half-life of tolerance (t1na,) of 1.5 hrs. The mean (± 
S.D.) estimate for koir was 1.3 (± 0.6) hr"1 across treatments and subjects. This translates 
to an offset half-life of tolerance (t1/2off) of 0.6 hrs. 
The PK-PD model used in this study was similar to the PK-PD model used in the oral 
study, the only exception being that this study used the sigmoidal E_. model to 
characterize the relationship between the direct effect and the serum ethanol 
concentration, while the oral study used a linear model to characterize this relationship. 
This was primarily because higher concentrations of ethanol and higher magnitudes of 
subjective impairment were achieved in this study, resulting in a levelling off of the 
effect-concentration relationship, thus necessitating the use of the E...a. model in this study 
compared to the oral ethanol study. The ratio of E...a. to EC50 was calculated using the 
mean values for responders and non-responders. The ratio was determined to be 0.15 for 
responders and 0.03 for non-r~ponders. These values are in the same range as the mean 
estimates for the parameter S in the model used in the oral ethanol study, and indicates 
that the ratio may be used as a measure of the sensitivity to ethanol. The onset and offset 
rate constants did not appear to be different between the two studies. 
One observation from the PK-PD modelling is that the model predicts a rebound effect, 
i.e., the net effect falls below the baseline. This is cannot be explained by the data since 
the impairment scales do not permit measurement of effects below the baseline (zero). 
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In summary, the feedback model of tolerance was adequately fit to the individual effect-
concentration data from this study. The estimated E,,,,,,. for responders was about four-fold 
higher than for the non-responders, while t)le estimates for the other parameters did not 
differ between the two groups. The parameter estimates were associated with fairly high 
degrees of inter-individual variability, probably reflecting individual differences in the 
subjective effects of ethanol as well as individual differences in acute tolerance 
development to these effects of ethanol. 
4.4 .3F Correlation of Pharmacodynamic Measures 
Since one of the aims of this study was to assess the relationship between the EEG 
changes and changes in PP as well as the relationship between the EEG changes and SRI, 
linear regression of the E,,.;., • for relative theta power on the E,,,,,,. o1>o for number vigilance 
reaction time, and on the E,,,,,,.o1>1 for SRI-ALCOHOL EFFECTS score were performed 
individually to assess the significance of the relationship between the EEG changes and 
changes in PP and SRI. Since this was a crossover study, the regression was only 
performed for observations for treatment A, since the greatest change would be expected 
for treatment A. 
Figure 4.33 shows the plot of E,,,;.,ob• for relative theta power vs. the E,,,,,,.ob• for number 
vigilance reaction . time for treatment A. The coefficient of determination was 0.028, 
which was not significant, indicating that there did not appear to be a significant 
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Figure 4.33 Baseline-corrected peak change iR relative theta power vs. peak change in number 
vigilance reaction time for treaunent.A for IV ethanol study 
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Figure 4.34 Baseline-corrected peak change in relative theta power vs. peak change in SRI-
ALCOHOL EFFECTS score for treaunent A for IV ethanol study 
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Figure 4.34 shows the plot of l;..;.,ob• for relative theta power vs. the E,,_o1>• for SRI-
Alcohol Effects score for treatment A. As figure 4.34 illustrates, there did not appear to 
be a consistent relationship between the two variables. Also, the coefficient of 
determination was 0.190. This indicated that there did not appear to be a relationship 
between changes in EEG measures and changes in subjective impairment measures. 
Thus, it appears from comparison of the regressions of EEG measures individually on 
psychometric performance measures and on subjective impairment measures, that the 
EEG changes are not related to PPT or to the subject-rated impairment measures. It 
should be noted that neither of the associations were statistically significant, and that 
these comparisons were only performed for peak changes in these measures, and that the 
comparisons were only done for one treatment. 
4.5 CONCLUSIONS 
The following conclusions can be made from the intravenous ethanol study which was 
designed to evaluate the effect of input-rate and degree of systemic exposure on the PK-
PD relationship for ethanol and development of acute tolerance to the pharmacological 
effects of ethanol in healthy male and female subjects. Table 4.19 lists the results of the 
inferential statistical analysis performed for the primary PK and PD measures evaluated 
in this study. 
1) Ethanol, after intravenous administration, follows non-linear, capacity-limited 
pharmacokinetics. ,The observed serum ethanol concentration vs. time profiles were best 
Table 4.19'. Summary of Inferentiali Statistical Analiysis 
Measure Treatment Muttiple Gender 
(frt) Effect comparisons Effect 
for Trt Effect 
Pharmaookinetic Measures 
V-.: p=0.003 A;,!C,B;,!C NS1 
K. NS - NS 
Vd 
I ss 
p=0.047 A;,!C p=0.0015 
Pharmacodynamic Measures 
Rel Theta Power .. 
E.,-E...., NS - NS 
t,,,.. p=0.042 A;,!B,A ;,!C NS 
Rel, Al11ha P2wer 
Eo,E..., by gender: NS 
M:p=0.006 A,B,C~D 
F:NS -
t,,.., p=0.025 A;,!B,B#D NS 
I 
NVRT 
E~-Eo p=0 .. 000 A,B,C;,!D NS 
I t-x p= 0.004 A;,!B,A;,!C NS 
Trt-by- Baseline as 
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described by a two-compartment model with zero-order input into the central 
compartment, first-order inter-compartmental rate constants, and capacity-limited 
elimination. The intrinsic PK para.meters ~ti mated for ethanol were V max• K..., k12, k21 
and Vds.9. The mean (± S.D.) VOWI. was 349 (± 75) mg/Uhr across subjects and 
treatments; the mean(± S.D.) K... was 252 (± 83) mg/Lacross subjects and treatments; 
the mean ± SD Vds.9 was 51 (± 9) Lacross treatments for male subjects, and 38 (± 8) 
Lacross treatments for female subjects. The mean(± S.D.) k12 was 0.92 (± 0.40) hr"1 
across subjects and treatments and the mean (± S.D.) k21 was 2.15 (± 1.4) hr"1 across 
subjects and treatments. This corresponds to a distribution half-life of around 0.22 hrs 
(or around 14 minutes). There was a significant difference in Vds.9 for ethanol between 
males and females that appeared to be related to differences in their body weight. There 
were no differences in the elimination PK para.meters between males and females 
observed in this study. The intrinsic PK para.meters were independent of input-rate and 
degree of exposure, but were associated with considerable inter-individual variability. 
Inter-individual variability was higher than inter-individual variability for all the intrinsic 
PK para.meters. The PK parameters estimated in this study are consistent with previously 
reported PK parameters for intravenous ethanol (Rangno et al., 1986, Wilkinson et al., 
1977, Holford, 1987). 
2) Ethanol induced changes in measures of psychometric impairment, as measured 
by the CDR battery. Word recognition sensitivity and number vigilance reaction time 
were the most sensitive measures showing significant treatment-related differences. Input-
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rate was a significant determinant of the degree of impairment induced by ethanol, with 
fast input resulting in a higher degree of psychometric impairment than the slow input. 
The ethanol-induced psychometric impairment appeared to be correlated with serum 
ethanol concentrations, although a clear quantitative relationship could not be established. 
Psychometric impairment was sustained during the period when ethanol levels were 
maintained constant indicating that there was no exposure-related acute tolerance to the 
psychometric effects of ethanol. 
3) EEG measures also showed some ethanol-induced changes, although they were 
associated with a large degree of inter-individual variability. In general, there was a 
transient increase in EEG power in the delta band along with corresponding decreases 
in theta and fast EEG bands (alpha and beta) consistent with slowing of the EEG 
following ethanol administration. The -EEG measures showed input-rate-related 
differences. Gender differences were observed in the EEG response to ethanol in that 
female subjects generally showed a lower magnitude of EEG effect, mainly in the 
decrease in theta and alpha power compared to the male subjects, despite achieving 
similar concentrations. There was no apparent relationship between ethanol-induced 
changes in EEG measures and serum ethanol concentrations. Also, there did not appear 
to be any acute tolerance development to the EEG effects of ethanol observed across 
treatments and subjects. 
4) Ethanol induced significant treatment-related changes in measures of subjective 
impairment. The SRI and ORI scales proved to be the most sensitive measures of 
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ethanol 's effect. The subjective measures showed input-rate-related changes following 
intravenous ethanol administration, with the fast-input treatment showing a greater degree 
of subjective impairment than the slow-input treatment across subjects. 
5) There was significant acute, exposure~related tolerance development to the 
subjective impairment (as measured by the SRI/ORI scales) induced by ethanol. The 
degree of subjective impairment perceived by the subjects was higher during the 
ascending limb of the serum-ethanol concentration-time profile than at similar 
concentrations during the descending limb of the serum ethanol concentration-time 
profile. Also, during the steady-state infusion for treatment C, subjective responses were 
not sustained and showed a premature return to baseline, even though concentrations 
were fairly constant. 
The tolerance development could be characterized by a PK-PD model incorporating 
tolerance as a compensatory feedback mechanism to the direct impairment effect of the 
drug. Acute tolerance development was not observed for the psychometric perfonnance 
measures or the EEG measures, indicating a temporal disparity between the perceived 
and performance impairment induced by ethanol. 
6) Two of the 8 male subjects and 4 of the 8 female subjects in the study were 
classified as "non-responders" based on their Jack of subjective response to ethanol 
administration, even though they demonstrated consistent psychometric impairment and 
EEG changes. 
7) The EEG changes were not correlated to the psychometric impairment or to the 
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subjective impairment induced by ethanol. 
CHAPTER 5 
OVERALL CONCLUSIONS 
The primary objective of this research was to test the following hypotheses: 
1) the rate and degree of ethanol exposure (oral and intravenous) in normal healthy males 
and females affect the PK and PD of ethanol in a non-linear fashion; 2) the EEG changes 
after ethanol administration correlate with changes in psychometric performance and 
subject-rated impairment, as well as serum ethanol concentrations; and 3) acute tolerance 
develops to the subjective effects of ethanol which is fl.Qt reflected in changes in EEG 
activity or psychometric performance. 
This research was conducted in two parts: Part I was a pilot study in 6 healthy male 
subjects to evaluate the effect of dose and dose-rate on the PK and subjective and 
objective measures of impairment following oral administration of ethanol. Part II was 
a concentration-controlled, crossover study in 16 healthy subjects (8 males and 8 females) 
to evaluate the effect of input-rate and degree of systemic exposure on the PK and 
subjective and objective measures of impairment as well as tolerance development to 
these measures following intravenous administration of ethanol. 
Based on the results obtained in the studies, the following conclusions can be made 
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regarding the primary objectives: 
1) Ethanol, after oral and intravenous administration, follows non-linear, capacity-limited 
pharmacokinetics. Intrinsic PK parameters, V mu, K,,, and Vd (or Vdss) were independent 
of dose and input-rate, but were associated with fairly high degrees of inter-individual 
variability. Intra-individual variability was lower than inter-individual variability for the 
PK parameters. 
2) Ethanol, after oral and intravenous administration, induced a transient impairment in 
psychometric performance. The degree of impairment in psychometric performance 
appeared to be dose-related as well as input-rate-related (observed in the IV study, but 
not in the oral study), however, there was a large degree of variability in psychometric 
impairment induced by ethanol between individuals. The psychometric impairment 
appeared to be correlated with serum ethanol concentrations, although a clear quantitative 
relationship could not be established. This may be partly because the magnitude of the 
changes in psychometric measures was only about 50% from baseline. 
3) Ethanol, after oral and intravenous administrations, induced transient changes in EEG 
activity. The primary effects on the EEG were an increase in EEG power and a 
generalized slowing of the EEG following ethanol administration. There was, however, 
a large degree of ,inter-individual variability in the EEG measures, both at baseline as 
well as in response to ethanol. The changes in EEG activity following ethanol appeared 
to be dose-related, as well as input-rate-related, however, a clear quantitative relationship 
between the EEG changes and serum ethanol concentrations could not be established. 
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4) Ethanol, after oral and intravenous administration, induced transient changes in 
measures of subjective impairment. The subjective impairment following ethanol 
administration was dose-related and input-rate-related and correlated with serum ethanol 
concentrations across treatments. A subset of subjects (2 out of 6 males in the oral 
ethanol study, and 2 out of 8 males and 4 out of 8 female subjects in the intravenous 
study) were classified as "non-responders" 'based on their lack of subjective response to 
ethanol, despite serum ethanol concentrations, psychometric impairment and EEG 
changes that were comparable with the other subjects. 
5) There was significant, exposure-related acute tolerance development to the subjective 
effects of ethanol observed following oral and intravenous administration of different 
doses at different rates and for different degrees of exposure of ethanol. The acute 
tolerance development to the subjective effects of ethanol was characterized by a PK-PD 
model incorporating tolerance as a compensatory feedback mechanism to counter-regulate 
the direct subjective impairment effect of the drug. Acute tolerance was not observed for 
the psychometric impairment or changes in EEG activity, indicating that there was a 
temporal disparity between objective impairment and subjective impairment following 
ethanol administration. 
6) The changes in EEG activity were not correlated with the psychometric impairment 
or with the subjective impairment following ethanol administration. 
7) There was a significant difference observed in the peak concentrations achieved 
following intravenous ethanol administration, as well as the volume of distribution for 
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ethanol between male and female subjects. This gender difference may be attributed to 
differences in body weight and body water content between males and females . There 
was also a significant gender difference observed with respect to the magnitude of 
subjective impairment induced by intravenous ethanol, with females showing a lower 
degree of ethanol induced-subjective impairment, despite achieving similar concentrations 
in the concentration-controlled study and despite demonstrating similar degrees of 
psychometric impairment and EEG chartges. The gender difference in subjective 
impairment may be partly confounded by the larger proportion of female "non-
responders" compared to the proportion of male "non-responders" in the intravenous 
ethanol study. 
The intravenous ethanol study was unique in its design since it involved the development 
of an experimental paradigm to study the development of acute tolerance to ethanol's 
effects. This paradigm involved the evaluation of tolerance development following the 
administration of IV ethanol infusions at different rates to achieve and maintain a given 
target concentration (1000 mg/L) for different durations of exposure. Due to the fairly 
large inter-individual variability in ethanol pharmacokinetics, the infusion-rates were 
individualized for each subject, based on his/her individual PK parameters estimated from 
data obtained following a PK screen where a test dose of ethanol was administered as a 
1-hour infusion to each subject. A dosing algorithm was developed to calculate the 
individualized infusion rates for each subject for the concentration-controlled phase of the 
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study. The results indicated that adequate concentration control was achieved for all 
subjects and treatments. The PK screen and dose individualization incorporated the PK 
variability in the achievement of serum ethanol concentrations that were precise and 
accurate with respect to the target concentrations. This paradigm can be used to evaluate 
the development of acute tolerance to the effects of ethanol for other measures of 
ethanol's effects, as well as to compare the tolerance development to the effects of 
ethanol in different populations of subjects (for e.g., healthy elderly volunteers, 
alcoholics etc.). This paradigm can also be used to evaluate the development of acute 
tolerance for other drugs. The necessity of a PK screen for other drugs would depend on 
the degree of variability in the PK for that drug, nevertheless, this approach would allow 
the evaluation and modelling of the acute tolerance development for these drugs. 
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Pbarmacokinetic-Pharmacodynamic Relationship for Ethanol in Healthy Male 
Subjects. ~ent of Electroencephalography (EEG), Psychometric Tests and 
Mood Scales. Effect of Dose and Rate of Ethanol Ingestion. 
INVF.STIGATORS: 
Principal Investigator: 
Jurgen Venitz, M.D., Ph.D. 
Co-Investigators: 
Vijay A. Ramchandani, B. Phann. Sc.(Bombay, India) 
Mark Johns, M.D. 
HYPOTHESIS AND SPECIFIC AIMS: 
Hypothesis 
The hypotheses guiding this research project are that 1) Ethanol induces changes in the 
electroencephalogram (EEG) that can be used as a surrogate measure to assess alcohol-
induced CNS effects; and 2) the rate of alcohol eltposure In normal healthy males affects 
the phannacokinetics and pharmacodyhamics of ethanol ln a non-linear fashion. 
Specific Aims 
The aim of this study is to investigate the phannacokinetics and pharmacodynamics of 
ethyl alcohol. The study will assess the changes in the electroencephalogram (EEG) after 
administration of ethanol as well as changes in performance on psychometric tests and 
subjective changes in mood. The study will also examine the relationship between EEG 
changes and 1) serum eµtanol concentrations, 2) psychometric performance and 3) 
subjective mood scales. The study will also evaluate the effect of different rates of oral 
alcohol administration on the phannacokinetics and phannacologic effects of ethanol as 
measured by the EEG, psychometric performance and subjective measures. 
BACKGROUND AND SIGNIFICANCE: 
Introduction 
Ethanol is probably the most widely used drug in the world. It is commonly self-
prescribed rather than prescribed by a clinician and the dose determined either by 
tradition, social context or the achievement of a pharmacological end-point (1). Almost 
no other substance has been as comprehensively lttvestlgated as ethanol, not only because 
it is one of the oldest and most ubiquitous ~bused 11drugs 11 in human history, but also 
because of its unique dynamic and kinetic behavior (2). Although considered at one time 
(in the Middle Ages) as the elixir of life, it is now recognized that the therapeutic value 
of ethanol is extremely limited and that chronic ingestion of excessive amounts is a major 
social and medical problem (3). 
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Pharmacoki netics 
Ethanol is unusual among drugs in several aspects of its pharmacokinetics. Particularly 
striking are the great biological inter-subject variabilities in alcohol consumption 
tolerance and in alcohol elimination, in the pattern of short-term fluctuations from the 
trend line of the time course of the blood aloohbl concentrations and in the partitioning 
of alcohol between the blood and other body fluids and tissues even at equilibrium (4). 
The pharmacokinetics of ethanol has been studied fairly extensively (5,6,7,8). When 
given orally, it is almost completely absorbed passively from the small intestine. The 
concentration of alcohol ingested is a determinant of its absorption rate. This is most 
readily explained by an inhibitory action on gastric emptying (I). Ethanol distributes into 
total body water and no protein binding has been reported. 
Elimination of ethanol occurs primarily through enzymatic oxidation by alcohol 
dehydrogenase to acetaldehyde in the liver with minute amounts being excreted in the 
breath (0.7%), sweat (0.1 %), and urine (0.3%) (1). The overall elimination process can 
be described by a capacity-limited model similar to the Michaelis-Menten model for 
enzyme kinetics first proposed by Lunquist and Wolthers (9,10). The use of the zero-
order model of Widmark (11) has been widespread in the past although the limitations 
of this model have been known for a long time (1). 
The alcohol concentration-time profile depends on a number of factors including the dose 
(10, 12, 13), the type of alcoholic beverage and the rate of drinking (4, 14), the 
consumption of a meal as well as the composition of the meal(l5), sex and body 
composition (16,17). 
In this study, two doses, 0.3 g/kg body weight (low dose corresponding to about 2 drinks 
of 80 proof vodka) and 0.6 g/kg body weight (moderate dose corresponding to about 4 
drinks of 80 proof vodka) will be administered. Based on simulations using a one-
compartment model with first order input and capacity-limited elimination, the moderate 
dose is expected to yield peak seum concentrations close to the legal limit for alcohol 
(0.1 mg%) (18). To study the effect of rate of drinking, the doses will be administered 
at two different rates: 1) over 20 minutes to simulate a bolus input, and 2) over 50 
minutes to simulate constant rate input. 
Differences in pharmacokinetics as well as in psychometric performance and mood states 
have been observed in males and females (16,17,19). Therefore to reduce variability in 
response, the study will be conducted in healthy normal male subjects only. 
Pharmacodynamics 
The relationship of the blood level of a drug to its pharmacologic effect has been the 
subject of numerous studies. Understanding this relationship is important because it 
contributes to the inter-individual variability observed In drug response. Ethanol is a 
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central nervous system depressant and its effects are secondary to CNS depression. These 
responses characteristically include euphoria, impaired thought processes, and decreased 
mechanical efficiency (20). Although alcoholic drinks are viewed as stimulating, this 
apparent stimulation is a result of depression of the inhibitory control mechanisms of the 
brain (3). However, as intoxication becomes more advanced, there is progressive 
depression of CNS function that can ultimately lead to respiratory depression, coma and 
even death. 
Ethyl alcohol has been the subject of many studies by investigators interested in the 
effects of ethanol on the CNS. Its detrimental effects on human performance are well 
documented (21,22,23). Ethanol also produces numerous behavioral effects ranging from 
increased alertness to relaxation and a state of well-being or euphoria (24,25). These 
behavioral effects have been measured by various subjective mood scales such as the 
Drug Effects Questionnaire (DEQ), Profile of mood states (POMS), and the Subjective 
High Assessment Scale (SHAS) (26,27). For this study, an alcohol impairment rating 
scale, adapted from the SHAS (28) will be used. The mood scales will be administered 
to the subject as well as a blinded observer repeatedly during the study to assess changes 
in mood following ethanol or placebo administration as well as to study the difference 
between the subject's own perception of his degree of intoxication and the observer's 
perception of the subject's degree of intoxication. 
The effects of ethanol on psychometric performance have also been studied 
(20,29,30,31). These psychomotor tests are being used to detect impairment of cerebral 
function. They provide a non-invasive and quantitative measure of motor and cognitive 
function and allow comparison between different drugs or between different doses of the 
same drug. Alcohol has been shown to produce impairment of psychometric function as 
tested by various tests including tracking, digit symbol substitution, reaction time, body 
sway, hand steadiness and finger tapping (32). However, these tests are not ideal 
pharmacodynamic measures. Although some tests can measure some aspects of behavior 
as a function of drug response, they are somewhat subjective and may not show good 
reproducibility. Many of these tests are not suitable for repeated measures, since learning 
and motivational factors can influence performance in subsequent testing (33). Also, the 
relationship of performance on psychometric tests to the "real life" psychological and 
behavioral effects of drugs are difficult to define. For this study, the computerized 
version of the card sorting test, a pen-and-paper digit-symbol substitution test and the 
computerized finger tapping test have been selected. Card sorting is an excellent example 
of a performance task which embraces sensory, motor and central components of 
psychometric performance (33). These assessments are widely used and have been shown 
to be sensitive to a range of psycho-active drugs including ethanol (34). The digit-symbol 
substitution task (adapted from the Wechsler Adult Intelligence Battery) (35) has been 
demonstrated to be a useful indicator of changes in sensory processing performance 
produced by many drugs including ethanol (18,36). The rate of finger tapping is one of 
the simplest of human motor activity and has been widely used to measure drug induced 
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changes in motor activity. 
Quantitative EEG is being increasingly used to study the pharmacodynamics of 
psychoactive drugs. The EEG provides an ongoing record of the neuroelectric activity 
of the brain, either in th~ resting state or under different activation procedures (e.g. 
repetitive photic stimulatibn, drug ingestion etc.). Although the scalp-recorded EEG is 
an overall measure of brai1n activity, it provides one of the best and most direct measures 
available for assessing the functional state of the CNS (21). Quantitative EEG is objective 
and non-invasive, and derived parameters change gradually with changes in plasma drug 
concentrations. Repeated or continuous measures of the EEG can be made, although a 
familiariution session before the study is advisable to avoid a first-session effect due to 
anxiety (37,38). Studies investigating the effects of acute ethanol administration on the 
adult human electroencephalogram (EEG) have been generally consistent (39). Most 
studies report an increase in voltage and a slowing of the dominant alpha frequency 
(21,23,40). Studies have also emphasized individual variability in responses to alcohol. 
This study aims to assess the relationship between EEG changes and serum ethanol 
concentrations, psychometric performance and subjective mood scales after oral 
administration of low to moderate doses of ethanol at different rates. Of particular 
interest is the question whether alcohol induced EEG changes closely parallel the more 
or less gradual changes in subjective state and behavior during drinking. 
It is well established and universally accepted that the concentration of ethanol, in blood 
or breath, constitutes the best and most objective indicator of the absence or presence and 
the degree of alcohol-induced impairment of driving ability in living subjects (4). Hence 
the understanding and appreciation of the major physiological and pharmacological 
factors associated with such alcohol concentrations are important for the appropriate use 
and interpretation of tests for alcohol in traffic law enforcement and in research on 
mental impairment by alcohol. Recognition of the complexity of the relationships between 
dose of alcohol, time and pharmacological effect is also essential to both research and 
public education in this field. 
METHODS AND PROCEDURES: 
I. SUBJECTS 
Six healthy volunteers will participate in the study. Volunteers will be considered 
for inclusion if they conform to the following criteria: 
1. Demographic: Subjects must be healthy male volunteers between the ages 
of 21 and 35 years and must not deviate more than 15% above or below 
the range of desirable weights according to the 1979 Build Study, Society 
of Actuaries and Association of Life Insurance Medical Directors of 
America (Attachment I). 
2. Medical History: Subjects must have no clinically significant history of 
renal, hepatic, cardiovascular, gastro-intestinal, neurological, pulmonary, 
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or hematologic disease; have no history of alcohol abuse, drug addiction, 
psychological dependence on drugs, or psychiatric illness. Subjects must 
have no first degree relatives (mother, father, or siblings) with a history 
of mental illness or alcohol/drug abuse. Subjects must be low to moderate 
alcohol drinkers with an average intake not greater than 3 oz. (90 ml) of 
ethanol (approximately six 12 oz. beers) per week (Attachment II). 
3. Physical: Subjects must successfully pass a physical examination, 
demonstrating no evidence of an active disease state or physical or mental 
impairment (Attachment ill). 
4. Laboratory screen: Subjects must have no clinically significant abnormal 
laboratory values on a laboratory screen consisting of 1) SMAC-20, 2) 
CBC and 3) urinalysis. Subjects must have a negative urine drug test and 
breath alco~ol test (Attachment IV). 
5. Electrocardiogram: Subjects must have no clinically significant 
abnormalities on a 12-lead EKG including a 30 second rhythm strip 
(Attachment V). 
6. Vital signs: Supine and standing systolic and diastolic blood pressure, 
heart rate, and oral body temperature must be within normal limits. An 
orthostatic test i.e. systolic and diastolic blood pressure and heart rate at 
5, 7 and 10 minutes supine and 0, 1, 3 and 5 minutes standing will have 
to be clinically acceptable (Attachment VI). 
7. Other medications: Subjects must not be taking medications chronically 
and must not have taken any prescription medication or investigational 
drugs for at least 4 weeks before entering the study. Subjects must have 
a normal daily caffeine intake equivalent to or less than two cups of 
coffee. No medications (including OTC medications and vitamins) or 
caffeine will be allowed in the 72-hour period before each study day and 
on each study day. Subjects must also abstain from alcohol starting 72 
hours before the first treatment period through the end of the study. 
Subjects must be non-smokers, meaning that they have abstained from 
smoking for at least 12 months before the start of the study. 
8. Familiarization Period: All subjects participating in the study will undergo 
an EEG and psychometric test familiarization period before enrolling in 
the study. Subjects with a high number of artifacts on the EEG or subjects 
who cannot tolerate wearing the electro-cap for extended periods of time 
will be excluded. 
Within one week after study completion, the physical examination and vital signs, 
laboratory tests, and EKG will be repeated for all subjects. Possible clinically 
significant abnormalities will be followed up until return to pre-study values. 
Subjects for this study will be recruited from within the hospital and schools at 
MCV/VCU. 
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II INFORMED CONSENT 
Each subject will provide written informed consent for study participation before 
the start of the study. The original signed consent forms will be kept in the 
subjects' confidential medical case record as a permanent document and a copy 
will be given to the subject. 
ill PROCEDURE 
During each of the five study periods, the following procedure will be followed: 
1) Admission to Clinical Research Unit: 
Subjects will enter the study facility on the evening of the day prior to each day 
of ethanol or placebo dosing and will not be released until the morning after the 
day of ethanol or placebo dosing. In addition, a breath alcohol (Alcosenser) test 
will be done at the end of each treatment period to ensure that the subjects do not 
have detectable ethanol levels. Subjects will fast from midnight on the evening 
before ethanol or placebo dosing until the six hours after the dose is administered. 
Water will be permitted ad libitum throughout each study period. 
All subjects must Have a negative urine drug screen and breath alcohol test before 
each study period before receiving ethanol or placebo. All subjects will complete 
a verbal probe concerning recent medical history and medication use (Attachment 
VII). 
2) Dosing: 
During each treatment period, Subjects will receive one of the following five 
treatments: 
A) eth.µiol 0.3 g/kg body weight given in four equal "drinks" every 5 minutes 
over 20 minutes followed by 2 placebo "drinks" at 30 and 45 minutes after start 
of dosing; 
B) ethanol 0.6 g/kg body weight given in four equal "drinks" every 5 minutes 
over 20 minutes followed by 2 placebo "drinks" at 30 and 45 minutes after start 
of dosing; 
C) ethanol 0.3 g/kg body weight given in four equal "drinks" every 15 
minutes over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the 
first "drink"; 
D) ethanol 0.6 g/kg body weight given in four equal "drinks" every 15 
minutes over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the 
first "drink"; 
E) Placebo given in 6 equal "drinks" over 50 minutes (Attachment VIII). 
Each treatment will be given exactly once and in random order according to the 
randomization sequence (Attachment IX). Both the subjects and the investigators 
will be blinded to treatment. 
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Ethanol will be administered as a 25 % solution of 80 proof Vodka in fruit juice. 
The "drink" will be given ice-cold in an opaque container with a lid and will be 
sipped with a straw. A vodka-soaked gauze pad will be placed under the lid in an 
attempt to blind the subject to the contents. The placebo "drink" will consist of 
fruit juice and wijl contain a small amount of ethanol (5% of the dose) in a 
further attempt at blinding the subject. 
Doses will be prepared by an unblinded pharmacist, who will assign subjects 
randomly to one of the randomization sequences. A sealed copy of the 
reandomization schedule will be available at the research unit in case of an 
emergency. 
3) Pharmacokinetic (PK) Measurements: 
Blood samplin~ <BAC} 
Prior to dosing, a heparin containing catheter will be inserted into the forearm 
vein for access to blood sampling. · 
6 ml samples for determination of ethanol concentration will be collected in red-
top tubes with no additives at the following times: pre-dose and 10 min, 20 min, 
35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 
hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing (Attachment X). The 
blood will ,be allowed to clot, centrifuged (within 1 hour of sampling) for 10 
minutes, serum harvested and stored at -200 C until analysis by the TDx Analyzer 
(Abbott Diagnostics). 
The total volume of blood drawn for ethanol determination during the study will 
be 540 ml over a five-week period. 
4) Pharmacodynamic (PD) Measurements: 
Electroencephalography <EEG} 
Five minute segments of 28-channel EEG, using a NeuroScience Brain lmager, 
will be recorded for each subjects with eyes closed at the following times: pre-
dose and 20 min, 35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 
hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing 
(Attachment XI) . Subjects will be asked to count back from 500 by threes to 
maintain constant vigilance during the recordings. The electrodes will be placed 
using an Electro-cap according to the 10/20 International System with 8 additional 
electrodes located 50% between the standard 10/20 placement. Linked ears will 
be used as the reference. Four additional channels will be used to monitor for 
vertical and lateral eye movements and electromyographic activity. The electrode 
impedances will be checked before each recording. Impedances should be less 
than 4 .0 kohms and similar between electrodes. Any disturbances in the room or 
subject movement during the EEG recording will be documented by the EEG 
technician. The raw EEG will be stored on an optical disk. The objective of each 
recording is to obtain at least 30 artifact-free frames for further analysis. 
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Psychometric tests 
i. A computerized card-sorting task (CST) (Neuroscan Inc.) will be 
completed by each subject at the following times: pre-dose and 1 hr, 1.25 
hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr 
and 12 hr after ethanol or placebo dosing (Attachment XIl). 
ii. A computerized motor performance task, finger tapping (FT) (Neuroscan 
Inc.), will be completed by each subject at the following times: pre-dose 
and 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 
6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing (Attachment 
XIII). 
iii. A pencil-and-paper digit symbol substitution test (DSST) will be 
completed by each subject at the following times: pre-dose and I hr, 1.25 
hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr 
and 12 hr after ethanol or placebo dosing (Attachment XIV). 
In the morning before dosing for each period, subjects will practice each 
psychometric task twice. 
Subject rated impairment scale (SRI) 
A 100 mm visual analog scale (At~chment XV), based on the Subjective High 
Assessment Scale (SHAS) will be completed by each subject at the following 
times: pre-dose and 20 min, 35 min, 1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 
3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing 
(Attachment XVI). Subjects will indicate their perceived level of intoxication 
response for each item by placing a mark on an unnumbered 100 mm scale that 
ranges from "not at all" to "extremely" . 
Observer rated impairment scale (ORI} 
A 100 mm visual analog scale (Attachment XVII) will be completed by the 
investigator for each subject at the following times: pre-dose and 20 min, 35 min, 
1 hr, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 
8 hr and 12 hr after ethanol or placebo dosing (Attachment XVIII). The blinded 
investigator will indicate his perception of the subject's level of intoxication by 
placing a mark on an unnumbered 100 mm scale that ranges from "not at all" to 
"extremely". 
5) Safety measurements: 
Vital Signs 
Blood pressure (sitting) and heart rate will be measured at the following times: 
pre-dose and 1 hr, 2 hr, 3 hr, 4 hr, ·s hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol 
or placebo dosing (Attachment XIX). 
The study will be conducted by Registered Nurses and the Physician Investigator 
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(Mark Johns) will be on call throughout each treatment period for each subject. 
Adverse effects 
All subjects will be observed for symptoms and signs of clinical intolerance to the 
drug or procedures and asked to report any adverse effects. These will be 
evaluated by the Physician Investigator for their clinical significance and potential 
need for treatment. 
6) Diet 
On the evening prior to the study, subjects will receive a light snack. 
No food or beverages, other than water, will be permitted from 10 hours before 
dosing until 6 hours after ethanol or placebo dosing. Dinner and a snack will be 
served 10 and 14 hours after dosing respectively. Caffeine-free beverages may be 
served with meals. The same menu will be served on corresponding days of each 
study period. 
When the above measurements are scheduled at the same time, they will be 
conducted in the following sequence: 1) blood samples 2) EEG 3) CST 4) DSST 
5) Ff 6) SRI and ORI scales and 7) vital signs with the blood sample being 
collected at exactly the scheduled time. If there is any unscheduled delay, 
measurements may be omitted as needed to conform to the schedule. 
A study flow sheet is included (Attachment XX). 
BIOST A TISTICAL DESIGN AND ANALYSIS: 
~ . 
This study will a randomized, double-blind , placebo-controlled five-period 
crossover study in 6 healthy male volunteers. Subjects will undertake the study 
one at a time. The start of each treatment period will be separated by a washout 
period of at least 1 week . Subjects will receive one of five treatments during 
each treatment period: 
A) ethanol 0.3 g/kg body weight given in four equal "drinks" every 5 minutes 
over 20 minutes followed by 2 placebo "drinks" at 30 and 45 minutes after start 
of dosing; 
B) ethanol 0.6 g/kg body weight given in four equal "drinks" every 5 minutes 
over 20 minutes followed by 2 placebo "drinks" at 30 and 45 minutes after start 
of dosing; 
C) Ethanol 0.3 g/kg body weight given in four equal "drinks" every 15 minutes 
over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the first 
"drink"; 
D) Ethanol 0.6 g/kg body weight given in four equal "drinks" every 15 minutes 
over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the first 
"drink"; 
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E) Placebo given in 6 equal "drinks" over 50 minutes (see attachment). 
Each subject will be assigned to one of the randomization sequences by an 
unblinded pharmacist and will receive each treatment exactly once. 
Data analysis 
I. Pharmacokinetic (PK) Analysis 
The serum concentration of ethanol obtained during the study will be 
presented in tabular and graphic form for each subject and treatment. 
Pertinent pharmacokinetic parameters for ethanol, including apparent 
volume of distribution (Vd/F), apparent total body clearance (CLtot/F), 
area under the concentration-time curve (AUC) , maximum concentration 
(Cmax) and time to maximum concentration (tmax) will be estimated for 
each subject and treatment. . Descriptive statistics will be calculated for 
each parameter. 
Extensive pharmacokinetic modelling to estimate the maximum elimination 
rate constant (Vmax) and Michaelis-Menten constant (Km) will be 
performed. 
Statistical Analysis: 
Pharmacokinetic parameters will be compared by means of analysis of 
variance (ANOV A) with treatment, sequence and subject as factors. 
Residuals will be tested for normality. If the data is not normally 
distributed, either the data will be transformed or appropriate non-
parametric methods will be used. The level of significance (a) will be set 
at 0 .05; in case no significant differences are observed, a power analysis 
will be performed. 
II. Electroencephalography (EEG) 
Each of the 5-minute recordings will be reviewed and edited to remove 
each 2.5 second epoch that is contaminated with artifacts (eye movement, 
muscle movement, electrode artifacts, or other disturbances noted during 
the recording). The remaining 2.5 second epochs or artifact-free frames 
will be averaged to form an average topographical map for each 
recording. The amplitude, power, and relative power of the EEG signal 
in the five classical frequency bands (delta: 0.39 - 3.0 Hz; theta: 4.3 - 7.8 
Hz; alpha: 8.2 - 11.7 Hz; beta I: 12.1 -16.0 Hz; and beta II: 16.4 - 30 
Hz) at each electrode will be determined for each average topographical 
map. The total amplitude and power for each average map will be 
calculated. Differences of each treatment from baseline as well as from 
placebo for each of these parameters will be calculated. 
III. Psychometric Tests 
1. Card Sorting Task (CST) 
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The total number of categories completed as well as the number of 
erroneous responses will be determined at each time point. 
2. Finger Tapping Task (FT) 
The average rate (taps per second) of finger tapping for the non-
dominant hand will be determined based on three trials at each 
time point. 
3. Digit Symbol Substitution Task (DSST) 
The total number of substitutions completed in the 90 second 
testing interval as well as the number of correct responses will be 
determined at each time point. 
IV. Rating Scales (SRI/ORI) 
A score between O and I 00 will be obtained for each item on the visual 
analog scale at each time point by measuring the number of millimeters 
between the left end of the scale and the mark placed by the subject. 
V. Pharmacodynamic Analysis 
Response-time profiles i.e. plots of change in response variable from 
predose baseline vs. time plots for each subject during each treatment 
period will be tabulated and plotted for each response measure. Pertinent 
pharrnacodynamic parameters including baseline response, maximal 
observed response (Emax), time to reach maximum response, and area 
under the effect-time curve (AUE) will be determined and descriptive 
statistics for each of the above will be calculated. 
Pharmacokinetic-pharmacodynamic modelling will be performed, if 
appropriate. 
Statistical Analysis 
Results of the above pharmacodynamic response measures for each 
treatment will be compared using statistical techniques appropriate for a 
5-way crossover study design with repeated measures. Residuals will be 
tested for normality. If normally distributed, a repeated measures analysis 
of variance (ANOV A) with subject, treatment, sequence and time as 
factors will be performed. If the data is not normally distributed, either 
the data will be transformed or appropriate non-parametric tests will be 
used. The significance level for a will be set at 0.05; in case of no 
significant differences, a power analysis will be performed. 
HUMAN SUBJECT CONCERNS: 
Subjects enrolled in the study will receive ethanol orally, have blood samples drawn for 
ethanol determination, and undergo a series of tests including EEG, psychometric tests 
and rating scales, repeatedly over a 12 hour period on 5 occasions. Subjects will remain 
in the study facility from the night before the study day until the morning after the study 
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day (approximately 36 hours for each treatment period) to preclude any motor or other 
accidents that may· result from the impairment caused by alcohol. 
I. Study drug 
Subjects will receive ethanol, in doses of 0 .3 g/kg and 0.6 g/kg, orally as a 
solution of vodka (80 proof) in fruit juice in four equivalent "drinks" in a 
crossover fashion. 
Alcohol (ethyl alcohol) may produce the following side-effects: gastric irritation, 
nausea, vomiting, flushing and feeling of warmth, changes in heart rate and blood 
pressure, diaphoresis, diuresis, dizziness, changes in sexual desire, drowsiness, 
euphoria or false feeling of confidence and well being (3). 
Subjects will be monitored for the development of adverse effects to the study 
drug by nurses in the study facility. Vital signs (blood pressure and heart rate) 
will be determined periodically during the study. Adverse effects will be managed 
as deemed necessary by the medical monitor. 
At the end of each treatment period (24 hours after dosing) it is anticipated that 
ethanol levels would have dropped to zero. However, a breath alcohol test will 
be performed to ensure that the subject does not have any detectable ethanol 
levels. 
II. Blood sampling 
Subjects will have eighteen 6-ml blood samples drawn during each treatment 
period. A total of 540 ml of blood will be drawn during the study over a period 
of five weeks. 
III. Test Battery 
The test battery consists of EEG, psychomotor tests and rating scales and will be 
administered periodically during each treatment period. The risk associated with 
these tests is minimal. Subjects will be expected to wear the electro-caps 
throughout the treatment period, which may result in some discomfort. 
IV. Pre- and post-study physical exam and laboratory tests 
Subjects may experience some discomfort during the physical exam, EKG and 
laboratory tests to be performed during screening and at the end of the study. 
Subjects will receive no personal benefits to their health from participating in the study, 
but the procedures will be conducted at no cost to them and they will receive an 
honorarium for their participation. Any information obtained about subjects from this 
research will be kept strictly confidential. Subjects will provide written informed consent 
and have the right to withdraw from the study at any time. 
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(min) A B C D E 
0 X X X X p 
5 X X p p p 
10 X X p p p 
15 X X X X p 
30 p p X X p 
45 p p X X p 
x : = ethanol dose 
p := placebo 
Treatment A: Ethanol 0.3 g/kg body weight given in four equal "drinks" every 5 
minutes over 20 minutes followed by 2 placebo "drinks". 
Treatment B: Ethanol 0.6 g/kg body weight given in four equal "drinks" every 5 
minutes over 20 minutes followed by 2 placebo "drinks". 
Treatment C: Ethanol 0.3 g/kg body weight given in four equal "drinks" every 15 
minutes over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after 
the first "drink". 
Treatment D: Ethanol 0.6 g/kg body weight given in four equal "drinks" every 15 
minutes over 50 minutes with 2 placebo "drinks" at 5 and 10 minutes after 
the first "drink". 
Treatment E: Placebo given in 6 equal "drinks" over 50 minutes. 
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RANDOMIZATION SEQUENCE 














II C D E A B 
m A B C D E 
A: Ethanol 0.3 g/kg body weight given in four equal "drinks" every 5 minutes over 
20 minutes followed by 2 placebo "drinks". 
B: Ethanol 0.6 g/kg body weight given in four equal "drinks" every 5 minutes over 
20 minutes followed by 2 placebo "_drinks". 
C: Ethanol 0.3 g/kg body weight given in four equal "drinks" every 15 minutes over 
50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the first "drink". 
D: Ethanol 0.6 g/kg body weight given in four equal "drinks" every 15 minutes over 
50 minutes with 2 placebo "drinks" at 5 and 10 minutes after the first "drink". 
E: Placebo given in 6 equal "drinks" over 50 minutes. 
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Pbannacokinetic-Phannacodynamic Relationship of Ethanol in Healthy Male 
Subjects - ~essment of Electroencephalography (EEG), Psychometric Tests and 
Mood Scales: Effect of Dose and Rate of Ethanol Ingestion. 
Investigators 
Jurgen Venitz, M.D., Ph.D. 
Vijay A. Ramchandani, B.Pharm.Sc.(Bombay, India) 
Mark Johns, M.D. (Medical Monitor) 
Introduction 
You are being asked to participate in this study because you are healthy and not taking 
any stimulant drugs or medication on a chronic basis. This study is designed to study the 
relationship between changes in your brain waves (electroencephalogram) and other 
mental tests after taking different doses of alcohol (ethanol) at different rates. 
If you agree to participate, you will be expected to provide information about your 
medical history, have laboratory tests done (including blood and urine tests), have a 
physical examination, and have an EKG (electric tracing of the heart) to determine 
whether you have any medical condition that would prevent you from participating in the 
study. Your urine will be tested for drugs of abuse. You will not be permitted to take 
any prescription medications for four weeks before the start of the study. You will not 
be permitted to take any over-the-counter medication (such as antacids, aspirin, vitamins 
or cold preparations) or any beverages containing caffeine for the 72 hours before each 
study day and on each study day. You will not be permitted to drink any alcohol starting 
72 hours before the first study day through the last day of the study. Prior to the start 
of the study, you will undergo a practice session with the EEG (measuring your brain 
waves) and other tests that will be used during the study. 
You will be expected to report to the study facility for a total of five (5) study periods 
on five consecutive weeks. During each period, you will come to the unit at 8:00 p.m. 
on the evening prior to ethanol dosing and will not be released until the morning after 
the day of dosing.- On the night before dosing, you will begin a fast that will continue 
until six hours after the start of dosing (about 2:00 p.m. on the day of dosing). At the 
end of each study period, a breath alcohol test will be done to ensure that you have no 
detectable ethanol levels. 
On the morning of dosing, a catheter will be inserted into your forearm vein and a blood 
sample (about 6 ml or 1.25 teaspoonful) will be drawn. You will then receive six 
"drinks" containing alcohol (0.3 or 0 .6 g/kg body weight) in the form of vodka in fruit 
juice or placebo ("drink" with no alcohol) over 50 minutes during each period. You will 
have received all five treatments once by the end of the study. You will not be told 
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which treatment you are receiving during a given period. 
During and after dosing, sixteen (16) additional blood samples will be collected through 
the catheter during each period. A total of 540 ml (about 1 pint) of blood, (approximately 
equal to the volume of blood collected in a single blood donation) will be collected 
during the entire study. If the catheter fails to work, a new catheter will be inserted or 
it may become necessary to obtain blood samples by sticking a needle directly into the 
vein. 
Beginning just prior to dosing, you will take a series of tests repeatedly throughout the 
day. These tests include: two computerized tests, one paper-and-pencil test, one 
questionnaire about your mood and the EEG (brain wave) recording. Each of the tests 
takes less than two minutes to complete and the EEG recording takes about five minutes. 
To have the EEG recorded, you must wear a bathing cap-like apparatus with 28 disks 
(electrodes). Through a hole in each electrode, your scalp will be cleaned and a small 
amount of jelly-like substance will be applied to the scalp to make a good contact. In 
addition, two small, round electrodes will be attached, one to each earlobe and four more 
electrodes will be taped to your face (above and below your eyes). The cap will remain 
on your head for most of the day. The tests will be repeated several times during each 
study period (EEG and the mood questionnaire: 16 times; other tests: 14 times). Your 
heart rate and blood pressure will be monitored _periodically throughout the day. 
You will not be able to leave the unit until the morning after dosing. In addition, a breath 
alcohol test will be performed to ensure that you have no detectable alcohol levels. 
For your safety, the pre-study physical examination and laboratory tests will be repeated 
at the end of the study. 
Benefits 
You are being asked to participate in this study as a volunteer. The study is of no direct 
medical benefit to you. There will be no charge to you for the screening examination and 
the results will be made available to you, if you want them. 
You will be paid $700.00 for the completion of the study. If you withdraw early or are 
discontinued by the Medical Monitor, the fee will be prorated (see Withdrawal}. 
Alternative Therapy 
There is no therapeutic benefit to you for participating in this study. Your participation 
is entirely voluntary. The alternative is not to participate in the study. 
Risks, Inconveniences, Discomforts 
A total of 85 blood samples will be drawn during the study period of five weeks. The 
total amount of blood will be 540 ml or about 1 pint over the five weeks of the study. 
298 
To obtain the blood samples a small catheter will be inserted into a vein in your arm. 
This procedure may cause some discomfort, pain, or slight bruising around the site of 
the needle stick. If the catheter fails to work, a new catheter will be inserted or blood 
samples will be collected through a needle inserted into the vein. While on the unit you 
will eat only the meals provided by the investigators at the times prescribed by the 
investigators. You will be required to remain at the study unit for about 36 hours during 
each study period. You may receive phone calls during the study, but no visitors will be 
allowed. 
Alcohol (ethyl alcohol) may cause the following side-effects: gastric irritation, nausea, 
vomiting, flushing and feeling of warmth, changes in heart rate and blood pressure, 
diaphoresis (sweating), diuresis (increase in urine output), changes in sexual desire, 
headache, drowsiness, euphoria or false feeling of confidence and well-being. 
If any undesirable effects occur, you should report them directly to the investigators. Dr. 
Mark Johns is the Medical Monitor for this study and is the person you contact in the 
case of a medical emergency. If you cannot reach Dr. Mark Johns, you may contact any 
of the study investigators. 
None of the tests in the study carry any significant medical risk. There may be some 
discomfort associated with the EEG cap that you have to wear throughout the study 
period. Although the tape and gel used for the EEG recording are hypoallergenic, they 
may rarely cause skin irritation. After the cap is removed, you will be able to wash your 
hair. 
There may be some discomfort associated with the physical exam, EKG, and laboratory 
tests conducted before and after the study. 
Costs of Participation 
There will be no charge to you for any laboratory tests, physical examination, hospital 
care, or other tests related to the conduct of this study. This is a time-consuming study 
that may interfere with your employment or other activities. You will be confined to the 
study unit for two nights and an entire day on each of the 5 study periods. You must 
provide your own transportation to and from the study site. 
Research Related Injui:y 
Every effort will be made to prevent any injury that could result from your participation 
in the study. In the event of any physical or mental injury resulting from your 
participation in this research project, Virginia Commonwealth University/Medical 
College of Virginia will not provide any compensation. If any injury occurs, medical 
treatment will be available at MCV hospitals. Fees for such treatment will be billed to 
you or appropriate third party insurance. 
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Confidentiality of Records 
The investigators will treat your identity with professional standards of confidentiality. 
It may be important for the United States Food and Drug Administration (FDA) to be 
able to inspect the results of this study. By signing this consent form, you authorize 
release of the portion of your medical records related to this study to the FDA. 
Information obtained from this study may be published, but your identity will not be 
revealed. 
Withdrawal 
Your participation in this study is voluntary. If you decide to participate, you may 
withdraw at any time. Neither refusal to participate nor withdrawal will result in any 
penalty to loss of benefits to which you are otherwise entitled. If you have any questions 
at any time concerning the study procedures, you may contact the study investigators: 
Office Home 
Jurgen Venitz 786-8317 330-4615 
Vijay A. Ramchandani 786-8372 359-0955 
Dr. Mark Johns is the Medical Monitor for this study. He can be reached during office 
hours at (beeper #) *60 1193 and at other times at 739-1030 (home phone). 
If you do not complete the study due to premature withdrawal, the honorarium will be 
prorated based on the amount of usable information which has been collected. If the 
Medical Monitor terminates your participation in the study you will receive the entire 
amount. 
You will receive a copy of this consent form. 
I have read the above information, and I have had an opportunity to ask questions to help 
me understand what my participation will involve. I freely give my consent to participate 
in this study. If I have any questions regarding my rights as a volunteer in a clinical 
research study, I can contact the Committee·on the Conduct of Human Research (CCHR) 
at the Medical College of Virginia at 786-0868. 
Signed----- ----- Date _ __ _ 
(volunteer) 
Signed ---------- Date. ___ _ 
(witness) 






CCHR #: 9108-2R 
Title: Pharmacokinetic-Pharmacodynamic Relationship for Ethanol in Healthy Male 
Subjects. Assessment of Electroencephalography (EEG), Psychometric tests, and 
Mood scales. Effect of Dose and Rate of Ethanol ingestion. 
The following revisions have been made to the protocol: (1) An additional baseline 
(predose) measurement of the EEG, psychometric tests and mood scales will be obtained 
in order to better define the predose response of the subject. (2) Additional measurements 
will be made during the first two hours after the start of dosing in order to better 
characterize the pharmacokinetics and pharmacodynamics of ethanol. Please note that the 
total volume of blood drawn during the study will remain the same and also that the 
revisions would not increase the minimal risk associated with the test battery. 
The changes are highlighted in the attached Modified Study Period Flow Sheet. 
Revision 1: Protocol Section III, 3. Blood samplioe {BAC) (p.8) : Change timing of 
samples to read "6 ml samples for determination of ethanol concentration will be 
collected in red-top tubes with no additives at the following times: predose and 10 min, 
20 min, 35 min, 50 min, 65 min, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 5 
hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing" (see Attachment). 
Revision 2: Protocol Section m, 4. Electroencephalography (EEG) (p.8) : Change timing 
of measurements to read "Five minute segments of 28-channel EEG, using a 
NeuroScience Brain Imager, will be recorded for each subjects with eyes closed at the 
following times: twice pre-dose and 20 min, 35 min, 50 min, 1.25 hr, 1.5 hr, 1.75 hr, 
2 hr, 2.5 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing" 
(see Attachment). 
Revision 3: Protocol Section m, 4. Psychometric tests - i. , ii., and iii. (p.9): Change 
timing of measurements for all three tests (Card-Sorting Task, Finger Tapping Task and 
Digit-Symbol Substitution Test) to read: 
"i. A computerized card-sorting task (CST) (Neuroscan Inc.) will be completed by 
each subject at the following times: twice pre-dose and 50 min, 1.25 hr, 1.5 hr, 
l. 75 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after 
ethanol or placebo dosing. · 
ii. A computerized motor performance task, finger tapping (FT) (Neuroscan Inc.), 
will be completed by each subject at the following times: twice pre-dose and 20 




hr, 7 hr, 8 hr and 12 hr after ethanol or placebo dosing. 
iii. A pencil-and-paper digit symbol substitution test (DSST) will be completed by 
each subject at the following times: .twice pre-dose and 50 min , 1.25 hr, 1.5 hr, 
1.75 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol 
or placebo dosing" (see Attachment). 
Revision 4: Protocol Section m, 4. Subject rated impairment scale (SRD (p.9): Change 
timing of measurements to read "A 100 mm visual analog scale (Attachment XV), based 
on the Subjective High Assessment Scale (SHAS) will be completed by each subject at 
the following times: twice pre-dose and 20 min, 35 min, 50 min, 1.25 hr, 1.5 hr, 1. 75 
hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr, 8 hr and 12 hr after ethanol or placebo 
dosing" (see Attachment). 
Revision 5: Protocol Section III, 4. Observer rated impairment scale (ORD (p.9): Change 
timing of measurements to read "A 100 mm visual analog scale (Attachment XVII) will 
be completed by the investigator for each subject at the following times: twice pre-dose 
and 20 min, 35 min, 50 min, 1.25 hr, 1.5 hr, 1.75 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 5 hr, 6 




MODIFIED STUDY PERIOD FLOW-SHEET 
Time Dose BAC EEG CST DSST FT SRI ORI vs 































































































































































24h (Discharge from Clinical Research Unit) 
Time: hours relative to ethanol (or placebo) dosing 
BAC: Sample for Blood Alcohol Concentration 
EEG: Electroencephalography 
CST: Card Sorting Task 
DSST: Digit-Symbol Substitution Task 
FT: Finger Tapping task 
SRI: Subject Rated Impairment scale 
ORI: Observer Rated Impairment scale 











Individual concentration-time profiles for oral ethanol study 
Bl Individual serum ethanol concentration vs. time profiles by treatment and subject 
B2 Individual serum ethanol concentration vs.time profiles (observed values and 
curves fitted by compartmental analysis by treatment and subject 
B3 Individual serum ethanol concentration vs. time profiles (observed values and 
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Figure B3.4 Serum ethan.ol concentralion vs. time profiles {observed points and curves by simultaneous fitting) for Subject. 4. 
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342 
Treatment A 
I 0-*>~ ... o .60 C { 0 .40 
< !: 0.20 J 0.00 +-.-~•~•=+-+-+--+-+-+-->-< 








I 0-*>ru:::: .., .60 { 0.40 
< 1t 0.20 
j 0.00 




0 I 2 3 4 S 6 7 8 9 10 11 12 
Time [hnJ 
Treatment E 
I 0-60 ~ 10.40 C 
< 0 .20 
~ j o.oo:*1°, , 
,:! 0 1 2 3 4 S 6 7 8 9 10 11 12 
Timc(hr,) 
Figure C4.5 Relative Alpha Power vs. time by treatment for Subject 5. 
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Figure C4.6 Relative Alpha Power vs. time by treatment for Subje,;t 6. 
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345 
Treatment A 
J:: ~ i O.o2 
~ 0.01 I o.oo 
0 I 2 3 4 S 6 7 8 9 10 11 12 
Timc{hn) 
Treatment C 
Jo.04~ O oJ 
I! O.o2 
.is o.oi 
e o.oo +~-+-+--+--+--+--+-<-> I-+-< ! 0 I 2 3 4 S 6 7 8 9 10 11 12 
Time (bn) 
Treatment B 
j; 0.04 t:::::::: I. 0.00 
-! O.o2 
~ 0.01 
'i ~ J.! 0.00 
0 I 2 3 4 S 6 1 8 9 10 II 12 
Time (bn) 
Treatmeot D 
!~: ~ J O.o2 
0.01 
.~ 0.00 +-+-t-<--+-+-+--+-+-+-1-+--< 







·~ 0.00 I 
;li O I 2 3 4 S 6 7 8 9 10 11 12 
Time (bn) 
Figure CS.2 Relative BetA I Power vs. time by treatment for Subject 2. 
346 
Treatment A Trutn1eot D 
:;:; 
J ~:~~b:::: 
- 0.06 : = J 0.04 
~ 0.01 ! 0.00 I I I 
... 




'i 0 .00 +-+-+-+-+-...._....__..._...._ ...... _.._ .......... 
J 0 I 2 3 4 S 6 7 8 9 10 11 12 0 l 2 3 4 5 6 7 8 9 IO 11 12 
Time (lln] Time [llrs) 
Treatment C Trutment D 
.!.. 
!~::~ J 0.04 
0.01 i 0.00 +-....... --+-+--+--+--+-+-1-t-+-i 
j O I 2 l 4 S 6 7 8 9 IO 11 12 
Time(bn) 
! 
''"f2::::: J 0.05 ~ 0.00 




ff 0.06 : : ,l! 4 
~ 0.02 
"il 0.00 -1-+---+--+--+-1---1-1-t-,I I I 
;:! 0 I 2 l 4 S 6 7 8 9 10 11 12 
T lmc(bn] 
Figure CS.3 Relative Beta I Power vs. time by treatment for Subject 3. 
I I I ~ 
9 IO 11 12 
347 
Treatment A 
f:::~ : 1 O.o2 i 0.01 
;;o. o~ ,,, 
0 I 2 3 4 S 6 7 8 9 10 11 12 
T,mc [br1] 
Treatment C 
!:::~ J O.o2 
·i 0.00 I I I ~ 










u 0.00 I I I I 




.il 0 .04 
., O.Ol 
"i 0.00 +-+-+-+-t-t-1-ll-l--+--+--+~ 
;lj O I 2 3 4 S 6 7 8 9 10 II 12 
lirn< [hn) 
0 I 2 3 4 S 6 7 8 9 10 II 12 
Timo[hn] 





.I O.Q2 i :: ~ ...... :..... :---, -, -,-: 
0 I 2 3 4 S 6 1 8 9 10 II 12 
Timc[hn] 
Treatmeet C 
Jo.oo~ - 0.02 
- 0.02 ~ ~:~: 
"i 0.00 +-+-+-+-+-+-+-+-1---,f-<---<---< 
;ii O I 2 J 4 S 6 7 8 9 10 II 12 
Time [bnJ 
Treatmeet B 
fo.os~ o. 0.06 
i 0.04 
~ 0.02 : i o. o!: : I I I 
0 I 2 3 4 S 6 7 8 9 10 II 12 
Timc[hn] 
Treatmeet D 
:rn~ ~ O.ot ._.:.__-_.. 
.• 0.00 - I I I 1 
;ii O I 2 3 4 S 6 7 8 9 10 II 12 
Time (bn] 
Treatmeet E 
i:: ~ J 0.01 
., 0.01 
.i ~ O.OO O I 2 J 4 S 6 7 8 9 10 II 12 
Time[hnJ 
Figure CS.5 Relative Beta I Power vs. time by treatment for Subject 5. 
349 





'i j 0.00 
~0.10~ ! 0.08 
- 0.06 j 0.04 
·! O.ol 
'il 0.00 I I I I 
0 I 2 3 4 5 6 7 8 9 10 II 12 .. 
Tune[hn) 
TreatmentC 












'i 0.00 .._.._.._.._.._._-._.._._._.~ 
~ 0 I 2 3 4 5 6 7 8 9 10 11 12 
Time[hn) 
!~: ~ j 0.04 : 
~ 0.02 
'j 0.00 I I 1 
~ 0 I 2 3 4 5 6 7 8 9 10 11 12 
Time[hn) 
Figure CS.6 Relative Beta I Power vs. time by treatment for Subject 6. 
350 
Trealmeot A J~:t::=: Cl 0.00 J 0 .02 
l! o.oi J 0.00 -+--t-+--l---lf-+-+-+-...-+--+--+--< 








0 I 2 J 4 5 6 7 8 9 10 11 12 
Timc {hr>] 
Trealment D 
Jo.osb c, 0.06 
~ ~: ~: : : I I I: 
'i ;ii O I 2 3 4 5 6 7 8 9 10 II 12 
Time {hr>] 
! 0.04t:::: j rn : .... :---~ 
-~ 0 .00 -1-.._,-+-+--l-_+-.._.l--+l -+-I :-1 
:ii O I 2 3 4 5 6 1 8 9 10 11 12 
Time {hr>] 
Figure C6.1 Relative Beta II Power vs. time by treatment for Subject 1. 
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APPENDIX D 
Individual baseline-corrected response-time profiles for PPT measures 
Dl average tap-rate for dominant hand for Fr vs. time by treatment and subject 
D2 average tap-rate for non-dominant band for Fr vs. time by treatment and subject 
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Figure DI .3 Dominant hand tap-rate vs. time by treatment for Subject 3. 
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Figure DI .6 Dominant hand tap-rate vs. time by treatment for Subject 6. 
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Figure El.4 SRI-IilGH score vs. time by treatment for Subject 4. 
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Figure El.5 SRl-lilGH score vs. time by treatment for Subject 5. 
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Figure El.6 SRI-IDGH score vs. time by treatment for Subject 6. 
Treatment B 
0 2 4 ' 6 
nme(hnJ 
Treatment D 




















,, I L~ .. • • • • • 














I ' 10 12 









~~.a S a 30 
oc .!!. 2() 
~ 10 
Treabneot A 





~ o ..... • • • • • 

















~ a ;g 






ii? 0 --+-4>-4t>-4• ..... •-+• ~•---<1-...... 
"' 0 2 4 6 8 10 12 
Time(bn] 
• • • • • I 
10 
• 
12 0 2 6 
Time(bn) 




~ Au..+,. • • • 
0 2 4 6 8 
11.0)e (llnJ 
Trealmeol C 
12 l 10 ~ . .:-.. • • • • • 










121 10 i __ .. 
• • • • • 
0 l 6 
Timo [hn] 
Trealmeol B 
12h 10 I .. • • • • • 
0 2 6 
Time (bn] 
Trea1meot D 





e I I I I 
Time [bn] 












































f • t • I 
























• I I I f 
4 6 8 
Time [bn) 
TreabDeot C 


























:;! o!....b ·, f 




10 ' 12 
.., 1-~k ~ j 1~ 
:;! 0 r--"'f-· ~·-·-·-·-•--11- ..... 
li! 0 2 4 6 8 10 12 
II) Ttme(hn) 
Treatment E 
i WL _, l;l _ IS ~ !! ~ 10 
0 ~ S 
~ o •Mt=• f * I 
li! 0 2 4 6 8 
II) Time (hn) 
Treabneot B 
0 2 4 6 8 
Ttmc(hn] 
Treabneot D 
lO l h._ i~ .. 















Treatmeot A Treatmeot B 
In~~ ~ 1g~ • ......., ........... ~ ................ ,-~,- ... lnijt\. • • 
0 2 4 6 8 10 12 0 2 4 6 8 10 12 
lime [bn) Timo(hn) 
Treatmeot C Treatmeot D I nij~. "' 
••••• I • 
inij(\ .. 
• • I • 




~ ~I s nqg 
Ill ~ .!!. 20 ~ 1g ··---··· ..... ~, ........... ~,e--+1- ... ,
0 2 4 6 8 10 12 
Time[bn) 
Figure B3.2 SRI-ALCOHOL EFFECTS score vs. time by treatment for Subject 2. 
Treatment A 
L~b g ; a 10 8 - s 
';/ 0 --.. ···-· ................... --+1- ... , 
ol 0 2 4 6 8 10 12 
.. Tome[hn] 
Treatment C 
~,-~bi g 9 10 8 - s 
~ 0 ................... ,......,t'="'•-• --+1- ... , 




~!-~h § 11~ 
~ o..._-.. ,,.,,...,_,...,.,.,....,,...,- ... ,-..... ,
lio O 2 4 6 8 10 12 
"' Tlll!e[hn] 
Treatment D 
1-~~ §1 I a 10 8 - 5 
~ o.__.:,,:~•-+•~•~, ...... , . ,-... ,-..... ,




n~b_ I • • • • • I • 0 .. 
i;l 0 2 4 6 8 10 12 
T ime(hn) 
Figure B3.3 SRI-ALCOHOL EFFECTS 8C-Ore va. time by treatment for Subject 3. 
389 
390 
Treatmeot A Treatmeot B 
I • 
ln~b 
. ' I I 
10 12 
.i 0 2 4 6 8 10 12 
., 
Time[hn] 
Treatmeot C Treatmeot D 
In~~ 
• 
0 2 4 6 8 W 12 
.i 0 2 4 6 8 10 12 
Tun<[hn] ., Time(hn] 
Treatmeot E 
~ ~, s ~ i' :;g 
:iia!.20 ~ •g ............ ~•~•-+1~, .... ,~~1~ ... . 
0 2 4 6 8 10 12 
T ime (hn) 
Figure B3.4 SRI-ALCOHOL EFFECTS 11COre vs. time by treatment for Subject 4. 
Treatment A 
I f 











~ ~l 5t'il0 
tll ~ S 10 
O - 10 ~ 0 *Tit I I f 















' 10 11 
392 
Treatment A Treabnent B ; ~ Tl!k Ti!~ ! !ij ,., @ ! ffi I f I 
' 
~ 0 I 1 I ft ' I • 
<il 0 2 4 6 8 10 12 <il 0 2 4 6 8 10 12 
"' Time [hn) "' Time [hn) 
TreatmentC Treatment D 
§ I»~ 
. li.. 1n~ . t--+-e If I ~nij . • • • I 
<il 0 2 4 6 8 10 12 o2 0 2 4 6 8 10 12 
.., 




Figure E3.6 SRI-ALCOHOL EFFECTS score vs. time by treatment for Subject 6. 
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Figure E4. l ORI-lilGH score vs. time by treatment for Subject 1. 
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Figure E4.3 ORI-1:UGH score vs. time by treatment for Subject 3. 
395 
Trealmeot A 
! ~bi_ ~ ii 40 
fil .! ~ 
' 10 ~ O o o o o O I 0 




' 10 ~ 0 0 0 0 0 0 0 I 0 
0 






' 10 ~ 0 0 o O I 0 
0 2 4 6 8 10 12 
Time (hnJ 
Trealmeat D 
!~~ [§- 40 sd.~ 
' 10 § 0 0 0 I 0 
0 2 4 6 8 10 12 
Timc(bn) 
1 
0 .......... . I 
10 
• 
12 0 2 4 6 8 
Timc(hn] 
Figure E4.4 ORI-IDGH score vs. time by treatment for Subject 4. 
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Figure E4.6 ORI-lflGH score vs. time by treatment for Subject 6. 
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Figure ES.2 ORI-DRUNK score vs. time by treat~ent for Subject 2. 
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Individual baseline-corrected response-concentration profiles for PD measures for oral 
ethanol study 
Fl Baseline-corrected relative theta power vs. concentration by treatment and 
subject 
F2 Baseline-corrected non-dominant hand tap-rate for Ff vs. concentration by 
treatment and subject 
F3 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. concentration by 
treatment and subject 
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Figure F3.3 Baseline-corrected SRI-ALCOHOL EFFECTS scor,e vs. serum ethanol concentration by treatment for Subject 3. ~ 
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APPENDIX G 
Individual response vs. time and response vs. concentration profiles (observed values 
and fitted curves) for SRI-ALCOHOL EFFECTS score for oral ethanol study 
Gl Baseline-corrected SRI-ALCOHOL EFFECTS score vs. time (observed values and 
fitted curves) by treatment and subject 
G2 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. serum ethanol 
concentration (observed values and fitted curves) by treatment and subject 
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Figure Gl.2 Baseline-oon:ected SRI-ALCOHOL EFFECTS score vs. time (observed values and fitted curves) 
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Phannacokinetic-Phannacodynamic Relationship for Intravenous Ethanol in Healthy 
Male and Female Subjects. 
Part Il: Modelling the Development of Tolerance to the Effects of Intravenous 
Ethanol administration in Healthy Male and Female Subjects: Effect 
of Systemic Input Rate and Degree of Ethanol Exposure. 
INVF.STIGATORS: 
Principal Investigator: 
Vijay A. Ramchandani, B.Pharm.Sc. (Bombay, India) 
Co-Investigators: 
Jurgen Venitz, M.D., Ph.D. 
Alan R. Towne, M.D. (Neurology) 
lndravadan Gatiwala, M.D. (Neurology) 
HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
The hypotheses guiding this research project are that l) the rate and degree of 
intravenous (IV) ethanol exposure in normal healthy males and females affect the 
pharmacokinetics and pharmacodynamics of ethanol in a non-linear fashion; and 2) acute 
tolerance, which is defined as a diminished effect at a given serum level during declining 
concentrations compared to the effect at the same serum level during ascending 
concentrations, develops to the subjective effects of prolonged exposure to ethanol which 
is n.Q1 reflected in electroencephalographic activity or psychometric performance. 
Specific Aims 
The aim of this study is to investigate the pharmacokinetics and pharmacodynamics of 
different doses and dose rates of intravenous ethyl alcohol and the development of acute 
tolerance to ethanol in healthy male and female subjects. The study will assess changes 
in the electroencephalogram (EEG) after IV administration of ethanol as well as changes 
in performance on psychometric tests and subjective changes in mood. The study will 
examine the relationship between changes in the EEG and changes in psychometric 
performance and subjective mood scales to compare the sensitivity of the EEG to serum 
ethanol concentrations with that of psychon;ietric performance and mood. The study will 
also evaluate the effect of different rates of infusions, designed to achieve and maintain 
"steady-state" concentrations of ethanol for different durations, on the pharmacokinetic 
profile and pharmacologic effects of ethanol as measured by the EEG, psychometric 
performance and subjective measures of mood. The study will also examine differences 
between male and female subjects with respect to pharmacokinetics as well as EEG 
changes, psychometric performance and mood changes following IV ethanol 
administration. 
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BACKGROUND AND SIGNIFICANCE 
Ethanol is probably the most widely used drug in the world. It is commonly self-
prescribed rather than prescribed by a clinician and the dose determined either by 
tradition, social context or the achievement of a pharmacological end-point (1). Almost 
no other substance has been as comprehensively investigated as ethanol, not only because 
it is one of the oldest and most ubiquitous abused "drugs" in human history, but also 
because of its unique dynamic and kinetic behavior (2). Although considered at one time 
(in the Middle Ages) as the elixir of life, it is now recognized that the therapeutic value 
of ethanol is extremely limited and that chronic ingestion of excessive amounts is a major 
social and medical problem (3). 
Pharmacokinetics 
Ethanol is unusual among drugs in several aspects of its pharmacokinetics. Particularly 
striking are the great biological inter-subject variabilities in alcohol consumption patterns 
and in alcohol elimination , in the pattern of short-term fluctuations from the trend line 
of the time course of the blood alcohol concentrations and in the partitioning of alcohol 
between the blood and other body fluids and tissues even at equilibrium (4). 
The pharmacokinetics of intravenous ethanol have been studied fairly extensively 
(5,6,7,8). Ethanol distributes into total body water and no protein binding has been 
reported. Elimination of ethanol occurs primarily through enzymatic oxidation by alcohol 
dehydrogenase to acetaldehyde in the liver with minute amounts being excreted in the 
breath (0.7%), sweat (0.1 %), and urine (0.3%) (1). The overall elimination process can 
be described by a capacity-limited model similar to the Michaelis-Menten model for 
enzyme kinetics first proposed by Lunquist and Wolthers (9,10). The use of the zero-
order model of Widmark (11) has been widespread in the past although the limitations 
of this model have been known for a long time (1). 
The alcohol concentration-time profile depends on a number of factors including the dose 
(10,12,13) , the type of alcoholic beverage and the rate of drinking (4,14), the 
consumption of a meal as well as the composition of the meal (15), sex and body 
composition (16,17). 
Differences in pharmacokinetics as well as in psychometric performance and mood states 
have been observed in males and females (16, 17, 19). This study will examine the 
differences between male and female subjects with respect to their pharmacokinetics as 
well as pharmacodynarnic effects following IV ethanol administration. 
Pharmacodynamics 
The relationship of the blood level of a drug to its pharmacologic effect has been the 
subject of numerous studies. Understanding this relationship is important because it 
contributes to the inter-individual variability observed in drug response. Ethanol is 
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~nsidered to ~ a_ cen~ nervous system depressant and its responses characteristically 
include euphona, impaired thought processes, and decreased mechanical efficiency (20). 
Although alcoholic drinks are viewed as stimulating, this apparent stimulation is a result 
of depression of the inhibitory control mechanisms of the brain (3). However, as 
intoxication becomes more advanced, there is progressive depression of CNS function 
that can ultimately lead to respiratory depression, coma and even death. 
Ethyl alcohol has been studied by investigators interested in its behavioral effects. The 
detrimental effects of alcohol on human performance are well documented (21,22,23). 
Ethanol produces numerous behavioral effects ranging from increased alertness to 
relaxation and a state of well-being or euphoria (24,25). These behavioral effects have 
been measured by various subjective mood scales such as the Drug Effects Questionnaire 
(DEQ), Profile of mood states (POMS), and the Subjective High Assessment Scale 
(SHAS) (26,27). 
The effects of ethanol on psychometric performance have also been studied 
(20,29,30,31). These psychomotor tests provide a non-invasive and quantitative measure 
of motor and cognitive function and allow comparison between different drugs or 
between different doses of the same drug. Alcohol has been shown to produce 
impairment of psychometric function as tested by various tests including tracking, digit 
symbol substitution, reaction time, body sway, hand steadiness and finger tapping (32). 
However, these tests are not ideal pharmacodynamic measures. Although some tests can 
measure some aspects of behavior as a function of drug response, they are somewhat 
subjective and may not show good reproducibility. Many of these tests are not suitable 
for repeated measures, since learning and motivational factors can influence performance 
in subsequent testing (33). Also, the relationship of performance on psychometric tests 
to the "real life" psychological and behavioral effects of drugs are difficult to define. 
Quantitative EEG is being increasingly used to study the pharmacodynamics of 
psychoactive drugs. The EEG provides an ongoing record of the neuroelectric activity 
of the brain, either in the resting state or under different activation procedures (e.g. 
repetitive photic stimulation, drug administration etc.). Although the scalp-recorded EEG 
is an overall measure of brain activity, it provides one of the best and most direct 
measures available for assessing the functional state of the CNS (21). Quantitative EEG 
is objective and non-invasive, and derived parameters change gradually with changes in 
plasma drug concentrations. Repeated or continuous measures of the EEG can be made, 
although a familiarization session before the study is advisable to avoid a first-session 
effect due to anxiety (37 ,38). Studies investigating the effects of acute ethanol 
administration on the adult human electroencephalogram (EEG) have been generally 
consistent (39). Most studies report an increase in voltage ~d a_sl~w!ng of th~ d~n:1in~t 
alpha frequency (21,23,40). Studies have also emphasized md1v1dual vanabihty m 
responses to alcohol. 
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Tolerance 
Acute tolerance to alcohol was first described by Mellanby, who reported a lower 
impairment at a given blood alcohol level in the descending limb of the blood alcohol 
curve than at the same level in the ascending limb of the curve (36). Since then, several 
studies have characteriz.ed the development of acute tolerance to single doses of ethanol, 
although there are reports describing the lack of tolerance to alcohol's effects 
(36,43 ,44,45,46). One explanation for this inconsistency may be the end point used to 
measure the pharmacological effects of ethanol. In general, data from studies measuring 
subjective assessments are consistent with the development of acute tolerance. The 
opposite conclusion is reached when objective psychological functions are assessed. 
Generally, studies measuring psychomotor performance fail to show significant acute 
tolerance to ethanol. The rate of change of concentration, direction of change of 
concentration, as well as the degree and rate of exposure to ethanol may also be 
important determinants of the development of acute tolerance to ethanol. 
Several paradigms can be used to study the development of acute tolerance to the effects 
of drugs, specially alcohol. One method would be to compare effects at the same 
concentrations during the ascending and descending limbs of the alcohol concentration-
time curve. Another method would be to study the time course of the effects of ethanol 
at "steady-state" i.e. when concentrations are constant. In such a paradigm, a diminishing 
of the effects of ethanol, despite maintaining constant concentrations, can be interpreted 
as the development of acute tolerance. Since ethanol follows non-linear capacity-limited 
pharmacokinetics, this is not true "steady-state", however, a dosing regimen can be 
designed to control the rate of input such that levels can be maintained fairly constant 
over prolonged durations. Intravenous administration of ethanol can provide good control 
of the input rate, which is critical to the achievement of these constant levels. 
In Part I of this study, six (6) healthy male volunteers were given two different doses of 
ethanol (0.3 g/kg and 0.6 g/kg), each ingested at two different rates (20 minutes and 50 
minutes). Serial blood samples (for serum alcohol concentrations) were drawn, and EEG 
recordings, psychometric tests and mood scales were completed by the subjects during 
each period. Preliminary analysis of the psychometric performance and mood data 
indicated that, in general, some of the items of the mood scale (viz. "HIGH", 
"DRUNK", "ALCOHOL EFFECTS") were fairly sensitive in discriminating different 
doses of ethanol, and also distinguishing dose rates at the high dose for some subjects. 
The psychometric tests indicated some trends toward dose-related impairment which were 
not significant. Practice effects were evident. Two of the six subjects were classified as 
"non-responders" based on their lack of response on the mood scales. The data also 
seemed to indicate that the rate of input may not have been controlled well enough to 
assess the effects of rate of input on the effects of ethanol. 
In this study, subjects will be administered an individualiz.ed regimen consisting of 
intravenous infusions of ethanol calculated to achieve and maintain concentrations of 
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ethanol at or about 1000 mg/L (the legal limit). This will be accomplished by 
determining the subjects' individual pharmacokinetic parameters from serum 
concentrations after administration of a test dose of ethanol during the Pharmacokinetic 
Screening and Familiarization period. These individual parameters can then be used to 
calculate a dosing regimen that will be designed to achieve the desired alcohol level and 
maintain it for different durations of exposure. Several pharmacodynamic end points: 
EEG, psychometric performance and mood will be measured and the relationship 
between these end-points and serum concentrations will be assessed to study the 
pharmacokinetic-pharmacodynamic relationship for IV ethanol as well as the development 
of acute tolerance to the effects of different rates and degrees of ethanol exposure. 
Relevance of the complexity of the relationships between alcohol dose, time and 
pharmacological effects is essential for the development of a paradigm for measuring the 
influence of factors such as gender, age and concomitant drugs on the effects of ethanol. 
Ethanol can also be examined as a model CNS depressant for the evaluation of objective 
pharmacodynamic end-points, such as EEG and psychometric tests, and subjective 
measures of mood and behavior, for other psychoactive drugs in order to correlate these 
surrogate measures with concentration or dose. 
METHODS AND PROCEDURES 
I. SUBJECTS 
Sixteen (16) healthy volunteers, (eight male and eight female), will participate in the 
study. Volunteers will be considered for inclusion if they conform to the following 
criteria: 
1. Demographic: Subjects must be healthy male or non-pregnant female volunteers 
between the ages of 21 and 35 years and must not deviate more than 15% above 
or below the range of desirable weights according to the 1979 Build Study, 
Society of Actuaries and Association of Life Insurance Medical Directors of 
America. 
2. Medical History: Subjects must have no clinically significant history of renal, 
hepatic, cardiovascular, gastro-intestinal, neurological, pulmonary, or hematologic 
disease. Subjects must have no history of alcohol abuse, drug addiction, 
psychological dependence on drugs, or psychiatric illness. Subjects must have no 
first degree relatives (mother, father, or siblings) with a history of mental illness 
or alcohol/ drug abuse. 
To participate in the study, female subjects must meet the following criteria: As 
determined by thorough enquiry, women must be found to practice acceptable 
methods of birth control and have a negative serum beta-hCG pregnancy test. 
Abstention, vaginal contraceptives, intra-uterine devices, or use of contraceptives 
by the women's partner, do not constitute acceptable birth control. Acceptable 
methods will be limited to oral contraceptives only. The method of birth control 
must be recorded in the subject's medical history. 
440 
3. Alcohol History: Subjects must complete an alcohol drinking history 
questionnaire based on the Khavari Alcohol Test and the Short Michigan 
Alcoholism Screening Test to quantify their alcohol intake and patterns of use 
(47). Subjects will also complete an alcohol use diary starting from the date of 
screening through the end of the study, approximately 5 - 6 weeks. 
4. Physical: Subjects must successfully pass a physical examination, demonstrating 
no evidence of an active disease state or physical or mental impairment. 
5. Laboratory screen: Subjects must have no clinically significant abnormal 
laboratory values on a laboratory screen consisting of 1) SMAC-20, 2) CBC and 
3) urinalysis. Subjects must have a negative urine drug test and breath alcohol 
test. Female subjects must have a negative serum beta-hCG test. 
6. Electrocardio2ram: Subjects must have no clinically significant abnormalities on 
a 12-lead EKG including a 30 second rhythm strip. 
7. Vital si2ns: Supine and standing sy~tolic and diastolic blood pressure, heart rate, 
and oral body temperature must be within normal limits. An orthostatic test i.e. 
systolic and diastolic blood pressure and heart rate at 5, 7 and 10 minutes supine 
and 0, 1, 3 and 5 minutes standing will have to be clinically acceptable. 
8. Other medications: Subjects must not be taking medications chronically and must 
not have taken any prescription medication or investigational drugs for at least 4 
weeks before entering the study. Female subjects will be permitted to continue 
their oral contraceptive medication. Subjects must have a normal daily caffeine 
intake equivalent to or less than two cups of coffee. No medications (including 
OTC medications and vitamins) or caffeine will be allowed in the 72-hour period 
before each study day and on each study day. Subjects must also abstain from 
alcohol starting 72 hours before the first treatment period through the end of the 
study. Subjects must be non-smokers, meaning that they have abstained from 
smoking for at least 12 months before the start of the study. 
Within one week after study completion, the physical examination and vital signs, 
laboratory tests, and EKG will be repeated for all subjects. Possible clinically significant 
abnormalities will be followed up until return to pre-study values. 
Subjects for this study will be recruited from within the hospital and schools at 
MCV/VCU. 
II INFORMED CONSENT 
Each subject will provide written informed consent for study participation before the start 
of the study. The original signed consent forms will be kept in the subjects' confidential 
medical case record as a permanent document and a copy will be given to the subject. 
III PROCEDURES 
The study will be conducted in two phases: 
Subjects who have successfully passed the medical screening will first undergo an open-
labelled Pharmacokinetic Screen and Familiarization Period (Leg 0); to assess their 
individual pharmacokinetic parameters, which will be used to design an appropriate 
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regimen, as well as to familiarize them with the study procedures, especially the EEG. 
After this, subjects will be randomized to the double-blind, four-treatment crossover 
phase (Legs 1 through 4) of the study. The washout period between treatments will be 
at least one week. 
Leg 0 
During the Pharmacokinetic screen and Familiarization Period, the following procedure 
will be followed: 
1. Admission to Clinical Research Unit 
Subjects will enter the study facility on the evening of the day prior to the day of dosing. 
A urine sample will be collected for a urine drug screen test and a breath alcohol test 
(Alcosensor) will also be completed. A blood sample will be collected from female 
subjects for a sef\.\m beta-hCG test. Subjec:ts must test negative on both the urine drug 
screen as well as the breath alcohol test. Female subjects must test negative on the beta-
hCG test. All subjects will complete a probe concerning recent medical history and 
medication use. 
2. Dosing 
On the morning of dosing, subjects will receive a one-hour infusion of ethanol 
administered via an indwelling catheter in the dominant arm. A total dose of 0.6 g 
ethanol/kg body weight for male subjects and 0.5 g ethanol/kg body weight for female 
subjects will be administered as a 10% solution in normal saline over 1 hour. Doses will 
be prepared by the investigational pharmacy and the treatment will be open-labelled. 
3. Pbannacokinetic (PK) Measurements 
Blood sampline (SAC) 
Prior to dosing, a heparin containing catheter will be inserted into the forearm vein of 
the non-dominant arm (contra-lateral to ethanol infusion) for access to blood sampling. 
6 ml samples for determination of ethanol concentration will be collected in red-top tubes 
with no additives at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 
1.33 hr, 1.66 hr, '?, hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the ethanol 
infusion. The blood will be allowed to clot, centrifuged (within 1 hour of sampling) for 
10 minutes, serum harvested and stored at -20° C until analysis by the TDx Analyzer 
(Abbott Diagnostics). 
4. Pbannacodynamic (PD) Measurements 
Electroencel)haloeraphy (EEG) 
Four minute segments of 28-channel EEG, using a Neuroscan Brain Imager, will be 
recorded for each subjects with eyes closed at the following times: twice pre-dose and 
15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 
8 hr after the start of the ethanol infusion. Subjects will be asked to count back from 500 
by threes to maintain constant vigilance during the recordings. The electrodes will be 
placed using an Electro-cap according to the 10/20 International System with 8 additional 
electrodes located 50% between the standard 10/20 placement. Linked ears will be used 
as the reference. Four additional channels will be used to monitor for vertical and lateral 
eye movements and electromyographic activity. The electrode impedances will be 
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checked before each recording. Impedances should be less than 5.0 kohms and similar 
between electrodes. Any disturbances in the room or subject movement during the EEG 
recording will be documented by the EEG technician. The raw EEG will be stored on 
an optical disk. The objective of each recording is to obtain at least 30 artifact-free 
frames for further analysis. 
Psychometric Performance Tests <PP} 
The Wesnes Test Battery (Cognitive Drug Research Computerized Assessment System) 
of psychometric tests will be administered to each subject at the following times: twice 
pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 
hr, 7 hr and 8 hr after the start of the ethanol infusion. 
The Wesnes test battery assesses cognitive function and the tasks include simple and 
choice reaction times, vigilance tests, tracking, memory scanning and immediate and 
delayed word recognition. A selection of these tests, Word Recognition, Number 
Vigilance, Immediate Word Recall and Visual Tracking, will be administered, and 
parallel forms of the tests will be presented at each session. All the tasks are 
computerized, the information being presented on high resolution monitors, and the 
responses recorded via response modules containing two buttons, one marked "NO" and 
the other "YES". 
On the evening prior to the day of dosing, ~ubjects will practice each psychometric task 
twice. 
Subject Rated Impairment Scale <SRD 
A 100 mm visual analog scale, based on the Subjective High Assessment Scale (SHAS) 
will be completed ·by each subject at the following times: twice pre-dose and 15 min, 30 
min, 45 min, I hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the 
start of the ethanol infusion. Subjects will indicate their perceived level of intoxication 
response for each item by placing a mark on an unnumbered 100 mm scale that ranges 
from "not at all" to "extremely". 
Observer Rated Impairment Scale (ORI) 
A 100 mm visual analog scale will be completed by the investigator for each subject at 
the following times: twice pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 
2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the ethanol infusion. The 
blinded investigator will indicate his perception of the subject's level of intoxication by 
placing a mark on an unnumbered 100 mm scale that ranges from "not at all" to 
"extremely". 
5. Safety measurements 
Vital Si2ns 
Blood pressure (sitting), heart rate and oral body temperature will be measured at the 
following times: twice pre-dose and 30 mi~, I hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 
8 hr after the start of the ethanol infusion. · 
Skin (facial) temperature, using the Genius tympanic thermometer (First Temp Inc.), will 
be measured at the following times: twice pre-dose and 15 min, 30 min, 45 min, 1 hr, 
1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr after the start of the ethanol 
infusion. 
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These measurements will be made by Registered Nurses and the Medical Monitor will 
be on call throughout the treatment period for each subject. 
Adverse effects 
All subjects will be observed for symptoms and signs of clinical intolerance to the drug 
or procedures and asked to report any adverse effects. These will be evaluated by the 
Medical Monitor for their clinical significance and potential need for treatment. 
6. Diet 
On the evening prior to dosing, subjects will receive a light snack. 
No food or beverages will be permitted starting 10 hours prior to dosing. A light 
standardized meal will be served at 4 hours after the start of ethanol infusion. Dinner and 
a snack will be served at 9 and 14 hours after start of dosing respectively. Caffeine-free 
beverages may be served with meals. The same menu will be served on corresponding 
days of each study period. Water will be permitted ad libitum. 
When the above measurements are scheduled at the same time, they will be conducted 
in the following sequence: 1) blood sample, 2) mood scales, 3) EEG, 4) psychometric 
tests, and 5) vital signs, with the blood sample being collected at exactly the scheduled 
time. If there is any unscheduled delay, measurements may be omitted as needed to 
conform to the schedule. 
7. Discharge from Clinical Research Unit 
At the end of the treatment period (24 hours after dosing), it is anticipated that ethanol 
levels would be below the detectable limit. However, to ensure subject safety, an alcohol 
breath test (Alcosensor) will be performed. If the test is negative, subjects will be 
discharged with instructions to return for the crossover phase of the study. 
A study flow sheet is included. 
Legs 1-4 
During each of the four randomized crossover legs of the study, the following procedure 
will be followed: 
1. Admission to Clinical Research Unit 
Subjects will enter the study facility on the evening of the day prior to the day of dosing. 
A urine sample will be collected for a urine drug screen test and a breath alcohol test 
(Alcosensor) will also be completed. A blood sample will be collected from female 
subjects for a serum beta-hCG test. Subjects must test negative on both the urine drug 
screen as well as the breath alcohol test. Female subjects must test negative on the beta-
hCG test. All subjects will complete a probe concerning recent medical history and 
medication use. 
2. Dosing 
On the morning of dosing, subjects will receive the infusion of ethanol administered via 
an indwelling catheter in the dominant arm. Dosing will consist of two infusions: 
Infusion I will be administered for I hour, followed by Infusion II which will be 
administered over the next 5 hours. The total dose of ethanol, which will be 
individualized for each subject based on his pharmacokinetic parameters, will be 
administered as a 10% solution in normal saline. Placebo doses will consist of normal 
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saline. 
Doses will be prepared by an unblinded pharmacist, who will assign subjects to one of 
the four randomization sequences such that 2 male and 2 female subjects will be 
randomized to each sequence. F.ach treatment will be given exactly once and in random 
order according to the randomization sequence. Both the subjects and the investigators 
will be blinded to treatment. A sealed copy of the randomization schedule will be 
available at the research unit in case of an emergency. 
3. Pbarmacokinetic (PK) Measurements 
Blood sampline (SAC) 
Prior to dosing, a heparin containing catheter will be inserted into the forearm vein for 
access to blood sampling. 
6 ml samples for determination of ethanol concentration will be collected in red-top tubes 
with no additives at the following times: pre-dose and 15 min, 30 min, 45 min, 1 hr, 
1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 
12 hr and 14 hr after the start of Infusion I. The blood will be allowed to clot, 
centrifuged (within 1 hour of sampling) for 10 minutes, serum harvested and stored at 
-200 C until analysis by the TDx Analyzer (Abbott Diagnostics). 
The total volume of blood drawn for ethanol determination during the study will be about 
560 ml over a five to six week period. 
4. Pbarmacodynamic (PD) Measurements 
Electroencephaloeraphy (EEG) 
Four minute segments of 28-channel EEG, using a Neuroscan Brain Imager, will be 
recorded for each subjects with eyes closed at the following times: twice pre-dose and 
15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 
6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr after the start of Infusion I. Subjects 
will be asked to count back from 500 by threes to maintain constant vigilance during the 
recordings. The electrodes will be placed using an Electro-cap according to the 10/20 
International System with 8 additional electrodes located 50% between the standard 10/20 
placement. Linked ears will be used as the reference. Four additional channels will be 
used to monitor for vertical and lateral eye movements and electromyographic activity. 
The electrode impedances will be checked before each recording. Impedances should be 
less than 5 .0 kohms and similar between electrodes. Any disturbances in the room or 
subject movement during the EEG recording will be documented by the EEG technician. 
The raw EEG will be stored on an optical disk. The objective of each recording is to 
obtain at least 30 artifact-free frames for further analysis. 
Psychometric Performance Tests <PP} 
The Wesnes Test Battery (Cognitive Drug Research Computerized Assessment System) 
of psychometric tests will be administered to each subject at the following times: twice 
pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 
hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr after the start of Infusion 
I. The Wesnes test battery assesses cognitive function and the tasks include simple and 
choice reaction times, vigilance tests, tracking, memory scanning and immediate and 
delayed word recognition. A selection of these tests, Word Recognition, Number 
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Vigilance, Immediate Word Recall and Visual Tracking, will be administered, and 
parallel forms of the tests will be presented at each session. All the tasks are 
computerized, the information being presented on high resolution monitors, and the 
responses recorded via response modules containing two buttons, one marked "NO" and 
the other "YES". On the evening prior to the day of dosing, subjects will practice each 
psychometric task once. 
Subject Rated Impairment Scale <SRI) 
A 100 mm visual analog scale, based on the Subjective High Assessment Scale (SHAS) 
will be completed by each subject at the following times: twice pre-dose and 15 min, 30 
min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 
8 hr, 9 hr, 11 hr, 12 hr and 14 hr after the start of Infusion I. Subjects will indicate their 
perceived level of intoxication response for each item by placing a mark on an 
unnumbered 100 mm scale that ranges from "not at all" to "extremely". 
Observer Rated Impairment Scale (ORI) 
A 100 mm visual analog scale will be completed by the investigator for each subject at 
the following times: twice pre-dose and 15 min, 30 min, 45 min, 1 hr, 1.33 hr, 1.66 hr, 
2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 hr, 11 hr, 12 hr and 14 hr 
after the start of Infusion I. The blinded in.vestigator will indicate his perception of the 
subject's level of intoxication by placing a mark on an unnumbered 100 mm scale that 
ranges from "not at all" to "extremely". 
5. Sarety measurements 
Vital Si~ns 
Blood pressure (sitting), heart rate and oral body temperature will be measured at the 
following times: twice pre-dose and 30 min, I hr, 2 hr, 3 hr, 4 hr, 6 hr, 7 hr, 8 hr, 9 
hr, 11 hr, 12 hr, 14 hr, and 24 hr after the start of the ethanol infusion. 
Skin (facial) temperature, using the Genius tympanic thermometer (First Temp Inc.), will 
be measured at the following times: twice pre-dose and 15 min, 30 min, 45 min, 1 hr, 
1.33 hr, 1.66 hr, 2 hr, 2.25 hr, 2.5 hr, 2.75 hr, 3 hr, 3.25 hr, 3.5 hr, 3.75 hr, 4 hr, 
4.25, 4.5 hr, 4.75 hr, 5 hr, 5.25, 5.5 hr, 5.15 hr, 6 hr, 6.33 hr, 6.66 hr, 7 hr, 8 hr, 9 
hr, 11 hr, 12 hr and 14 hr after the start of Infusion I. 
The study will be conducted by Registered Nurses and the Medical Monitor will be on 
call throughout each treatment period for each subject. 
Adverse effects 
All subjects will be observed for symptoms and signs of clinical intolerance to the drug 
or procedures and asked to report any adverse effects. These will be evaluated by the 
Physician Investigator for their clinical significance and potential need for treatment. 
6. Diet 
On the evening prior to dosing, subjects will receive a light snack. 
No food or beverages will be permitted starting 10 hours prior to dosing. A light 
standardized meal will be served at 4 hours after the start of ethanol infusion. Dinner and 
a snack will be served at 9 hours and 14 hours after start of dosing respectively. 
Caffeine-free beverages may be served with meals. The same menu will be served on 
corresponding days of each study period. Water will be permitted ad libitum. 
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When the above measurements are scheduled at the same time, they will be conducted 
in the following sequence: 1) blood sample, 2) mood scales, 3) EEG, 4) psychometric 
tests, and 5) vital signs, with the blood sample being collected at exactly the scheduled 
time. If there is any unscheduled delay, measurements may be omitted as needed to 
conform to the schedule. 
7. Discharge from Clinical Research Unit 
At the end of each treatment period (24 hours after dosing), it is anticipated that ethanol 
levels would be below the detectable limit. However, to ensure subject safety, an alcohol 
breath test (Alcosensor) will be performed. If the test is negative, subjects will be 
discharged with instructions to return on the following week for the next treatment. At 
the end of the last treatment period , subjects will return the alcohol diary prior to leaving 
the unit. 
A study flow sheet is included. 
BIOSTATISTICAL DESIGN AND ANALYSIS 
~ 
This study is designed as a randomized, double-blind, placebo-controlled four-period 
crossover concentration-controlled trial in sixteen (eight male and eight female) healthy 
volunteers. Subjects will undertake the study one at a time and will receive each 
treatment exactly once. The start of each treatment period will be separated by a washout 
period of at least one week. Prior to randomization, subjects will undergo a single-blind 
Pharmacokinetic Screen and Familiarization Period to obtain individual pharmacokinetic 
parameters that can then be used to determine the appropriate infusion rate to be 
administered to achieve and maintained desired concentrations in the different legs of the 
study. Pharmacodynamic data obtained during this period may be used as covariates to 
classify subjects as "responders" and "non-responders". 
Sixteen healthy volunteers (eight male and eight female) will complete the study. Since 
this is a pilot study, no formal sample size calculations were performed, the number of 
subjects selected is the minimum required to ensure that exactly two male and two female 
subjects will be randomized to each treamtnet sequence. After the medical screening, and 
the Pharmacokinetic screening period, subjects will be randomized to one of the four 
sequences, and will receive each of the following treatments exactly once: 
Treatment Infusion I Infusion n 
A ethanol placebo 
B placebo ethanol 
C ethanol ethanol 
D placebo placebo 
Exactly two males and two females will be assigned to each of the four treatment 
sequences. The appropriate dose and infusion rate of the ethanol solutions administered 
intravenously will. be determined based on the subject's individual pharmacokinetic 
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parameters which will be assessed from the serum concentration data obtained during Leg 
0. Placebo treatments will consist of normal saline infusions. 
Data analysis 
I. Pharmacokinetic (PK) Analysis 
1. Pharmacokinetic (PK) Methods 
The serum concentration of ethanol obtained during the study will be presented in tabular 
and graphic form for each subject and treatment. Pertinent pharmacokinetic parameters 
for ethanol, including volume of distribution (VJ, total body clearance (CI..,,J, area under 
the concentration-time curve (AUC), maximum concentration (CmaJ and time to 
maximum concentration (U will be estimated for each subject and treatment. 
Descriptive statistics will be calculated for each parameter. 
If appropriate, pharmacokinetic modelling will be performed to estimate the maximum 
elimination rate constant (V maJ and Michaelis-Menten constant (K,J. 
2. Statistical Analysis 
Pharmacokinetic parameters will be compared using univariate analysis of variance 
(ANOV A) to fit a crossover model to the data of the form: 
... eq. 1 
i = 1,2,3,4; j = 1,2,3,4; k = 1,2, ... ,16; l = 1,2; m = 1,2,3,4 
where Y;~ is the response for the kth subject of the 1th gender in the ith sequence in the 
jth period after the mth treatment, µ is the overall mean, o; is the effect of the ith 
sequence, ..-i is the effect of the jth period, rk<J) is the effect of the kth subject within the 
ith sequence, r 1 is the effect of the Ith gender, am is the effect of the mth treatment, Acm-i> 
is the carryover effect of the (m-l)st treatment, and e;jk.lm is the random error associated 
with Y ijklm· The e1jk.lm are assumed to be normally distributed random variables with mean 
of O and variance u,2. 
The residuals will be tested for normality. If the data are not normally distributed, the 
data may be transformed. The level of significance (a) will be set at 0.05. In case of 
significant differences, multiple comparisons will be performed. In case no statistical 
differences are observed, a 'post-hoc' power analysis will be performed to assess the 
discriminative ability of the statistical tests performed for future studies in the same 
setting, and to calculate appropriate sample sizes for future studies. Because the 
calculation of power for crossover models is quite complex, the power of the F test for 
analysis of variance (associated with the first period data) will be determined. This 
estimation of power does not take into account the crossover design of the study and 
therefore is a conservative estimate. The Pearson-Hartley charts of the power of the F 
test will be used to determine power ( 41). 
IT. Pharmacodynamic (PD) Analysis 
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1. Electroencephalography (EEG) 
F.ach of the 5-minute recordings will be reviewed and edited to remove each 2.5 second 
epoch that is contaminated with artifacts (eye movement, muscle movement, electrode 
artifacts, or other disturbances noted during the recording). The remaining 2.5 second 
artifact-free frames will be averaged to form an average topographical map for each 
recording. The amplitude, power, and relative power of the EEG signal in the five 
classical frequency bands (delta: 0.39 - 3.0 Hz; theta: 4.3 - 7 .8 Hz; alpha: 8.2 - 11. 7 
Hz; beta I: 12. l -16.0 Hz; and beta II: 16.4 - 30 Hz) at each electrode will be 
determined for each average topographical map. The total amplitude and power for each 
average map will be calculated. Differences of each treatment from baseline as well as 
from placebo for each of these parameters will be calculated. 
2. Psychometric Performance (PP) Tests 
The following measures will be derived from the Wesnes test battery: 
Task Primary Measure Secondary Measure 
Word Recognition Sensitivity Speed (msec) 
Number Vigilance Accuracy (%) Speed (msec) 
Tracking Mean errors (cm) 
Immediate Recall Accuracy (%) 
3. Rating Scales (SRI/ORI) 
A score between O and 100 will be obtained for each item on the visual analog scale at 
each time point by measuring the number of millimeters between the left end of the scale 
and the mark placed by the subject. 
4. Pharmacodynamic (PD) Methods 
Response-time profiles, i.e., plots of change in response variable from predose baseline 
vs. time plots for each subject during each treatment period will be tabulated and plotted 
for each response measure obtained from the EEG, PP tests and SRI/ORI scales. 
Pertinent summary pharmacodynamic parameters including baseline response, maximal 
observed response (E,,,.J, time to reach maximum response(f....J, and area under the 
effect-time curve _(AUE) will be determined and descriptive statistics for each of the 
above will be calculated. 
Effect-concentration profiles will be plotted for each subject at each treatment. Tolerance 
development will be assessed by visual observation of these plots. Pharmacokinetic-
pharmacodynamic modelling will be performed, if appropriate. 
5. Statistical Analysis 
Because there are many variables of interest in this statistical analysis, the multiplicity 
of desired inferential statements about the data become problematic. Adjusting the level 
of significance (a) for the multiple statistical comparisons, as made in traditional 
confirmatory analysis, would result in extremely small a values and virtually no 
likelihood of detecting any statistically significant differences. Therefore, using the 
concept of exploratory data analysis, expected differences between treatments based on 
previously reported studies and patterns apparent from examining the data may be 
evaluated statistically without adjusting the level of significance. The results of these 
analyses will be used to make descriptive inferential statements about the data, but not 
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to reject the null hypothesis. Hypotheses generated by this study would have to be 
confirmed by prospective studies involving a larger number of subjects. 
Primary pharmacodynamic measures that will be evaluated include: changes in relative 
EEG power in the delta, theta, and alpha .- bands, changes in primary measures of the 
Wesnes battery, and changes in the items, "HIGH", "DRUNK", "DROWSY", and 
"ALCOHOL EFFECTS" on the SRI scales. Statistical comparisons for the other 
pharmacodynarnic parameters will be treated as exploratory data analysis. These will be 
used to generate hypothesis rather than to make formal conclusions based on the data. 
Results of the summary pharmacodynamic parameters <Emu, Tmax, AUE) for each 
response measure for each treatment will be compared using statistical techniques 
appropriate for a 4-way crossover design with repeated measures. The model used to fit 
the data would be identical in form to the model described above in eq. l (see Statistical 
Analysis for the Pharmacokinetic (PK) Analysis). 
The residuals will be tested for normality. If the data are not normally distributed, the 
data may be transformed. The level of significance (a) will be set at 0.05. In case of 
significant differences, multiple comparisons will be performed. In case no significant 
differences are observed, a power analysis similar to the one described above (see 
Statistical Analysis under PK analysis) will be performed. 
Since one of the aims of this study is to assess the relationship between the different PD 
measures viz. EEG changes, psychometric performance and mood changes, linear 
regression (using a mixed effects regression model) of the EEG parameters on the 
different psychometric performance and mood parameters will be performed to determine 
the significance of the relationship between the different PD response measures. The 
model will incorporate different variance structure matrices (simple, unspecified and 
autoregressive) to model the variance of the response measure (42). Residuals will be 
tested for normality. The level of significance (a) will be set at 0.05. 
HUMAN SUBJECT CONCERNS 
Subjects enrolled in the study will receive ethanol intravenously, have blood samples 
drawn for ethanol determination, and undergo a series of tests including EEG, 
psychometric tests and rating scales, repeatedly over a 12 hour period on 5 occasions. 
Subjects will remain in the study facility from the night before the study day until the 
morning after the study day (approximately 36 hours for each treatment period) to 
preclude any motor or other accidents that may result from the impairment caused by 
alcohol. 
I. Study drug 
Subjects will receive infusions of 10% v/v ethanol, over a one or six hour period in a 
crossover fashion. These infusions may produce some local irritation to the veins. 
Alcohol (ethyl alcohol) may produce the following side-effects: local irritation, nausea, 
vomiting, flushing and feeling of warmth, changes in heart ra_te and blood_ pressure, 
diaphoresis, diuresis, dizziness, changes in sexual_ desire, drowsiness, eup~ona o_r false 
feeling of confidence and well being (3). Alco~ol 1s known to b~ teratogenic ~d 1~ used 
in pregnant women, it can result in morphological and neurological abnormalities m the 
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child, called fetal alcohol syndrome. The features of this syndrome include CNS 
dysfunction, slowness of growth, characteristic facial abnormalities and a variable set of 
major and minor malformations (3). 
Subjects will be monitored for the development of adverse effects to the study drug by 
nurses in the study facility. Vital signs (blood pressure, heart rate and temperature) will 
be determined periodically during the study. Adverse effects will be managed as deemed 
necessary by the medical monitor. 
At the end of each treatment period (24 hours after dosing) it is anticipated that ethanol 
levels would hav~ dropped to zero. Howeyer, a breath alcohol test will be performed 
prior to discharge to ensure that the subject does not have any detectable ethanol levels. 
II. Blood sampling 
Subjects will have fourteen 6-ml blood samples drawn during Leg O and twenty 6-ml 
blood samples drawn during each treatment period (Legs 1-4). A total of about 560 ml 
of blood will be drawn during the study over a period of five to six weeks. 
m. Test Battery 
The test battery consists of EEG, psychomotor tests and rating scales and will be 
administered periodically during each treatment period. The risk associated with these 
tests is minimal. Subjects will be expected to wear the Electro-caps throughout the 
treatment period, which may result in some discomfort. 
IV. Pre- and post-study physical exam and laboratory tests 
Subjects may experience some discomfort during the physical exam, EKG and laboratory 
tests to be perforn;ied during screening and at the end of the study. 
Subjects will receive no personal benefits to their health from participating in the study, 
but the procedures will be conducted at no cost to them and they will receive an 
honorarium for their participation. Any information obtained about subjects from this 
research will be kept strictly confidential. Subjects will provide written informed consent 
and have the right to withdraw from the study at any time. 
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I Medical Screening I 
Pharmacokinetic Screen and Familiarization Period 
Males: 0.6 g/kg IV Ethanol infused over 1 hour 




v ... , .. K,., yd 
Dose Individualization 
RANDOMIZATION 
Four-way Crossover (Legs 1 - 4) 
Treatment Infusion I Infusion II 
(1 hour) (5 hours) 
A ethanol . placebo 
B placebo ethanol 
C ethanol ethanol 
D placebo placebo 
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Randomization sequences for intravenous ethanol study 
Sequence Leg 1 Leg 2 Leg 3 Leg 4 
A B C D 
II B D A C 
m C A D B 
IV D C B A 
1 rt A: J.nIUSIOn I: i:tnanol lntUs1on ll: ~alllle 
Trt B: Infusion I: Saline Infusion Il: Ethanol 
Trt C: Infusion I: Ethanol Infusion II: Ethanol 
Trt D: Infusion I : Saline Infusion Il: Saline 
Infusion I: 0 - I hr, Infusion Il: 1 - 6 hrs. 
Study Period Flow Sheet for Leg O of intravenous ethanol study 
-12 -10 -I 0 0 .25 0.5 0.15 1.0 1.33 1.66 2.0 3.0 4.0 5.0 6 .0 7.0 8.0 9.0 14 24 
Admimoo X 
Infusion I lnfu,ion I 
SAC X X X X X X X X X X X X X X 
EEG X X X X X X X X X X X X X X X 
pp X X X X X X X X X X X X X X X 
SRJ/ORJ X X X X X X X X X X X X X X X 
I 
I 
VS X X X X X X X X X X X 
Skin Temp X X X X X X X X X X X X X X X 
Meals/Sna.cks X I X X X 
Disc huge I I X 
SAC: S .rum .,._,es tor"""'°" . ucu:munauoo. ,c.u: l!.lectroeDcel>llalOIUOl>llY, l'I': l'Jychometnc l'ertomw,ce &uen. "KIi v1<1: sut 1ec111<.au:a uwaumen1 & Observer Jt<a<e< 





Study Period Flow Sheet for Legs l -4 of intravenous ethanol study 
-12 I - 10 - I 0 11.25 o.s 0.75 I J..3J 1.66 2 3 4 6 6.33 6.66 1 g 9 11 12 I 14 16 24 
I I ' I 
Admission X 
I I 
lnfusi'cm. I !Inf [ I I lnf U I 
I 'I 1' 
SAC 
11 
X X X X X X X I x X X X X X X X I X X X X X 
EEG X X X X X x i X X X X X X X X X X X X X X X 
PP X X X X X X X X X X X X X X X X X X X X X 
SJU/ORI X X X X X X X X X X X X X X X X X X X X I X 
I 
I 
I vs X X X X X X X X X X X X X X X 
Skin Temp X X X X X X 
I 









Ac: ~m ,amp1es tor Alcohol hon, . :i:.u: blect:roeooepw.ograpby, ' '.r: sycbometnc Pe.r onnance, Battery, ~·-- •!"l: .Sub1ect Rated 










DETERMINATION OF DOSING REGIMENS 
I. Estimation of Pbannacokinetic Parameters from Phannacokinetic Screen and 
Familiarization period (Leg 0) 
The following patient-specific parameters will be estimated from the individual serum 
concentration-time data from Leg O (Pharmacokinetic Screen and Familiarization 
Period)(l): 
V mu: Maximum elimination rate 
Km_: Michaelis-Menten constant 
Yd: Volume of distribution. 
1. Population Estimates 
Population parameter estimates for the parameters, V mu, K,.., and V d (see table) will be 
used as a plausability reference for the estimates obtained for each subject (2,3). 
Parameter . Population Estimate ± SD 
V mu [mg/L/hr] 232 ± 26 
K,., [mg/L] 82.1 ± 28.7 
yd [L/70 kg] 37.3 ± 2.9 
2. Initial Estimates 
Initial estimates for the pharmacokinetic parameters will be obtained from the slopes of 
the linear and semi-log concentration-tme plots as follows: 
V mu will be estimated as the slope of the initial linear (apparent zero-order) part of the 
linear concentration-time plot. 
K,., will be estimated from the terminal slope of the log concentration-time plot using 
equation I. 
K,., = - V mu/(2.303*slope) ............. . .. ..... 1 
V d can be estimated using equation 2: 
V d = CL * MRT . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 
where CL is the total clearance and MRT i~ the mean residence time calculated by non-
compartmental methods (1). 
3. Model Fittin~ 
A one compartment model with capacity-limited elimination model will be used to fit the 
concentration-time data for each subject using MINSQ (Scientific Software lnc.). The 
model equations are as follows: 
during infusion: 
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dC _ Ko ( Vmax *C) 
Tt - vd - ( K,,,+C) . ... ....... . ....... . ... 3 
after infusion: 
dC ( Vmax*C) 
dt =- ( K,,,+C) ......................... 4 
The final estimates of the parameters, V mm K..,, and V d• will be used in the 
determination of an appropriate dosing regimen for that subject for the remaining four 
legs of the study. 
n. Calculation of Doses for Legs 1 - 4 
1. The dose for Infusion I (Dose I) will be calculated from the patient's individual 
parameters to achieve a target concentration (Cl&Ji.J of 1000 mg/L (± 10%) at the 
end of the infusion (1 hour). 
The dose for Infusion II (Dose II) will be calculated to maintain concentrations 
at the target level (1000 mg/L ± 10%) over the next 5 hours. 
2. A nomogram based on the complete pharmacokinetic model with capacity-limited 
elimination will be developed to determine the doses required for each leg of the 
study for each subject based on his/her individual pharmacokinetic parameters. 

















Dose I will be administered as a 10%v/v ethanol solution over 1 hour. Dose II will be 
administered as a 10%v/v ethanol solution over the next 5 hours. Placebo solutions will 
consist of 0.9% (normal) saline. 
4. Dose calculations and dose preparation will be performed by an unblinded 
pharmacist. 
References: 
1. Gibaldi M, Perrier D ; Pharmacokinetics 2nd edition; Marcel Dekker (1982). 
2. Wagner JG; Pharmacokinetics for the Pharmaceutical Scientist; Technomic 
Publishing Co (1993). 




Pbannacokinetic-PbannacodynamicRelationship for Intravenous Ethanol in Healthy 
Male and Female Subjects. 
Part II: Modeling the Development of Tolerance to the Effects of Intravenous 
Ethanol Administration in Healthy Male and Female Subjects: Effect of Systemic 
Input Rate and Degree of Ethanol Exposure 
1. Investigators 
Vijay A. Ramchandani, B.Pharm.Sc. (Bombay, India) 
Jurgen Venitz, M.D., Ph.D. 
Alan R. Towne, M.D. (Medical Monitor) 
Indravadan Gatiwala, M.D. 
2. Introduction 
I am being asked to participate in this study because I am healthy and not taking any 
stimulant drugs or medication on a chronic basis. This study is designed to study the 
effects of intravenous alcohol (ethanol) on my brain wave recordings 
(electroencephalogram or EEG) and other ·psychological tests, as well as on my mood 
and behavior. 
Screenin" 
If I agree to participate, I will be expected to provide information about my medical 
history and alcohol use, have laboratory tests done (including blood and urine tests and 
a breath alcohol test), have a physical examination, and have an EKG (electric tracing 
of the heart) to detect whether I have any medical condition that would prevent me from 
participating in the study. My urine will lie tested for drugs of abuse. 
I will not be allowed to take any prescription medications for four weeks before the start 
of the study. I will not be allowed to take any over-the-counter medication (such as 
antacids, aspirin, vitamins or cold preparations) or any beverages containing caffeine for 
the 72 hours before each study day and on each study day. I will not be allowed to drink 
any alcohol starting 72 hours before the first study day through the last day of the study. 
For Female Subjects: A blood sample will be collected for a pregnancy test. This test 
must be negative in order to qualify for participation in the study. This test will be 
repeated during each visit, on the night before dosing. 
Pharmacokinetic Screen and Familiarization Period 
After J complete the medical screening examination successfully, I will also have to 
undergo a Pharmacokinetic Screen and Familiarization Period; the following description 
explains the procedures to be followed during this period: 
I will come to the Clinical Research Unit the night before the study (about 6:00 p.m.) 
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and will not be released until the morning after the day of dosing; I will have to spend 
a total of two (2) nights and one (1) day. On the night before dosing (at about 10:00 
p.m.), I will start a fast that will continue until nine (9) hours after the start of dosing 
(about 5:00 p.m. on the day of dosing). On the morning of dosing, two (2) catheters will 
be inserted, one in each of my forearm veins. I will then receive a one (1) hour infusion 
of ethanol through one catheter. This dose is expected to achieve a blood alcohol level 
of about 0.1 mg%, slightly higher than the legal limit for alcohol in Virginia, which is 
0 .08mg% effective July 1, 1994 (approximately the same concentration resulting from 
two (2) alcoholic drinks). During and after the infusion, I will have to take the following 
tests several times during the day: a series of computerized tests, a questionnaire about 
my mood, and a recording of my brain waves (EEG). F.ach of these tests takes no more 
than five (5) minutes. My heart rate, blood pressure and temperature will be monitored 
throughout the period. During and after the infusion, fourteen (14) blood samples will 
be collected through the other catheter during this period. If the catheter fails to work, 
a new catheter will be inserted or it may ~me necessary to obtain blood samples by 
sticking a needle directly into the vein. At the end of the period, a breath alcohol test 
will be done to ensure that I have no detectable ethanol levels, before I am discharged 
the following day. 
Study Periods 
After I complete the first phase as described above, I will have to return to the Clinical 
Research Unit for a total of four (4) study periods over four (4) consecutive weeks. I will 
have to spend a total of four (4) days and eight (8) nights during this phase of the study. 
During each period , I will come to the unit at 6:00 p.m. on the evening before ethanol 
dosing and will not be released until the morning after the day of dosing (a total of two 
(2) nights and one (1) day for each period). On the night before dosing, I will begin a 
fast that will continue until four (4) hours after the start of dosing (about noon on the day 
of dosing). 
During each study period, on the morning of dosing, two (2) catheters will be inserted, 
one in each of my forearm veins. I will then receive a six-hour infusion divided into two 
parts: the first infusion (Infusion I) will last for one (1) hour, and the second infusion 
(Infusion U) will start as soon as the first infusion ends and last for another five (5) 
hours. Depending on the treatment assigned to the period, I will receive the following 
treatments, Infusion I will contain alcohol, Infusion II will be placebo (Treatment A), 
Infusion I will be placebo, Infusion II will contain alcohol (Treatment B), Infusion I and 
Infusion II will both contain alcohol (Treatment C), or Infusion I and Infusion II will 
both contain placebo (Treatment D). This dose is expected to achieve a blood alcohol 
level of about 0.1 mg%, slightly higher than the legal limit for alcohol in Virginia, which 
is 0.08mg% effective July 1, 1994 (approximately the same concentration resulting from 
two (2) alcoholic drinks). I will have received all four treatments once by the end of the 
study. Neither I nor the Investigators will know which treatment I am receiving during 
a given period, however a sealed copy of the treatments will be available on the Clinical 
Research Unit in case of an emergency. 
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During and after the infusion, I will have to take the following tests several times during 
the day: a series of computerized tests, a qtJestionnaire about my mood, and a recording 
of my brain waves (EEG). Each of these tests takes no more than five (5) minutes. My 
heart rate, blood pressure and temperature will be monitored throughout the period. 
During and after the infusion, nineteen (19) additional blood samples will be collected 
through the catheter during this period. If the catheter fails to work, a new catheter will 
be inserted or it may become necessary to obtain blood samples by sticking a needle 
directly into the vein. 
At the end of the period, i.e., on the morning of the second day, a breath alcohol test 
will be done to ensure that I have no detectable ethanol levels before I am discharged. 
For my safety, the pre-study physical examination, EKG, and laboratory tests will be 
repeated at the end of the study, i.e. , after completion of all four periods. If I discontinue 
the study prematurely, the physical examination, EKG and laboratory tests would be 
repeated. · 
This study is being conducted at the Virginia Commonwealth University/Medical College 
of Virginia by Vijay A. Ramchandani B.Pharm.Sc., Jurgen Venitz M.D., Ph.D., Alan 
R. Towne, M.D., and Indravadan Gatiwala, M.D. Dr. Towne is the Medical Monitor 
for this study and is the first person to be contacted in the case of a medical emergency. 
3. Benefits 
I am being asked to participate in this study as a volunteer. The study is of no direct 
medical benefit to me. There will be no charge to me for the screening examination and 
the results will be made available to me, if I want them. 
I will be paid $800.00 for the completion of the study. If I withdraw early or am 
discontinued by the Medical Monitor, the fee will be prorated (see Section 9). 
4. Alternative Therapy 
There is no therapeutic benefit to me for participating in this study. My participation is 
entirely voluntary. The alternative is not to participate in the study. 
5. Risks, Inconveniences, Discomforts · 
During the study, I will receive infusions of ethanol, either over a ooe .. or six hour 
period. These infusions may produce some local irritation to the veins. 
Alcohol (ethyl alcohol) may cause the following side-effects: local irritation, nausea, 
vomiting, flushing and feeling of warmth~ changes in heart rate and blood pressure, 
diaphoresis (sweating), diuresis (increase in urine output), changes in sexual desire, 
headache, drowsiness, euphoria or false f~ling of confidence and well-being. 
For female subjects: Alcohol is known to be harmful to the fetus, and if used in a 
pregnant woman, it can cause a condition called fetal alcohol syndrome in the baby. The 
features of this syndrome include low birth weight, decreased brain function and 
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development, facial abnormalities as well as other malformations. 
A total of 94 blood samples will be drawn during the study period of five to six weeks. 
The total amount of blood will be 560 ml (a little over 1 pint) over the entire duration 
of the study. To obtain the blood samples as well as to administer the infusions, two (2) 
small catheters will be inserted into a vein in each of my forearms. This procedure may 
cause some discomfort, pain, or slight bruising around the site of the needle stick. 
Sometimes fainting or infection may occur. If the catheter fails to work, a new catheter 
will be inserted or blood samples will be collected through a needle inserted into the 
vein. 
I will be observed for evidence of any untoward effects and I will be treated promptly 
and appropriately for any adverse effects, should they occur. I will be informed of any 
changes in the study and of any new risks that become evident; any new information 
obtained during the study that may be related to my willingness to continue participation 
will be provided to me. If any undesirable effects occur, I should report them directly 
to the investigators. Dr. Alan R. Towne is the Medical Monitor for this study and is the 
person I should contact in the case of a medical emergency. If I cannot reach Dr. Alan 
R. Towne, I may contact any of the study investigators. 
To have the EEG recorded, I must wear a bathing cap-like apparatus with 28 disks 
(electrodes). Through a hole in each electrode, my scalp will be cleaned and a small 
amount of jelly-like substance will be appiied to the scalp to make a good contact. In 
addition, two small, round electrodes will be attached, one to each earlobe and four more 
electrodes will be taped to my face (above and below my eyes). The cap will remain on 
my head for most of the day. There may be some discomfort associated with the EEG 
cap. Although the tape and gel used for the EEG recording are hypoallergenic, they may 
rarely cause skin irritation. After the cap is removed, I will be able to wash my hair. 
None of the other tests in the study carry any significant medical risk. 
There may be some discomfort associated with the physical exam, EKG, and laboratory 
tests conducted before and after the study. 
While on the Clinical Research Unit I will eat only the meals provided by the 
investigators at the times prescribed by the investigators. I will be required to remain at 
the Clinical Research Unit for about 36 hours during each study period. I may receive 
phone calls during the study, but no visitors will be allowed. 
6. Costs of Participation 
There will be no charge to me for any laboratory tests, physical examination, hospital 
care, or other tests related to the conduct of this study. 
This is a time-consuming study that may interfere with my employment or other 
activities. I confirm that I understand this before the beginning of the study. I will be 
confined to the study unit for two nights and an entire day on each of the 5 study 
periods. I must provide my own transportation to and from the study site. 
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7. Pregnancy 
For Female Subjects: I am aware that every effort will be made to have females enter 
the study on an equal basis with male subjects. Medically accepted birth control is 
required to enter this study. This will be limited only to regular use of birth control pills. 
Use of IUDs, condoms, diaphragms, implants, jellies, foams, sponges,being surgically 
sterile, abstention, or being in a post-menopausal state are nQt acceptable methods of 
birth control for this study. However, no birth control method completely eliminates the 
risk of pregnancy. If pregnancy occurs, there may be a risk of miscarriage, birth-defects, 
or other unforseen medical conditions. A pregnancy test will be conducted during each 
period of the study, before dosing. If I am found to be pregnant, I will be withdrawn 
from the study. 
8. Research Related Injury 
Every effort will be made to prevent any injury that could result from my participation 
in the study. In the event of any physical or mental injury resulting from my participation 
in this research project, Virginia Commonwealth University/Medical College of Virginia 
will not provide any compensation. If any injury occurs, medical treatment will be 
available at MCV hospitals. Fees for such treatment will be billed to me or the 
appropriate third party insurance. 
9. Confidentiality of Records 
The investigators will treat my identity with professional standards of confidentiality. 
Information obtained from this study may be published , but my identity will not be 
revealed. 
10. Withdrawal 
My participation in this study is voluntary. If I decide to participate, I may withdraw at 
any time. Neither refusal to participate nor withdrawal will result in any penalty to loss 
of benefits to which I am otherwise entitled. If I have any questions at any time 
concerning the study procedures, I may contact the study investigators: 
Pager Office Home 
Vijay A. Ramchandani 828-5429 648-6808 
Jurgen Venitz 756-1034 828-6249 754-0282 
Alan R. Towne 756-4106 828-9720 379-5568 
lndravadan Gatiwala *60-1801 828-0840 743-8299 
Dr. Alan Towne is the Medical Monitor for this study. He is the first person to be 
contacted in the case of an emergency. 
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If I do not complete the study due to premature withdrawal, the honorarium will be 
prorated based on the amount of usable information which has been collected. If the 
Medical Monitor terminates my participation in the study I will receive the entire 
amount. 
I have received a copy of this consent form. I have read the above information, and I 
have had an opportunity to ask questions to help me understand what my participation 
will involve. 
I freely give my consent to participate in this study. If I have any questions regarding my 
rights as a volunteer in a clinical research study, I can contact the Committee on the 
Conduct of Human Research (CCHR) at the Medical College of Virginia at 828-0868. 
Signed------------- Date ___ _ 
(volunteer) 
Signed------ ------- Date. ___ _ 
(witness) 
Signed------------ Date ___ _ 
(investigator) 
APPENDIX I 
Individual concentration-time profiles for intravenous ethanol study 
11 Individual serum ethanol concentration vs. time profiles by subject for Leg 0 
12 Individual serum ethanol concentration vs. time profiles by treatment and subject 
for treatments A, B and C 
13 Individual serum ethanol concentration vs.time profiles (observed values and 
curves fitted by compartmental analysis by treatment and subject for treatments 
A, Band C. 
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Figure 11.1 Serum ethanol concentration vs. time profile 
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Figure n .3 Serum ethanol concentration vs. time profile 
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Figure 11.2 Serum ethanol concentration vs. time profile 















0 2 4 6 8 
Time [hrs) 
Figure 11.4 Serum ethanol concentration vs. time profile 
for Leg O for Subject 4. ~ 8; 
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Figure 11.5 Serum ethanol concentration vs. time profile 
for Leg O foi; Subject 5. 
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Figure 11. 7 Serum ethanol concentration vs. time profile 
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Figure 11.6 Serum ethanol concentration vs . time profile 
for Leg O for Subject 6. 
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Figure H.8 Serum ethanol concentration vs. time profile 
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Figure 11 .9 Serum ethanol concentration vs. time profile 





., 1000 0 
C 
8 ~ 800 
- Oj) I j .§. 600 
Pl 400 






Figure 11.11 Serum ethanol concentration vs . time profile 
for Leg O for Subject 11. 
= 1400 0 
·~ 1200 
a g 1000 





0 2 4 
Time [hrs) 
6 8 
Figure 11.10 Serum ethanol concentration vs. time profile 
for Leg O for Subject 10. 
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Figure H .12 Serum ethanol concentration vs . time profile 
for Leg O for Subject 12. 
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Figure 11.13 Serum ethanol concentration vs. time profile 
for Leg O for Subject 13 : 
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Figure 11.15 Serum ethanol concentration vs. time profile 
for Leg O for Subject 15. 
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Figure 11 .14 Serum ethanol concentration vs. time profile 
for Leg O for Subject 14. 
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Figure ll.16 Serum ethanol concentration vs. time profile 
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for Treatment A for Subject 3 . 
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g - 1000 
U ~ 800 J .§. : 
~ 200 
~ oi-~-+~~,-~--1----=:.:_-+-~---1~~-+-~---1 
0 2 4 6 8 !O 12 14 
Time (hrs] 
Figure 12.4 Serum ethanol concentration vs. time profile 
for Treatment A for Subject 4. 
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Figure 12.5 Serum ethanol concentration vs. time profile 
·for Treatment A for Subject 5. 
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for Treatment A for Subject 6. 
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Figure 12.9 Serum ethanol concentration vs. time profile 
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Figure 12.10 Serum ethanol concentration vs. time profile 
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Figure 12.12 Serum ethanol concentration vs. time profile 
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Figure 12.13 Serum ethanol concentration vs. time profile 
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Figure 12.16 Se.rum ethanol concentration vs . time profile 
for Treatment A for Subject 16. 
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Figure 12.17 Serum ethanol concentration vs. time profile 
for Treatment B for Subject 1. 
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Figure 12.19 Serum ethanol concentration vs. time profile 
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Figure 12.18 Serum ethanol concentration vs. time profile 




cl, 1200 Q) g 
o: - 1000 U· ...I 
_ , } 800 





0 2 4 6 8, 10 12 14 
Time (hrs] 
Figure l2.20 Serum ethanol concentration vs. time profile 
for Treatment B for Subject 4. """ -.J w 
-~ 1600 I .~ 1600 
~ 1400 t E 1400 j :r !: ' ~ J, :r' ~=·----------------
0 ob &00 . s. ob 800 ij ..§. 600 _a .§. 600 
fil ~+ m 400 
l ~ + I I I J ~ ----l------f--4-- -+-- ----f--+---l 
0 2 4 6 8 10 12 14 
Time [hrs] 
Figure 12.21 Serum ethanol concentration vs . time profile 
for Treatment B for Subject 5. 
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Figure 12.23 Serum ethanol concentration vs. time profile 
for Treatment B for Subject 7. 
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Figure 12.22 Serum ethanol concentration vs . time profile 
for Treatment B for Subject 6. 
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Figure 12.24 Serum ethanol concentration vs. time profile 
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Figure 12.25 Serum ethanol concentration vs. time profile 
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Figure 12.27 Serum ethanol concentration vs. time profile 
for Treatment B for Subject 11. 
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Figure 12.26 Serum ethanol concentration vs. time profile 
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Figure 12.28 Serum ethanol concentration vs. time profile 
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Figure 12.29' Serum ethanol concentration vs. time profile 
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Figure 12.31 Serum ethanol concentration vs. time profile 
for Treatment B for Subject 15. 
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Figure 12.30 Serum ethanol concentration vs. time profile 
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Figure 12.32 Serum ethanol concentration vs. time profile 
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Figure 12.33 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 1. 
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Figure 12.35 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 3. 
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Figure 12.34 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 2. 
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Figure 12.36 Serum ethanol concentration vs. time profile 
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Figure 12.37 Serum ethanol concentration vs . time profile 
for Treatment C for Subject 5. 
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Figure 12.39 Serum ethanol concentration vs. time profile 
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Figure 12.38 Serum ethanol concentration vs . time profile 
for Treatment C for Subject 6. 
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Figure 12.40 Serum ethanol concentration vs . time profile 
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Figure 12.41 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 9. 
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Figure 12.43 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 11. 
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Figure 12.42 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 10. 
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Figure 12.44 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 12 . 
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Figure 12.45 Serum ethanol conceRtration vs. time profile 
for Treatment C for Subject B. 
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Figure 12.47 Serum ethanol concentration vs. time profile 
for Treatment C for Subject 15. 
Figure 12.46 Serum ethanol concentration vs. time profile 
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Figure 12.48 Serum ethanol concentration vs. time profile 
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Figure 13.1 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.2 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.3 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.4 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.5 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.6 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.7 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.8 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.9 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.10 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.11 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.12 Serum ethanol concentration vs time {observed values and fitted 
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Figure 13.13 Serum ethanol concentration vs time (observed values and fitted 
curves) by treatment for Subject 13 . 
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Figure 13 . 14 Serum ethanol concentration vs time (observed values and titted 
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Figure 13.15 Serum ethanol concentration vs time (observed values and fitted 
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Figure 13.16 Serum ethanol concentration vs time (observed values and fitted 
curves) by treatment for Subject 16. 
496 
PHARMACOKINETICS AND PHARMACODYNAMICS OF 
ETHANOL IN HEALTHY VOLUNTEERS: EFFECT OF 
INPUT-RATE AND DEGREE OF ETHANOL EXPOSURE ON 
SUBJECTIVE AND OBJECTIVE l\.IBASURES OF 
IMPAIRMENT 
A dissertation submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy at the Medical College of 
Virginia at Virginia Commonwealth University 
by 
Vijay A. Ramchandani 
B.Pharm.Sc. Bombay University (Bombay, India), 1990 
DIRECTOR: Jurgen Venitz, M.D., Ph.D., 
Associate Professor, Department of Pharmacy and Pharmaceutics 




Individual baseline-corrected response-time promes ror EEG measures 
J1 total power across all bands vs. time by treatment and subject 
Jl relative delta power vs. time by treatment and subject 
JJ relative theta power vs. time by treatment and subject 
J4 relative alpha power vs. time by treatment and subject 
JS relative beta I power vs. time by treatment and subject 
J6 relative beta II power vs. time by treatment and subject 
Treatment A TreatmmtB 
N...., 600 ~600 
> > e 500 G soo 
,u 






'3 100 1 100 ~ 0 E-, 0 
0 5 10 IS 0 5 10 15 
Time [hrs) Time (bi's] 
Ti:eatmcotC TreatmentD 
N...., 600 
> e ,soo 
.. ~ 600 
=e 500 
u , u 
!400 ]. 400 
8 300 "" 300 ! 200 ~ 200 i;.. 
'3 moo ] 100 
~ 0 ~ 0 
0 5 IO 15 0 s 10 IS 
Time [hrs] Time(hn) 




Treatment A Treatmeo!B 
.. ~ 700 N~ 700 
:> 600 > e e 600 
·i 500 -~ soo 
':' 400 -- 400 
; . 300 ; 300 
£ 200 2. 200 
3 100 ] 100 
0 o , 
f,.. 0 f-o, 0 
0 s IO IS 0 s IO lS 
Time []us] Time [b.r:s) 
Treatment C Tratmeot,D 
.. ~ 700 ..-- 700 
> 600 > 600 e e 
-~ soo -~ 500 
-:: 400 ~ 400 
; 300 J 300 
&, 200 &_ 200 
S 100 3 100 
{:. 0 ?:! 0 
0 5 lO IS 0 s 10 15 
Time (hrs] Tum [hrs] 







.. - 700 
=e 600 
·i 500 -~ soo, 
-;:" 400 - 400, 
.; 300 I 100 £ 200 ~ W(), 
'3 100 ~ 100 
,0 
f- 0 f- 0 
0 5 10 is: 0 s 10 15 
Tiine [hrs) Time [hrs] 
Tieatment C TIC&tment D 
.. - 700 .. - 700 
=e 600 >· e: 600 
-~ 500 ·~ 500 
'::' 400 ~ 400 
~ 300 l 300 2. 200 200 
S 100 3 100 
0 i2 f- 0 0 
0 s 10 lS 0 s 10 15 ,, 
Time (hrs) Time [hrs) 




Treatment A Treatm:otB 
N- 700 
.. - 700 
~ 600 > 600 
·i 500 ·i 500 
-: 400 - 400 
; 300 f 300 
£ 200 £ 200 
1 100 '3 100 0 
I-< 0 I-< 0 
0 5 IO IS 0 s 10 15 
Tune [hrs] Time[hrs] 
Treatme:ntC TreatmentD 






; 300 ~ 300 
£ 200 cf 200 
3 100 '3 100 
0 ~ i-, 0 0 
0 5 JO 15 0 5 10 15 
Time [hrs) Time [hrs] 
FigureJl.4 Total Power vs. time profiles by treatment for Subject 4. 
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VI 
s 
Treatment A TreatmmtB 
.. 7"' 800 .;--' 800 
> > g 600 2 
! ! 600 
, .. I 400 0 
·~ ,o 0.. 200 0.. 200 
J ] 0 ~ 0 
0 5 10 15 I 0 5 10 15 
Time [hrsl Time [hrs! 
TreaementC TreatmeotD 
... ~ 800 ,.. 800 
> > e e 
0 ! 600 ! 
t 400 I 400 ~ 
0 
0.. 200 0.. 200 
s 3 0 ~ f-, 0 0 
0 5 IO IS 0 s lO 15 
Time [hrs! Time Dus] 




Treatment A Treatment B 
........ 700 .r 700 
> 600 > 600 e 
-~ 500 -~ 500 
.... 400 ..... 400 
.. I 300 ; 300 
£ 200 ce 200 
'3 100 3 100 {:. 0 {:. 0 
0 s 10 1.5 0 5 10 [5 
Time [hrs] Time [hrs) 
Treat:mentC Treatment D 
... - 700 .. __, 700 
> 600 1: e -~ 500 
....... 400 
';:' 400 .. 
J 300 I 300 
£ 200 i,.. 200 
'3 100 '.3 100 
i2 0 {:. 0 
0 5 10 15 0 5 IO IS 
Time [hrs] Time [hrs) 
Figure Jl.8 Tota1 Power vs. time profdes by treatment for Subject 8. 
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Figure JI . 13 Total Power vs. time profiles by treatment for Subject 13. 
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Figure Jl .16 Total Power vs. time profiles by treatment for Subject 16. 
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Figure 12. l Relative Delta Power vs. time profiles by treatment for Subject I. 
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Figure J3.3 Relative Theta Power vs. time profiles by treatment for Subject 3. 
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Figure 13.12 Relative Th.eta Power vs. time profiles by treatment for Subject 12 . 
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Figure J4.3 Relative Alpha Power vs. time profiles by treatment for Subject 3. 
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Figure J4.4 Relative Alpha Power vs. time profiles by treatment for Subject 4. 
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Figure 14. 16 Refative A1pha Power vs. time profiles by treatment for Subject 16. 
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Figure JS.I Relative Beta I Power vs. time profiles by treatment for Subject 1. 
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FigureJ5.3 Relative Beta I Power vs. time profiles by treatment for Subject 3. 
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FigureJ5.4 Relative Beta I Power vs. time profiJes by treatment for Subject 4. 
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Figure J5.6 Relative Beta I Power vs. time profiles by treatment for Subject 6. 
VI 
°' °' 
Treatment A Treatment B 
Z 0.20 Z 0.20 
.. i O. lS ! 0.15 
0.. 0.. 
·- -
. ! 0.10 j 0. 10 
<D 
IXI. a:i 
-~ 0 .05 ~ o.os 
ai "j 
~ ' 0 .00 ~ 0.00 
() 5 IO 15 0 5 lO 1:S 
T ime [hrs] Time [b.rs) 
Treatment C Treatmeo.t D 
:I:. 0.20 Z 0.20 




. :! 0.10 .! O.lO 
11 ... 
a:i jlQ, 
-~ 0 .05 -~ 0.05 
ai I o.oo i ~ 0.00 
0 s 10 15 0 5 10 15 
Time [hrs] Time [hrs] 
FigureJ5.7 Relative Beta I Power vs. lime profiles by treatment for Subject 7. 
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FigureJ5.8 Relative Beta l Power vs. time profiles by treatment for Subject 8. 
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FigureJ5.9 Relative Beta I Power vs. time profiles by treatment for Subject 9. 
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Figure J5. 10 Relative Beta I Power vs. time profiles by treatment for Subject 10. 
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Figure 15 .11 Relative Beta I Power vs. time profiles by treatment for Subject 11. 
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Figure JS. 14 Relative Beta I Power vs. time profiJes by treatment for Subject 14. 
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Figure 15.15 Relative Beta I Power vs. time profiJes by treatment for Subject 15. 
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Figure J6.5 Relative Beta II Power vs. time profiles by treatment for Subject 5. 
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FigureJ6.6 Relative Beta II Power vs. time profiles by treatment for Subject 6. 
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Fi.gure J6.14 Relative Beta II Power vs. time profiles by treatment for Subject 14. 
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Figure J6..15 Relative Beta II Power vs. time profiles by treatment for Subject 15. 
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Figure Kl.15 Number Vigilance Reaction Time vs. time profile by treatment for Subject 15. 
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Treatmeo.t B 
JO 12 14 
TreatmeotD 




















. ..... P"""'li 
·t .!.. 0.4 
~ 
'2 
0 2 4 6 8 10 12 14 
Time [hrs) 
Treatment C 
0 ~ O.O +-- -t----;1-----1---1----t--,---.... 




















-~ ~ 0.6 
·t .!.. 0.4 
Iii:: 0.2 
"E 
0 2 4 6 8 10 12 14 
Time [hrs) 
Treatmen.t D 
0 ~ 0.0 4--- -1----4---+---+---+----+----! 
0 2 4 6 8 10 12 14 
Time [hrs] 
Figure K2.1 Word Recognition Sensitivity vs. time profile by treatment for Subject 1. 
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Figure K2.4 Word Recognition Sensitivity vs. time profile by treatment for Subject 4. 
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Figure K2. l0 Word Recognition Sensitivity vs. time profile by treatment for Subject 10. 
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Figure K2. 14 Word Recognition Sensitivity vs. time profile by treatment for Subject 14. 
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Figure Ll.7 SRI-HIGH Score vs time by treatment for Subject 7. 
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FigureLI.9 SRI-HIGH Score vs time by treatment for Subject 9. 
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Figure Ll.10 SRI-HIGH Score vs time by treatment for Subject 10. 
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Figure Ll.16 SRI-HIGH Score vs time by treatment for Subject 16. 
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Figure L2. 1 SRI-DRUNK Score vs time by treatment for Subject 1. 
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Figure L2.2 SRI-DRUNK Score vs time by treatment for Subject 2. 
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Figure L2.3 SRI-DRUNK Score vs time by treatment for Subject 3. 
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Figure L2.4 SRI-DRUNK Score vs time by treatment for Subject 4. 
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FigureL2.5 SRI-DRUNK Score vs time by treatment for Subject 5. 
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Figure L2.6 SRI-DRUNK Score vs time by treatment for Subject 6. 
~ 
°' 
80 Treatment A 80 T Treatment B 
I I 
!! 60 j 60 8 
c,:i 
~ 40 ~ 40 
z ~ :i 
P: 20 Ci:: 20 Cl Cl 
I I 
I ~ 2 II) 0 0 
0 5 10 IS 0 s 10 15 
Time [hrs] Time [hrs) 
80 Treatment C 80 T TreatmentD 
1 60 l 60 f f 










0 s 10 15 0 5 10 15 
Tmie [hrs] Time ,[hrs] 
















11"1 0 11'1 0 11'1 ~ 11"1 0 QC 
- - -
[mm] a.JOOS )IN[lllG&nfS (urm) IUOOS )IN[lllQ-nfS 8 'E 
::I 
ti) 






I I ~ -~ >-, .. 









l I ii> ... i= 8 II] 
11'1 







0 0 ~ 
11'1 5: 11'1 0 11'1 s V'I 0 
- -
~ 




..... 25 TreatmcorA 25 T Tll2lmr.nt. B 
l 20 I 20 
e ;f 
I ~ 15 ~ 15 
~ ;.,: 
';:) 10 ~ 10 ~ 






O· s 10 IS 0 5 10 15 
Time [hrs] Time [hrsJ 
..... 25 Treatment C 25 T T reatme.o.t D 
! 20 I 20 
f ' e 
8 15 8 15 (I] (I] 
~ . 
:..: 
:> 10 ~ JO 
i:,::; i:,::; 




0 5 10 15 0 5 IO 15 
Time [hrs] Time l[bts] 
Figure L2.9 SRI-DRUNK Score vs time by treatment for Subject 9. 
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Figure L2. lJ SRI-DRUNK Score vs time by treatment for Subject 11. 
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Figu.re L2. l2 SRI-DRUNK Score vs time by treatment for Subject 12. 
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Figure L3.l SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 1. 
~ 
-..J 
r:n 100 Treatment A r:n 100 T Treatment B 
t t> 
re 80 ~~ 80 ""~ 
r;IJ I 60 tJl ~ 60 
..J - ..J -o e o e 5 8 40 sj 40 u en 
·~ 20 ~ 20 
. 2 2 
r:n 0 r:n 0 
0 2 4 6 g IO 12 14 0 2 4 6 g 10 12 14 
Time [hrs] Time [hrs] 
r:n 100 t [{)() T TreatmeotD t 
tJl 80 U) so t:., 1.1, 
i:z..-. 
~i w ~ 60 60 
....l_ 
..J -o e o e 
::C. 0 40 8 8 40 0 0 u r:n u r:n 
~ 20 ~. 20 
. 
' 2 ;! 
r:n 0 r.,), 0 
0 2 4 6 g 10 12 14 ' 0 2 4 6 8 10 12 14 
Time [hrs} Time [hrs] 
Figure L3.2 SRJ-ALCOHOL EFFECTS Score vs time by treatment for Subject 2. 
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Figure L3..3 SRI-ALCOHOL EFFECTS Score. vs time by treatment for Subject 3. 
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Figure L3.4 SRI-ALCOHOL EFFECTS Scme vs time by treatment for Subject 4. 
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Figure L3.6 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 6. 
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Figure L3.9 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 9. 
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Figure L3.10 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 10. 
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Figure L3.13 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 13. 
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Figure L3 .14 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 14. 
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Figure L3 .16 SRI-ALCOHOL EFFECTS Score vs time by treatment for Subject 16. 
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~ 
w 
30 Treatment A 30 T TreatmentB 
I I 
~ 20 j 20 (I) 
::c: ::r: 0 0 10 ~ 10 :2 
ii2 2 0 0 
0 0 
0 5 10 15 0 5 IO IS 
Time [hrs] Time(bB] 
30 Treatmeo.t C 30 T Treatment D 
I I 
§ 20 2 20 J! j (I) 
= = 0 10 ~ IO ~ I 
oil § 0 
0 0 
0 5 10 15 0 5 10 15 
Time [hrs] Time [hrs] 
Figure L4.2 ORI-HIGH Score vs time by treatment for Subject 2. 
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Figure IA.3 ORI-HIGH Score vs time by treatment for Subject 3. 
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Figure IA.4 ORI-HIGH Score vs time by treatment for Subject 4. 
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Figure IA.7 ORI-HJ.GH Score vs time by treatment for Subject 7. 
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Figure lA.8 ORI-IIlGH Score vs time by treatment for Subject 8. 
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Figure lA.9 ORI-HIGH Score vs Hme by treatment for Subject 9. 
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Figure IA.10 ORI-HIGH Score vs time by treatment for Subject 10. 
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Figure IA.12 ORI-HIGH Score vs time by treatment for Subject 12. 
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Figure 1.4.14 ORI-lllGH Score vs time by treatment for Subject 14. 
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Figure IA.15 ORI-IDGH Score vs time by treatment for Subject 15. 
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Figure lA.16 ORI-HIGH Score vs time by treatment for Subject 16. 
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Figure L5.2 ORI-DRUNK Score vs time by treatment for Subject 2. 
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Figure L.5.4 ORI-DRUNK Score vs time by treatment for Subject 4. 
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Figure 15.5 ORI-DRUNK Score vs time by treatment for Subject 5. 
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Figure l.5 .6 ORI-DRUNK Soore vs time by treatment for Subject 6. 
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Figure L5.10 ORI-DRUNK Score vs time by treatment for Subject 10. 
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Figure 1.5. 11 ORI-DRUNK Score vs time by treatment for Subject 11. 
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Figure LS.12 ORI-DRUNK Score vs time by treatment for Subject 12. 
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Figure L5.16 ORI-DRUNK Score vs time by treatment for Subject 16. 
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APPENDIX M 
Individual baseline-corrected response-concentration pro mes for PD measures for 
intravenous ethanol study 
Ml Baseline-corrected relative theta power vs. concentration by treatment and 
subject 
M2 Baseline-corrected non-dominant hand tap-rate for FT vs. concentration by 
treatment and subject 
M3 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. concentration by 
treatment and subject 
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Figure M 1.1 Baseline-corrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml .2 Baseline-corrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml .3 Baselin1H:Orrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml.5 Baselin~rrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml .6 Baseline-corrected Relative Theta Power vs . Serum ethanol concentration 
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Figure Ml.7 Baseline-corrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml.8 Baseline--corrected Relative Theta Power vs. Serum ethanol concentration 
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Figure Ml.9 Baseline-corrected Relative Theta Power vs . Serum ethanol concentration 
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Figure Ml .11 Baseline-corrected Relative Theta Power vs . Serum ethanol concentration 
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Figure M 1.12 Baseline--corrected Relative Theta Power vs. Serum ethanol concentration 





l l 0.10 0.05 j~ 0.00 
--0.0S J -~ --0.10 j --0.lS 
1200 1400 
--0.20 
Scrum Ethanol Concentration [mg/L) 
0 .20 Trutmcnl B 
-
0.15 
l l 0.10 0 .05 i~ 0.00 --0.05 
al 1 --0.10 
Ill: --0. lS 
1000 1200 1400 
--0.20 
Serum Ethanol Concentration [mg/LJ 
0.20 Treatment C 
:c 0.15 
l l 0.10 0.05 i~ 0.00 -0.0S j -0.10 
a:: -0.IS 
200 400 600 800 1000 1200 1400 
-0.20 
Serum Ethanol Concenlnllion [mg/Ll 
Figure M 1.13 Baseline-corrected Relative Theta Power vs. Serum ethanol concentration 
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Figure M 1. 15 Baseline--corrected Relative Theta Power vs . Serum ethanol concentration 
profiles by treatment for Subject 15 . 
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Figure M2. l Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
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by treatment for Subject 2. 
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by treatment for Subject 3. 
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Figure M2.4 Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
by treatment for Subject 4. 
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Figure M2.6 Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
by treatment for Subject 6. 
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Figure M2.7 Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
by treatment for Subject 7. 
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by treatment for Subject 8. 
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Figure M2.10 Number Vigil.ance Reactioo Time vs . Serum Ethanol Concentration profiles 
by treatment for Subject 10. 
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Figure M2.13 Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
by treatment for Subject 13 . 
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Figure M2. 14 Number Vigilance Reaction Time vs . Serum Ethanol Concentration profiles 
by treatment for Subject 14. 
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Figure M2.16 Number Vigilance Reaction Time vs. Serum Ethanol Concentration profiles 
by treatment for Subject 16. 
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Figure M3.l Baseline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject I . 
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Concentration profiles by treatment for Subject 2. 
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Concentration profiles by treatment for Subject 3. 
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Concentration profiles by treatmenl for Subject 4. 
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Figure M3.5 B11Seline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject 5. 
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Figure M3.7 Bueline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject 7. 
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Figure M3.9 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject 9. 
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Figure M3 .10 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject 10. 
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Figure M3.12 Baseline-corrected SRI-ALCOHOL EFFECTS score vs. Serum Ethanol 
Concentration profiles by treatment for Subject 12. 
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Figure M3. I3 Biu;elioe-corTected SRI-ALCOHOL EFFECTS score vs. Senim Ethanol 
Concentration profiles by treatment for Subject 13. 
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Figure M3.14 Baseline-corrected SRI-ALCOHOL EFFECTS score vs . Serum Ethanol 
Concentration profiles by treatment for Subject 14. 
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Cooceotration profiles by treatment for Subject 15. 
751 
j 100 Treatment A 
i~ 80 60 
w e 40 
..J e 
o-





-20 200 400 600 800 1000 1200 1400 
Scrum Ethanol Concentration [mg/LJ 
e 100 1 
Treatment B 
"' 
80 i~ 60 
w e 40 
..J e 
o-
:x: 20 0 
~ 0 
2 -20 200 400 600 800 1000 1200 1400 
"' Scrum Ethanol Concentration [mg/I.] 
TreatmentC 





LU E 40 
..J e 
o-
::c 20 0 
:s 0 < 2 
-20 
"' 
200 400 600 800 1000 1200 1400 
Scrum Ethanol Concentration [mglLJ 
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by subject for treatment C 
N2 Number vigilance reaction time vs. time and serum ethanol concentration vs. time 
profiles by subject for treatment C 
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time profiles by subject for treatment C 
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Figure N 1.3 Relative Theta Power vs. time and serum ethanol 
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Figure NI . 7 Relative Theta Power vs. time and serum ethanol 
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Pl Subject-Rated Impairment (SRI) Scale 
P2 Observer-Rated Impairment (ORI) Scale 
797 
SUBJECT - RATED ALCOHOL IMPAIRMENT SCALE 




Please mark on the line below how you feel ri~ht now with respect to each of the following: 
1. high D 
not at all extremely 
2. drunk D oot at all extremely 
3. confused D 
not at all extremely 
4. dizzy D 
not at all extremely 
5. clumsy D 
oot at all extremely 
6. floating D 
oot at all extremely 
7. uncomfortable D 
oot at all extremely 
8. slurred speech D 
oot at all 
extremely 
9. feel great D extremely 
not at all 
10. feel terrible extremely D 
oot at all 
11. drowsy extremely D 
oot at au 
12. alcohol effects extremely D 
not at all 
•ri.fnn/N AR: :6/19/96 
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Leg:---------Date: __________ ~ 
Please mark on the line below how you perceive the subject feels right now with respect to 
each of the following: 
l. high D 
not at all extremely 
2. drunk D 
not at au extremely 
3. confused D 
not at aU extremely 
4. drowsy D 
not at alJ extremely 
ori.frm//V AR::6/19/96 
APPENDIX Q 
Program code for model equations in Scientist 
Qt One compartment body model for oral ethanol 
Q2 PK-PD model for acute tolerance to SRI effects of oral ethanol 
Q3 One compartment body model for intravenous ethanol 
Q4 Two compartment body model for intravenous ethanol 
QS PK-PD model for acute tolerance to SRI effects of intravenous ethanol 
IIQl 
II PK Model for oral ethanol 
II etoralpk.eqn Version 1.0 
II VAR and JV, Dec 19, 1995 
II 
II ETOH ORAL PK 
II Zero order input into absorption compartment, First order absorption 




Pararns: VMAX, KM, V, KA , D , TI.NF 
II 




CRA TE=CRA TEA *(1-FLAG) +CRA TEB 
II First order absorption 
A'=CRAT&(KA*A) 
II One compartment body model with saturable elimination 
C' =KA* A-(VMAX*C/(KM +C)) 







II PK-PD Model for Acute Tolerance to SRI effects of Oral Ethanol 
II ethmood6.eqn Version 1.0 
II VAR and JV, Dec 19, 1995 
II 
II PK-PD Modelling of Subjective Effects of Ethanol 
II 
lndVars:T 
DepVars: C, CSAL 
Params: VMAX, KM, V, KA, D, TINF, S, Icon, koff 
II 
II PK 
II Zero order input into absorption compartment, First order absorption 
II One compartment body model with Michaelis-Menten elimination 
II 




CRA TE=CRA TEA *(1-FLAG)+CRATEB 
II First order absorption 
A'=CRATE-(KA*A) 




II Direct effect linearly related to concentration 
II Feedback effect (tolerance) related to direct effect by first-order process 
II Effect: SRI-ALCOHOL EFFECTS Score 
II 
//Drug-induced direct effect - Linear 
CSALD=S*C 
II Feedback effect 
CSALFB' = kon*CSALD-koff*CSALFB 
II Total effect 
CSAL= CSALD-CSALFB 








II PK Model for Intravenous Ethanol ( I-compartment) 
II ethanoll.eqn Version 1.0 
II VAR and N June 3, 1994 
II 
I I ETOH infusion PK 




Pararns: VMAX, KM, Dl, 02, V, TINFl, TINF2 
II 
II Dose administration as two consecutive IV infusions 
II INFUSION 1 
CRA TElA = (D 1/V)/TINF 1 
CRATElB=O 
FLAGl =UNIT(T-TINFl) 
CRA TEl =CRA TElA *(1-FLAG l)+CRA TElB*FLAG 1 
II INFUSION 2 
CRA TE2A = (D2/V)/(TINF2-TINF 1) 
CRATE2B=O 
FLAG2 = UNIT(T-TINF2) 
CRATE2=CRATE2A*FLAG1 *(1-FLAG2)+CRATE2B*FLAG2 
CRA TE=CRA TEl +CRA TE2 
II 
II One compartment body model with saturable elimination 
C' =CRA TE-VMAX*C/(KM +C) 






/ I PK Model for Intravenous Ethanol (2-compartment) 
II ethivpk.eqn Version 2.0 
II VAR and JV March 13, 1996 
II 
// ETOH infusion PK 
II 2 compartment model with zero-order input, first-order distribution, 




Params: Dl, D2, TINFl, TINF2, VMAX, KM, V, K12, K21 
II 
II Dose administration as two consecutive IV infusions 
// INFUSION 1 
CRA TElA = (D 1/V)/TINF 1 
CRATElB=O 
FLAGl =UNIT(T-TINFl) 
CRATEl =CRA TElA *(1-FLAG l)+CRA TElB*FLAG 1 
I /INFUSION 2 
CRA TE2A = (D2/V)l(TINF2-TINF1) 
CRATE2B=O 
FLAG2 = UNIT(T-TINF2) 
CRATE2=CRA TE2A *FLAGl *(1-FLAG2) +CRA TE2B*FLAG2 
CRATE=CRATEl +CRATE2 
II 
// Two compartment body model with saturable elimination 
C' =CRA TE-VMAX*C/(KM +C)-Kl2*C + K21 *CT 
CT' =Kl2*C-K21 *CT 








II PK-PD Model for Acute Tolerance to SRI effects of intraveoous Ethanol 
II ETHEMAX2.EQN Version 2.0 
II VAR and N March 13, 1996 
II 
II PK-PD Modelling of Subjective effects of Ethanol 
II 
lndVus:T 
DepVars: C, CSAL 
Params: Dl, D2, TINFl, TINF2, VMAX, KM, V, Kl2, K21, Emax, EcSO, n, Kon, Koff 
II 
II PK 
II 2-<:<>mpartment model with zero.order input, first-order distribution, Micbaelis-Menten elimination 
II 
I I Dose administration as two consecutive IV infusions 
II INFUSION 1 
CRATE IA= (D lN)/TINF l 
CRATElB=O 
FLAG l = UNIT(T • TINF l ) 
CRATEl=CRATElA~l-FLAGl)+CRATElB*FLAGl 
II INFUSION 2 
CRA TE2A =(D2N)l(TINF2-TINFl) 
CRATE2B=O 
Fl..AG2 = UNIT(T • TINF2) 
CRATE2=CRATE2A*Fl..AG1*(1-FLAG2)+CRATE2B•FI..AG2 
CRA TE=CRA TEI +CRA TE2 
II 





I I Direct effect related to concentration by sigmoidal Emax model 
II Feedback effect (tolerance) related to direct effect by first-order process 
II Effect: SRI-ALCOHOL EFFECTS Score 
II 
II Drug-induced Effect • sigmoidal Emax model 
CSALD = (Emax•(c·n))/((ECSO· n) + (C.n)) 
II Feedback Effect 
CSALFB' = Kon•CSALD-Koff*CSALFB 
II Total Effect 
CSAL= CSALD-CSALFB 
// Initial conditions 
T=O 
C=O 
CT=O 
CSALFB=O 
••• 
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